ANNUAL MEETING PROGRAM BOOK. DECEMBER 5-9 Washington State Convention Center Seattle, WA 5 th Biennial North American Regional Epilepsy Congress

Transcription

1 ANNUAL MEETING PROGRAM BOOK 2014 DECEMBER 5-9 Washington State Convention Center Seattle, WA 5 th Biennial North American Regional Epilepsy Congress

2

3 Visit BOOTH #405 to learn more Ready to Fight ONFI (clobazam) is FIERCELY DEDICATED to helping Bobby & Julian fight their seizures. ONFI is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. Bobby, age 47, diagnosed with LGS. Julian, age 6, diagnosed with LGS. Important Safety Information ONFI causes somnolence and sedation. In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related. In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment. Prescribers should monitor patients for somnolence and sedation, particularly with concomitant use of other central nervous system (CNS) depressants. Prescribers should caution patients against engaging in hazardous activities that require mental alertness, such as operating dangerous machinery or motor vehicles, until the effect of ONFI is known. ONFI has a CNS depressant effect. Patients should be cautioned against the simultaneous use with other CNS depressant drugs or alcohol, and cautioned that the effects of other CNS depressant drugs or alcohol may be potentiated. As with all antiepileptic drugs (AEDs), ONFI should be gradually withdrawn to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus. Withdrawal symptoms have been reported following abrupt discontinuation of ONFI; the risk of withdrawal symptoms is greater with higher doses. Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period. ONFI should be discontinued at the first sign of rash, unless the rash is clearly not drug-related. Patients with a history of substance abuse should be under careful surveillance when receiving ONFI or other psychotropic agents because of the predisposition of such patients to habituation and dependence. In clinical trials, cases of dependency were reported following abrupt discontinuation of ONFI. The risk of dependence increases with increasing dose and duration of treatment. AEDs, including ONFI, increase the risk of suicidal thoughts or behavior in patients. Patients, their caregivers, and families should be informed of the risk and advised to monitor and report any emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior, or thoughts of self-harm. If these symptoms occur, consider whether it may be related to the AED or illness, because epilepsy itself can increase these risks. The most commonly observed adverse reactions reported in an LGS randomized, double-blind, placebo-controlled, parallel group clinical trial who received clobazam as adjunctive therapy ( 10% in any treatment group and at least 5% greater than placebo, respectively) were somnolence or sedation (32% vs. 15%), somnolence (25% vs. 12%), pyrexia (17% vs. 3%), lethargy (15% vs. 5%), drooling (14% vs. 3%), aggression (14% vs. 5%), irritability (11% vs. 5%), ataxia (10% vs. 3%), and constipation (10% vs. 0%). Please see Brief Summary of Prescribing Information on the following pages. For full Prescribing Information, Medication Guide, and Instructions for Use, go to Lundbeck. All rights reserved. ONFI is a registered trademark of Lundbeck CLB-B /2014 1

4 ONFI (clobazam) tablets, for oral use, ONFI (clobazam) oral suspension, Brief Summary of Prescribing Information (See package insert for full Prescribing Information or visit Rx Only INDICATIONS AND USAGE ONFI (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. CONTRAINDICATIONS None [see Contraindications]. WARNINGS AND PRECAUTIONS Somnolence or Sedation: ONFI causes somnolence and sedation. In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related. In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment. Prescribers should monitor patients for somnolence and sedation, particularly with concomitant use of other central nervous system depressants. Prescribers should caution patients against engaging in hazardous activities requiring mental alertness, such as operating dangerous machinery or motor vehicles, until the effect of ONFI is known [see Warnings and Precautions]. Potentiation of Sedation from Concomitant Use with Central Nervous System Depressants: Since ONFI has a central nervous system (CNS) depressant effect, patients or their caregivers should be cautioned against simultaneous use with other CNS depressant drugs or alcohol, and cautioned that the effects of other CNS depressant drugs or alcohol may be potentiated [see Warnings and Precautions]. Withdrawal Symptoms: Abrupt discontinuation of ONFI should be avoided. ONFI should be tapered by decreasing the dose every week by 5-10 mg/day until discontinuation [see Dosage and Administration]. As with all antiepileptic drugs, ONFI should be withdrawn gradually to minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus. Withdrawal symptoms have been reported following abrupt discontinuance of benzodiazepines. The more severe withdrawal symptoms have usually been limited to patients who received excessive doses over an extended period of time, followed by an abrupt discontinuation. Generally milder withdrawal symptoms have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic doses for several months [see Warnings and Precautions]. Serious Dermatological Reactions: Serious skin reactions, including Stevens- Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period. Patients should be closely monitored for signs or symptoms of SJS/TEN, especially during the first 8 weeks of treatment initiation or when re-introducing therapy. ONFI should be discontinued at the first sign of rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered [see Warnings and Precautions]. Physical and Psychological Dependence: Patients with a history of substance abuse should be under careful surveillance when receiving ONFI or other psychotropic agents because of the predisposition of such patients to habituation and dependence [see Drug Abuse and Dependence]. Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including ONFI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Anyone considering prescribing ONFI or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers [see Warnings and Precautions]. ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. During its development for the adjunctive treatment of seizures associated with LGS, ONFI was administered to 333 healthy volunteers and 300 patients with a current or prior diagnosis of LGS, including 197 patients treated for 12 months or more. The conditions and duration of exposure varied greatly and included single- and multiple-dose clinical pharmacology studies in healthy volunteers and two double-blind studies in patients with LGS (Study 1 and 2) [see Clinical Studies]. Only Study 1 included a placebo group, allowing comparison of adverse reaction rates on ONFI at several doses to placebo. Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1): The adverse reactions associated with ONFI treatment discontinuation in 1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia. Most Common Adverse Reactions in an LGS Placebo Controlled Clinical Trial (Study 1): Table 3 in the full Prescribing Information lists the adverse reactions that occurred in 5% of ONFI treated patients (at any dose), and at a rate greater than placebo treated patients, in the randomized, double-blind, placebo-controlled, parallel group clinical study of adjunctive AED therapy for 15 weeks (Study 1). Table 3. Adverse Reactions Reported for 5% of Patients and More Frequently than Placebo in Any Treatment Group ONFI Dose Level Placebo N=59 % Low a N=58 % Medium b N=62 % High c N=59 % All ONFI N=179 % Gastrointestinal Disorders Vomiting Constipation Dysphagia General Disorders and Administration Site Conditions Pyrexia Irritability Fatigue Infections and Infestations Upper respiratory tract infection Pneumonia Urinary tract infection Bronchitis Metabolism and Nutrition Disorders Decreased appetite Increased appetite Nervous System Disorders Somnolence or Sedation Somnolence Sedation Lethargy Drooling Ataxia Psychomotor hyperactivity Dysarthria Psychiatric Disorders Aggression Insomnia Respiratory Disorders Cough a Maximum daily dose of 5 mg for 30 kg body weight; 10 mg for >30 kg body weight b Maximum daily dose of 10 mg for 30 kg body weight; 20 mg for >30 kg body weight c Maximum daily dose of 20 mg for 30 kg body weight; 40 mg for >30 kg body weight Post Marketing Experience: These reactions are reported voluntarily from a population of uncertain size; therefore, it is not possible to estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions are categorized by system organ class. Blood Disorders: Anemia, eosinophilia, leukopenia, thrombocytopenia; Eye Disorders: Diplopia, vision blurred; Gastrointestinal Disorders: Abdominal distention; Investigations: Hepatic enzyme increased; Musculoskeletal: Muscle spasms; Psychiatric Disorders: Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination; Respiratory Disorders: Aspiration, respiratory depression; Skin and Subcutaneous Tissue Disorders: Rash, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), urticaria. DRUG INTERACTIONS Effect of ONFI on Other Drugs: ONFI is a weak CYP3A4 inducer. As some hormonal contraceptives are metabolized by CYP3A4, 2

5 their effectiveness may be diminished when given with ONFI. Additional non-hormonal forms of contraception are recommended when using ONFI [see Clinical Pharmacology, Patient Counseling Information]. ONFI inhibits CYP2D6. Dose adjustment of drugs metabolized by CYP2D6 may be necessary [see Clinical Pharmacology]. Effect of Other Drugs on ONFI: Strong and moderate inhibitors of CYP2C19 may result in increased exposure to N-desmethylclobazam, the active metabolite of clobazam. This may increase the risk of dose-related adverse reactions. Dosage adjustment of ONFI may be necessary when coadministered with strong CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole) [see Clinical Pharmacology]. CNS Depressants and Alcohol: Concomitant use of ONFI with other CNS depressants may increase the risk of sedation and somnolence [see Warnings and Precautions]. USE IN SPECIFIC POPULATIONS Pregnancy - Pregnancy Registry: To provide information regarding the effects of in utero exposure to ONFI, physicians are advised to recommend that pregnant patients taking ONFI enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number , and must be done by patients themselves or their caregiver. Information on the registry can also be found at the website Pregnancy Category C: There are no adequate and well-controlled studies of ONFI in pregnant women and no adequate developmental toxicity studies of clobazam in animals. Although limited, the available animal data suggest developmental toxicity, including an increased incidence of fetal abnormalities following oral administration of clobazam to pregnant animals at doses similar to those used clinically. Data for other benzodiazepines suggest the possibility of adverse effects in animals and humans. Long-term effects on neurobehavioral and immunological function have been reported in rodents following prenatal exposure to benzodiazepines. Neonatal flaccidity, respiratory and feeding difficulties, hypothermia, and withdrawal symptoms have been reported in infants born to mothers who received benzodiazepines, including clobazam, late in pregnancy. Therefore, ONFI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [see Use in Specific Populations]. Nursing Mothers: ONFI is excreted in human milk. The effects of this exposure on infants are unknown [see Use in Specific Populations]. Pediatric Use: The safety and effectiveness in patients less than 2 years of age have not been established. In a study in which clobazam (4, 36, or 120 mg/kg/day) was orally administered to rats during the juvenile period of development (postnatal days 14 to 48), adverse effects on growth (decreased bone density and bone length) and behavior (altered motor activity and auditory startle response; learning deficit) were observed at the high dose. The effect on bone density, but not on behavior, was reversible when drug was discontinued. The no-effect level for juvenile toxicity (36 mg/kg/day) was associated with plasma exposures (AUC) to clobazam and its major active metabolite, N-desmethylclobazam, less than those expected at therapeutic doses in pediatric patients. Geriatric Use: Clinical studies of ONFI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly subjects appear to eliminate clobazam more slowly than younger subjects based on population pharmacokinetic analysis. For these reasons, the initial dose in elderly patients should be 5 mg/day. Patients should be titrated initially to mg/day. Patients may be titrated further to a maximum daily dose of 40 mg if tolerated [see Dosage and Administration, Clinical Pharmacology]. CYP2C19 Poor Metabolizers: Concentrations of clobazam s active metabolite, N-desmethylclobazam, are higher in CYP2C19 poor metabolizers than in extensive metabolizers. For this reason, the initial dose in patients known to be CYP2C19 poor metabolizers should be 5 mg/day. Dose titration should proceed slowly according to weight to mg/day, and may be titrated further to a maximum daily dose of 40 mg on day 21 based upon clinical response [see Dosage and Administration, Clinical Pharmacology]. Renal Impairment: The pharmacokinetics of ONFI were evaluated in patients with mild and moderate renal impairment. There were no significant differences in systemic exposure (AUC and C max ) between patients with mild or moderate renal impairment and healthy subjects. No dose adjustment is required for patients with mild and moderate renal impairment. There is essentially no experience with ONFI in patients with severe renal impairment or ESRD. It is not known if clobazam or its active metabolite, N-desmethylclobazam, is dialyzable [see Dosage and Administration, Clinical Pharmacology]. Hepatic Impairment: ONFI is hepatically metabolized; however, there are limited data to characterize the effect of hepatic impairment on the pharmacokinetics of ONFI. For this reason, the initial dose in patients with mild to moderate hepatic impairment (Child-Pugh score 5-9) should be 5 mg/day. These patients should be titrated according to weight to 10 to 20 mg/day, and may be titrated further to a maximum daily dose of 40 mg on day 21 based upon clinical response. There is inadequate information about metabolism of ONFI in patients with severe hepatic impairment. Therefore no dosing recommendation in those patients can be given [see Dosage and Administration, Clinical Pharmacology]. DRUG ABUSE AND DEPENDENCE Controlled Substance: ONFI contains clobazam which is a Schedule IV controlled substance. Abuse: ONFI can be abused in a similar manner as other benzodiazepines, such as diazepam. The pharmacological profile of ONFI is similar to that of other benzodiazepines listed in Schedule IV of the Controlled Substance Act, particularly in its potentiation of GABAergic transmission through its action on GABA A receptors, which leads to sedation and somnolence. The World Health Organization epidemiology database contains reports of drug abuse, misuse, and overdoses associated with clobazam [see Drug Abuse and Dependence]. Dependence: In clinical trials, cases of dependency were reported following abrupt discontinuation of ONFI. The risk of dependence is present even with use of ONFI at the recommended dose range over periods of only a few weeks. The risk of dependence increases with increasing dose and duration of treatment. The risk of dependence is increased in patients with a history of alcohol or drug abuse. Withdrawal: Abrupt discontinuation of ONFI causes withdrawal symptoms. As with other benzodiazepines, ONFI should be withdrawn gradually [see Dosage and Administration, Warnings and Precautions]. In ONFI clinical pharmacology trials in healthy volunteers, the most common withdrawal symptoms after abrupt discontinuation were headache, tremor, insomnia, anxiety, irritability, drug withdrawal syndrome, palpitations, and diarrhea [see Warnings and Precautions]. Other withdrawal reactions to clobazam reported in the literature include restlessness, panic attacks, profuse sweating, difficulty in concentrating, nausea and dry retching, weight loss, blurred vision, photophobia, and muscle pain and stiffness. In general, benzodiazepine withdrawal may cause seizures, psychosis, and hallucinations [see Warnings and Precautions]. OVERDOSAGE Signs and Symptoms of Overdosage: Overdose and intoxication with benzodiazepines, including ONFI, may lead to CNS depression, associated with drowsiness, confusion and lethargy, possibly progressing to ataxia, respiratory depression, hypotension, and, rarely, coma or death. The risk of a fatal outcome is increased in cases of combined poisoning with other CNS depressants, including alcohol [see Overdosage]. Management of Overdosage: The management of ONFI overdose may include gastric lavage and/or administration of activated charcoal, intravenous fluid replenishment, early control of airway and general supportive measures, in addition to monitoring level of consciousness and vital signs. Hypotension can be treated by replenishment with plasma substitutes and, if necessary, with sympathomimetic agents. The efficacy of supplementary administration of physostigmine (a cholinergic agent) or of flumazenil (a benzodiazepine antagonist) in ONFI overdose has not been assessed. The administration of flumazenil in cases of benzodiazepine overdose can lead to withdrawal and adverse reactions. Its use in patients with epilepsy is typically not recommended [see Management of Overdosage]. Lundbeck Deerfield, IL 60015, U.S.A. ONFI is a registered trademark of Lundbeck November 2013 CLB-L-00001a 3

6 4 Upsher-Smith Laboratories, Inc., 6701 Evenstad Drive, Maple Grove, MN Upsher-Smith Laboratories, Inc

7 Booth 823 5

8 FRIDAY November 30, 2007 UCB welcomes you to AES Visit us at booth 205 for exciting new information on VIMPAT for your patients. VIMPAT is a registered trademark under license from Harris FRC Corporation. 2014, UCB, Inc., Smyrna, GA All rights reserved. LCM-PRM

9 Visit the AES Booth to 1 in 3 readers take action as a result of reading AES Connections in their inbox every other Friday Socialize Watch Video Interviews Review Publications See Live Demos Learn More About AES See You at Booth #125 in the Exhibit Hall AES Connections Become an Engaged Member AES Career Center Your hub for hundreds of jobs, maximum exposure to top opportunities, and highly qualified applicants Clinical and research positions for epilepsy and neurology professionals Easy-to-use and highly targeted resources for online employment connections Access to the National Healthcare Career Network (NHCN), connecting you to the career centers of over 290 top healthcare associations and professional organizations....great Conversation...Connected Community...Different Perspectives Share Yours Today AES Connect connect.aesnet.org careers.aesnet.org 7

10 WELCOME MESSAGE Welcome to Seattle and our 68th AES Annual Meeting! To previous attendees, we are thrilled to have you back. To first time attendees, it is a pleasure to welcome you into the AES Community. As you settle in and start off your week, I encourage you to take notice of the energy within the convention center. I like to refer to the Annual Meeting as the Annual Reunion, a time when colleagues, friends and even family, reunite under the common goal to cure the epilepsies. I assure you that your time in Seattle will be filled with learning, networking and fun. Don t forget to connect with the larger AES Community on Twitter #aesmtg14. Within this program book you will find a broad schedule of programs, exhibits, social events and networking opportunities that invite your participation. Quality educational sessions have been organized by your AES Annual Meeting and Scientific Program Committees targeted to the professional needs and wide interests of meeting attendees. This year s lineup of programs was carefully selected based on your feedback: Poster Walking Tours Take a stroll through the Exhibit Hall and experience an enhanced learning opportunity as authors present their posters throughout the week. Enjoy this feature of the AES meeting by joining one of the popular Poster Walking Tours led by thought leaders. See page 15 for the schedule. Fellows Program We are proud to continue the AES Epilepsy Fellows Program, which supports 95 trainees in epilepsy fellowships, and 10 Ph.D.s doing epilepsy research. Fellows are paired with mentors for career guidance and support, giving them the opportunity to learn and connect with others throughout the meeting. Social Networking Groups SIG, Investigators Workshops and symposium participants have a greater opportunity to meet and continue group discussions during social networking hours on Sunday from 8:00 p.m. to 10:00 p.m. Annual Meeting Mobile App Access meeting information. Network with fellow attendees. Even organize your schedule at your fingertips! If you have not done so already, download the AES Annual Meeting App to your smartphone. I invite you to join me at that this year s Presidential Symposium, The AES International Biomarker Competition: The Crowd, the Cloud, Detection and Prediction, taking place on Saturday, December 6 from 8:30 a.m. to 11:45 a.m. Together we will find out who the winners are and their novel solutions in seizure detection and prediction. This session is a must see, I guarantee it! Have a great meeting! Elson So, M.D. President, American Epilepsy Society 2014 AES BOARD OF DIRECTORS PRESIDENT Elson L. So, M.D. FIRST VICE PRESIDENT Amy Brooks-Kayal, M.D. SECOND VICE PRESIDENT Michael D. Privitera, M.D. TREASURER William D. Gaillard, M.D. PAST PRESIDENT Jacqueline A. French, M.D. BOARD MEMBERS Bruce E. Hermann, Ph.D. David M. Labiner, M.D. Jack M. Parent, M.D., Ph.D. Helen E. Scharfman, Ph.D. Shlomo Shinnar, M.D., Ph.D. Karen S. Wilcox, Ph.D. EX-OFFICIO Eileen M. Murray, MM, CAE, AES Executive Director Brandy Fureman, Ph.D. (NIH/NINDS) Philip Gattone (Epilepsy Foundation) Sheryl Haut, M.D. (North American Commission / ILAE) Robert E. Hogan, M.D. (Education) Jaideep Kapur, M.D., Ph.D. (Development) Kimford J. Meador, M.D. (Research) Joseph I. Sirven, M.D. (Epilepsy Foundation PAB) Carl E. Stafstrom, M.D., Ph.D. (Epilepsy Currents) William H. Theodore, M.D. (Communications & MOC Liaison) James W. Wheless, M.D. (Clinical Council & AAN Liaison) 8

11 TABLE OF CONTENTS Meeting Information FRIDAY SATURDAY Schedule-at-a-Glance...12 Poster Walking Tours...15 Poster Schedule...17 AES Special Recognition...18 Berry, Grass and Nurse Awardees...20 Young Investigator Awardees...21 Special Interest Group Schedule...22 Scientific Exhibit Schedule...23 Exhibitor Locations...82 Abstract Author Index...93 General Information Faculty Ready Room and Photos Epilepsy Specialist Symposium...28 Annual Fundamentals of Epilepsy Symposium th Annual Advances in the Management of Epilepsy and the Epilepsy Clinic...29 Professional Development in AES...29 Special Interest Group Meetings...29 Hoyer Lecture...30 Spanish Symposium...30 Special Interest Group Meetings...30 Mentoring Session for Junior Investigators...32 Special Interest Group Meetings...32 Presidential Symposium...33 Antiepileptic Therapy Symposium...33 Investigators Workshop...34 Professionals in Epilepsy Care Symposium...34 North American Commission Symposium...35 Poster Session Watch for these 2015 dates! Annual Meeting Call for Abstracts Available March 1, 2015 AES Research Recognition and Distinguished Achievement Awards Nominations August 1, 2015 TABLE OF CONTENTS SUNDAY Investigators Workshops...47 Annual Course...49 Special Interest Group Meetings...50 Social Networking Groups...50 Poster Session AES 2015 Annual Meeting December 4-8 Philadelphia, PA Pennsylvania Convention Center MONDAY Special Interest Group Meetings...61 Merritt-Putnam Symposium...61 Special Interest Group Meetings...62 Lennox and Lombroso Lecture...62 Investigators Workshop...63 FDA Town Hall Update...63 Pediatric Epilepsy Highlights Session...63 Pediatric State of the Art Symposium...64 Platform Sessions...65 Poster Session TUESDAY Special Interest Group Meetings...77 Hot Topics Symposium...78 Scientific Symposium...78 AES is an ACCME accredited provider. 9

12 Lighten your load and receive session handouts and important meeting information electronically! Accounts have been pre-created for all pre-registered attendees. On-site registrants may sign up online. For instructions: Please refer to the flyer provided in your meeting bag or for further details go to annual_meeting/general_info Questions virtualtotebag Support Desk: Go here: annual_meeting/meeting_app The AES Annual Meeting is at your fingertips! Stay up to the minute about sessions, schedules, conversations and activities at the 68th Annual Meeting. #AESMTG14 official meeting hashtag Wi-Fi available throughout Convention Center (except in the Exhibit Hall and Poster Sessions) American Epilepsy Society 10

13 is proud to recognize the following supporters of the 2014 Annual Meeting. Benefactor Level $500,000 + Sunovion Pharmaceuticals, Inc. Leader Level $250,000 $499,999 Eisai, Inc. UCB, Inc. Partner Level $100,000 $249,999 Lundbeck Pharmaceuticals, Inc. Upsher-Smith Laboratories, Inc. Supporter Level $50,000 $99,999 Cyberonics, Inc. Natus Neurology Incorporated Supernus Pharmaceuticals, Inc. Mallinckrodt Pharmaceuticals Acorda Therapeutics Contributor Level $25,000 $49,999 Nihon Kohden America, Inc. Cadwell Laboratories, Inc Compumedics Limited Pfizer Inc. Advocate Level $10,000 $24,999 Neuropace, Inc. ELEKTA Electrical Geodesics, Inc. GW Pharmaceuticals Medtronic, Inc. Blackrock Microsystems, LLC Patron Level $5,000 $9,999 Rhythm Link Ad-Tech Medical Instrument Corp. Monteris Medical, Inc. Medical Neurogenetics, LLC Nexstim, Inc. Neurolynx, Inc. PMT Corporation Ripple LLC Lifelines Neurodiagnostics Systems, Inc. The Jack Pribaz Foundation Listing is in order of support level as of October XX, 2014 Listing is in order of support level as of October 21,

14 SCHEDULE-AT-A-GLANCE THURSDAY December 4 5:00 p.m. - 7:00 p.m. Registration Convention Center South Lobby, Level 4 FRIDAY December 5 7:00 a.m. - 6:00 p.m. Registration Convention Center South Lobby, Level 4 8:30 a.m. - 11:30 a.m. Epilepsy Specialist Symposium: The Generalized Epilepsies Convention Center Ballroom 6E, Level 6 12:30 p.m. - 3:00 p.m. Annual Fundamentals of Epilepsy Symposium: The Side Effects of Epilepsy Treatment Convention Center Ballroom 6E, Level 6 1:30 p.m. - 3:00 p.m. Professional Development in AES: A Program for Junior Members and Those in Transition Convention Center Room 603, Level 6 Special Interest Group Meetings See page 29 3:30 p.m. - 5:30 p.m. Hoyer Lecture Convention Center Ballroom 6E, Level 6 3:30 p.m. - 6:00 p.m. Spanish Symposium: Complementary and Alternative Approaches to Epilepsy Treatments Convention Center Room 612, Level 6 5:30 p.m. - 6:15 p.m. Symposia Break Convention Center Level 6 6:00 p.m. - 7:30 p.m. Special Interest Group Meetings See page 30 SATURDAY December 6 6:30 a.m. - 6:00 p.m. Registration Convention Center South Lobby, Level 4 6:30 a.m. - 7:00 a.m. Continental Breakfast Convention Center Level 6 7:00 a.m. - 8:30 a.m. Mentoring Session for Junior Investigators Convention Center Room 307 / 308, Level 3 7:00 a.m. - 8:30 a.m. Special Interest Group Meetings See page 32 8:30 a.m. - 11:45 a.m. Presidential Symposium: The AES International Biomarker Competition: The Crowd, the Cloud, Detection and Prediction Convention Center Ballroom 6C, Level 6 Noon - 6:00 p.m. Exhibit Hall Grand Opening Convention Center Hall 4B, Level 4 Poster Session 1 Convention Center Hall 4B, Level 4 Lunch: Noon - 1:00 p.m. 2:15 p.m. - 5:00 p.m. Antiepileptic Therapy Symposium: The New AEDs: Where Do They Belong in Your Armamentarium? Convention Center Ballroom 6C, Level 6 2:30 p.m. - 4:00 p.m. Investigators Workshop Convention Center Ballroom 6E, Level 6 5:00 p.m. - 6:00 p.m. Symposium Break Convention Center Hall 4B, Level 4 5:15 p.m. - 7:45 p.m. Professionals in Epilepsy Care Symposium: Practical Applications for the Comprehensive Treatment of Epilepsy Convention Center Ballroom 6C, Level 6 5:30 p.m. - 7:30 p.m. North American Commission Symposium: Pediatric Epilepsy Surgery: Update on Current Practice Convention Center Ballroom 6E, Level 6 7:00 p.m. - 10:00 p.m. Third Annual Wine Tasting and Silent Auction See page 27 SUNDAY December 7 7:30 a.m. - 6:00 p.m. Registration Convention Center South Lobby, Level 4 8:00 a.m. - 5:00 p.m. Scientific Exhibits See page 23 8:00 a.m. - 6:00 p.m. Poster Session 2 (includes late-breaking abstracts) Continental Breakfast Convention Center Hall 4B, Level 4 8:45 a.m. - 4:45 p.m. Investigators Workshops IW Posters / Boxed Lunch: Noon - 1:30 p.m. See page 47 8:45 a.m. - 5:15 p.m. Annual Course: Seizures and EEG in the Critically Ill Patient Convention Center Ballroom 6C, Level 6 10:00 a.m. - 6:00 p.m. Exhibit Hall Reception: Suds for Science 5:00 p.m. - 6:00 p.m. Convention Center Hall 4B, Level 4 6:00 p.m. - 7:30 p.m. Special Interest Group Meetings See page 50 8:00 p.m. - 10:00 p.m. Social Networking Groups Sheraton Madrona, Second Floor 12

15 SCHEDULE-AT-A-GLANCE MONDAY December 8 6:30 a.m. - 6:00 p.m. Registration Convention Center South Lobby, Level 4 6:30 a.m. - 7:00 a.m. Continental Breakfast Convention Center Level 6 7:00 a.m. - 8:30 a.m. Special Interest Group Meetings See page 61 8:00 a.m. - 3:00 p.m. Poster Session 3 Continental Breakfast Convention Center Hall 4B, Level 4 8:00 a.m. - 5:00 p.m. Scientific Exhibits See page 23 8:45 a.m. - Noon Merritt-Putnam Symposium: Stress, Cannabinoids and Epilepsy: The Science Behind the Buzz Convention Center Ballroom 6C, Level 6 9:00 a.m. - 10:30 a.m. Special Interest Group Meetings See page 62 10:00 a.m. - 3:00 p.m. Exhibit Hall Convention Center Hall 4B, Level 4 2:15 p.m. - 3:00 p.m. Lennox and Lombroso Lecture Convention Center Ballroom 6C, Level 6 3:00 p.m. - 4:30 p.m. Investigators Workshop Convention Center Room 607, Level 6 3:00 p.m. - 5:00 p.m. FDA Town Hall Update: SUDEP and Clinical Trials Convention Center Room 612, Level 6 3:00 p.m. - 5:15 p.m. Pediatric Epilepsy Highlights Session Convention Center Ballroom 6E, Level 6 Platform Sessions (3 Concurrent) See page 65 5:00 p.m. - 5:30 p.m. Symposia Break Convention Center Level 6 5:30 p.m. - 8:00 p.m. Pediatric State of the Art Symposium: Long-term Outcomes of Neonatal Seizures Convention Center Ballroom 6C, Level 6 SCHEDULE-AT-A-GLANCE TUESDAY December 9 6:30 a.m. - 11:00 a.m. Registration Convention Center South Lobby, Level 4 6:30 a.m. - 7:00 a.m. Continental Breakfast Convention Center Level 6 7:00 a.m. - 8:30 a.m. Special Interest Group Meetings See page 77 8:45 a.m. - 10:45 a.m. Hot Topics Symposium: Epilepsy Updates Convention Center Ballroom 6C, Level 6 Scientific Symposium: The Epidemiology, Pathophysiology & Prevention of SUDEP Convention Center Ballroom 6E, Level 6 Suds for Science and Exhibit Hall Reception Sunday, December 7 5:00 p.m. 6:00 p.m. Convention Center Hall 4B, Level 4 Network with attendees from around the world at the general reception in the Exhibit Hall. Join us for appetizers and visit Sunovion Pharmaceuticals at Booth #105 to receive your complimentary drink tickets. A portion of the funds received from support and beverage sales will benefit the Lennox and Lombroso Trust. EQUIPMENT AUCTION TO BENEFIT: The Lennox and Lombroso Trust for Research & Training and The Susan S. Spencer Fund for Clinical Education and Research AES thanks Natus for participating in the equipment auction. Supported by Sunovion Pharmaceuticals, Inc. 13

16 EQUIPMENT AUCTION TO BENEFIT: The Lennox and Lombroso Trust for Research & Training and The Susan S. Spencer Fund for Clinical Education and Research EEG Machine Becomes Research Dollars for AES For six years, Nihon Kohden has pioneered a unique giving program by auctioning off its EEG-1200 machine and donating 100 percent of the proceeds to the Lennox and Lombroso Trust for Research & Training and the Susan S. Spencer Fund for Education and Research. This year, Dignity Health Neurological Institute of Northern California (Sacramento) is the EEG-1200 Auction winner at $23, Nihon Kohden executives will present a check to the American Epilepsy Society on Saturday, December 6 at 1:00 p.m. on the floor of the Exhibit Hall. AES thanks Nihon Kohden Booth #617 for their continued support and for again participating in the annual equipment auction. We also thank those that participated in the bidding. The American Epilepsy Society is pleased to announce INNOVATION PAVILIONS located inside the Exhibit Hall Convention Center Hall 4B, Level 4 These pavilions offer companies an opportunity to provide education and training to Annual Meeting attendees in a convenient and more personal environment. The Innovation Pavilions will be open on the following days: Saturday, December 6: Noon 6:00 p.m. Sunovion Pharmaceuticals, Inc. (A) Lundbeck Pharmaceuticals, Inc. (B) NeuroPace, Inc. (C) Cyberonics, Inc. (D) Sunday, December 7: 10:00 a.m. 6:00 p.m. Sunovion Pharmaceuticals, Inc. (A) Lundbeck Pharmaceuticals, Inc. (B) NeuroPace, Inc. (C) Cyberonics, Inc. (D) Monday, December 8: 10:00 a.m. 3:00 p.m. Eisai, Inc. (C) 14

17 Poster Walking Tours Convention Center Exhibit Hall 4B, Level 4 The Poster Walking Tours will take place on the days noted below, beginning at 12:15 p.m. each day, and tours will depart every 10 minutes. Join AES leaders and visit interesting, compelling or novel posters and discuss perspectives on how the presented data is meaningful. Leaders and participants will meet and gather at the Poster Information table near the front of the Poster Hall. Announcements will be made in the Poster Hall prior to each tour departure. A schedule of topics and tour leaders will be available at the Poster Information Table. POSTER SESSION 1: Saturday, December 6 Poster tour leaders: David Prince, Andres Kanner, Jean Gotman, Bruce Hermann, Karen Wilcox POSTER SESSION 2: Sunday, December 7 Poster tour leaders: Jackie French, Ilo Leppik, Steve Roper, Joseph Sirven, Andrew Cole POSTER SESSION 3: Monday, December 8 Poster tour leaders: Anne Anderson, Greg Bergey, Dennis Spencer, Kimford Meador, Eric Kossoff Poster tour leaders are subject to change Participate in the AES PASSPORT TO PRIZES PROGRAM Join us in the Epilepsy Resource Center (located in the Exhibit Hall) for daily prize drawings and a grand prize drawing on Monday, December 8. Prize Drawing Schedule: SATURDAY, DECEMBER 6 Prize Drawing 5:30 p.m. SUNDAY, DECEMBER 7 Prize Drawing 5:30 p.m. MONDAY, DECEMBER 8 Prize Drawing & Grand Prize Drawing 2:30 p.m. In your AES Annual Meeting bag, as well as the virtualtotebag, you will find a Passport brochure. To be included in the drawing to win a variety of great prizes, visit the booths of participating exhibitors to get your Passport validated. The more exhibitors you visit, the better your chances. Please complete your contact information and drop the passport in the raffle drum located in the Epilepsy Resource Center. Participants must be present to win. See your Passport for a list of participating exhibitors. 15

18 applause fellow insight colleague inspire COLLABORATION COMMUNITY friend THANKYOU mentor mentee innovation catalyst admiration GRATITUDE appreciation CARING Show your appreciation to Someone Who... è Has influenced your career or your work in epilepsy è Is someone you admire è Has been a great colleague or collaborator è Is celebrating a personal or professional milestone The Community of Caring pin symbolizes the collaborative energy, the community spirit and the supportive professional exchange among AES members. Pins are available for sale at the AES Booth #125 in the Exhibit Hall. All proceeds will benefit the AES New Initiatives Fund, supporting research and education to advance the prevention, treatment and cure of epilepsy. Those who purchase and receive pins will be recognized in a special way during the Annual Meeting. Community of Caring Pin 16

19 POSTER SCHEDULE Detailed map of the Poster Hall is available in the virtualtotebag and at the Poster Information Table Saturday, December 6 Poster Session 1: Noon 6:00 p.m. Convention Center, Hall 4B, Level 4 (see pages 36-46) Authors Present: Noon 2:00 p.m. Poster Walking Tours: 12:15 p.m. 1:45 p.m. (see page 15) Translational Research Behavior / Neuropsychology / Language Genetics Neuropathology of Epilepsy Neurophysiology Clinical Epilepsy Neuroimaging Comorbidity (Somatic and Psychiatric) Antiepileptic Drugs Surgery POSTER SCHEDULE Sunday, December 7 Poster Session 2: 8:00 a.m. 6:00 p.m. Convention Center, Hall 4B, Level 4 (see pages 51-60) Authors Present: Noon 2:00 p.m. Poster Walking Tours: 12:15 p.m. 1:45 p.m. (see page 15) Behavior / Neuropsychology / Language Health Services , Practice Resources Epidemiology Public Health History of Epilepsy Case Studies Professionals in Epilepsy Care Neurophysiology Clinical Epilepsy Neuroimaging Comorbidity (Somatic and Psychiatric) Antiepileptic Drugs Surgery Investigators Workshop Lunch Poster Session Noon 1:30 p.m. Convention Center Room 6F, Level 6 (see pages 47-48) Monday, December 8 Poster Session 3: 8:00 a.m. 3:00 p.m. Convention Center, Hall 4B, Level 4 (see pages 66-75) Authors Present: Noon 2:00 p.m. Poster Walking Tours: 12:15 p.m. 1:45 p.m. (see page 15) Translational Research Behavior / Neuropsychology / Language Genetics Neuropathology of Epilepsy Epidemiology Neurophysiology Clinical Epilepsy Neuroimaging Antiepileptic Drugs Non-AED / Non-Surgical Treatments Surgery Abstract Author Index see pages

20 AES SPECIAL RECOGNITION AES Service Award Co-Recipients Friday, December 5 3:30 p.m. Convention Center Ballroom 6E, Level 6 (Immediately preceding the Hoyer Lecture) AES Service Award Co-Recipients Friday, December 5 3:30 p.m. Convention Center Ballroom 6E, Level 6 (Immediately preceding the Hoyer Lecture) Robert L. Ruff, M.D., Ph.D. Dr. Robert Ruff is a Professor of Neurology and Neurosciences at Case Western Reserve University. He has been the VA s National Director for Neurology for eight years. Dr. Ruff received his M.D. and Ph.D. in Physiology and Biophysics from the University of Washington. He did his Neurology Residency at New York Hospital Cornell Medical Center. Served as Chief of Neurology at the Cleveland VAMC, Chairman of the Neurology Field Advisory Committee, and oversaw the operations of the six Parkinson s Disease Research, Educational, and Clinical Centers (PADRECC), four Epilepsy Centers of Excellence (ECoE), and the two Multiple Sclerosis Centers of Excellence (MSCoE). Under his direction, the ECoEs, PADRECC and MSCoE developed into national neurology care networks with more than 50 sites in each of the networks. Dr. Ruff developed the ECoE program in response to a request from Congress. Under his leadership, the ECoE program passed through a trail period which demonstrated its value to veterans and the ECoE program will be continuously funded. In addition, Dr. Ruff served as the VA s Acting Director, Rehabilitation Research and Development Service. Dr. Ruff is Medical Director of the Functional Stimulation Center at Case Western Reserve University School of Medicine. He also serves as the Deputy Editor, Journal of Rehabilitation Research and Development. Karen L. Parko, M.D. Dr. Karen Parko is a Professor of Neurology at the University of California, San Francisco (UCSF), and the National Director of the Veterans Affairs Epilepsy Centers of Excellence. She is a retired Commissioned Officer from the United States Public Health Service (USPHS). Dr. Parko received a B.A. degree in Psychobiology from New York University and an M.D. degree from the F. Edward Hebert School of Medicine at the Uniformed Services University in Bethesda, M.D. Following an internship in Internal Medicine at the Washington Hospital Center in Washington, D.C., she completed a residency in Neurology at UCSF. After residency she worked in the Indian Health Service as a solo neurologist for ten years on the Navajo reservation, where she established the reservation s first neurology clinic, providing adult and pediatric neurology services and neurodiagnostic testing to this population of nearly 300,000. Dr. Parko has been involved in disaster and humanitarian relief medicine and served as a medical officer aboard NOAA vessel McArthur during its Stenella Mission in the Eastern Pacific. Dr. Parko serves on the National Professional Advisory Board of the Epilepsy Foundation and previously chaired the Professional Advisory Board of the Northern California Chapter. She has received many awards for her work including being named the Public Health Service Clinical Physician of the Year in 2001, was a finalist for The Frank Brown Berry Prize in Federal Healthcare in 2003, and she received the Epilepsy Foundation of Northern California s Commitment to Progress Award in The American Epilepsy Society Epilepsy Research Recognition Awards are given annually to active scientists and clinicians working in all aspects of epilepsy research. The awards are designed to recognize professional excellence reflected in a distinguished history of research of important promise for the improved understanding and treatment of epilepsy. The awards of $10,000 each are part of the AES grant and fellowship program. Award for Basic Science Saturday, December 6 8:30 a.m. Convention Center Ballroom 6C, Level 6 (Immediately preceding the Presidential Symposium) Award for Clinical Science Saturday, December 6 8:30 a.m. Convention Center Ballroom 6C, Level 6 (Immediately preceding the Presidential Symposium) Carolyn R. Houser, Ph.D. Dr. Carolyn Houser is Professor of Neurobiology in the David Geffen School of Medicine at the University of California, Los Angeles. She received her Doctoral degree in Anatomy from UCLA, and completed postdoctoral training in the Division of Neuroscience at the City of Hope Research Institute, Duarte, CA. Dr. Houser then joined the Comprehensive Epilepsy Program at the VA Greater Los Angeles Healthcare System and the faculty of the Department of Neurobiology at UCLA. Dr. Houser s research has focused on neuroanatomical alterations and plasticity in epilepsy. Her studies provided the first descriptions of granule cell dispersion in patients with temporal lobe epilepsy and contributed to the early descriptions of mossy fiber sprouting in humans with epilepsy. Dr. Houser s studies have been published in leading journals of neuroscience, neurology and epilepsy, and have provided a neuroanatomical foundation for numerous electrophysiological and neurochemical studies in the field. Dr. Houser is strongly committed to education in neuroscience and has received numerous teaching awards. Her service to the profession has includes AES Committees boards and Committees of the Epilepsy Foundation, NIH and other epilepsy-related organizations, and Chair of a recent Gordon Research Conference. Ruth Ottman, Ph.D. Dr. Ruth Ottman is Professor of Epidemiology (in Neurology and the Sergievsky Center), Deputy Director for Research, Gertrude H. Sergievsky Center, Columbia University, and Research Scientist, Division of Epidemiology, New York State Psychiatric Institute. She is also Deputy Director of the Columbia Center for Research on Ethical, Legal, and Social Implications of Psychiatric, Neurologic, and Behavioral Genetics. She received her B.A. in zoology and Ph.D. in genetics from the University of California at Berkeley, and has been at Columbia University throughout her career. Dr. Ottman is a genetic epidemiologist whose research addresses the role of inherited factors in susceptibility to neurologic disorders, primarily focusing on epilepsy. Her research group was the first to recognize the epilepsy syndrome autosomal dominant epilepsy with auditory features and to identify LGI1 as a major susceptibility gene for the disorder. She developed and validated several research instruments for standardized data collection on epilepsy in large-scale studies. She has recently begun to focus on the clinical and psychosocial impact of genetic information on individuals with epilepsy and their family. She is a major collaborator in the Epilepsy Phenome / Genome Project and in the Epi4K Center without Walls for Collaborative Research in the Epilepsies. 18

21 AES SPECIAL RECOGNITION J. Kiffin Penry Excellence in Epilepsy Care Award Saturday, December 6 2:15 p.m. Convention Center Ballroom 6C, Level 6 (Immediately preceding the AET Symposium) Joyce A. Cramer, B.S. Joyce A. Cramer is now a consultant after a career in basic and clinical research at Yale University School of Medicine. She also served as President and Chief Scientific Officer of Epilepsy Therapy Project, a non-profit organization providing grants and investments for new epilepsy therapies. Joyce worked in pre-clinical research before initiating several decades of work in clinical trials. She developed methods for the evaluation of drug efficacy and adverse effects, study design and management, and enhancement of medication compliance and persistence, as well as instruments to assess quality of life, treatment satisfaction and other patientreported outcomes for various medical disorders. The QOLIE quality of life instruments, Seizure Severity Questionnaire (SSQ), and Systemic and Neurotoxicity Scales are widely used in research around the world. A current focus is on development of the Personal Impact of Epilepsy Scale (PIES). Her publications include five books, more than 200 peer-reviewed papers, and numerous book chapters covering a variety of topics. She is a frequent lecturer and consultant on these topics. Joyce served as AES Treasurer and on the AES Board of Directors. She was Chair of the Board of Trustees of the Lennox Trust Fund. She has served on the Boards of Directors of the International Society for Pharmacoeconomics and Outcomes Research and the Society for Clinical Trials, as well as the Editorial Boards of Epilepsia and Epilepsy & Behavior and currently of Acta Neurologica Scandinavica. She has received the ILAE International Ambassador Award and the AES Service Award. William G. Lennox Award Monday, December 8 8:45 a.m. Convention Center Ballroom 6C, Level 6 (Immediately preceding the Merritt-Putnam Symposium) A $10,000 award is provided by the Lennox and Lombroso Trust Fund Hans O. Lüders, M.D., Ph.D. Dr. Hans O. Lüders is Professor of Neurology and staff at the Epilepsy Center, Case Medical School, Cleveland, OH. He received his degree in medicine from the Catholic University, Santiago, Chile and trained in neurology at the Neurological Institute, Kyushu University, Fukuoka, Japan. He joined the Mayo Clinic as a clinical fellow in Electroencephalography and received a Ph.D. in Neurophysiology from the University of Minnesota. He trained under Prof. Eli Goldensohn at the Neurological Institute in New York. He became head of the Epilepsy Center at the Department of Neurology, Cleveland Clinic Foundation where he served as Chairman of Neurology until he moved to University Hospital, Case Medical Center, to lead and develop the epilepsy program. Dr. Lüders established the intensive course in Epilepsy and Clinical Neurophysiology and developed the highly specialized Epilepsy Surgery Program which are now offered at the Cleveland Clinic and at University Hospitals. He has edited of more than 19 books including the most advanced Textbook of Epilepsy Surgery. Dr. Lüders established the Cleveland Clinic International Epilepsy Symposia and the International Epilepsy Colloquia sponsored by France, Germany, England and Cleveland, OH. He developed an original, strictly semiological classification of epileptic seizures and the original description of several semiological seizure types as well as identified several cortical centers by electrical stimulation of the human brain. Dr. Lüders pioneered the use of subdural electrodes in the presurgical evaluation of epilepsy surgery in the 1980s and is supporting the introduction from Europe of depth electrodes in the U.S. Extraordinary Contributions Award Monday, December 8 2:15 p.m. Convention Center Ballroom 6C, Level 6 (Immediately preceding the Lennox and Lombroso Lecture) Karen Gale, Ph.D. Awarded posthumously The AES community was saddened by the recent passing of, Karen Gale, Ph.D., Professor in the Department of Pharmacology & Physiology at Georgetown University. During her more than 35 years at Georgetown, Dr. Gale left an indelible mark as a researcher, educator and stalwart advocate for faculty, students and staff. Dr. Gale was a widely recognized expert in seizure circuitry, and the mechanisms of seizure-induced brain damage and neuroprotection. She was an NIH-funded researcher for more than 20 years, and the founding director of Georgetown s Interdisciplinary Program in Neuroscience (IPN) that has 50 faculty members from 11 departments campus-wide. AES selected Dr. Gale for her pioneering research on the critical roles of subcortical structures, including the substantia nigra, and on seizure control and propagation that has been seminal in shaping the understanding about the distributed nature of seizures and how they might be controlled, and her recent work on comorbidities of epilepsy including deleterious effects of antiepileptic compounds on neural development. Dr Gale was also recognized for her tireless commitment to the development of early career investigators, women and minority scientists in the epilepsy community through mentorship and advocacy. Lennox and Lombroso Lecturer Monday, December 8 2:15 p.m. Convention Center Ballroom 6C, Level 6 Anne Berg, Ph.D. Dr. Anne Berg received her Ph.D. from Yale University in The focus of her research for over 25 years has been in the area of pediatric seizures and epilepsy with a specific emphasis on seizure outcomes, developmental and cognitive consequences, the impact on quality of life and the implications of all of these considerations for care and care-models. She is the lead investigator of the NINDS-funded Connecticut Study of Epilepsy which spanned two decades and is providing an unprecedented understanding of the impact of childhood epilepsy later in early adulthood. In 2007, she played a key role in focusing NINDS research priorities on the cognitive, developmental, and behavioral comorbidities of epilepsy and has organized sessions at American Epilepsy Society meetings to investigate these areas and identify research opportunities for improving patients outcomes. Dr. Berg was Co-Chair of the 2013 NINDS-sponsored Curing Epilepsies conference and also organized and led the workshop, Priorities in Pediatric Epilepsy Research: Improving Children s Futures Today held in Chicago, November She helped spearhead the formation of the Pediatric Epilepsy Research Consortium (PERC) which has grown to 37 centers nationwide and is laying the foundation and creating the infrastructure for practice-changing clinical research to improve the diagnosis, treatment, and outcomes of children with pediatric epilepsies. Dr. Berg received a Jacob K. Javits Neuroscience Investigator Award from NINDS in 2007 and the American Epilepsy Society Research Recognition Award for Clinical Research, AWARDEES 19

22 SUZANNE AND PETER BERRY INTERNATIONAL TRAVEL AWARDEES This award is given to recognize and honor two young investigators doing research in clinical neuroscience related to epilepsy in Asia, Africa, Oceania, Middle East or Latin America by supporting travel to present research at the AES Annual Meeting. Contact Author Abstract Title Poster Leyla Baysal Kirac, M.D. Importance Of Routine Ictal Heart Rate Analysis In Drug Resistant Epilepsies: Possible Prediction of Patients at Risk For SUDEP Rie Sakuraba, M.H.Sc. High-Rate REM Sleep High Frequency Oscillations (HFOs) Are Specific To Epileptogenicity GRASS YOUNG INVESTIGATOR AWARDEES This award is intended to recognize and honor outstanding young investigators conducting research in basic or clinical neuroscience related to epilepsy. Awardees are selected from young investigators who submit an accepted abstract. The Grass Foundation and the American Epilepsy Society have combined resources to present these awards to eight deserving candidates to help support travel costs to present their research at the Annual Meeting of the American Epilepsy Society. The award is composed of a $1,000 travel stipend, a waiver of AES meeting registration fees and recognition during the Hoyer Lecture on Friday, December 5. Congratulations to the following awardees: Contact Author Abstract Title Poster / Platform Chad R. Frasier, Ph.D. Dravet Syndrome Patient-Derived Induced Pluripotent Stem Cell Cardiac Myocytes C.02 Have Increased Sodium Current Density And Increased Beating Rate Ethan M. Goldberg, M.D., Ph.D. A Novel Mouse Model Of Chromosome Xq22.1 Deletion Syndrome Displays Epilepsy C.06 And Cortical Circuit Dysfunction SeokJun Hong, M.Sc. Automated Detection Of Cortical Dysplasia In MRI-Negative Epilepsy: B.04 Class II Diagnostic Evidence Lawrence Hsieh, Ph.D. New Model Of Focal Cortical Dysplasia Associated Epilepsy Esther Krook-Magnuson, Ph.D. Cerebellar Control Of Spontaneous Seizures In A Mouse Model Of Temporal Lobe Epilepsy C.03 Lena H. Nguyen, B.S. Late Inhibition Of mtor Suppresses Fully Established Epilepsy And Associated Neuropathology In The NS-Pten KO Mouse Model Of Cortical Dysplasia Vineet Punia, M.D., M.S. Factors Influencing Driving Impairment In Persons With Refractory Epilepsy A.02 Jacy Wagnon, Ph.D. Seizures And SUDEP In A Mouse Knock-In Model Of SCN8A Related Epileptic Encephalopathy C.09 NURSE AWARDEES Contact Author Abstract Title Poster Rachael Mealey, M.S.N., CRNP Improving Quality Of Care Following EMU Discharge Kimberly Orton, RN To Coordinate Or Not To Coordinate? Guinevere T. Que, NP Pregnancy And Seizures: Review Of Practice At George Washington University In The Past 5 Years Patsy Ramey, MSN, RN Unexplained Spikes In Lamotrigine Serum Concentration Suggest Nonlinear Elimination Kinetics In Some Individuals Acknowledgment: Nurse awards are supported by Eisai Inc. 20

23 YOUNG INVESTIGATOR AWARDEES Poster / Contact Author Abstract Title Platform Karlene T. Barrett, Ph.D. TRPV1 Receptors Modulate The Expression Of Experimental Febrile Seizures During Development In Mice Monica Dhakar, M.D. Broadband Intracranial Ictal EEG Analysis In Lesional And Non-lesional Pharmacoresistant Epilepsy Dario J. Englot, M.D., Ph.D. Factors Associated With Failed Extra-Temporal Lobe Epilepsy Surgery Alejandra M. Fernandez, B.S. A 35% Triheptanoin Diet Reduces Spontaneous Electrographic Seizures In Pilocarpine-Induced Epileptic Mice AWARDEES Federica Frigerio, Ph.D. Pro-Resolving Receptors ChemR23 and ALXR Expression During Epileptogenesis In Mice Stephen Gliske, Ph.D. Generalized, Automated Algorithm For Detecting HFOs And The Extent Of The Seizure Onset Zone Abhijeet Gummadavelli, B.A. Thalamic Deep Brain Stimulation To Improve Consciousness After Seizures Se Hee Kim, M.D. Adaptive Function In Dravet Syndrome Seongtaek Lee, M.S, B.S. Investigation Of White Matter Integrity In Patients With Psychogenic Non-Epileptic Seizures Tiffani L. McDonough, M.D. Prediction Of Future Epilepsy In Neonates Who Received Selective Head Cooling For HIE Rawad Obeid, M.D. The Application Of Conventional EEG For Early Prognosis In Infants Born With Hypoxic Ischemic Encephalopathy Undergoing Hypothermia Reesha R. Patel, B.S. Epilepsy-Associated Mutant Voltage-Gated Sodium Channels Alter Resurgent Current Generation That Could Be Preferentially Targeted With Cannabidiol Sandra Petty, M.B.B.S, FRACP Ph.D. Carbamazepine Inhibits Native Sodium Currents In Murine Osteoblasts Craig A. Press, M.D., Ph.D. Parental Reporting Of Response To Oral Cannabis Extracts As Adjunctive Treatment For Medically Refractory Epilepsy Rajsekar R. Rajaraman, M.D. Predictive Model For Early Posttraumatic Seizures In The PICU A.09 Udaya K. Seneviratne, FRACP Electroencephalographic Correlates Of Seizure Freedom In Genetic Generalized Epilepsies Kyle Thomson, Ph.D. Use Of An Automated-Feeding System For The Testing Of Potential Anticonvulsant Compounds In Chronic Epileptic Rats Ebru Nur Vanli-Yavuz, M.D. How Different Are Patients With Bilateral Hippocampal Sclerosis From The Unilateral Ones? Matthew Weston, Ph.D. Hyperactivation Of mtor Signaling In A Two-Neuron Microcircuit Alters The Dynamics Of Synaptic Transmission Jennifer Wong, Ph.D. Selective Targeting Of Scn8a Expression Confers Seizure Resistance In Two Mouse Models Of Refractory Epilepsy Ackowledgment: Young Investigator Awards are supported by Eisai Inc. and Medtronic, Inc. 21

24 SPECIAL INTEREST GROUP SCHEDULE Friday, December 5: 1:30 p.m. 3:00 p.m. Basic Mechanisms: Inflammation, Microglia and Their Role in Neuronal and Dendritic Homeostasis (Convention Center Room 620, Level 6) Neuroimaging: MRI Normalcy A Moving Target! (Convention Center Room 607, Level 6) Quality, Value and Safety: Improving the Epilepsy Monitoring Unit (Convention Center Room 617, Level 6) Friday, December 5: 6:00 p.m. 7:30 p.m. Cognitive and Behavioral Interventions for Epilepsy: PNES Case Reports and Underlying Mechanisms (Convention Center Room 607, Level 6) EEG: Dense Array EEG and EEG Source Localization in Clinical Practice (Convention Center Room 609, Level 6) Head Trauma and Military Epilepsy Care: Practical Guide to Caring for Epilepsy Patients in the VA System (Convention Center Room 620, Level 2) Junior Investigators: Mentorship (Convention Center Room 615, Level 6) Neuropharmacology: Medication Discontinuation Post Surgery: To Do or Not to Do? (Convention Center Room 617, Level 6) SUDEP: Hot Topics in SUDEP (Convention Center Room 603, Level 6) Saturday, December 6: 7:00 a.m. 8:30 a.m. Basic Neuroscience: Brain Mosaicism in Epilepsy (Convention Center Room 607, Level 6) Children s Hour: Dravet Syndrome in 2014 (Convention Center Room 609, Level 6) Ictal Semiology Cases: How Semiology Helps to Localize the Seizure Onset Zone and Elucidate the Propagation Pattern (Convention Center Room 612, Level 6) Neurostimulation and Neuroengineering: New Developments (Convention Center Room 603, Level 6) Private Practice: How to Survive with Private Epilepsy Centers in the Changing Health Care Environment (Convention Center Room 617, Level 6) Psychiatry in Epilepsy: Aggression in People with Epilepsy, Diagnosis and Treatment Issues (Convention Center Room 615, Level 6) Sunday, December 7: 6:00 p.m. 7:30 p.m. Drug Resistant Epilepsy Definition, Epidemiology, Predictors, Using Big Data for Epidemiological Research (Convention Center Room 617, Level 6) Frontal Lobe Epilepsy: Semiology and Cognitive Aspects (Convention Center Room 608, Level 6) MEG / MSI Source Imaging (MSI) Source Localization Results: Blind Faith, Black Art, or Scientific Method? (Convention Center Room 620, Level 6) Neonatal Seizures: Should We Pursue Comparative Effectiveness Studies for the Treatment of Neonatal Seizures? (Convention Center Room 609, Level 6) Neuroendocrinology: Sex Differences in Epileptogenesis (Convention Center Room 613, Level 6) Pediatric Case Discussions (Convention Center Room 612, Level 6) Psychogenic Nonepileptic Seizures: What Can We Learn From PNES Semiology? (Convention Center Room 615, Level 6) Monday, December 8: 7:00 a.m. 8:30 a.m. Ketogenic Diet: Does the Ketogenic Diet Offer a Cure for Epilepsy? (Convention Center Room 613, Level 6) Neuropsychology: Can We Spare Memory With Newer Surgical Approaches for Temporal Lobe Epilepsy? Emergent Outcome Data from Laser Ablation, Multiple Hippocampal Transection, and Fornix DBS (Convention Center Room 609, Level 6) NINDS and Non-Profit Research Resources (Convention Center Room 620, Level 6) Nursing (Convention Center Room 608, Level 6) Status Epilepticus Are We Over-Treating Status Epilepticus, and Especially, Nonconvulsive Status Epilepticus? (Convention Center Room 612, Level 6) Monday, December 8: 9:00 a.m. 10:30 a.m. NEW Epilepsy and Aging (Convention Center Room 620, Level 6) Surgery: Surgical Failure in Pediatric and Adult Epilepsy: The Slam Dunk Case that Wasn t! (Convention Center Room 609, Level 6) Tuberous Sclerosis: Thinking Outside the Tuber in TSC (Convention Center Room 612, Level 6) Tuesday, December 9: 7:00 a.m. 8:30 a.m. Critical Care (ICU EEG Monitoring): Controversies in ICU EEG Interpretation and Management (Convention Center Room 612, Level 6) Genetics: Personalized Epilepsy Diagnosis and Treatment (Convention Center Room 613, Level 6) NEW Global Health in Epilepsy: How Can You Get Involved? (Convention Center Room 603, Level 6) Practice Management (Convention Center Room 618, Level 6) Sleep and Epilepsy: Sleep Polygraphy Monitoring in the EMU: Are We Missing A Diagnostic / Therapeutic Opportunity? (Convention Center Room 606, Level 6) Temporal Lobe Club: The Thalamus in Epilepsy Player or Bystander? (Convention Center Room 620, Level 6) Tumor Induced Epilepsy Meningiomas (Convention Center Room 604, Level 6) Women s Issues: Controversies in Caring for Women with Epilepsy (Convention Center Room 615, Level 6) 22

25 SCIENTIFIC EXHIBIT SCHEDULE Scientific exhibits will be on display at this year s annual meeting and will be located in Rooms 603, 604, 607, 612 and 615 on Level 6 of the Washington State Convention Center. These exhibits will provide meeting attendees an opportunity to update themselves on the latest research. Authors will be present throughout the exhibit. Sunday, December 7 8:00 a.m. 11:00 a.m. Room Cyberonics, Inc. 603 VNS Therapy : Foundational Treatment for Drug-Resistant Epilepsy Lundbeck Pharmaceuticals, Inc. 607 Research Updates for Antiepileptic Therapies Clobazam, Vigabatrin, and IV Carbamazepine UCB, Inc. 612 Continuing UCB s Long-Term Commitment to Epilepsy Management Sunday, December 7 8:00 a.m. 5:00 p.m. EQUIGEN 604 Equivalence Among Generic Antiepileptic Drugs: Research Funded by FDA, AES, and Epilepsy Foundation Monday, December 8 8:00 a.m. 11:00 a.m. Upsher-Smith Laboratories, Inc. 603 Upsher-Smith CNS Update Sunovion Pharmaceuticals, Inc. 607 Aptiom (eslicarbazepine acetate) Scientific Exhibit Room Sage Therapeutics 615 Clinical Progress of SAGE-547 in Status Epilepticus and Advances in Next-Generation Neurosteroids Monday, December 8 8:00 p.m. 5:00 p.m. EQUIGEN 604 Equivalence Among Generic Antiepileptic Drugs: Research Funded by FDA, AES, and Epilepsy Foundation 23

26 S! R E T C A R A H C F O T S A C R U O JOIN WALK FOR AES RESEARCH & TRAINING RAISE FUNDS FOR EPILEPSY RESEARCH & TRAINING The National Walk for Epilepsy Washington, D.C. April 11, 2015 Walk with your colleagues! Join Lorna Myers, Nathan Fountain, Patrice Jackson-Ayotunde, Dennis Spencer, Martin Penry, Elson So, Jaideep Kapur, Mike Privitera, Jacqueline French, Patty Shafer, and many others for the 2015 National Walk for Epilepsy. All funds raised by AES Teams Support AES Research and Training efforts even virtual teams can participate! Teams can support any AES fund: Spencer, Lennox and Lombroso, Dreifuss, Penry, Goldberg-Kaufman and New Initiatives Fund. Raise the most money and win the AES trophy! Sign up or get more information today! Contact Kathy Hucks at x512 or khucks@aesnet.org. 24

27 Your place for ongoing professional education in epilepsy. ELI is the new AES online tool offering quick access to: Relevant CME-based programs for epilepsy Tailored Self-Assessments in Epilepsy (SAEs) Rich archived educational content Easy portal to AES partner projects for epilepsy Organized records for self-directed learning It s all here at: aesnet.org/professional_education AES is an ACCME accredited provider. 25

28 Join Today! WHY JOIN THE AMERICAN EPILEPSY SOCIETY? The American Epilepsy Society serves as a resource for its membership and the epilepsy community by providing access to data on the latest breakthroughs, technologies and methodologies in epilepsy research. The American Epilepsy Society promotes interdisciplinary communication, scientific investigation and exchange of clinical information about epilepsy. Membership in AES opens doors to educational sessions, networking and knowledge-sharing among its members and Annual Meeting attendees. Become a member today by going to or visit the AES Booth #125 at the AES Annual Meeting located in the Exhibit Hall. AES MEMBERS ARE: Adult Neurologists Advanced Practice Nurses Basic Science Researchers Clinical Researchers Consultants Doctors of Osteopathic Medicine Doctors of Veterinary Medicine Emergency Room Physicians Epileptologists Fellows Government/Regulatory Internists Licensed Practical Nurses Neurosurgeons Non-Profit Staff Nutritionists Office Managers Pediatric Neurologists Pharmacists Pharmacologists Presidents/CEOs in Industry Industry/Marketing Professionals Psychiatrists Psychologists Physicians Assistants Registered Nurses Residents Social Workers Students Technologists and Others AES MEMBERS RECEIVE: Epilepsy Currents, the official journal of AES Epilepsia, the official journal of ILAE Reduced annual meeting registration fees Discounted subscriptions to scientific journals Listing in Find-A-Doctor online directory Network with members through AES Connect Members-only discussion blogs Research funding opportunities Distinguished Achievement and Research Recognition Awards Weekly e-newsletters with relevant, timely news Full service career center 26

29 Raise Your Glass for the... Third Annual Wine Tasting & Silent Auction Join your friends, colleagues and hosts Mike Privitera, Greg Bergey and Dennis Spencer in an evening to benefit the Susan S. Spencer Fund and Lennox and Lombroso Trust Featuring locally sourced cuisine and hand-selected regional wines for your enjoyment. Saturday, December 6th 7:00 PM to 10:00 PM Where: 1927 EVENTS rd Avenue, Seattle, WA a short stroll from the Convention Center! Purchase your tickets today at the solutions counter at the registration desk, Convention Center, South Lobby, Level 4. More than 12,000 people visit the AES website each month -- are you one of them? The NEW AES website features: Fresh news and daily updates Dynamic content Online community forum for AES members Mobile friendly content Learning and research opportunities JOIN US ON THE AES SITE TODAY! 27

30 AES Fellows Program Friday, December 5, 2014 The goal of the AES Fellows program is to encourage and support epilepsy fellows in training to attend the AES Annual Meeting where they will receive the latest updates in clinical and basic science research. A breakfast and lunch will be provided to allow fellows the opportunity to meet and pair with mentors who will provide guidance regarding career planning, potential research paths, and clinical endeavors. Following the breakfast the fellows will attend the Epilepsy Specialist Symposium and the Annual Fundamentals of Epilepsy Symposium, as well as the Hoyer Lecture. A panel of experts will present and discuss their experiences in the fields of research, and clinical and private practice. This program is supported by UCB, Inc., Eisai, Inc., Supernus Pharmaceuticals, Inc., Upsher-Smith Laboratories, Inc. and Acorda Therapeutics. 8:30 a.m. 11:30 a.m. Epilepsy Specialist Symposium: The Generalized Epilepsies (3.0 CME Credits) Convention Center Ballroom 6E, Level 6 12:30 p.m. 3:00 p.m. Annual Fundamentals of Epilepsy Symposium: The Side Effects of Epilepsy Treatment (2.5 CME Credits) Convention Center Ballroom 6E, Level 6 28 Overview This symposium will address current knowledge regarding generalized epilepsies including idiopathic, symptomatic and progressive generalized epilepsies. Faculty will address current understanding of their pathophysiology, review data regarding prognosis and criteria for diagnosis, and discuss management options for patients with generalized epilepsies. Learning Objectives u u u Develop treatment plans and provide counseling based on current understanding of the pathophysiology of generalized epilepsies and their prognosis Apply current criteria in diagnosing generalized epilepsies Recognize behavioral and cognitive comorbidities of generalized epilepsies and provides appropriate interventions. Target Audience Basic and Intermediate (see page 120 for details) Program Chair: Michael R. Sperling, M.D. 8:30 a.m. Introduction Michael R. Sperling, M.D. 8:45 a.m. Pathophysiology of the Generalized Epilepsies Solomon L. Moshé, M.D. 9:15 a.m. Seizure Types and Syndromes in the Generalized Epilepsies Prakash Kotagal, M.D. 9:45 a.m. Prognosis of the Generalized Epilepsies Katherine Nickels, M.D. 10:15 a.m. Treatment of the Idiopathic Generalized Epilepsies Michael S. Duchowny, M.D. 10:45 a.m. Treatment of Symptomatic and Progressive Generalized Epilepsies Sandra L. Helmers, M.D., M.P.H. 11:15 a.m. Case Studies and Conclusions Michael R. Sperling, M.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 3.0 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 3.0 contact hours (0.3 CEUs). UAN L01-P. Initial Release Date: 12/5/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Epilepsy Specialist Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Practice-based Learning and Improvement, and Medical Knowledge Acknowledgment This program is supported by an educational grant from Eisai, Inc. Overview This activity will provide comprehensive information about the potential side effects of different epilepsy therapies, not limited to the usual side effects of antiepileptic drugs. Included will be a synopsis of the adverse effects that can be encountered from treatment of seizures and epilepsy providing a comprehensive overview that will assist in tailoring treatment to individual patients. The speakers will discuss antiepileptic drug side effects; side effects of acute treatments for epilepsy (especially status epilepticus); side effects of devices that provide neuromodulation (VNS, RNS, DBS); side effects of epilepsy surgery evaluation and epilepsy surgery; and side effects of other treatments (diet, hormones, cannabinoids, herbal medications). Learning Objectives u Implement appropriate medical treatment based on improved understanding of potential adverse effects of treatment options u Refer patients earlier in course of treatment for consideration of surgery or for use of a device for seizure control u Counsel patients more knowledgeably about the potential adverse effects of their treatment and helps identify potential hazards arising from treatment u Help patients communicate effectively about their care, including identifying previously unrecognized adverse effects of their treatment u Identify treatment-related cognitive and emotional adverse effects of newly emergent and alternative treatments. Target Audience Basic and Intermediate (see page 120 for details) Program Co-Chairs: Elinor Ben-Menachem, M.D., Ph.D. and Tracy A. Glauser, M.D. 12:30 p.m. Introduction Tracy A. Glauser, M.D. 12:40 p.m. Antiepileptic Drug Side Effects Eugen Trinka, M.D., M.Sc. 1:05 p.m. Side Effects of Acute Treatments for Epilepsy David M. Treiman, M.D. 1:30 p.m. Side Effects of Devices (VNS, RNS, DBS) Robert S. Fisher, M.D., Ph.D. 1:55 p.m. Side Effects of Epilepsy Surgery Evaluation and Epilepsy Resective Surgery Mary L. Zupanc, M.D. 2:20 p.m. Side Effects of Other Treatments (Diet, Hormones, Cannabinoids, Herbal Medications) Kristen Park, M.D. 2:45 p.m. Conclusions Elinor Ben-Menachem, M.D., Ph.D. Continued on page 29

31 FRIDAY December 5, 2014 Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.5 contact hours for this session. Nurse Practitioners may claim 1.5 hours of pharmacology for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN L01-P. Initial Release Date: 12/5/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Annual Fundamentals of Epilepsy Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Patient Care, Medical Knowledge and System-based Practice Acknowledgment This program is supported by an educational grant from UCB, Inc., Eisai, Inc. and Lundbeck Pharmaceuticals, Inc. with additional support from Supernus Pharmaceuticals, Inc. and Cyberonics, Inc. separate registration required see below for instructions 9:00 a.m. 3:15 p.m. 28th Annual Advances in the Management of Epilepsy and the Epilepsy Clinic Sheraton Metropolitan Ballroom A, Level 3 This session will be useful to trainees, basic scientists, clinicians and other allied health professionals (nurses, psychologists, Pharm.D.s) who want to know more about AES organizational structure or who want to become more involved. The session will provide an overview of the professional development and volunteering opportunities within the Society, followed by short presentations by members active in AES leadership. The session will end with a chance to meet with AES staff and committee leaders to learn more about available opportunities. 1:30 p.m. 3:00 p.m. Special Interest Group Meetings Location listed under each session Basic Mechanisms: Inflammation, Microglia and Their Role in Neuronal and Dendritic Homeostasis Convention Center Room 620, Level 6 Coordinators: Amy L. Brewster, Ph.D., Dane M. Chetkovich, M.D., Ph.D. Speakers: Sookyong Koh, M.D., Ph.D., Robert S. Fujinami, Ph.D., Viji Santhakumar, Ph.D. Activation of inflammatory mechanisms that include recruitment of reactive microglia and associated signaling molecules such as cytokines and complement cascade activation, among others, are often seen in surgical resections from individuals with epilepsy and have been widely described before, during, and after seizures in experimental models. The goal of this session is to discuss potential mechanisms by which inflammatory mediators may contribute to pathological epileptogenic changes in the brain. Neuroimaging: MRI Normalcy A Moving Target! Convention Center Room 607, Level 6 Coordinators: Matthias J. Koepp, M.D., Ph.D., Neda Bernasconi, M.D., Ph.D. Speakers: Boris Bernhardt, M.D., R. Edward Hogan, M.D., William D. Gaillard, M.D. FRIDAY This intensive, one-day conference is designed for those professionals who participate in the care of persons with epilepsy. The overall purpose is to improve services to individuals and families affected by epilepsy. The conference is presented by the Department of Neurology of Wake Forest University School of Medicine, Winston-Salem, North Carolina, through an unrestricted grant committed to the education of health professionals, in an effort to promote the comprehensive care of those with epilepsy and their families. Registration for this program is done separately from the AES Annual Meeting and begins on September 1, You may register by calling Wake Forest School of Medicine at Up to 5.0 AMA Category 1 CME credit will be given. 1:30 p.m. 3:00 p.m. Professional Development in AES: A Program for Junior Members and Those in Transition Convention Center Room 603, Level 6 The American Epilepsy Society invites all interested meeting attendees to come to a special session on volunteer and leadership opportunities within the Society. AES has a variety of programs year round to improve the care and treatment of patients with epilepsy. These efforts include education for basic scientists and clinicians, research grant programs, leadership and organizational activities, community outreach and advocacy. Greater participation in the Society offers members extensive career development opportunities by providing a chance to hone leadership skills, to network with other AES members and outside funding organizations, and most importantly, to make significant contributions to improve the lives of patients with epilepsy. About 30% of patients with electrographic evidence of temporal lobe epilepsy (TLE) have normal MRI scans. The location of the seizure focus is unclear in this patient population. Possibilities include (i) a subtle form of hippocampal sclerosis that is not apparent on MRI; (ii) alterations in synaptic or receptor physiology not visible on MRI; or (iii) pathology not detected by MRI, such as certain forms of cortical dysplasia. Patients with MRI- negative TLE may be candidates for additional neuroimaging techniques including advanced MR imaging with novel acquisition or post-processing techniques, MRS, PET, and SPECT. Peri-ictal imaging may increase the yield to detect abnormalities. This SIG will focus on the management of MRI-normal TLE, emphasizing the neuroimaging perspective. Quality, Value and Safety: Improving the Epilepsy Monitoring Unit Convention Center Room 617, Level 6 Coordinator: Katherine Noe, M.D., Ph.D. Speakers: Gabriel U. Martz, M.D., Nathalie Jetté, M.D., Khara M. Sauro, Ph.D., Janice Walbert, R.EEG/EPT This year s SIG will focus on current efforts to improve the quality, safety, and value of care provided in epilepsy monitoring units. Reduction in 30-day readmission rates is an ongoing focus of quality improvement efforts for all hospitalized patients, and influences payments to hospitals from the Centers for Medicare and Medicaid Services. Dr. Gabriel Martz, from the Medical University of South Carolina will present his research into EMU readmissions. Continuing prior discussions on ways to improve the patient experience in the EMU, Dr. Nathalie Jetté and colleague Dr. Khara Sauro will discuss their unique experience with a multidisciplinary EMU Quality Improvement Team at the University of Calgary. Finally, Janice Walbert, Executive Director of ABRET, will describe their challenges / successes to date in developing and implementing certification of EEG laboratories. Time will be available for audience questions and discussion. 29

32 FRIDAY December 5, :30 p.m. 5:30 p.m. 12th Judith Hoyer Lecture in Epilepsy: Reshaping Epilepsy As a Spectrum Disorder: Implications for Clinical Care, Research and Education Convention Center Ballroom 6E, Level 6 Presentation: Robert L. Ruff, M.D., Ph.D. and Karen L. Parko, M.D., AES Service Awards, NINDS Update Lecturer: Frances Jensen, M.D. The 12th Judith Hoyer Lecture in Epilepsy, presented by invited Lecturer Dr. Frances Jensen, is sponsored by the National Institute of Neurological Disorders and Stroke. Dr. Jensen s presentation is the twelfth in a series of lectures highlighting the promise of epilepsy research. This series is held in memory of Mrs. Judith Hoyer, an active member of the Board of Directors of the Epilepsy Foundation and the late wife of Representative Steny Hoyer (D-MD). Mrs. Hoyer spent her life both helping families to cope with epilepsy and promoting research into a cure and a better quality of life for those with the disorder. The purpose of the lecture is to raise awareness of epilepsy among researchers and the public and provide intellectual stimulation that will encourage continuing progress toward finding a cure for epilepsy. Supported in part by Upsher-Smith Laboratories, Inc. and NINDS. 3:30 p.m. 6:00 p.m. Spanish Symposium: Complementary and Alternative Approaches to Epilepsy Treatments (2.5 CME Credits) Convention Center Room 612, Level 6 Overview This symposium will present an overview on the role of neurostimulation, diet, vitamins and other supplements, herbal therapies, non-conventional medical treatments (acupuncture, cannabis, others), and psychological and Mind-body therapies (biofeedback, meditation, yoga, relaxation techniques) in the treatment of epilepsy. Treatment paradigms and evidence-based approach will be addressed. As a result of attending this symposium, the attendee will recognize alternative treatments when managing patients with medically refractory epilepsy and become familiar with current evidence and rationale for their use, allowing for consideration of neurostimulation and other available alternative treatment options. Learning Objectives u Utilize newer as well as established treatments such as neurostimulation, dietary therapy and other alternative methods as therapeutic options in refractory epilepsy u u Counsel families regarding neurostimulation and alternative therapies based on currently defined indications Treat patients with refractory epilepsy through use of alternative treatments not previously considered u Recognize the value of treating refractory epilepsy through use of new techniques such as mind-body techniques and psychological therapy. Target Audience Basic and Intermediate (see page 120 for details) Program Co-Chairs: Patricio E. Abad, M.D. and Mario A. Alonso-Vanegas, M.D. 3:30 p.m. Introduction Patricio E. Abad, M.D. 3:40 p.m. Neurostimulation for Epilepsy David King-Stephens, M.D. 4:10 p.m. Dietary Measures, Vitamins and Other Supplements, Herbal Therapies Carlos Medina-Malo, M.D. 4:40 p.m. Non-conventional Medical Treatments, Mind-body Therapies Blanca Vazquez, M.D. 5:10 p.m. Round Table Mario A. Alonso-Vanegas, M.D., Patricio Abad, M.D. 5:50 p.m. Conclusions Mario A. Alonso-Vanegas, M.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.5 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN L01-P. Initial Release Date: 12/5/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Spanish Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Patient Care, Medical Knowledge, Practice-based Learning and System-based Practice 6:00 p.m. 7:30 p.m. Special Interest Group Meetings Location listed under each session Cognitive and Behavioral Interventions for Epilepsy: PNES Case Reports and Underlying Mechanisms Convention Center Room 607, Level 6 Coordinators: Lauren Frey, M.D., Marcio Sotero de Menezes, M.D., Rosa Michaelis, M.D., Steven C. Schachter, M.D., Siegward M. Elsas, M.D. Speakers: Ivan Osorio, M.D., W. Curt LaFrance, Jr., M.D., M.P.H., Janelle Wagner, Ph.D. Cognitive behavioral therapy, mind body approaches, and multimodal educational interventions have consistently demonstrated positive effects on patient well-being. Nevertheless, the evidence for their effects on seizure control remains inconsistent, which is partly attributable to the methodological difficulties inherent in rigorously testing these interventions. In the first part of this SIG, Dr. Osorio will present observations from invasive EEG monitoring that inform the hypothesis for a possible physiological antiseizure mechanism of cognitive tasks. In the second part, we will review case-based tools that may help SIG participants identify suitable candidates for behavioral interventions, select appropriate interventions and monitor intervention outcomes. A number of experienced therapists will demonstrate how their therapeutic approaches would work in practice. Dense Array EEG and EEG Source Localization in Clinical Practice Convention Center Room 609, Level 6 Coordinators: Kitti Kaiboriboon, M.D., Susan T. Herman, M.D. Speakers: Susan T. Herman, M.D., Kitti Kaiboriboon, M.D., Serge Vulliemoz, M.D. This SIG will review the use of dense array (64 or more channels) EEG and EEG source localization for routine EEG and epilepsy monitoring. Routine EEG using 21 scalp electrodes has excellent temporal but relatively poor spatial resolution,

33 FRIDAY December 5, 2014 limiting its utility in localization of epileptiform activity and seizures. Recent advances in amplifier technology and electrode technology now allow recording of channels of EEG. EEG source imaging (ESI) is a model-based imaging technique that determines the inverse EEG solution, or the generating source of electrical potentials recorded on the scalp. Improved ESI software can now build realistic head models based on individual patients MRIs, perform source localization, and co-register results to imaging studies in less time and without need for programming skills. These advances now put dense array EEG and ESI tools in the hands of clinical electroencephalographers, but the clinical utility of these techniques has not yet been fully explored. Speakers will debate the pros and cons of dense array EEG in comparison to other techniques used for epilepsy diagnosis and localization. Head Trauma and Military Epilepsy Care: Practical Guide to Caring for Epilepsy Patients in the VA System Convention Center Room 620, Level 6 Coordinators: Tung Tran, M.D., Jonathan Halford, M.D., Enrique A. Feoli, M.D., Joseph Drazkowski, M.D. Speakers: Tung Tran, M.D. and Kenneth R. Perrine, Ph.D. We will discuss how epilepsy care in the VA system is different from epilepsy care outside of a Veterans Affairs Medical Center (VAMC). Specifically, we will discuss (1) how the VA medication formulary system works on a local VAMC and national level and changes to the formulary for 2014 (2) technical challenges to setting up a neurophysiology lab in a VAMC (3) the structure of VA administration and how to request expansion of services for epilepsy care at your VAMC and (4) an update on progress to develop the VA Epilepsy Centers of Excellence (ECoEs) and what services they can provide non-ecoe VAMCs. This SIG is designed to dovetail with a book, VA Epilepsy Manual that is being prepared now (editor Aatif Husain, M.D.) and will be published a few months before this SIG and will be handed out at this SIG meeting. Junior Investigators: Mentorship Convention Center Room 615, Level 6 Coordinators: William Stacey, M.D., Ph.D. and Mackenzie Cervenka, M.D. Speakers: Kevin J. Staley, M.D., Gregory K Bergey, M.D., Frances E. Jensen, M.D. Whether you are a clinician, a researcher, or both, effective mentorship is critical to your academic success. Our interactive panel will discuss and answer questions about finding and utilizing mentors at this early stage in your career. Topics will include the importance of mentorship in grant proposals, finding faculty positions, and collaborations. This panel discussion is independent of the AES mentoring program, which attendees are also encouraged to attend. Neuropharmacology: Medication Discontinuation Post Surgery: To Do or Not to Do? Convention Center Room 617, Level 6 Coordinators: Jeannine Conway, Pharm.D., M.D. and Laura Strom, M.D. Speakers: Laura Strom, M.D. and Pei Shieen Wang, Pharm.D. This SIG brings together individuals in a debate format with an interest in anticonvulsants and optimizing their use. This year s session will address the decision to discontinue anticonvulsants post surgery; encouraging audience participation. We will also discuss the practical challenges that can occur as medication is being withdrawn, including adverse reactions and medication interactions. Upon completion of the session, the participant should be able to present reasonable options to their patients about making a decision about medication discontinuation. SUDEP: Hot Topics in SUDEP Convention Center Room 603, Level 6 Coordinators: Elizabeth J. Donner, M.D. and Lawrence J. Hirsch, M.D. Speakers: TBA Our understanding of SUDEP is moving forward thanks to a broad range of research including animal models, the search for clinical biomarkers, and collaborative work with coroners, medical examiners and device developers. This year, we will delve into hot topics with experts in the field. Speakers and topics will be selected based on cutting-edge SUDEP-related research presented at this AES meeting and at the recent Partners Against Mortality in Epilepsy (PAME) conference. Ample time will be allowed for discussion with audience members. Supported by Sunovion Pharmaceuticals, Inc. FRIDAY Get Your Annual Meeting CME / CE Credit Online Go to See page 120 for details 31

34 AES 68 TH ANNUAL MEETING Seattle, WA SATURDAY December 6, :00 a.m. 8:30 a.m. Mentoring Session for Junior Investigators Convention Center Room 307 / 308, Level 3 Pre-application required This program is targeted to fellows, postdoctoral researchers, instructors and assistant professor level junior faculty. Epilepsy professionals at the Associate Professor level will volunteer to serve as mentors. Accepted applicants will meet with their assigned mentors during this time. 7:00 a.m. 8:30 a.m. Special Interest Group Meetings Location listed under each session Basic Neuroscience: Brain Mosaicism in Epilepsy Convention Center Room 607, Level 6 Coordinators: Martin Gallagher, M.D., Ph.D., Laura A. Jansen, M.D., Ph.D. Speakers: Annapurna Poduri, M.D., Laura A. Jansen, M.D., Ph.D., Kathleen Millen, Ph.D., Franck K. Kalume, Ph.D. The speakers will present an overview of genetic mosaicism in the brain, studies of mosaic PI3K/AKT pathway mutations in human brain malformations, and animal models of PI3K/AKT pathway activation. Implications for the diagnosis and treatment of epilepsy in patients with malformations of cortical development will be highlighted, and plenty of time will be available for audience questions and discussion. Children s Hour: Dravet Syndrome in 2014 Convention Center Room 609, Level 6 Coordinators: Elaine C. Wirrell M.D., Lieven Lagae, M.D., Ph.D. Speakers: Joseph Sullivan, M.D., Sarah Weckhuysen, M.D., Rima Nabbout, M.D., Ph.D. In recent years, considerable progress has been made in the diagnosis and treatment of Dravet syndrome. The speakers will focus on these clinically relevant new achievements and present the key clinical features, guide us through the complex genetic background and discuss the newer treatment options in this drug-resistant childhood epilepsy syndrome. The goal of this SIG is to be able to recognize a young child with Dravet Syndrome, to order the right genetic testing and to apply standard and newer treatment options. Supported by Acorda Therapeutics and GW Pharmaceuticals. Ictal Semiology Cases How Semilogy Helps to Localize the Seizure Onset Zone and Elucidate the Propagation Pattern Convention Center Room 612, Level 6 Coordinators: Phillipe Kahane, M.D., Ph.D., Charles A. Szabo, M.D. Speakers: Charles A. Szabo, M.D., Philippe Kahane, M.D., Ph.D., Hans O. Lüders, M.D., Ph.D., Andrew Bleasel, M.D. We will be presenting 4-8 cases of patients undergoing epilepsy surgery. The cases will be primarily discussed in strong interaction with the audience based on seizure semiology, to show how the careful analysis of subjective and observable clinical elements help to localize the seizure onset zone and to reconstruct the propagation pattern. The final explanation will be briefly given at the end of each case presentation, based on intracranial EEG and / or surgical result. Neurostimulation and Neuroengineering: New Directions Convention Center Room 603, Level 6 Coordinators: Christopher DeGiorgio, M.D., Catherine Schevon, M.D., Ph.D., Steven J. Schiff, M.D., Ph.D. Speakers: Marom Bikson, Ph.D., Robert Fisher, M.D., Ph.D., Selim Benbadis, M.D. The SIG will focus on the following topics: Transcranial Magnetic Stimulation for the Treatment of Epilepsy Seizure Detection Devices: Detection Strategies, Sensitivity, and Clinical Impact; Controversies in Neurostimulation : An Interactive Debate with Audience Participation. The topics will be followed by a period of interactive discussion. Private Practice: How to Survive with Private Epilepsy Centers in the Changing Health Care Environment Convention Center Room 617, Level 6 Coordinators: Marcelo E. Lancman, M.D., Pavel Klein, M.D. Speakers: John S. Ebersole, M.D., David J. Anschel, M.D., Thomas H. Swanson, M.D. We will discuss several topics related to the ability of private practice centers to survive and thrive in the fast-changing healthcare environment. First, we will discuss the dramatic changes underway in many communities of large academic institutions and hospital chains buying out private practice physicians and how this may impact private epilepsy centers in terms of competition, referral patterns, hospital access, and hospital and insurance contract negotiations. Second, we will discuss the impact of ACA on the practice of epilepsy at private centers the competing forces of decreased utilizations (increased co-pays and physician access restriction vs. potential increased coverage of previously uninsured patients with epilepsy); and the flux/chaos (changes in insurance policies and insurance among insured patients). Third, we will address the increased burden on time and resources of both insurance and governmental requirements of medication and procedure authorizations and denials, which have accelerated remarkably in the last months. Fourth, to end on a positive note, we will highlight possibilities for how to compete in this changing environment, e.g. by offering highly specialized services such as MEG by virtue of greater control over resources, and of routine services at better access by virtue of flexibility and responsiveness; and how in in both areas, super-specialized epilepsy care and the routine epilepsy care private centers can have a competitive advantage over large academic centers and hospital chains. Supported by Acorda Therapeutics. Psychiatry in Epilepsy: Aggression in People with Epilepsy, Diagnosis and Treatment Issues Convention Center Room 615, Level 6 Coordinators: John J. Barry, M.D., Rochelle Caplan, M.D. Speakers: Mary Wojnaroski, Ph.D., Michael Kerr, M.B.ChB., FRCPSYCH Aggressive behaviors in individuals with epilepsy have been a controversial topic. The association of aggression or violence with epilepsy has been debated despite being reproduced in some animal models and may have significant psychological and environmental consequences. The Psychiatric SIG will focus on 1) Evidence-based diagnostic and treatment options for aggressive behaviors in children and adolescents and 2) Aggression in adults appearing in the post-ictal state, especially affiliated with comorbid psychosis and finally 3) Aggression seen in individuals with developmental delay. The format of the SIG will utilize cases for both children and adults as a nidus for group discussion. Supported by Sunovion Pharmaceuticals, Inc. 32

35 SATURDAY December 6, :30 a.m. 11:45 a.m. Presidential Symposium: The AES International Biomarker Competition: The Crowd, the Cloud, Detection and Prediction (2.25 CME Credits) Convention Center Ballroom 6C, Level 6 Presentation: Carolyn R. Houser, Ph.D. and Ruth Ottman, Ph.D., Research Awards, ILAE Update Overview This symposium will address the role of electrophysiological biomarkers in diagnosis, localization, and prediction of focal seizures and epilepsy. We review the current state of the art of electrophysiological biomarkers in epilepsy. Utilizing a large electrophysiology database (NIH-sponsored International EEG Database) the concepts of data-sharing, large-scale computation, and reproducible research will be introduced. Specific applications using electrophysiological biomarkers to predict epilepsy (epileptogenesis), predict seizures (ictogenesis), and map the epileptogenic zone will be presented. Algorithms for detection and spatiotemporal mapping of electrophysiological biomarkers from multiple research groups will be presented. The performance of these algorithms will be rigorously evaluated in an open competition applied to large-scale clinical and basic research datasets: 1) Prediction of epilepsy in animal models, 2) Seizure forecasting in dogs and humans, and 3) Localization of epileptogenic zone in humans. The results of the competition between multiple international research groups will be reviewed and awards presented for the best performance for predicting epilepsy, predicting seizures, and mapping the epileptogenic zone. Learning Objectives u u Recognize the role of the International EEG Database in developing spatial and temporal prediction of epilepsy and seizures Understand the physiologic basis of epileptogenesis, understand impact of localization on surgery outcomes and appreciate issues related to research into seizure prediction u Researchers will utilize described approaches with quantitative analysis using large NIH database for developing new research questions and methodology. Target Audience Advanced (see page 120 for details) Program Co-Chairs: Brian Litt, M.D. and Gregory A. Worrell, M.D., Ph.D. 9:30 a.m. Introduction Elson So, M.D. 9:35 a.m. Review Current State of the Art of Electrophysiological Biomarkers Gregory A. Worrell, M.D., Ph.D. 10:05 a.m. Review Current State of the Art of Seizure: Detection and Devices Kathryn Davis, M.D. 10:30 a.m. Review Current State of the Art: Prediction and Devices Mark J. Cook, M.D. 10:55 a.m. NIH International Electrophysiology Database and the Competition Brian Litt, M.D. 11:20 a.m. The Seizure Detection & Prediction Contest Benjamin Brinkmann, Ph.D. 11:40 a.m. Conclusions Brian Litt, M.D., Gregory A. Worrell, M.D., Elson So, M.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.25 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.25 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.25 contact hours (0.25 CEUs). UAN L01-P. Initial Release Date: 12/6/2014. Acknowledgment The International Competition is co-sponsored by the American Epilepsy Society, National Institute of Neurological Disorders and Stroke and the Epilepsy Foundation. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Presidential Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Medical Knowledge 2:15 p.m. 5:00 p.m. Antiepileptic Therapy Symposium: The New AEDs: Where Do They Belong in Your Armamentarium? (2.5 CME Credits) Convention Center Ballroom 6C, Level 6 Presentation: Joyce A. Cramer, J. Kiffin Penry Award Overview This symposium will present an overview of the 8 newest antiepileptic drugs (AEDs) that include clobazam, eslicarbazepine, ezogabine, lacosamide, perampanel, rufinamide, stiripentol, and vigabatrin. Discussion will cover the developmental history of the drug, mechanisms of action, indications for use, efficacy, safety issues, tolerability and ease of use to include drug interactions, formulations and dosing. Treatment paradigms that demonstrate the differential role of the medications will be presented. As a result of attending this symposium, the attendee will have an understanding of how to incorporate the newest AEDs into an integrative treatment algorithm for their clinical practice and will be able to counsel patients and their families regarding risks, benefits and alternatives. Learning Objectives u Recognize opportunities in their clinical practice to use one or more of the eight newest AEDs and appropriately counsel patients regarding risks, benefits and alternatives u u u Participate in counseling patients and their families regarding use of one or more of the eight newest AEDs Assist clinicians in their prescribing of one or more of the eight newest AEDs through an understanding of pharmacology and drug-to-drug interactions Assist in identifying tolerability of adverse effects in the use of one or more of the eight newest AEDs, particularly in reference to cognitive and behavioral outcomes. SATURDAY 33

36 SATURDAY December 6, 2014 Target Audience Basic and Intermediate (see page 120 for details) Programs Co-Chairs: Angus A. Wilfong, M.D. and Jerry J. Shih, M.D. 2:30 p.m. Introduction Angus A. Wilfong, M.D. 2:45 p.m. Ezogabine / Eslicarbazepine Martin J. Brodie, M.D. 3:10 p.m. Stiripentol / Vigabatrin Elinor Ben-Menachem, M.D., Ph.D. 3:35 p.m. Lacosamide / Perampanel John Pollard, M.D. 4:00 p.m. Clobazam / Rufinamide Joan A. Conry, M.D. 4:25 p.m. Integration of New AEDs Into Clinical Practice William E. Rosenfeld, M.D. 4:50 p.m. Conclusions Jerry J. Shih, M.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.5 contact hours for this session. Nurse Practitioners may claim 2.5 hours of pharmacology for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN L01-P. Initial Release Date: 12/6/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Antiepileptic Therapy Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Patient Care and Medical Knowledge Acknowledgment This program is supported by an educational grant from Eisai, Inc., UCB, Inc., Lundbeck Pharmaceuticals Inc. and Sunovion Pharmaceuticals, Inc. 5:15 p.m. 7:45 p.m. Professionals in Epilepsy Care Symposium: Practical Applications for the Comprehensive Treatment of Epilepsy (2.5 CME Credits) Convention Center Ballroom 6C, Level 6 Overview Recent research and practice recommendations include the comprehensive care of persons with epilepsy and their families. Despite this recommendation no guideline exists for comprehensive epilepsy care. This symposium will present recent research and practice evidence to assist interdisciplinary providers about practical ways to provide comprehensive care for persons with epilepsy and their families through the lifespan. Cases will be used to apply interventions to improve health outcomes through early comorbidity screening and health outcomes including: behavioral health screening, behavioral interventions and resources, antiepileptic medication through the lifespan, as well as care of special populations such as veterans and adolescents. Learning Objectives u Recognize when to screen for comorbid epilepsy conditions, initiate appropriate treatment, and refer to the appropriate health care professional u u Participate in providing education, resources, and counseling to persons with epilepsy and their families regarding the comprehensive treatment needs of persons with epilepsy Assist the epilepsy care team / provider in identifying and treating the comorbid conditions and identifying antiepileptic medication issues for children, men, women, and the elderly u Assist the epilepsy care team / provider in identifying and using best screening instruments regarding epilepsy psychiatric / psychological / neurodevelopmental comorbid conditions for persons with epilepsy and their families. Learner will also assist in the practical provision of or access to behavioral treatment of such comorbid conditions. Target Audience Basic and Intermediate (see page 120 for details) Program Co-Chairs: Georgette Smith, Ph.D., APRN, CPNP and Janelle Wagner, Ph.D. 5:15 p.m. Introduction and Case Presentation Georgette Smith, Ph.D., APRN, CPNP 5:30 p.m. Behavioral Health and Cognitive Screening as Part of the Epilepsy Clinic Visit Bruce P. Hermann, Ph.D. 5:50 p.m. Finding Resources and Practical Solutions for Behavioral Interventions Loretta Carbone, M.S.W. SATURDAY 2:30 p.m. 4:00 p.m. Investigators Workshop Convention Center Ballroom 6E, Level 6 Cannabinoids in Epilepsy: Do They Work? If So, How? Moderator: Kamil Detyniecki, M.D. Speakers: Charlotte Hill, Ph.D., Benjamin J. Whalley, BPharm, Ph.D., Orrin Devinsky, M.D. This Investigator Workshop is supported in part by GW Pharmaceuticals. 6:10 p.m. Antiepileptic Therapy: Pediatric, Elderly, Women s and Men s Issues Jeannine Conway, Pharm.D. 6:30 p.m. Special Populations Mary Jo Pugh, Ph.D., RN (Veterans) Jonathan Edwards, M.D. (Adolescents) 7:10 p.m. Review of Cases: Panel Discussion Sandra Cushner Weinstein, M.S.W. 7:30 p.m. Conclusions Janelle Wagner, Ph.D. 34

37 SATURDAY December 6, 2014 Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.5 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN L01-P. Initial Release Date: 12/6/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Professionals in Epilepsy Care Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Professionalism, Practice-based Learning, Interpersonal and Communication Skills and System-based Practice Acknowledgment This program is supported by an educational grant from Eisai, Inc., and UCB, Inc. 5:30 p.m. 7:30 p.m. North American Commission Symposium: Pediatric Epilepsy Surgery: Update on Current Practice (2.0 CME Credits) Convention Center Ballroom 6E, Level 6 Overview This symposium will present an overview of pediatric epilepsy surgery presenting, in part, data from the ILAE Pediatric Epilelpsy Surgery Task Force. This symposium will address criteria for when to refer, what constitutes pediatric epilepsy surgery, what are effective outcome measures, the social impact and co-morbities of pediatric epilepsy surgery syndromes, and the emergence of non-profit parent groups to influence care and practice in the field. Learners will be provided with established criteria for diagnosis of intractable pediatric epilepsy. Learning Objectives u Determine which pediatric patients are candidates for epilepsy surgery based on international standards suggested by the ILAE Pediatric Epilepsy Surgery Task Force u Refer pediatric patients for epilepsy surgery based on international experience Programs Chair: Gary W. Mathern, M.D. 5:30 p.m. Introduction Gary W. Mathern, M.D. 5:40 p.m. What Is Pediatric Epilepsy Surgery? Gary W. Mathern, M.D. 6:05 p.m. What Is So Special About Children? J. Helen Cross, M.D. 6:30 p.m. Pediatric Epilepsy Surgery: Is it Only Rare Syndromes? William D. Gaillard, M.D. 6:55 p.m. What is the Role of Social Media and Nonprofits? Adam Hartman, M.D. 7:20 p.m. Conclusions Gary W. Mathern, M.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.0 contact hours for this session. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the North American Commission Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Professionalism, Patient Care, Practice-based Learning, Systems-based Practice AES ANNUAL BUSINESS MEETING All AES members are encouraged to attend this yearly meeting. SATURDAY u u Counsel family regarding diagnosis of intractable epilepsy as currently defined Explain the process of evaluating a child for epilepsy surgery in view of international experience u Assess children with intractable epilepsy in anticipation of referral for surgical evaluation using current criteria, defining current psychological and neuropsychological status. Target Audience Basic, Intermediate, and Advanced (see page 120 for details) You re invited to attend Sunday, December 7 8:00 a.m. 8:30 a.m. Sheraton Seattle Hotel Metropolitan Ballroom B, Third Floor Coffee will be available 35

38 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center Hall 4B, Level 4 Authors Present: Noon 2:00 p.m. Poster Walking Tours begin at 12:15 (see page 15 for details) Translational Research Mechanisms Enhanced Histamine Release During The Pilocarpine-Induced Status Epilepticus Is Associated To Hippocampal Neuronal Damage In Rats: Effects Of Sodium Cromoglycate/ L. Rocha, M. Valle-Dorado, C. Santana-Gomez, S. Orozco-Suarez PET Imaging Of Translocator Protein In Temporal Lobe Epilepsy/ L. Dickstein, P. Zanotti-Fregonara, I. Dustin, J. Liow, J. Hirvonen, W. Kreisl, K. Jenko, S. Inati, M. Fujita, C. Morse, J. Hong, V. Pike, S. Zoghbi, R. Innis, W. Theodore Time- And Region-Specific Alterations In Cyclin D1 Expression Following STAT3 Inhibition In A Rat Model Of Temporal Lobe Epilepsy/ Y. Cruz Del Angel, D. Strode, A. Brooks-Kayal, H. L. Grabenstatter Basic Mechanisms Of Acute And Chronic Neocortical Epilepsy Revealed By Multi-Electrodes Extracellular Field Recordings In Brain Slices/R. Serafini, J. Loeb Adenosine Kinase Expression In Cortical Dysplasia With Balloon Cells: A Developmental Lineage Of Cell Types Analysis Epilepsy Center, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing , China/ T. Li, G. Luan Proteomic Analysis Of TrkB- Mediated Synaptic Changes Following Status Epilepticus/E. B. Ludmir, Y. Huang, B. Gu, E. J. Soderblom, M. Moseley, J. O. McNamara Differential Toll-Like Receptor 4 Modulation Of Dentate Excitability In The Normal And Injured Brain/ A. A. Korgaonkar, Y. Li, V. Santhakumar T Cells Rapidly Relocate From Spleen And Accumulate During Epileptogenesis In A Rat Brain Of Cortical Dysplasia Following A Second Hit/K. Ayasoufi, A. Nemes, A. Valujskikh, Z. Ying, I. Najm Developmental Plasticity Of Dentate Gyrus Granule Cells Following Epileptiform Activity In Vitro/ K. P. Patterson, Y. Chen, G. P. Brennan, C. Ly, T. Baram New Animal Model Of SUDEP: Brainstem Ictal EEG Is Associated With Respiratory Arrest/T. Salam, G. Montandon, R. Genov, J. Perez Velazquez, P. Carlen Mechanisms Underlying Transitions Between Bursting And Seizing In A Computational Network Model/W. Swiercz, K. Lillis, K. Staley Increased Expression Of Growth Associated Protein 43 After Seizures In Rodent Model Of Irradiation-Induced Cortical Dysplasia/A. Nemes, Z. Ying, I. Najm Hyperactivation Of mtor Signaling In A Two-Neuron Microcircuit Alters The Dynamics Of Synaptic Transmission/M. Weston, H. Chen, J. Swann Unit Activity Of Subicular, CA1, CA3, And Dentate Gyrus Principal Cells And Interneurons Before Spontaneous Seizures In A Rat Model Of Temporal Lobe Epilepsy/ P. Buckmaster, I. Toyoda, S. Fujita, A. Thamattoor GABAB Receptors Regulate Trafficking Of Extrasynaptic GABAA Receptors In Dentate Gyrus Granule Cells Via PKA- And PKC-Dependent Signaling Pathways/W. Tao, W. Spain, C. Ransom Potassium Concentration Bidirectionally Modulates Seizure-Like Events In The 4-AP Epilepsy Model In Vitro And In Vivo/P. Bazzigaluppi, L. Wang, S. Dufour, T. Valiante, P. Carlen Onset Of Spontaneous Limbic Seizures Is Associated With Changes In Firing Dynamics Of Neuronal Ensembles In Hippocampus And Parietal Association Cortex/ A. Neumann, A. Luczak, M. Sprengers, H. Steenland, K. Bzymek, J. Xie, V. Lapointe, Z. Navratilova, F. Kloosterman, K. Vonck, P. Boon, B. L. McNaughton, R. Raedt Human Single Neuron Correlates Of High Frequency Oscillations During Seizures/ O. J. Ahmed, E. N. Eskandar, L. R. Hochberg, S. S. Cash Invited Speaker Abstract Submission Pro-Resolving Receptors ChemR23 And ALXR Expression During Epileptogenesis In Mice/ F. Frigerio, A. Torello, M. Neveux, K. Leclercq, A. del Prete, S. Sozzani, R. Kaminski, A. Vezzani Impermeant Anions Are Involved In Setting The Neuronal Chloride Concentration, Implications For Seizure Treatment/J. Glykys, V. Dzhala, K. Egawa, T. Balena, Y. Saponjian, K. Kuchibhotla, B. Bacskai, K. T. Kahle, T. Zeuthen, K. Staley Adenosinergic Pathway Involvement In Protective Effect Of Atorvastatin In Pentylenetetrazol- Induced Seizures In Rats/A. Goyal, R. Kumar, Y. K. Gupta Does Enhancement Of Ventilation Reduce Respiratory Arrest In DBA/1 Mice?/C. Zeng, X. Long, J. Cotten, S. Forman, K. Solt, C. Faingold, H. Feng The mtor Inhibitor, Rapamycin, Attenuates Acute Seizure-Induced Dendritic Injury In Mice/D. Guo, N. Rensing, M. Wong TRPV1 Receptors Modulate The Expression Of Experimental Febrile Seizures During Development In Mice/K. Barrett, L. Scott, S. Mandadi, P. Whelan, M. Scantlebury Hypothermia Prevents The Development Of The Calcium Plateau Following Status Epilepticus/ K. Phillips, L. Deshpande, R. DeLorenzo Models Tonic GABAergic Inhibitory Signaling To Dentate Granule Cells In Mice Following Controlled Cortical Impact/J. Boychuk, C. Butler, B. Smith The Action Potential Firing Frequency Of Fast-Spiking Basket Cells Is Reduced After Status Epilepticus/H. Sun, H. Goodkin Benzodiazepine Resistant Status Epilepticus And Brain Injury In DFP Model Of OP Intoxication/ R. Kuruba, X. Wu, D. Reddy Postnatal Disruption Of The Cytoskeletal Protein Ndel1 Induces Hippocampal Structural Pathology And Spontaneous Recurrent Seizures/ C. Gavrilovici, Y. Jiang, M. Chansard, R. Liu, K. Parsons, S. Park, M. Scantlebury, G. Teskey, J. M. Rho, M. Nguyen Midazolam Refractory Seizures And Brain Injury Following Acute Organophosphate Intoxication/X. Wu, R. Kuruba, D. Reddy Diminished Antiepileptogenic Effects Of Neurosteroids In Mice Lacking Delta-Subunit Extrasynaptic GABA-A Receptors/B. Clossen, D. Reddy Perimenstrual Upregulation Of Delta-Subunit Extrasynaptic GABA-A Receptors Mediating Tonic Inhibition And Neurosteroid Sensitivity/ C. Carver, X. Wu, O. Gangisetty, D. Reddy Alcohol And SUDEP In Genetically Epilepsy Prone Rats (GEPR-9s)/C. Faingold, M. Randall, S. P. Kommajosyula Hyperthermic Seizures And Seizure Susceptibility: A Novel Approach Using Zebrafish/J. Ullmann, G. Leanage, D. Reutens Alterations Of Neurometabolites And Fear Responses After NMDA-Induced Spasms In Infant Rats/M. Lee, M. Yum, D. Woo, T. Ko Progesterone Increases AMPA Receptor Cell Surface Expression Via Mechanisms Involving Progesterone Receptors/J. Kapur, S. Joshi, C. Passmore, J. Williamson Antiseizure Effects Of TrkB Kinase Inhibition/R. Kotloski, G. Liu, J. McNamara 36

39 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center Hall 4B, Level GABA Agonists Restore Inhibitory GABA Neurotransmission In Mesiotemporal Lobe Epilepsy: In Vivo And In Silico Modeling Evidence/ S. Stamboulian-Platel, A. Legendre, T. Chabrol, P. Polack, J. Platel, F. Pernot, V. Duveau, C. Roucard, S. Charpier, M. Baudry, A. Depaulis Higher Seizure Susceptibility In Rats With Cortical Dysplasia: A Feedback Systems Perspective/ B. Krishnan, A. Nemes, Z. Ying, Z. I. Wang, I. Najm, A. Alexopoulos Early Structural Changes In The Methionine Sulfoximine Model of Mesial Temporal Lobe Epilepsy/ H. Wang, Y. Huang, R. Dhaher, D. Coman, H. Zaveri, F. Hyder, T. Eid Changes In Neurotransmitter Gene Expression Correlated With EEG Stages During Lithium/Pilocarpine- Induced Experimental Status Epilepticus/D. M. Treiman, D. E. Schooley, S. T. Marsh, L. J. Treiman Modeling PIK3CA-Related Malformations Of Cortical Development And Epilepsy In Mice/ A. Roy, J. Ni, J. Skibo, S. Rankin, W. Dobyns, S. Baker, J. Zhao, F. Kalume, K. J. Millen Thalamic Deep Brain Stimulation To Improve Consciousness After Seizures/A. Gummadavelli, J. Motelow, N. Smith, Q. Zhan, N. Schiff, H. Blumenfeld Electrical Stimulation Of The Cerebral Cortex With A Disk Electrode: A Modeling Study/P. Kudela, W. Anderson Examining The Roles Of SCN3A And SCN9A In Epilepsy/T. Lamar, J. Wong, L. Papale, A. Escayg Neuroanatomical And Neurodevelopmental White Matter Differences Between Rat Strains With Differing Vulnerability To Epileptogenesis And Behavioural Comorbidities/P. Sharma, M. E. Wlodek, L. A. Johnston, K. L. Powell, K. Gilby, T. J. O Brien PTEN Deletion From Adult- Generated Dentate Granule Cells Disrupts Granule Cell Mossy Fiber Axon Structure/C. L. LaSarge, V. R. Santos, S. C. Danzer Effects Of Seizures On Breathing And Survival Are Dependent On Vigilance State/K. I. Claycomb, M. A. Hajek, D. A. Rappoport, G. Buchanan Use Of An Automated-Feeding System For The Testing of Potential Anticonvulsant Compounds in Chronic Epileptic Rats/K. Thomson, C. H. Rueda, M. Barker-Haliski, H. White Analysis Of Postictal Period In Developing Rats/Z. Ben Salem, H. Hanáková, J. Otáhal, P. Mares Early-Life Clonazepam Exposure Leads To Persistent Alteration Of Seizure Susceptibility/ H. Kubova, G. Tsenov, J. Virta, P. Mares Blood-Brain Barrier Integrity In Epileptic WAG/Rij rats with rotational movements/c. Gurses, D. Sahin, C. Ugur Yilmaz, N. Orhan, B. Ahishali, M. Kucuk, N. Arican, N. Ates, M. Kaya Treatment Of Convulsive Status Epilepticus In An Animal Model Of Glucose Transporter Type 1 Deficiency (G1D) Syndrome/C. Trent, L. Good, D. Kelly, S. Kayani, J. Pascual, K. Rajasekaran Minocycline Reverses Pro- Epileptogenic Effect Of Viral-Like Brain Inflammation In The Mature And Immature Rat Brain/N. Dupuis, A. Mazarati, B. Desnous, S. Auvin Systemic TLR3 Agonist Injection Enhances Epileptogenesis In Rat Pups But Does Not Affect The Adult Rats/B. Desnous, A. Mazarati, N. Dupuis, S. Auvin Human Studies Improving Seizure Outcomes In Patients With Neocortical Epilepsy By Resecting Brain Regions Generating Ictal Phase Locked High-Frequency Oscillations (HFOs)/S. A. Weiss, R. Connors, G. Banks, E. Smith, A. Lemesiou, B. Zhao, C. Filippi, R. Emerson, L. Bateman, M. Nowell, R. Rudoinov, B. Diehl, M. Walker, C. Schevon The Gamma Band Effect For Episodic Memory Encoding Is Absent In Epileptogenic Hippocampi/B. Lega, A. Dionisio, W. Bingaman, I. Najm, J. Gonzalez-Martinez Structure And Risk Factors of Epileptic Seizures At Patients With Severe Head Injury/I. Trifonov, V. Krylov, A. Talypov Alternation Of Cross Frequency Coupling In The Pre-Ictal ieeg Of Epileptic Patients/K. Edakawa, H. Kishima, T. Yanagisawa, S. Oshino, Y. Inoue, H. Khoo, T. Maruo, M. Kobayashi, M. Hirata, T. Yoshimine Brain State Dynamics And The Role Of The Epileptogenic Zone/ S. Burns, S. Santaniello, W. Anderson, S. V. Sarma Prospective Evaluation Of The Effects Of Clinical And Subclinical Epileptoform Discharges On Driving Safety/Y. Si, E. Gudbranson, W. Chen, M. Midura, R. Wu, B. Geng, P. Vitkovskiy, A. Sivaraju, R. Sainju, A. Fernandez, A. Alareddy, I. Quraishi, R. Duckrow, L. Hirsch, H. Blumenfeld The Frontal And Insular Network: A Corticocortical Evoked Potentials Study/R. Enatsu, J. Gonzalez-Martinez, J. Bulacio, Y. Kubota, J. Mosher, R. Burgess, I. Najm, D. Nair Seizure Propagation Across Micro Domains In Epileptic Patients Undergoing Intracranial Monitoring/ I. Basu, W. S. Anderson Why Do Placebos Decrease Seizures In Clinical Trials?/ D. Goldenholz, R. Moss, W. Theodore Devices, Technologies, Stem Cells Commercial Development Of Advanced Wireless Technologies In Implantable Neurostimulators For The Treatment Of Epilepsy/E. Chow, C. Warren, A. Shen, K. Venkatraman, A. Jones, A. Adkins, O. Abdel-Latief, D. Thompson, B. Byerman Cardiac-Based Seizure Detection: Long-Term Patient Follow- Up From The AspireSR E-36 Trial/ P. Boon, K. van Rijckevorsel, R. El Tahry, C. Elger, N. Mullatti, A. Schulze-Bonhage, K. Vonck, G. Wagner, W. Van Grunderbeek, R. McGuire VNS Therapy Automatic Magnet Mode Outcomes Study In Epilepsy Patients Exhibiting Ictal Tachycardia/R. Fisher, J. Harvey, P. Afra, B. Najimipour Immunomodulation For Long- Lasting Anticonvulsant Effects After Neural Xenografting In Rats Neonatal Induction Of Tolerance Versus Pharmacological Immunosuppression/A. Handreck, B. Backofen-Wehrhahn, E. M. Mall, B. Petersen, H. Niemann, M. Gernert Chronic Delivery Of Vigabatrin Into The Subthalamic Nucleus Is Anticonvulsant In A Rat Seizure Model/L. Gey, M. Gernert, W. Loscher Development Of A Technique For Assessing The Effects Of Selective Sleep Restriction In Mice/ S. Sunderam, F. Yaghouby, C. Schildt, K. D. Donohue, B. F. O Hara Multichannel Portable fnirs- EEG System For Long-Term Monitoring Of Seizures/A. Kassab, P. Vannasing, J. Tremblay, D. Safi, F. Lesage, M. Sawan, D. Nguyen Sensing-Enabled Hippocampal Deep Brain Stimulation In Idiopathic Nonhuman Primate Epilepsy/ W. J. Lipski, V. DeStefino, S. Stanslaski, A. Antony, J. Cameron, M. Richardson Development Of A Depth Electrode Placement Planning System For Direct Cortical Stimulation Therapy/L. Cendejas, R. Dawe, M. A. Rossi Performance Of Limb-Based Accelerometers In The Detection Of Hypermotor Seizures/G. Carlson, S. Sabesan, K. Rose, I. Chekhovtsov SATURDAY 37

40 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center Hall 4B, Level Prospective Driving Performance Evaluation Using A Portable Handheld Device In The Epilepsy Monitoring Unit/N. Li, J. Thomson, W. Chen, D. Kluger, C. Cunningham, R. Gebre, Y. Si, J. Blumenfeld, E. Chen, M. Johnson, P. Vitkovskiy, Y. Baykara, E. Gudbranson, A. Morawo, H. Blumenfeld Scoring Sleep In Interictal Electrocorticographic Recordings/ F. Yaghouby, P. Modur, S. Sunderam Medial Septal Theta Stimulation Increases Seizure Threshold And Improves Cognition In A Rat Model Of Epilepsy/A. Izadi, S. Seidl, D. Lee, A. Ekstrom, K. Shahlaie, G. Gurkoff Behavior/Neuropsychology/ Language Adult Direct Physiologic Evidence For A Heteromodal Convergence Region For Proper Naming In The Left Anterior Temporal Lobe/T. J. Abel, A. E. Rhone, K. V. Nourski, H. Kawasaki, H. Oya, T. Ando, M. Howard, D. Tranel Executive Functioning Changes In A Clinical Sample Of Older Adult Patients With Temporal Lobe Epilepsy/C. Sylvester, G. Risse, R. Doss Factors Analysis Of Korean Version Of Liverpool Adverse Event Profile (K-LAEP): Factors Explaining The Scores Of K-LAEP And Their Association With Drug Load And Drug Number Of Antiepileptic Drugs/ O. Kwon, S. Kim, S. Park The Influence Of Gender On Personality Assessment Inventory Scores Used To Support The Diagnosis Of Psychogenic Nonepileptic Seizures/M. Hoerth, K. Corallo, D. Locke, R. Lanyon Stress Coping Strategies In Patients With Epilepsy And How They Relate To Mood/K. Isaacs Lebeau, L. Myers, M. Lancman, M. E. Lancman Barriers And Facilitators To Self-Management Among Persons With Epilepsy And Mental Illness/ M. Sajatovic, R. K. Ramsey, E. Welter, K. Colón-Zimmermann, A. T. Perzynski Effects Of Adjunctive Lacosamide On Mood And Quality Of Life In Adult Patients With Localization Related Epilepsy/ L. Nakhutina, S. D. Kunnakkat, M. Coleman, C. Lushbough, V. Arnedo, N. Soni, A. C. Grant A Randomized Controlled Trial Of HOBSCOTCH: A Self-Management Intervention For Cognitive Impairment In Epilepsy/T. A. Caller, K. L. Secore, R. J. Ferguson, R. M. Roth, F. P. Alexandre, J. Kleen, J. Harrington, P. L. Henegan, B. C. Jobst Effect Of Seizures On Sleep Quality In Patients With Chronic Epilepsy/K. Hwang, S. Cho, J. Kim, E. Joo, S. Hong Depression, Anxiety And Quality Of Life In Hispanic Spanish- Speaking Patients With Psychogenic Non-Epileptic Seizures (PNES) Compared To Those With Epilepsy/ L. Myers, R. Zeng Correlation Of Pre-Diagnosis Illness Perception And Clinical Outcome In Patients With Psychogenic Non-Epileptic Seizures/ S. Majmudar, D. K. Chen Pediatrics Development Of The PedsQL- Epilepsy Module/A. Modi, K. Junger, A. Arnett, K. Mann, S. Guilfoyle, D. Morita, J. Varni Behavioral Medicine Services Integrated Into Pediatric Epilepsy Care/S. Guilfoyle, K. Junger, A. Arnett, A. Modi Children With Early Onset Epilepsy Display Thalamic Abnormalities At Diagnosis/M. Yoong, M. Hunter, J. Shetty, M. McPhillips, A. McLellan, R. F. Chin Impact Of Epilepsy Surgery On Behavior In Children/L. Ferguson, R. M. Busch, K. Kim, J. Haut, P. Klaas, W. Bingaman, D. Lachhwani, T. Lineweaver Treatment Of Psychogenic Non-Epileptic Seizures In The Pediatric Population/J. Doss, E. Adams, M. Palmquist Memory Functioning In Long- Term Outcome After Epilepsy Surgery In Childhood/M. Smith, K. Puka Epilepsy Education: Parents And Adolescents Learn Differently/ L. Carbone, R. Derry, M. Plegue, S. Rau, R. Shellhaas Behavioral Co-Morbidities In Pediatric Epilepsy: What Is The Role Of Cognition?/S. Eom, R. Caplan, A. Berg Continuous spikes And Waves During Sleep (CSWS). Changes In Seizure Frequency, Epileptiform Activity And Cognition After High- Dose Clobazam Treatment/J. Klehm, I. Sánchez Fernández, C. Vega, J. Peters, S. Thome-Souza, C. Harini, M. Takeoka, G. Wilkening, K. Chapman, T. Loddenkemper Intellectual And Memory Outcome Following Pediatric Epilepsy Surgery Using Reliable Change Methods/J. Haut, L. Ferguson, T. Lineweaver, P. Klaas, D. Lachhwani, W. Bingaman, R. M. Busch Predictors Of Quality Of Life In Childhood Epilepsy: The Child s Perspective/N. Fayed, A. M. Davis, D. L. Streiner, P. L. Rosenbaum, L. Lach, C. E. Cunningham, M. Boyle, G. Ronen Support For Use Of The Meyers Neuropsychological System With Pediatric Patients With Epilepsy/ Y. C. Leon, S. Benbadis, D. Lisicki, C. Ramirez, J. Ferreira Genetics Human Studies WITHDRAWN The Expanding Role For Chromatin Remodeling In Epilepsy: Gene Discovery To Pathogenic Mechanisms/G. L. Carvill, J. McMahon, H. Wang, J. Stamatoyannopoulos, I. Scheffer, H. Mefford Mutations In WWOX Gene In Early Infantile Epileptic Encephalopathy: Expansion Of The Phenotype And Genotype Disease Spectrum/ B. Melaiki, F. ALMutairi, A. ALHashem Distinct Phenotypes And Genotypes Of SPTAN1 Encephalopathy/ J. Tohyama, M. Nakashima, Z. Rener Primec, C. Gaik-Siew, S. Nabatame, M. Kato, N. Matsumoto, H. Saitsu Cornelia de Lange Syndrome:Clinical Features & Course of The Largest SMC1A Deletion/ L. R. Kaplan, N. Zadeh, A. Spitz, G. Fernandez De Novo Mutation In Sodium Channel Gene SCN8A Causes Delay In Neuromuscular Junction Development In Early Onset Epileptic Encephalopathy /N. Barisic Familial Focal Epilepsy With Paroxysmal Arousals Due To A Novel CHRNA2 Loss Of Function Mutation/ V. Conti, P. Aracri, L. Chiti, S. Brusco, F. Mari, C. Marini, A. Romigi, A. Becchetti, R. Guerrini WITHDRAWN Presenilin 1 Mutation In A Sporadic, Early-Onset Dementia With Myoclonus And Epilepsy/M. Kinoshita, H. Nakano, K. Park, H. Yamashita, T. Kondo, R. Takahashi, A. Ikeda A Novel LGI1 Variant In Autosomal Dominant Lateral Temporal Lobe Epilepsy/W. O. Pickrell, C. Hope, J. G. Mullins, P. E. Smith, M. I. Rees, S. Chung Antecollis And Levodopa- Responsive Parkinsonism Are Late Features Of Dravet Syndrome/ A. Fasano, F. Borlot, A. E. Lang, D. Andrade DEPDC5 Mutations In Familial Temporal Lobe Epilepsies/C. Nobile, E. Serioli, E. Dazzo, P. Striano, S. Striano, R. Michelucci De Novo Mutations In Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies/ S. Weckhuysen Copy Number Variations In Early Onset Absence Epilepsies/ H. Muhle, M. Pendziwiat, P. Striano, R. S. Møller, C. Marini, A. Suls, P. De Jonghe, B. Neubauer, M. von Deimling, J. Jähn, S. von Spiczak, Y. Weber, G. Kurlemann, T. Polster, I. Vater, I. Scheffer, T. Sander, R. Siebert, U. Stephani, I. Helbig

41 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center Hall 4B, Level Epilepsy In STXBP1 Encephalopathy: Clinical Delineation Of 32 Japanese Patients Including 14 Novel Patients/M. Kato, H. Saitsu, H. Osaka, K. Nakamura, T. Watanabe, H. Terashima, T. Ikeda, T. Kumada, H. Matsumoto, T. Yamaguchi, J. Azuma, Y. Tominaga, M. Shinpoo, H. Arai, S. Hirai, S. Takeshita, E. Nakagawa, H. Uchio, Y. Nonoda, T. Iwasaki, T. Chiyonobu, A. Sudo, Familial Focal Seizures And Anterior Pachyghria In A Large Family With A Novel DCX Mutation Combined With A TUBB1 Mutation That Might Be A Modifier For The Phenotype Of Cognitive Deficit/Y. Kim, M. Kim, S. Choi, Y. Woo Distinctive Electro-Clinical Features Of Epilepsy In Severe Early Onset SCN8A Encephalopathy/ E. Gardella, J. Larsen, M. Wolff, G. Schmiedel, M. Kirkpatrick, N. Barisic, C. Depienne, M. Troncoso, B. Jepsen, M. Nikanorova, L. Troncoso, A. Bevot, H. Hjalgrim, S. Beniczky, R. S. Møller Targeted Massively Parallel Sequencing Of Infantile Onset Epileptic Encephalopathy/B. Lim, H. Kim, H. Hwang, J. Chae, K. Kim, Y. Hwang Familial Epilepsy Due To A Point Mutation In LIS1/D. E. Crompton, M. S. Hildebrand, R. J. Leventer, Y. Perchyonok, J. A. Damiano, C. A. Wise, I. E. Scheffer, G. D. Jackson, S. Berkovic The Subcortical Band Heterotopia/Lissencephaly Spectrum And Epilepsy: Phenotypic, Molecular, Functional, And Structural Analysis Of Novel Causative DCX And LIS1 Mutations/D. Amrom, G. Brouhard, S. Bechstedt, K. Toropova, F. Andermann, F. Dubeau, D. Melanson, D. Tampieri, S. Reck-Peterson, E. Andermann Neuropathology of Epilepsy Human Studies Temporal Lobe Epilepsy With Hippocampal Sclerosis: The Role Of 5HT1A and 5HT2A Receptos In Human Epileptogenesis/N. Fonseca, H. P. Joaquim, V. D. de Paula, S. Vincentiis, L. L. Talib, W. F. Gattaz, K. Valente Neurophysiology Video EEG Epilepsy-Monitoring Electroencephalographic Patterns During Sleep In Children With Chromosome 15q Duplications (Dup15q)/D. Arkilo, O. Devinsky, R. Thibert A Reduction Of Sleep Spindles Precedes Seizures In Focal Epilepsy By Minutes/J. Remi, F. Tezer-Filik, S. Noachtar How Long Is A Single, Scalp Video EEG Monitoring Evaluation Valid In The Pre-Surgical Evaluation For Focal Epilepsy?/D. M. Bonno, A. Fessler Representation Of Memory Strength And Subjective Confidence By Individual Neurons In The Human Medial Temporal Lobe/U. Rutishauser, S. Ye, M. Koroma, J. Chung, A. Mamelak Synergy Between Epileptogenic Cortex And Thalamus Projecting Generalized Paroxysmal Fast Activity (GPFA) In Children With Intractable Localization-Related Epilepsy/S. Baba, M. Mohammadi, T. Okanishi, K. Okanari, S. Sakuma, A. Ochi, E. Widjaja, C. Go, O. C. Snead III, H. Otsubo Importance Of Routine Ictal Heart Rate Analysis In Drug Resistant Epilepsies: Possible Prediction Of Patients At Risk For SUDEP/L. Baysal Kirac, B. Baykan, C. Gurses, N. Bebek, A. Gokyigit Scalp High Frequency Oscillations Help To Identify Patients With Poor Postsurgical Seizure Outcome/C. Klus, M. Duempelmann, M. Mader, A. Schulze-Bonhage, J. Jacobs A Study On Clinical Usefulness Of 3D EEG Source Localization Analysis/C. Park, D. Kim, B. Abibullaev, H. Kwon, J. Seo, E. Joo, D. Seo, Y. Lee, S. Hong The Diagnostic Yield Of Video- EEG in the inpatient versus Ambulatory Settings In Adults With Episodes Of Unclear Nature/E. Fertig, E. Feoli, J. Sabri, C. Lambrakis, O. Laban-Grant, S. Mesad, J. Politsky, M. Lancman Electroencephalogram Characteristics In Pediatric Patients With Anti-NMDA Receptor Encephalitis/E. Cruz, S. Manganaro, L. Bello, M. Andriola, L. Manganas Interictal And Ictal Video EEG Findings In Patients With Epilepsy And Autism Spectrum Disorder/ J. Avallone, J. Misajon, S. Iyer, O. Devinsky Pathognomonic Electroencephalogram Findings In A Case Of Isodicentric Chromosome 15/V. S. Vajjala, J. B. Wollack, S. A. Hosain ICU EEG Clinical Correlates And Outcome Of Lateralized Periodic Discharges In Patients Without Acute Brain Injury: A Case-Control Study/ R. Sainju, L. Manganas, E. Gilmore, O. Petroff, N. Rampal, L. Hirsch, N. Gaspard Interrater Agreement In The Interpretation Of Neonatal Electroencephalography/C. J. Wusthoff, J. Sullivan, H. C. Glass, R. Shellhaas, N. Abend, T. Chang, T. Tsuchida Development Of Epilepsy In Neonates With Hypoxic Ischemic Encephalopathy (HIE) Receiving Whole Body Therapeutic Hypothermia(TH) Compared To A Non-TH Group/ K. Khusiwilai, M. Cordeiro, T. Czech, K. Harris, A. Massaro, T. Chang, T. Tsuchida Seizure Detection In Adults Using Feature Baseline Correction On A Neonatal EEG Trained Classifier/ G. Bogaarts, E. Gommer, D. Hilkman, V. van Kranen-Mastenbroek Comparison Of Seizures Captured With Extended Versus Reduced EEG Electrode Arrays In Neonates Undergoing Therapeutic Hypothermia/G. Diaz-Medina, Y. Lai, A. L. Thompson, W. Laura, A. Anderson Early Identification Of Patients With PRES Using Continuous EEG Reduces The Comorbidity Of SAH And Impacts its Treatment Approach/ J. Politsky, I. Ugorec, D. Baker, P. Rodgers, E. Fertig Prognostic Value Of Continuous EEG During And After Therapeutic Hypothermia In Patients With Cardiac Arrest/B. Legros, M. Lamartine Sabido Monteiro, C. Depondt, I. Lamanna, N. Ligot, N. Mavroudakis, G. Naeije, J. Vincent, F. Taccone Analysis Of Pediatric Electroencephalogram Characteristics During Therapeutic Hypothermia In Post Cardiac Arrest Patients/L. Bello, E. Cruz, S. Manganaro, M. Andriola MEG Pre-Ictal And Ictal Pathological High Frequency Oscillations (HFOs) In Focal Epilepsy: Analysis Of MEG Recording/J. Velmurugan, S. Sinha, N. Mariyappa, P. Satishchandra Magnetoencephalographic Characteristics Of Cortical Dysplasia In Children/N. Agarwal, U. Thome Costa, B. Krishnan, R. Burgess, R. Prayson, A. Alexopoulos, A. Gupta Volume And Location Of Focal Cortical Dysplasia Type Ii Correlating With Magnetoencephalography; Convexity Vs. Bottom Of Sulcus/ M. Nakajima, Y. Sato, S. Wong, K. Okanari, S. Sakuma, C. Boelman, S. Baba, A. Ochi, S. Doesburg, H. Otsubo Automatic Detection Of Focal Slow Waves In Patients After Epilepsy Surgery Is Related To Recurring Seizures/S. Rampp, M. Schönherr, K. Roessler, M. Buchfelder, H. Hamer, H. Stefan Comparative Analysis Of Spike Source Between High-Density EEG And MEG/R. Honda, Y. Kaneko, Y. Saito, E. Nakagawa, K. Sugai, M. Sasaki, T. Kaido, A. Takahashi, T. Otsuki SATURDAY 39

42 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center Hall 4B, Level Coherence And Source Localisation In Reflex-Eating Epilepsy: A MEG Based Analysis/S. Sinha, V. Jayabal, M. Narayanan, S. Parthasarathy Application Of Multiple Equivalent Current Dipole Modeling And Minimum Norm Modeling For Analyzing Magnetoencephalography Activities Of An Unusual Form Of Benign Childhood Epilepsy With Occipito-Frontal Sharp Waves/ H. Murakami, J. Mosher, A. Naduvil Valappil, E. Wyllie, A. Alexopoulos, R. Burgess MEG Source Imaging Of Interictal Spikes Using Samepi: Comparison With Area Of Surgical Resection And Seizure Outcomes/ J. Scott, S. Robinson, K. Zaghloul, J. Heiss, S. Sato, W. Theodore, S. Inati Epileptic Networks In Genetic Generalized Epilepsy: A MEG Study/ A. Zillgitt, B. Assaad, J. Moran, K. Mason, D. Burdette, J. Constantinou, G. L. Barkley, S. Bowyer Comparison Of Ictal And Interictal Source Localization Using MEG And deeg In Pediatric Drug Resistant Epilepsy/H. Fujiwara, H. Greiner, J. Tenney, D. Rose Brain Stimulation Cortical-Cortical Evoked Potentials (CCEPs) Distinguish Early Versus Late Seizure Spread In Stereoelectroencephalography/ A. Dionisio, B. Lega, J. Gonzalez-Martinez, P. Flanagan, D. Nair Physiological Consequences Of Abnormal Connectivity In A Developmental Epilepsy/M. Shafi, M. Vernet, D. Klooster, M. E. Barnard, K. Romatoski, M. Westover, J. Christodoulou, J. D. Gabrieli, S. Whitfield-Gabrieli, A. Pascual-Leone, B. S. Chang Chronic Cortical Optogenetic Stimulation For The Prevention Of Posttraumatic Epileptogenesis In Mice/X. Ping, W. Xiong, G. Chavez, J. Gao, X. Jin (DYS) Functional Connectivity Of The Seizure Onset Zone: Low Frequency Stimulation And Cortico- Cortical Evoked Responses Study/ R. Alkawadri, H. Zaveri, R. Duckrow, D. Spencer, J. Gerrard, L. Hirsch Exploring Seizure Networks Using Cortico-Cortical Evoked Potentials: Internally Hyperconnected, Externally Hypoconnected?/L. Entz, P. Megevand, D. Groppe, E. Toth, D. Fabo, Z. Fallil, C. Harden, S. Hwang, S. Bickel, C. Keller, A. Mehta Paired-Pulse Transcranial Magnetic Stimulation (pptms) In Measures Of Cortical Inhibition During Propofol Infusion/C. F. Paredes Saenz, R. Gersner, J. Goldie, A. Rotenberg State-Dependent Modulation Of Cortical Activity By Intracranial Stimulation/S. Alagapan, S. Schmidt, D. Bernardo, F. Frohlich, H. Shin Sleep, Seizures And Cortico- Cortical Evoked Potentials: A Dynamical System Perspective/ J. Slater, G. Kalamangalam Animal Studies Short-Term Synaptic Reorganization In The Rat Neocortex After Perinatal Hypoxia-Ischemia/ J. Bastar, J. Spampanato, F. Dudek Supramammillary Hypothalamic Neurons That Co-Release GABA And Glutamate Promote Wakefulness And Hippocampal Theta Rhythm/ N. P. Pedersen, L. Ferrrari, J. L. Wang, E. Arrigoni, P. M. Fuller, C. B. Saper Electroconvulsive Seizure Induces The Changes Of NMDAR, AMPAR, And STEP61 Protein In Rat Hippocampus/S. Jang Peri-Ictal Impairment Of Brainstem 5-HT Neurons: Insight Into Depressed Arousal, Reduced Ventilation And Sudden Unexpected Death In Epilepsy (SUDEP)/Q. Zhan, G. Buchanan, J. Motelow, F. Serout, W. Chen, A. Gummadavelli, J. Andrews, P. Vitkovskiy, M. Furman, W. Li, G. Richerson, H. Blumenfeld Seizure-Induced Kcnq Upregulation Alters The Functional Properties Of Hippocampal M Currents In The Pilocarpine Model Of Temporal Lobe Epilepsy/C. T. Taylor, D. B. Jaffe, M. S. Shapiro Selective, Unilateral Ablation Of Hippocampal Interneurons Causes Acute Seizures/J. Spampanato, F. E. Dudek Computational Analysis & Modeling Of EEG Power-Weighted Narrowband Changes During Epileptic Bursts In Invasive EEG Identify The Epileptogenic Zone/M. Heers, X. Wang, M. Duempelmann, J. Jacobs, A. Schulze-Bonhage, T. Ball An Interictal EEG Spectral Metric For Temporal Lobe Epilepsy Lateralization/L. Cara, G. Kalamangalam Correlation Of EEG Spectra With Quantitative Measures Of Intelligence And Attention In Children With Idiopathic Epilepsy/D. Hsu, K. Rayer, M. Hsu, P. Ferrazzano, K. Dabbs, D. Jackson, C. Stafstrom, G. Worrell, J. Jones, B. Hermann Lateralizing Shift Of Current Source Of Generalized Spikes In Childhood Absence Epilepsy: Relationship Between The Shift And Response To Valproic Acid/O. Kwon, T. Yang, S. Jung, J. Yeom High Frequency Oscillations And Spikes: Separating Oscillations From Broad Band Activities/M. Amiri, J. Gotman Spatial Relationship Between The Fast And Slow Components Of Ictal Activities And Interictal Epileptiform Discharges In Children With Epileptic Spasms/T. Akiyama, M. Akiyama, K. Kobayashi, T. Okanishi, C. Boelman, D. A. Nita, A. Ochi, C. Go, C. Snead, J. Rutka, J. Drake, S. Chuang, H. Otsubo Dynamic Measures Applied To A Cohort Of Children With Childhood Absence Seizures/M. J. Schwabe, K. C. Hecox Epileptogenic Networks Revealed By Varying Patterns Of Propagation Of High Frequency Ictal Activity ( Hz)/A. Korzeniewska, P. Franaszczuk, M. Cervenka, C. Jouny, G. Bergey, N. Crone Pathologic Generation Of High Frequency Oscillations In The Seizure Onset Zone During A Motor Task/ P. A. Peters, J. Cimbalnik, B. Brinkmann, V. Svehlik, V. Vasoli, M. T. Kucewicz, R. Marsh, F. Meyer, M. Stead, G. Worrell, J. Matsumoto WITHDRAWN Modulation Of Neuronal Activity And Functional Connectivity In Transition To Ictus/T. Matsuo, R. Staba, A. Bragin, I. Fried Scale-Free Properties Of Intracerebral EEG Improve Seizure Prediction In Mesial Temporal Lobe Epilepsy/K. Gadhoumi, J. Gotman, J. Lina Coherence Analysis Of Diffuse Bisynchronous Ictal ieeg Discharges For Seizure Localization/P. Chen, M. Korostenskaja, E. Castillo, J. Seo, J. Baumgartner, K. Lee Noninvasive Dense Array Electroencephalography For Localizing The Seizure Onset Zone/C. Kuo, D. Tucker, P. Luu, K. Jenson, M. D. Holmes Clinical Epilepsy Clinical Diagnosis A Case Of Takotsubo Cardiomyopathy Due To Status Epilepticus An Underreported And Lethal Sequela/N. Mirchandani, I. Khan, G. Pushchinska Development And Validation Of A Seizure Prediction Model In Critically Ill Children/A. Yang, D. Arndt, R. Berg, J. Carpenter, K. Chapman, D. Dlugos, W. Gallentine, C. Giza, J. Goldstein, C. Hahn, J. Lerner, T. Loddenkemper, J. Matsumoto, K. Nash, E. Payne, I. Sánchez Fernández, J. Shults, A. Topjian, K. Williams, C. Wusthoff, N. Abend Obesity In Adult Patients With Psychogenic Non-Epileptic Seizures/ A. Abubakr, I. Wambacq Ambulatory EEG In Epilepsy Diagnosis For Adults Aged 65 And Older/K. Upchurch, D. McCarthy, E. Baker, J. Pathmanathan 40

43 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center Hall 4B, Level Coprolalia As A Manifestation Of Epileptic Seizures/A. Massot-Tarrús, C. Dove, R. McLachlan, J. G. Burneo, S. Mirsattari Comparison Of Patients With Coexisting Epileptic Seizures And Psychogenic Nonepileptic Spells To Patients With Psychogenic Nonepileptic Spells Only: A Search For Unique Clinical Characteristics/ S. C. Block, B. Abou-Khalil, H. Sonmezturk Which Clinical Features Help In Differentiating Epileptic From Nonepileptic Convulsive Seizures? A Systematic Review Of Initial Clinic Encounters/K. Kleinfeld, A. Peltier, N. Azar Delays In Diagnosis And Treatment Of Acute Seizures/ S. VanHaerents, E. Bachman, K. Romatoski, L. Knopf, M. Ebril, T. Pang Clinical, EEG, MRI And Surgical Outcomes Of Pediatric Epilepsy With Astrocytic Inclusions Versus Focal Cortical Dysplasia/L. Alshafai, A. Ochi, C. Go, B. McCoy, C. Hawkins, H. Otsubo, O. Snead, J. Rutka, E. Widjaja Sleep Homeostasis In Children With Focal Epilepsy Following Sleep Deprivation: Relationship To Seizure Propensity/S. Chan, C. Chevalier-Riffard, T. Baldeweg, J. Cross Networks Of Laughing Seizures A Stereoelectroencephalographic Study/I. Mindruta, L. Minotti, A. Job, D. Hoffmann, S. Chabardes, A. Barborica, J. Ciurea, P. Kahane Super Refractory Status Epilepticus: A Case Report/ I. Noviawaty, A. Naduvil Valappil, A. Zeft, D. Lachhwani Predictors Of Length Of Stay In Children Admitted For A Pre- Surgical Evaluation/P. Y. Sun, K. Wyatt, K. Nickels, L. Wong-Kisiel, E. Wirrell Navigating The Benefits And Limitations Of Current Molecular Testing Options For The Clinical Identification Of Disease-Causing PCDH19 Mutations/S. Gandomi, M. Parra, K. D. Farwell Gonzalez, K. Waller, R. Baxter, B. Tippin Davis Electroencephalographic Findings By Stage In Rasmussen s Encephalitis/H. Kim, H. Ryu, B. Lim, H. Hwang, J. Chae, J. Choi, K. Kim, Y. Hwang Type I Interferon Levels In Cerebrospinal Fluid Samples From Newborn Infants With Seizures, Rotavirus Infections, And Diffuse Cerebral White Matter Lesions/ K. Lee, C. Moon A Retrospective Study Of Continuous EEG Monitoring In A Single Tertiary Care Pediatric Site/ L. St. Louis, A. Sansevere, I. Sánchez Fernández, E. Nagarajan, J. Klehm, P. Pearl, R. Tasker, T. Loddenkemper Comparison Of Number Of Patient-Reported Allergies In Adult Patients With Epileptic And Non- Epileptic Seizures/A. Fu, D. Denny, S. Cerven, N. Moorley, S. S. Chung Prevalence Of Headache In Patients With Epileptic Versus Non- Epileptic Seizures/S. Cerven, A. Fu, N. Moorley, D. denny, S. S. Chung Comparing Duration To Diagnosis Made Via Video- Electroencephalography For Non- Epileptic Seizures And Epileptic Seizures/D. denny, A. Fu, S. Cerven, N. Moorley, S. S. Chung Comparison Of Number Of Events Captured In Epilepsy Monitoring Unit Between Patients With Epileptic Versus Non-Epileptic Seizures/N. Moorley, A. Fu, D. Denny, S. Cerven, S. S. Chung Cefepime Induced Encephalopathy In A Tertiary Medical Center In Korea/J. Jeon, H. Moon, G. Motamedi, Y. Cho Clinical Treatments What Do Epileptologists Recommend About Discontinuing AEDs For A Second Time In Seizure- Free Children When The First Attempt Failed?/A. McCarthy, C. Camfield, P. Camfield, I. Valencia Clinical Predictors For Delirium Tremens In Patients With Alcohol- Withdrawal Seizures/D. Kim Repetitive Transcranial Magnetic Stimulation For Refractory Focal Status Epilepticus/ S. VanHaerents, S. Herman, T. Pang, A. Pascual-Leone, M. Shafi Why Do Patients Get Admitted For ACTH For Infantile Spasms?A Survey Of ACTH Delivery Across United States/C. Joshi, A. Berg, E. Wirrell Ictal Religious Speech In Temporal Lobe Epilepsy/I. Yildirim Capraz, M. Mercan, E. Bilir Maximizing The Efficacy Of The Ketogenic Diet Treatment For Super- Refractory Status Epilepticus/ Y. C. Liu, H. Lowe, S. C. Shen, M. Zak, V. Chan, J. Kobayashi, E. J. Donner Interrater Reliability In Interpretation Of Electrocorticographic Seizure Detections Of The Responsive Neurostimulator/M. Quigg, B. Jobst, N. Fountain, V. S. Wong, F. Sun, E. Mirro, S. Brown, D. Spencer Hereditary Hyperekplexia And Generalized Epilepsy In A Child Responsive To Levetiracetam/ A. Lowden, J. Munoz, R. Said Comparison Of Efficacy Between A Modified Atkins Diet And A Classic Ketogenic Diet In Childhood Intractable Epilepsy/J. Kim, J. Yoon, E. Lee, J. Lee, H. Kim, H. Kang WITHDRAWN Clinical Characteristics And Treatment Pattern In Cluster Seizures: A Preliminary Chart Review Analysis/B. Vazquez, E. Wu, D. Macaulay, M. Sidovar, H. Roberts, D. Squillacote, A. L. Rabinowicz, A. Guo IV Lacosamide As Adjunctive Therapy In Treatment Of Refractory Status Epilepticus/S. Kohli, P. Li, B. Teter, K. Kavak, A. Weinstock Effectiveness Of Routine Management Of Status Epilepticus In Dravet Syndrome/S. N. Misra, S. Agadi Responsive Neurostimulation in Patients with Mesial Temporal Lobe Epilepsy and Prior Temporal Lobectomy/T. Crowder Skarpaas, R. Duckrow, A. Herekar, C. Heck, C. Skidmore, D. Spencer, G. Bergey, D. Shields, D. Nair, D. King-Stephens, M. Morrell The Effects Of Experimental Febrile Seizures On The Expression Of Forelimb Motor Maps In A Rodent Model Of Mesial Temporal Lobe Epilepsy/K. B. Rivard, K. Scullion, G. Teskey, M. Scantlebury Prognosis Family Factors Contributing To Depression In People With Epilepsy/ S. Han, B. Kim, E. Koh, M. Kim, D. Shin, J. Lee, K. Ji, S. Park, H. Nam, Y. Cho, E. Joo, S. Kim, D. Kim, K. Park, S. Han, Y. Sohn, K. Heo, E. Lee, H. Han, K. Kim, W. Shin, G. Kim, J. Lee, S. Koh, W. Kim, Y. Cho, J. Kim, S. Lee Early Intensive Care Is Critical For The Outcome Of The Refractory Status Epilepticus/Y. Choi, K. Kang, S. Lee, M. Kim Demographics And Outcomes Of Pediatric Febrile Convulsive Status Epilepticus/M. Nishiyama, T. Tanaka, K. Fujita, A. Maruyama, H. Nagase, D. Toyoshima, T. Nakagawa, N. Morisada, S. Takada, K. Iijima Predictors Of Recurrent Febrile Seizure/M. Oh, S. Kim Early Anatomical Injury Patterns Predict Post-neonatal Epilepsy In Infants Treated With Selective Head Cooling For Neonatal Hypoxic Ischemic Injury/D. Jung, C. Venkatesan, D. Nordli, D. G. Ritacco, S. Koh Gender Alters The Prognosis Of Cryptogenic Epilepsy/F. Babtain, M. Abu Abthan, S. Al Ghamdi, H. Bhatia, M. Velmurugan SATURDAY 41

44 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center Hall 4B, Level Epilepsy In Childhood After Acute Encephalopathy With Reduced Subcortical Diffusion/Y. Ito, J. Natsume, H. Kidokoro, N. Ishihara, Y. Azuma, T. Tsuji, A. Okumura, T. Kubota, N. Ando, K. Miura, T. Negoro, K. Watanabe Succinic Semialdehyde Dehydrogenase Deficiency And Worsening Epilepsy In Adulthood/ S. LaPalme-Remis, E. Lewis, W. Theodore, M. Gibson, P. Pearl The Relevance Of Somatosensory Auras In Refractory Temporal Lobe Epilepsies/G. Perven, L. Jehi, R. Yardi Electroencephalographic Correlates Of Seizure Freedom In Genetic Generalized Epilepsies/ U. Seneviratne, M. Cook, W. D Souza How Many Patients With Temporal Lobe Epilepsy Are Well Controlled With Medications?/ J. Tellez-Zenteno, L. Hernandez Ronquillo, S. Buckley, L. D. Ladino The Evaluation Of Left Ventricular Diastolic Function Of Newly Diagnosed Idiopatic Generalized Epilepsy Patients With Tissue Doppler Imaging/O. Dokgoz, C. Yilmaz, A. Ünalp, T. Mese, U. Karaarslan Clinical Outcome Following Medical Treatment In Drug-Naïve Epilepsy Patients With Cavernous Malformation/K. Cho, Y. Lee, Y. Cho, K. Heo, B. Lee Mortality In Patients Assessed For Suspected New-Onset Seizures/ T. O Brien, T. Hakami, M. Todaro, L. Danny, P. Kwan, S. Yerra, M. Tan, C. French, S. Li, Z. Matkovic, A. McIntosh Long Term Surgical Outcome Of Non-Lesional Temporal Lobe Epilepsy (NLTLE)/J. Chu, W. D Souza, M. Murphy, S. Schachter, M. Cook Neuroimaging Animal Studies Intrinsic Optical Signal Imaging Of Afterdischarges Induced By Acute Kindling Of The Rat Hippocampus/ K. Tsuchiya, A. Kobayashi, N. Inoue, S. Kogure, M. Nemoto The Effect Of De Novo KCNQ2 Epileptic Encephalopathy Mutations On KCNQ2/3 Channel Trafficking And Hippocampal Neuronal Excitability/ J. Cavaretta, K. Lee, H. Chung Structural Imaging Diffusion Tensor Imaging Study In Dravet Syndrome/J. Natsume, O. Chikako, H. Yamamoto, Y. Ito, T. Takeuchi, S. Yokoi, Y. Sakaguchi, Y. Azuma, N. Ishihara, H. Kidokoro, K. Miura, T. Negoro, K. Watanabe Investigation Of White Matter Integrity In Patients With Psychogenic Non-Epileptic Seizures/S. Lee, J. Allendorfer, T. Gaston, K. Hernando, R. C. Knowlton, J. Szaflarski, L. W. Ver Hoef The Severity Of Brain Atrophy In Temporal Lobe Epilepsy Is Unrelated To The Side Of The Focus: An Engel Class I Study/M. Liu, N. Bernasconi, A. Bernasconi, B. Bernhardt Epileptogenic Tubers: Conventional MRI Findings/Y. Hirata, A. Yogi, R. Harris, B. Ellingson, N. Salamon Unilateral Brain Oedema Related To Focal Status Epilepticus/ N. Ali, S. Palat Chirakkara, J. Reddy, S. Sinha Voxel-Based Morphometric MRI Post-Processing May Provide Relevant Targets For Reoperation In Nonlesional Epilepsies/Z. Wang, P. Suwanpakdee, S. E. Jones, Z. Jaisani, B. Krishnan, R. Prayson, R. Burgess, I. Najm, J. Gonzalez-Martinez, W. Bingaman, A. Alexopoulos Callosal And Diffusion Features In High-Functioning Subjects With Pyridoxine-Dependent Epilepsy/ S. D. Friedman, G. E. Ishak, A. V. Poliakov, S. L. Poliachik, C. B. Budech, D. W. Shaw, S. M. Gospe A Case Of Periodic Lateralized Epileptiform Discharges (PLEDs) Causing Concordant Reversible MRI Changes/S. Chen, S. Schmitt, K. Davis Longitudinal Diffusion Tensor Imaging Study In Cryptogenic West Syndrome/C. Ogawa, J. Natsume, T. Fukasawa, H. Kidokoro, H. Yamamoto, Y. Sakaguchi, Y. Ito, T. Takeuchi, S. Yokoi, Y. Azuma, N. Ishihara, K. Miura, T. Kubota, N. Ando, T. Negoro, K. Watanabe MRI Spectrum Of Unilateral Temporal Lobe Epilepsy: A Surface- Based Pattern Analysis Of Mesiotemporal Sub-structures/ B. Bernhardt, H. Kim, A. Bernasconi, N. Bernasconi Usefulness Of DTI Analysis Of Brain Tissue Surrounding The Cortical Tuber For Predicting Epileptogenicity In Tuberous Sclerosis Patients/A. Yogi, Y. Hirata, E. Karavaeva, J. Wu, S. Yudovin, B. Ellingson, G. Mathern, N. Salamon Impaired Perception Of Anxiety In Others Is Related To Right Superior Temporal Gyrus Volume In Temporal Lobe Epilepsy/G. P. Thomas, K. Bujarski Hippocampal Internal Architecture Asymmetry In Well- Controlled And Drug-Resistant Temporal Lobe Epilepsy/T. E. Gaston, L. Perry, L. Ver Hoef Evidence Of Regional Thinning Of The Cerebral Cortex In Asymptomatic Siblings Of Patients With Mesial Temporal Lobe Epilepsy/ S. Alhusaini, C. Doherty, M. Fitzsimons, G. Cavalleri, N. Delanty Toward A Quantitative Measure Of Hippocampal Internal Architecture Clarity: A Proposed Method And Its Utility In Predicting Seizure Laterality In Temporal Lobe Epilepsy/L. Perry, T. E. Gaston, L. Ver Hoef Volume Renderings Of Intraoperative Electrocorticography In Epilepsy/S. Poliachik, R. Hevner, E. Novotny, A. V. Poliakov, G. Ishak, H. Eslamy, J. Kuratani, R. Saneto, J. Ojemann Cortical Thickness And Surgical Outcome In Patients With Non-Lesional Neocortical Epilepsy/ V. Pilli, D. Kamson, C. Juhasz, J. Jeong, E. Asano, S. Sood, H. Chugani Psychopathology, Cortical Thickness And Sulcal Depth In Pediatric Epilepsy/R. Caplan, P. Siddarth, D. Tosun, S. Gurbani, J. Levitt Loss Of Hippocampal Internal Architecture In Temporal Lobe Epilepsy Demonstrated With High Resolution 4.7-T Fast Spin Echo Imaging/T. A. Steve, Y. Huang, N. V. Malykhin, A. H. Wilman, D. W. Gross Pediatric Epilepsy: Developmental Vulnerability Of Cortical Thickness And Sulcal Depth/ P. Siddarth, D. Tosun, S. Gurbani, J. Levitt, R. Caplan Functional Imaging Can Resting-State Functional Connectivity Predict Seizure Outcome After Anterior Temporal Lobectomy?/G. Doucet, D. Pustina, P. Barnett, A. Ghani, C. Skidmore, A. Sharan, J. Evans, M. Sperling, J. Tracy Spatiotemporal Mapping Of Multiple Spikes Using Distributed Source Analysis/N. Tanaka, N. Suzuki, S. Stufflebeam Stress Perception And Seizure Control Modulate The Neural Response To Psychosocial Stress In Patients With Left Temporal Lobe Epilepsy/J. B. Allendorfer, H. Heyse, B. A. Szaflarski, L. Mendoza, N. Cohen, E. B. Nelson, J. C. Eliassen, J. M. Storrs, J. Szaflarski Language Mapping In Epileptic Patients Represented By Magnetoencephalography: Utility Of Movement Compensation Algorithm/ N. Suzuki, N. Tanaka, S. Stufflebeam Temporal Lobe Spikes: EEGfMRI Contributions to the Mesial Vs. Lateral Debate/S. Watanabe, F. Dubeau, J. Gotman Modeling Channel-Specific Hemodynamic Response Function In Epilepsy With EEG-fNIRS Data/ K. Peng, D. K. Nguyen, T. Tayah, P. Vannasing, J. Tremblay, M. Sawan, F. Lesage, P. Pouliot 42

45 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center Hall 4B, Level Can FDG-PET Find Epileptogenic Tuber In Tuberous Sclerosis Complex?/Y. Hirata, A. Yogi, E. Karavaeva, R. Harris, B. Ellingson, N. Salamon Studies In Epilepsy Patients Using Simultaneous PET/MR: Preliminary Results/Y. S. Ding, B. Chen, C. Glielmi, K. Friedman, O. Devinsky Electric Source Imaging (ESI) In Presurgical Epilepsy Investigations: The Importance Of High Electrode Density And Temporal Lobe Coverage In Patients With Mesiotemporal And Neocortical Temporal Foci/G. Lantz, M. Terrill, T. Gilbert, P. Luu, A. Bunnenberg, D. Tucker Widespread BOLD Activation In MR Negative Patients With Bi-Temporal Epileptiform Discharges Studied With Simultaneous Intracranial EEG fmri/ C. Beers, I. Gaxiola Valdez, D. J. Pittman, Y. Aghakhani, P. Federico Evaluation Of The Changes In Interictal Magnetoencephalography (MEG) Spikes By Gradient Magnetic Field Topography (GMFT) Analysis Before And After Anterior Corpus Callosotomy For Symptomatic Generalized Epilepsy With Drop- Attacks/K. Kagawa, K. Iida, A. Hashizume, M. Kartagiri, Y. Kiura, R. Hanaya, K. Arita, K. Kurisu Quantitative FDG-PET Neuroimaging In Medically Refractory Epilepsy: UPenn Experience/ A. A. Thaker, J. G. Dubroff, M. Brown, K. A. Davis MRI, PET, SPECT, And Pathology Results Do Not Predict Seizure Outcome Following Epilepsy Surgery In Children With Focal Cortical Dysplasia/R. W. Dudley, B. Badesch, V. Allen, A. White, D. Mirsky, S. Nick, B. O Neill, S. Koh, M. Handler, P. Laoprasert Effect Of EEG Electrode Number On Epileptic Source Localization In Pediatric Patients/ A. Sohrabpour, Y. Lu, P. Kankirawatana, B. He Dynamic FRET-FLIM Imaging Of TrkB Activation In Living Cells/ S. C. Harward, N. G. Hedrick, R. Yasuda, J. McNamara Comorbidity (Somatic and Psychiatric) Medical Conditions Analgesic Opioid Use In A Health-Insured Epilepsy Population During 2012/A. Wilner, B. Sharma, A. Soucy, A. Krueger Prevalence Of Restless Leg Syndrome In Patients With Epilepsy/ N. K. Sethi, T. Tropea, L. Katus Prevalence Of Epilepsy As A Comorbidity With Stroke In The U.S./ A. K. Birnbaum, I. E. Leppik, K. H. Svendsen, L. E. Eberly Association Between Depressive Symptoms And Seizure Response Among Subjects With Refractory Partial-Onset Seizures In Clinical Trials Of Eslicarbazepine Acetate/F. F. Velez, T. C. Bond, X. Wang, K. P. Anastassopoulos, R. Sousa, D. Blum, F. Rocha, J. A. Cramer Non-Epileptic Seizures In A Population Of Diagnosed Pediatric Epilepsy Patients/R. Villalobos, E. Gonzales Reproductive Health In Indian Women With Epilepsy A Cross Sectional Quantitative Survey/ M. Singh, A. EB, M. Agarwal, R. Pandey Psychiatric Conditions Paroxysmal Non-Epileptic Events In A Pediatric Population/ T. Sawchuk, J. D. Smith, S. D Alfonso, J. Buchhalter Medications Implicated In Psychogenic Seizures: Insights From The OpenFDA Initiative/V. S. Wong, P. Motika Differentiating Epileptic From Non-Epileptic Seizures Through Patterns Of Comorbidities And Pharmacologic Management/ W. T. Kerr, E. A. Janio, C. T. Braesch, J. M. Hori, J. M. Le, K. R. Raman, A. B. Patel, S. E. Barritt, E. S. Hwang, E. C. Davis, D. Torres-Barba, N. Salamon, J. Engel, J. Stern, M. S. Cohen Psychiatric Comorbidity In Idiopathic Generalised Epilepsies/ A. Loughman, N. Bendrups, S. C. Bowden, W. D Souza Stress-Triggered Seizures: A Focus On Anxiety, Depression, And Childhood Trauma/H. R. McKee, A. Linane, R. Azzam, B. Abou-Khalil Personalities Of Patients With Psychogenic Non-Epileptic Seizures/ P. Rawal, M. Szaflarski, J. Saenz, Z. Richardson, B. Dworetzky, J. Szaflarski The Impacts Of Attention- Deficit Hyperactivity Disorder On Epilepsy Children/S. Park Behavioural Features Of Patients With Psychogenic Non- Epileptic Seizures (PNES)/ C. Helmstaedter Why Are We Excluding Patients With Epilepsy From Clinical Trials Of Transcranial Magnetic Stimulation To Treat Depression?/ S. D. Forman, J. Roberts, B. A. Congedo, B. H. Hanusa, A. C. Van Cott Patterns And Frequency Of The Treatment Of Depression In Persons With Epilepsy/K. M. Fiest, S. B. Patten, C. Altura, A. G. Bulloch, C. Maxwell, S. Wiebe, S. Macrodimitris, N. Jetté Reducing Severity Of Comorbid Psychiatric Symptoms In An Epilepsy Clinic Using A Co-Location Model/ J. J. Chen, T. Caller, J. N. Mecchella, D. S. Thakur, K. A. Homa, C. Finn, E. Kobylarz, K. Bujarski, V. Thadani, B. Jobst Seizure Severity Among Subjects With Refractory Partial- Onset Seizures: Analysis Of The Seizure Severity Questionnaire In A Phase III Trial Of Eslicarbazepine Acetate/J. A. Cramer, T. C. Bond, F. F. Velez, X. Wang, K. P. Anastassopoulos, R. Sousa, F. Rocha, D. Blum New Risk Factor Considerations In The Nonepileptic Patient Population: A Medication Use Review/S. Mason, P. Penovich, R. Lyons Animal Studies Interaction Between Recurrent Seizures And Autism-Like Behavior In A Mouse Model Of Maternal Immune Activation/A. Mazarati, J. Washington III, R. Sankar, D. Shin, U. Kumar Seizures Amplify Autistic Behavioral Deficits In Mouse Models Of 15q Duplication: A Potential Role For Heightened PI3K/AKT Signaling/ V. Krishnan, M. Anderson Carbamazepine Inhibits Native Sodium Currents In Murine Osteoblasts/S. J. Petty, C. J. Milligan, M. Todaro, T. J. O Brien, J. D. Wark, E. J. Mackie, S. Petrou A Single Acute Pre-Training Seizure Impairs Long Term Fear Memory In Mice/A. Holley, J. Lugo Seizure Propagation To Sleep Triggers In The Lateral Hypothalamus Of Kcna1-Null Knockout Mice/ K. Simeone, T. Simeone Antiepileptic Drugs Mechanisms Of Action Epilepsy-Associated Mutant Voltage-Gated Sodium Channels Alter Resurgent Current Generation That Could Be Preferentially Targeted With Cannabidiol/R. Patel, C. Barbosa-Nunez, T. R. Cummins Levetiracetam Modify Synaptic Vesicle Protein Expression And Reduce Abnormally Augmented Presynaptic Vesicular Release After Pilocarpine-Induced Status Epilepticus/E. Garrido, L. Pacheco, V. Funck, N. Ruvalcaba, J. Rodriguez, D. Taylor, R. Garcia, J. Martinez, C. Castro, C. Upreti, P. Stanton Novel GABAA Positive Alllosteric Modulator Neuroactive Steroids As Potential Therapies For Epilepsy/A. J. Robichaud, J. Doherty, R. Hammond, G. Belfort, F. Salituro, G. Martinez, M. Ackley SATURDAY 43

46 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center Hall 4B, Level 4 Animal Studies Inhibitory Effect Of Cys LT Receptor Antagonist Pranlukast On MES And PTZ Induced Seizures/ Y. Ueda, L. Willmore Consistent Seizure Suppression By Brivaracetam In Animal Models Of Partial Epilepsy Includes Protection Against Pilocarpine- And Kainic Acid-Induced Partial Seizures In Rats/A. Matagne, H. Klitgaard TrkB Receptor Activation Improves Interneuronal Function And Suppresses Epileptiform Activity Following Traumatic Brain Injury/F. Gu, Y. Ma, I. Parada, L. Faria, F. M. Longo, D. A. Prince High Dose Levetiracetam Could Be Used Prophylactically To Reduce The Severity Of Brain Damages Associated With Status Epileptics In Pilo Model/K. Itoh, Y. Ishihara, Y. Chiba, M. Ueno Lacosamide And Levetiracetam Modulate The Development Of Interictal Spikes And High-Frequency Oscillations During Epileptogenesis/ M. Lévesque, C. Behr, M. Avoli Huperzine A Increases Cortical Inhibition And Prevents Pentylenetetrazole-Induced Seizures In Rat/R. Gersner, D. Ekstein, S. Schachter, A. Rotenberg Neuroactive Steroids Halt Electrographic Seizures In The Lithium-Pilocarpine Model Of Pharmaco-Resistant Status Epilepticus/G. Belfort, R. Hammond, E. Christian, M. Ackley, C. Maciag, A. Robichaud, J. Doherty Acute Spasm Reduction With Celastrol In The Multiple-Hit Rat Model Of Infantile Spasms/ O. Shandra, W. Mowrey, A. S. Galanopoulou Efficacy And Tolerability Of An Interleukin 1 Receptor Antagonist (IL-1Ra) In The Multiple- Hit Rat Model Of Refractory Infantile Spasms/T. Brima, W. Mowrey, S. Moshé, A. S. Galanopoulou Clinical Trials An Evaluation Of The Impact Of Memory On Antiepileptic Drug Adherence/J. McAuley, N. Passen, C. Prusa, J. Jih, S. Hart, B. Shneker Efficacy Of USL255 (Qudexy XR; Extended-Release Topiramate) In Patients With Refractory Partial- Onset Seizures: PREVAIL and PREVAIL OLE/A. M. Clark, S. S. Chung, I. Blatt, B. Anders, M. B. Halvorsen, R. E. Hogan Long-Term Efficacy Of USL255 (Qudexy XR; Extended-Release Topiramate) In Patients With Refractory Partial-Onset Seizures: PREVAIL OLE/R. Hogan, I. Blatt, A. M. Clark, B. Anders, M. B. Halvorsen, S. S. Chung Effects Of Topiramate On Growth And Development In Children With New Or Recent- Onset Epilepsy: A Phase-4 Randomized, Active- Controlled Study/L. Ford, Y. Shi, P. Manitpisitkul Prospective Randomized Single-Blinded Trial Of Lacosamide Versus Fosphenytoin For Seizure Prophylaxis In Traumatic Brain Injury/J. Szaflarski, L. A. Shutter, L. Mendoza, M. Szaflarski Treatment Of Refractory Status Epilepticus With Enteral Topiramate/A. Asadi-Pooya Relationship Between Eslicarbazepine Exposure And Safety Endpoints For Eslicarbazepine Acetate Monotherapy/T. Fakhoury, J. Harvey, R. T. Wechsler, J. Passarell, J. Fiedler-Kelly, E. Ludwig, D. Blum, S. Sunkaraneni The Impact Of Anticonvulsants On Neurological Outcomes In Neonatal Seizures/J. Han, I. Lee, E. Kim, S. Park Relationship Between Exposure And Efficacy Of Eslicarbazepine Acetate Monotherapy/J. Rogin, A. J. Cole, L. Strom, J. Passarell, J. Fiedler-Kelly, E. Ludwig, D. Blum, S. Sunkaraneni Incidence Of Falls, Fractures, And Injuries With Adjunctive Eslicarbazepine Acetate In Patients With Refractory Partial-Onset Seizures: A Pooled Analysis Of Three Placebo-Controlled Trials/ W. Rosenfeld, S. Benbadis, P. Klein, L. Specchio, P. Kowacs, H. Gama, F. Rocha, R. Claus, D. Blum Hepatic Safety Of Eslicarbazepine Acetate: Summary Of Five Phase II And Three Phase III Adjunctive Trials/D. Blum, P. Van Ness, G. Krauss, S. Chung, C. Elger, C. Galimberti, H. Gama, F. Rocha, R. Claus Eslicarbazepine Acetate As Adjunctive Therapy For Refractory Partial-Onset Seizures: Analysis Of Cognitive Adverse Events/ E. Andermann, S. Benbadis, A. Shah, E. Trinka, A. Biraben, R. Sousa, H. Gama, D. Blum, R. Claus Eslicarbazepine Acetate Monotherapy In Adults With Partial- Onset Seizures: A Pooled Analysis Of Two Randomized Double-Blind Studies With Use Of A Historical Control/ L. Pazdera, J. French, M. Sperling, M. Jacobson, H. Cheng, D. Blum Relationship Between Eslicarbazepine Exposure And Efficacy Of Eslicarbazepine Acetate Adjunctive Therapy/J. Harvey, E. Andermann, S. Chung, E. Trinka, F. Cendes, J. Passarell, J. Fiedler-Kelly, E. Ludwig, S. Sunkaraneni, R. Sousa, F. Rocha, D. Blum Relationship Between Eslicarbazepine Exposure And Safety Endpoints For Eslicarbazepine Acetate Adjunctive Therapy/ P. Penovich, G. Krauss, M. R. Sperling, S. Striano, C. Elger, J. Passarell, J. Fiedler-Kelly, E. Ludwig, S. Sunkaraneni, R. Sousa, F. Rocha, D. Blum Eslicarbazepine Acetate Monotherapy: A Population Pharmacokinetic Analysis/ B. Abou-Khalil, I. Ali, A. Shah, J. Fiedler-Kelly, E. Ludwig, S. Sunkaraneni, D. Blum Lack Of Exacerbation Of Partial-onset Seizures During Adjunctive Treatment With Eslicarbazepine Acetate: A Pooled Analysis Of Three Phase III Controlled Trials/S. Benbadis, M. Carreño, S. Striano, R. Sousa, F. Rocha, D. Blum, H. Cheng Evaluation Of Physical Dependence Potential Following Abrupt Discontinuation Of Adjunctive Eslicarbazepine Acetate: A Pooled Analysis Of Adverse Events From Ten Studies/K. A. Schoedel, M. R. Sperling, M. Bensalem-Owen, D. Blum, R. Sousa, H. Gama, R. Claus Bioequivalence Testing Of Disparate Generic Lamotrigine Products Using Chronic Dosing In People With Epilepsy: The Equigen Study/M. Privitera, F. Diaz, B. Dworetzky, P. Bolger, R. Krebill, B. Gidal, E. Elder, A. Paige, J. Szaflarski, T. Welty, J. Pollard, W. Jiang, N. McBee, M. Berg Assessment Of Renal Toxicity In Perampanel-Treated Subjects: Pooled Results From Phase III Clinical Studies/I. Leppik, H. Yang, B. Williams, D. Xing, A. Laurenza Cohort Studies Parental Reporting Of Response To Oral Cannabis Extracts As Adjunctive Treatment For Medically Refractory Epilepsy/C. Press, K. Knupp, K. Chapman Lacosamide Efficacy And Tolerability In Clinical Practice Post Marketing Analysis/M. Baker, H. Sonmezturk, A. Arain, K. Haas, N. Azar, B. Abou-Khalil Efficacy And Tolerability Of Intravenous Levetiracetam Versus Phenobarbital In Children With Status Epilepticus Or Acute Repetitive Seizures/Y. Lee, M. Yum, E. Kim, T. Ko Clobazam Higher-Evening Differential Dosing As An Add-On Therapy In Refractory Epilepsy/ M. Jackson, S. Thome-Souza, J. Klehm, N. E. Kadish, I. Sánchez Fernández, T. Loddenkemper 44

47 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center Hall 4B, Level The Effects Of Antiepileptic Drugs On Cortical Irritability In Patients With Tumoral Epilepsies/ P. Warren, L. B. Nabors, J. Szaflarski Adjunctive Perampanel For Focal-Onset Seizures An Interim Analysis/K. Kelly, L. Stephen, P. Parker, M. Brodie Fydata Study: Retrospective Analysis Of Perampanel In A Real-Life Setting/V. Villanueva, M. Garces, F. López Gonzalez, X. Rodriguez-Osorio, J. Rodriguez Uranga, E. López-Gomáriz, J. Montoya, J. Poza Aldea, A. Molins, R. Saiz-Diaz, J. González de la Aleja, J. Mauri, A. Castillo, F. Lopez-Trigo Picho, M. Toledo, J. Salas Puig, D. Campos Blance, J. Flores Intravenous Intiation Of Lacosamide For Status Epilepticus And Following Video EEG Monitoring/ G. Morris, J. Burgos, A. Van Kampen, M. Hanson, J. Dagam Clobazam Vs. Clonazepam For Adults With Epilepsy: Long-Term Results From A UK Primary Care Database/M. Brodie, S. S. Chung, A. G. Wade, C. Quelen, A. Guiraud-Diawara, C. François, P. Verpillat, V. Shen, D. Jones, J. Isojarvi Long-Term Utilization Differences Between Children Treated With Clobazam Vs. Clonazepam For Epilepsy In The UK/S. S. Chung, M. Brodie, A. G. Wade, C. Quelen, A. Guiraud-Diawara, C. François, P. Verpillat, V. Shen, D. Jones, J. Isojarvi Evolution Of Clobazam, Clonazepam, And Diazepam Usage In The UK For Epilepsy And Other Diseases/D. Jones, S. S. Chung, M. Brodie, A. G. Wade, C. Quelen, A. Guiraud-Diawara, P. Verpillat, V. Shen, J. Isojarvi, C. François Other Population Pharmacokinetic Modeling Of Immediate And Extended- Release Topiramate (SPN-538, Trokendi XR ) In Adults With Epilepsy: Characterization f Different Absorption Rates/E. Roers, S. T. Brittain, J. D. Stocks, J. K. Johnson Unexplained Spikes In Lamotrigine Serum Concentration Suggest Nonlinear Elimination Kinetics In Some Individuals/P. Ramey, M. Osborn, K. Lowen, B. Abou-Khalil A New Method To Determine Linear Non-Steady State Pharmacokinetic Parameters In The Acute Care Setting/L. Olson A Comparison Among The Various Carbamazepine-Related Antiepileptic Drugs/E. Vernier, S. R. Benbadis, M. Giarratano Acute Seizure Management With Intravenous Levetiracetam In Neonates And Children/B. Kirmani, W. Hastings, O. Khan, P. Patel, A. Sarode, R. Castillo, M. Kempapura, S. Agadi, J. Aceves A Systematic Review And Network Meta-Analysis Of Eslicarbazepine Acetate And Other Recently-Approved Anti-Epileptic Drugs For Adjunctive Treatment Of Partial-Onset Seizures In Adults/ K. Betts, V. Bollu, G. De, D. Blum, F. Velez Once-Daily Trokendi XR (SPN-538) Dosing In Children With Epilepsy/J. D. Stocks, S. T. Brittain, J. K. Johnson Cost-Effectiveness Of Eslicarbazepine Acetate In Refractory Partial-Onset Epilepsy/K. O Day, F. Velez, K. Meyer Ezogabine Usage In Pediatric Patients: A Retrospective Review Of Safety And Efficacy From Two Academic Institutions/J. Toler, K. Chapman, T. Loddenkemper, J. Klehm Surgery Adult Magnetoencephalography- Guided Surgery In MRI Negative Or Ill-Defined Frontal Lobe Epilepsy Using Neuronavigation And Intraoperative MR Imaging/B. Sommer, K. Roessler, I. Blumcke, S. Rampp, H. Hamer, M. Buchfelder, H. Stefan Effects Of Invasive EEG Monitoring On Memory And Language After Left Anterior Temporal Lobectomy: A Propensity Model Analysis/R. M. Busch, T. E. Love, L. E. Jehi, L. Ferguson, R. Yardi, W. Bingaman, J. Gonzalez-Martinez Temporal Plus Seizures Are The Main Prognostic Factor For Unfavourable Surgical Outcome In Patients With Temporal Lobe Epilepsy/C. Barba, S. Rheims, L. Minotti, J. Isnard, D. Hoffmann, S. Chabardes, M. Guenot, P. Ryvlin, P. Kahane Stereotactic Laser Ablation Is A Potentially Curative Procedure After Unsuccessful VNS Or RNS For Mesial Temporal Lobe Epilepsy/J. J. Shih, R. Wharen, W. Tatum, R. Gross, J. Willie, D. Labiner, M. Weinand, A. Sharan, M. Sperling Intraoperative Supplementary Motor Area (SMA) Monitoring For Medial Frontal Lesions/S. Shibata, T. Kunieda, R. Matsumoto, Y. Yamao, R. Inano, S. Nishida, T. Nakae, T. Kikuchi, Y. Arakawa, Y. Takagi, A. Ikeda, R. Takahashi, S. Miyamoto Postoperative Interictal Epileptiform Discharges Within One Month After Selective Amygdalohippocampectomy For Mesial Temporal Sclerosis/H. Yu, S. Hsu, C. Lin, Y. Shih Individualized Epilepsy Surgical Outcome Prediction Based On Neural Network Architecture/L. Bonilha, J. Lin, D. Drane, J. Jensen, R. Kuzniecky Pediatrics Language Mapping By Spontaneous Conversation Related High-γ Synchronization And Comparison With Conventional Electrical Cortical Stimulation/ R. Arya, J. A. Wilson, J. Vannest, A. W. Byars, H. Greiner, J. Buroker, H. Fujiwara, F. Mangano, K. Holland, N. Crone, D. Rose The Influence Of Lesion Volume, Perilesional Resection Volume And Completeness Of Resection On Seizure Outcome Following Resective Epilepsy Surgery For Cortical Dysplasia In Children/C. Oluigbo, D. Depositario-Cabacar, S. Magge, J. Myseros, M. Whitehead, R. Keating, W. Gaillard Yield And Predictors Of Epilepsy Surgery Candidacy In Children Admitted For Surgical Workup/ O. Haque, K. Nickels, N. Wetjen, L. Wong-Kisiel, E. Wirrell Epilepsy Surgery Outcomes For Lesionectomy In Non-Dysplastic Lesions In Children With Intractable Epilepsy/R. Villalobos, E. Gonzales, J. Torrez-Corzo A Circuitous Journey: Parent Perspectives Of Getting To Pediatric Resective Epilepsy Surgery/C. Bower Baca, H. Pieters, T. Iwaki, G. Mathern, B. Vickrey Posterior Quadrant Disconnection Surgery For Sturge-Weber Syndrome/H. Sugano Central Cortex-Preserving Multilobar Surgery: An Alternative Option For Patients With Hemispheric Pathology And Minimal Motor Deficit/T. Ono, H. Baba, K. Toda, R. Honda The Impact Of Epilepsy Surgery On Paediatric Quality Of Life/W. Hader, L. Ruttle-Soon, H. Carlson, D. Slick, L. Bello-Espinosa, E. Sherman Is Diffusion Tensor Imaging Useful To Localize The Epileptic Focus In Children With MRI-Negative Epilepsy?/K. Toda, H. Baba, T. Ono, R. Honda Seizure Outcomes After Resective Epilepsy Surgery In Children With Lennox-Gastaut Syndrome/ P. Suwanpakdee, A. Naduvil Valappil, L. Jehi, A. Gupta, W. Bingaman, J. Gonzalez-Martinez, I. Najm, E. Wyllie Analysis Of Epileptic Discharges Using Implanted Subdural Electrodes In Patients With Sturge- Weber syndrome/y. Iimura, H. Sugano, M. Nakajima, T. Higo, H. Arai SATURDAY 45

48 Saturday December 6, 2014 Poster Session 1 Noon - 6:00 p.m. Convention Center Hall 4B, Level Risk Of Seizure Recurrence In Children With Pathology Confirmed Focal Cortical Dysplasia Undergoing Surgical Resection/A. Mrelashvili, E. Wirrell, K. Nickels, L. Wong-Kisiel Surgical Versus Medical Treatment For Children With Epileptic Encephalopathy In Infancy And Early Childhood. An Observational Cohort Study By Far-East Asia Catastrophic Epilepsy (FACE) Study Group/T. Otsuki, H. Kim, G. Luan, Y. Inoue, H. Baba, H. Oguni, S. Hong, S. Kameyama, K. Kobayashi, S. Hirose, H. Yamamoto, S. Hamano, K. Baba, A. Takahashi, T. Kaido, K. Sugai Visualization Of Epileptogenic Networks From Interictal ieeg Using Granger Causality/J. R. Madsen, E. Park Clinical Factors For Long-Term Seizure Remission And Developmental Outcome After One-Stage Total Corpus Callosotomy/M. Iwasaki, M. Uematsu, T. Nakayama, N. Hino-Fukuyo, K. Haginoya, S. Osawa, Y. Shimoda, K. Jin, N. Nakasato, T. Tominaga All Ages Long-Term EEG And Clinical Outcome Of Laser Thermal Ablation In Large Series Of Lesional And Non- Lesional Epileptic Foci In Adults And Children/M. Chez, A. Ghassemi, S. Ciricillo Factors Associated With Failed Extra-Temporal Lobe Epilepsy Surgery/D. J. Englot, K. Raygor, P. Garcia, R. C. Knowlton, K. I. Auguste, E. Chang Inflammatory Mediators Role In Epileptogenesis Caused By Cavernous Angioma/M. Nakajima, H. Sugano, Y. Iimura, T. Higo, Y. Harada, H. Arai The Role Of Corpus Callosotomy And Vagus Nerve Stimulation For Medically Refractory Epilepsy And Their Future As Palliation In Epilepsy Surgery/T. Yamamoto, A. Fujimoto, T. Yamazoe, T. Okanishi, T. Yokota, H. Enoki Temperatures Achieved In Human And Canine Neocortex During Intraoperative Passive Or Active Focal Cooling/R. Han, C. Yarbrough, S. Rothman, E. Patterson, X. Yang, J. Miller, R. D Ambrosio, M. Smyth Medical Cost Reduction By Vagus Nerve Stimulation/A. Onomura, T. Yamamoto, H. Iseki, K. Iwasaki, M. Umezu Surgical Outcome Of Lesionectomy Vs Lesionectomy + Temporal Lobectomy For Lesional Temporal Lobe Epilepsy/V. Rajasekaran, D. B. Burkholder, G. Worrell, R. Marsh, F. Meyer, J. Mandrekar, J. Britton Long-Term Product Reliability For Implantable VNS Therapy Generators And Leads/C. M. Gordon, M. T. Bunker Conformal Laser Ablation: A Safe & Effective Treatment For Focal, Non-Mesial Temporal Lobe Epilepsy/ S. Bandt, A. H. Hawasli, R. E. Hogan, E. Leuthardt Development And Validation Of A Prognostic Nomogram Of Seizure- Freedom After Resective Epilepsy Surgery/L. Jehi, R. Yardi, K. Chagin, L. Tassi, G. Worrell, F. Cendes, M. Morita, F. Bartolomei, P. Chauvel, I. Najm, J. Gonzalez-Martinez, W. Bingaman, M. Kattan 46

49 AES 68 TH ANNUAL MEETING Seattle, WA SUNDAY December 7, :45 a.m. 4:45 p.m. Investigators Workshops Location listed under each session Overview These workshops, conducted informally and designed to encourage interaction, will address several important areas of rapidly-emerging knowledge in clinical and basic research in epilepsy. The workshops are intended to identify challenges in current research, propose methods to overcome those challenges, and encourage areas for future investigation. The Basic Science Investigator Workshops will highlight a number of research areas that have been developing rapidly over the last year. Participants include established and junior epilepsy investigators as well as researchers outside the epilepsy community who have specialized expertise that may be applied to epilepsy basic science. In addition, one of the workshops features presentations by junior investigators in cutting-edge areas of research. The Clinical Investigators Workshops provide a series of working seminars in matters of active clinical investigation and controversy. Speakers present results from their ongoing research and place their findings in the context of current understanding. Most of the workshops will run as concurrent sessions on Sunday, with a single workshop on Saturday afternoon on cannabis and epilepsy and another Monday afternoon on stem cells. Target Audience Basic scientists, neurologists, neuroscientists, pharmacologists, neuropsychologists and neurosurgeons who are performing research in epilepsy Program Investigators Workshop Chair: Michael Wong, M.D., Ph.D. Clinical Investigators Workshop Chair: Hal Blumenfeld, M.D., Ph.D. Morning Session I 8:45 a.m. - 10:15 a.m. 1. Yes, Focal Epilepsy Is a Network, But Does it Matter? Convention Center Room 608, Level 6 Moderator: Jean Gotman, Ph.D. Speakers: Christophe Grova, Ph.D., Philippe Kahane, M.D., Ph.D., Michael R. Sperling, M.D. This Investigator Workshop is supported in part by Acorda Therapeutics. 2. How Does Status Epilepticus Provoke the Generation of 'Epileptic Neurons'? Convention Center Room 613, Level 6 Moderator: Tallie Z. Baram, M.D., Ph.D. Speakers: Katja Kobow, Ph.D., Jong M. Rho, M.D., Ph.D., Gary P. Brennan, Ph.D. 3. Unraveling the Basis of Heterogeneity in Genetic Epilepsy Convention Center Room 609, Level 6 Moderator: Samuel F. Berkovic, M.D. Speakers: Christopher Reid, Ph.D., Dennis Dlugos, M.D., Peter B. Crino, M.D., Ph.D. Break: 10:15 a.m. - 10:30 a.m. Morning Session II 10:30 a.m. - Noon 4. Teratogenesis of Antiepileptic Drugs Convention Center Room 608, Level 6 Moderator: Kimford J. Meador, M.D. Speakers: Patrick Forcelli, Ph.D., Page B. Pennell, M.D., Kimford J. Meador, M.D. 5. Hot Topics and Late-breaking Research from Young Investigators in the Epilepsy Community Convention Center Room 613, Level 6 Moderators: Chris Dulla, Ph.D., Michael Wong, M.D., Ph.D. Speakers: Gemma Carvill, Ph.D.: The Expanding Role for Chromatin Remodeling in Epilepsy: Gene Discovery to Pathogenic Mechanisms Bethany Hosford, Ph.D.: Impact of Targeted Ablation Of Developing Dentate Granule Cells On Temporal Lobe Epileptogenesis Matt Weston, Ph.D.: Hyperactivation of mtor Signaling in a Two- Neuron Microcircuit Alters the Dynamics of Synaptic Transmission Dan Xu, Ph.D.: A Novel Therapy for Status Epilepticus Using Biodegradable Immune-Modifying Nanoparticles 6. Low-frequency Stimulation in Epilepsy Convention Center Room 609, Level 6 Moderator: Mohamad Koubeissi, M.D. Speakers: Mohamad Koubeissi, M.D., Dominique Durand, Ph.D., G. Campbell Teskey, Ph.D. Noon - 1:30 p.m. Poster Session (Lunch) Convention Center Room 6F, Level 6 Note: Number below refers to poster assignment Enhanced Histamine Release During The Pilocarpine-Induced Status Epilepticus Is Associated To Hippocampal Neuronal Damage In Rats: Effects Of Sodium Cromoglycate/Luisa Rocha Time- And Region-Specific Alterations In Cyclin D1 Expression Following STAT3 Inhibition In A Rat Model Of Temporal Lobe Epilepsy/ Y Cruz Del Angel Differential Toll-Like Receptor 4 Modulation Of Dentate Excitability In The Normal And Injured Brain/Viji Santhakumar Unit Activity Of Subicular, CA1, CA3, And Dentate Gyrus Principal Cells And Interneurons Before Spontaneous Seizures In A Rat Model Of Temporal Lobe Epilepsy/Paul Buckmaster Human Single Neuron Correlates Of High Frequency Oscillations During Seizures/Omar Ahmed The mtor Inhibitor, Rapamycin, Attenuates Acute Seizure-Induced Dendritic Injury In Mice/Dongjun Guo TRPV1 Receptors Modulate The Expression Of Experimental Febrile Seizures During Development In Mice/Karlene Barrett Hypothermia Prevents The Development Of The Calcium Plateau Following Status Epilepticus/Kristin Phillips Tonic GABAergic Inhibitory Signaling To Dentate Granule Cells In Mice Following Controlled Cortical Impact/Jeffery Boychuk Postnatal Disruption Of The Cytoskeletal Protein Ndel1 Induces Hippocampal Structural Pathology And Spontaneous Recurrent Seizures/Cezar Gavrilovici GABA Agonists Restore Inhibitory GABA Neurotransmission in Mesiotemporal Lobe Epilepsy: In Vivo And In Silico Modeling Evidence/ Antoine Depaulis Modeling PIK3CA-Related Malformations Of Cortical Development And Epilepsy In Mice/Franck Kalume Thalamic Deep Brain Stimulation To Improve Consciousness After Seizures/Abhijeet Gummadavelli SUNDAY 47

50 SUNDAY December 7, Treatment Of Convulsive Status Epilepticus In An Animal Model Of Glucose Transporter Type 1 Deficiency (G1D) Syndrome/Cary Trent Minocycline Reverses Pro-Epileptogenic Effect Of Viral-Like Brain Inflammation In The Mature And Immature Rat Brain/Nina Dupuis Systemic TLR3 Agonist Injection Enhances Epileptogenesis In Rat Pups But Does Not Affect The Adult Rats/Stephane Auvin Distinct Phenotypes And Genotypes Of SPTAN1 Encephalopathy/ Jun Tohyama Epilepsy-Associated Mutant Voltage-Gated Sodium Channels Alter Resurgent Current Generation That Could Be Preferentially Targeted With Cannabidiol/Reesha Patel Neuroactive Steroids Halt Electrographic Seizures In The Lithium-Pilocarpine Model Of Pharmaco-Resistant Status Epilepticus/ James Doherty Development And Validation Of A Prognostic Nomogram Of Seizure-Freedom After Resective Epilepsy Surgery/Lara Jehi Increase In Dendritic Spines Correlates With Increased Synapses In Hippocampal CA1 Following Hypoxia-Induced Neonatal Seizures/ Jocelyn Lippman-Bell Retrograde Monosynaptic Tracing Of Inputs To Neonatal- Vs. Adult- Born Dentate Granule Cells In A Rodent Temporal Lobe Epilepsy Model/ Xi Du Disabled 1-Deficient Mice Exhibit Hippocampal Structural Abnormalities And A Reduced Seizure Threshold/Matthew Korn Functional Evaluation Of A De Novo GRIN2A Mutation In A Patient With CSWSS, Continuous Spike And Waves During Slow-Wave Sleep Syndrome/Hongjie Yuan Mechanisms Of Epilepsy And Epileptic Encephalopathy Due To KCNT1 Mutations/Imran Quraishi A KCNQ2/3 Mutation Causing Severe Epilepsy Disrupts Channel Targeting To The Axon Initial Segment/Baouyen Tran Modulation Of NKCC1 And KCC2 Co-Transporters For Control Of Drug-Resistant Seizures/Volodymyr Dzhala Unravelling The EEG Footprints That Develop Into Spontaneous Recurrent Seizures (SRS) During Epileptogenesis In C57BL6/J Mouse Model Of Temporal Lobe Epilepsy (TLE)/Thimmasettappa Thippeswamy New Model Of Focal Cortical Dysplasia Associated Epilepsy/ Lawrence Hsieh Oxidative Stress-Mediated Mitochondrial Dysfunction And Neuronal Loss Contribute To Cognitive Deficits In Experimental Temporal Lobe Epilepsy/Jennifer Pearson Enhancing KCC2 By Acute TrkB Inhibition Rescues Phenobarbital- Resistant Seizures In A Model Of Neonatal Ischemia/Shilpa Kadam Cardiac Consequences Of Repeated Brief Seizures In Chronic Experimental Temporal Lobe Epilepsy/John Jefferys Flupirtine Is More Efficacious Than Phenobarbital In The Treatment Of Hypoxia-Ischemia Induced Neonatal Seizures In A Rodent Model/ Dayalan Sampath Lithium-Pilocarpine And DFP-Induced Status Epilepticus In Immature Rats: Behavioral, Electrographic, And Neuropathological Characteristics/Erika Scholl Comparison Of Spike-Wave Discharges And Other Oscillatory Activity In Normal Animals With Spontaneous Recurrent Seizures Across Several Animal Models Of Acquired Epilepsy/F. Edward Dudek Late Inhibition Of mtor Suppresses Fully Established Epilepsy And Associated Neuropathology In The NS-Pten KO Mouse Model Of Cortical Dysplasia/Lena Nguyen Tracking Inflammation In Epileptogenic Brain Tissue In The Rat By Nanoparticles/Sara Eyal Early Seizure Detection Using Relative Gamma And Ripple Band Phase Decoherence/Zoltan Nadasdy Whole-Exome Sequencing In 84 Cases Of Unsolved Progressive Myoclonus Epilepsy/Mikko Muona Etiologies And Yield Of Investigations For Infantile Spasms: Results Of A US Multicenter, Prospective Study/Elaine Wirrell Afternoon Session I 1:30 p.m. - 3:00 p.m. 7. Brain Connectivity in Health and Epilepsy Convention Center Room 608, Level 6 Moderator: Jeffrey G. Ojemann, M.D. Speakers: Catherine Chu-Shore, M.D., Luigi Maccotta, M.D., Ph.D., Kurt Weaver, M.D. 8. SUDEP Mechanisms: A Basic Science Perspective Convention Center Room 613, Level 6 Moderators: Gordon F. Buchanan, M.D., Ph.D. Speakers: Gordon F. Buchanan, M.D., Ph.D., Isamu Alba, Ph.D., Carl L. Faingold, Ph.D. 9. Finding Risk Alleles in Generalized Epilepsies: Next Generation Sequencing and the Virtues of Large Collaborations Convention Center Room 609, Level 6 Moderator: Slavé Petrovski, Ph.D. Speakers: Slavé Petrovski, Ph.D., Roland Krause, Dr. Sci., Patrick Cossette, M.D. Break: 3:00 p.m. - 3:15 p.m. Afternoon Session II 3:15 p.m. - 4:45 p.m. 10. Stress and Seizures Convention Center Room 608, Level 6 Moderators: Michael D. Privitera, M.D. Speakers: Jane B. Allendorfer, Ph.D., James Herman, Ph.D., Michael D. Privitera, M.D. 11. Understanding Infantile Spasms: A Pathogenic Perspective Convention Center Room 613, Level 6 Moderators: Chris Dulla, Ph.D., Aristea S. Galanopoulou, M.D., Ph.D. Speakers: Chris Dulla, Ph.D., Jeffrey L. Noebels, M.D., Ph.D., John W. Swann, Ph.D. 12. Which Parts of the Brain Participate in Seizures, and Why Does It Matter? Convention Center Room 609, Level 6 Moderator: Catherine Schevon, M.D., Ph.D. Speakers: Andrew Trevelyan, M.D., Ph.D., Hal Blumenfeld, M.D., Ph.D., Catherine Schevon, M.D., Ph.D. 48

51 SUNDAY December 7, :45 a.m. 5:15 p.m. Annual Course: Seizures and EEG in the Critically Ill Patient (6.0 CME Credits) Convention Center Ballroom 6C, Level 6 Overview The Annual Course will focus on diagnosis and management of seizures in patients admitted to intensive care units (ICU), both those with known epilepsy and those with seizures due to systemic illnesses or infection. Topics include: diagnostic challenges, initially regarding etiologies of seizures in ICU patients; how routine and / or continuous EEG can help (or hinder) management. Financial issues and management options for patients having seizures as well as Status Epilepticus in ICU settings. Lectures will cover standard anticonvulsants, sedative and coma-inducing agents, as well as non-standard treatments such as surgery, diet, immunomodulatory agents, and TMS. The Annual Course will conclude with a discussion of prognosis and outcomes from seizures as well as status epilepticus. The course will include case presentation, debate and use of audience response system. Learning Objectives u Recognize interictal and ictal EEG patterns in critically ill patients u Define intervention strategies for critically ill patients with both subclinical and refractory clinical Status Epilepticus u Implements rational medical therapy for seizures in critically ill patients u Counsel families regarding implications and prognosis of sub-clinical and clinical Status Epilepticus u Assist physicians in treating subclinical and clinical seizures through use of appropriate medications u Recognize the implications of seizures in a critically ill patient who survived and is now facing neuropsychological difficulties. Target Audience Intermediate and Advanced (see page 120 for details) Program Chair: Eric Kossoff, M.D. Diagnostic Challenges 8:45 a.m. Introduction to Morning Session Eric Kossoff, M.D. 8:55 a.m. Case Presentation (Johnny, Part 1) Andreas Alexopoulos, M.D., M.P.H. 9:00 a.m. Lecture: Etiologic Considerations in Seizure Screening Nicholas S. Abend, M.D. 9:25 a.m. Lecture: EEG in the ICU: Nomenclature and Current Trends Susan T. Herman, M.D. 9:50 a.m. Debate: Utility of Continuous EEG Monitor All vs. Be Selective? Lawrence J. Hirsch, M.D. (Pro) / Paul Vespa, M.D. (Con) 10:20 a.m. Break 10:35 a.m. Case (Johnny, Part 2) Lily Wong-Kisiel, M.D. 10:40 a.m. Lecture: Neonates and Children: Are They Different? Cecil Hahn, M.D. 11:05 a.m. Lecture: NORSE, FIRES, and Encephalitis Nicolas Gaspard, M.D., Ph.D. 11:30 a.m. Flash Panel: Financial and Logistical Issues Is Continuous EEG Worth the Cost and Use of Resources? Thomas P. Bleck, M.D. Who Should be Reading ceegs? The Role of the Neurointensivist Edward M. Manno, M.D. 11:50 a.m. Morning Wrap-Up Eric Kossoff, M.D. Noon-2:00 p.m. Lunch Break in Exhibit Hall Treatment Challenges 2:00 p.m. Introduction to Afternoon Session Eric Kossoff, M.D. 2:05 p.m. Case (Johnny, Part 3) Jack Lin, M.D. 2:10 p.m. Lecture: Pharmacologic Treatment of Status Epilepticus in the ICU Daniel H. Lowenstein, M.D. 2:30 p.m. Lecture: Pharmacologic Treatment of Super-refractory Status Epilepticus Joseph I. Sirven, M.D. 2:55 p.m. Debate: Should We Treat Anoxic / Myoclonic Seizures? David M. Ficker, M.D. (Pro) / Jennifer L. Hopp, M.D. (Con) 3:25 p.m. Lecture: AES Treatment Guidelines for Status Epilepticus Tracy A. Glauser, M.D. 3:40 p.m. Break 3:55 p.m. Flash Panel: Other Treatments to Try When Nothing Else Works Surgery Yu-tze Ng, M.D. Ketogenic Diet Mackenzie Cervenka, M.D. Steroids / IVIG How Do They Work? Annamaria Vezzani, Ph.D. Transcranial Magnetic Stimulation Alexander Rotenberg, M.D., Ph.D. 4:35 p.m. Lecture: Long-term Prognosis and Outcomes Elizabeth J. Waterhouse, M.D. 4:55 p.m. Case (Johnny, Part 4 and Conclusion) Jerzy P. Szaflarski, M.D., Ph.D. 5:00 p.m. Conclusions Eric Kossoff, M.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 6.0 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 6.0 contact hours (0.6 CEUs). UAN L01-P. Initial Release Date: 12/7/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Annual Course Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Patient Care, Medical Knowledge and Practice-based Learning Acknowledgment This program is supported in part by an educational grant from Electrical Geodesics, Inc. 49 SUNDAY

52 SUNDAY December 7, :00 p.m. 7:30 p.m. Special Interest Group Meetings Location listed under each session Drug Resistant Epilepsy Definition, Epidemiology, Predictors, Using Big Data for Epidemiological Research Convention Center Room 617, Level 6 Coordinator: Nathalie Jetté, M.D., FRCPC Speakers: Samuel Wiebe, M.D., Martin J. Brodie, M.D., Elaine C. Wirrell, M.D., Jakob Christensen, M.D., Ph.D. This SIG will provide participants with an up to date review about drug-resistant epilepsy. We will begin by reviewing the latest definition of drug resistant epilepsy and consider the evidence behind it. We will review the epidemiology of drug-resistant epilepsy and whether patterns are changing over time, discuss risk factors for pharmaco-resistance in children with epilepsy and will examine whether big data can be exploited to study drug-resistance in epilepsy. Frontal Lobe Epilepsy: Semiology and Cognitive Aspects Convention Center Room 608, Level 6 Coordinators: Andrea Bernasconi, M.D., Fernando Cendes, M.D., Ph.D. Speakers: Prof. Patrick Chauvel, Bruce Hermann, Ph.D. Frontal lobe epilepsy is the second most common type of localization-related epilepsy that undergoes surgical treatment, and probably the most challenging in terms of medical and surgical management. The causes are diverse and often undetected by current standards of neuroimaging investigation, and a large proportion of patients need invasive EEG investigation. Despite advances in technology, many patients with frontal lobe epilepsy cannot undergo surgery either due to the seizure onset zone being close to or involving eloquent areas (motor and language) or because there is a lack of clear localization of epileptogenic lesion / seizure focus. We will discuss the pathophysiological aspects of the complex seizure semiology and cognitive changes in frontal lobe epilepsy. Magnetoencephalography (MEG) / Magnetic Source Imaging (MSI) Source Localization Results: Blind Faith, Black Art, or Scientific Method? Convention Center Room 620, Level 6 Coordinators: Anto I. Bagic, M.D., Ph.D. Speakers: Steven Stufflebeam, M.D., Ph.D., Richard C. Burgess, M.D., Ph.D., Michael Funke, M.D., Ph.D., John S. Ebersole, M.D. Although MEG is an established tool for localizing normal and pathological fields, and clinical MEG is a recognized diagnostic subspecialty, there is a need to improve the understanding and thus usefulness of MEG source modeling results for the practitioner to facilitate further growth of the field. To this end, it is essential to review the concepts of source localization accuracy based not only on the equivalent current dipole (ECD) but also on various extended models. Thus, Dr. Stufflebeam will introduce distributed source localization methods; Dr. Burgess will scrutinize the criteria for acceptance of a dipole fit; Dr. Funke will discuss the methods for improving source localization yield and accuracy (spike averaging, tsss, region of interest sub-selection, etc.) and Dr. Ebersole will elucidate on the concept of dipole-worthiness. Neonatal Seizures: Should We Pursue Comparative Effectiveness Studies for the Treatment of Neonatal Seizures? Convention Center Room 609, Level 6 Coordinators: Renee A. Shellhaas, M.D., M.S., Courtney Wusthoff, M.D. Speakers: Ronnie Guillet, Tracy A. Glauser, M.D. There remains a paucity of evidence regarding optimal treatment for neonatal seizures. While there are a few ongoing RCTs for specific agents in the treatment of neonatal seizures, all have faced significant challenges. Some have proposed the solution to this knowledge gap lies in comparative effectiveness research, using the existing wide variation in clinical practice to study impact on outcomes. Others argue that a well-designed and executed RCT remains feasible and is preferable as the gold standard to provide an evidence basis in this area. Following presentation of three relevant posters, our speakers will debate the sides of this issue. Neuroendocrinology: Sex Differences in Epileptogenesis Convention Center Room 613, Level 6 Coordinator: D. Samba Reddy, Ph.D., RPh Speakers: Aristea S. Galanopoulou, M.D., Ph.D., Cynthia L. Harden, M.D., D. Samba Reddy, Ph.D., RPh, Asla Pitkanen, M.D., Ph.D. Sex difference in seizure susceptibility is one of the long-standing issues of epilepsy. Clinical evidence shows gender- and age-related expression of many seizure syndromes. The incidence of epilepsy is generally higher in males than in females. More women than men are diagnosed with idiopathic generalized epilepsy, but localization-related symptomatic epilepsies are more frequent in men, and cryptogenic localization-related epilepsies are more frequent in women. Changes in seizure sensitivity are also evident at puberty, which is associated with rigorous changes in reproductive hormones and behavioral patterns. Overall, there is considerable evidence indicating that men exhibit greater seizure susceptibility than females, while many females exhibit greater fluctuations in susceptibility to seizures, including menstrual cycle-related changes in seizure activity. Although sex differences in epileptogenesis are widely recognized, there is little discussion on their mechanisms and therapeutic implications. In this SIG, sex-based differences in seizure sensitivity and epileptogenesis will be discussed, with emphasis on variations between men and women in factors such as steroid hormones, gender-specific developmental consequences, biologic differences in neuronal networks in the brain and gender-based differential therapeutic interventions. Pediatric Case Discussions Convention Center Room 612, Level 6 Coordinator: Elaine Wyllie, M.D. Speakers: TBA Six expert faculty will present impactful cases illustrating important clinical points in diverse topics including pediatric epilepsy diagnosis, seizure semiology, EEG, antiepileptic medications, surgery, genetics, comorbidities, and other topics. Psychogenic Nonepileptic Seizures: What Can We Learn from PNES Semiology? Convention Center Room 615, Level 6 Coordinators: Markus Reuber, M.D., Ph.D., FRCP, Sigita Plioplys, M.D. Speakers: Roderick Duncan, M.D., Ph.D., FRCP, Gaston C. Baslet, M.D., Julia Doss, Psy.D., LPN This SIG will focus on the visible and subjective symptomatology of PNES in adults and children and explore whether different semiological features can tell us anything about the etiology, course or optimal management of patients with PNES. A wide range of subjective semiological features have been reported during PNES, including sensory experiences from different modalities, symptoms indicative of hyperarousal, distressing experiences and varying degrees of preserved awareness. Similarly, the objectively observable semiology of PNES has been studied extensively, and characteristic features have been described. Some PNES experiences have been linked to antecedent trauma and better or worse outcome. Other than this, little is known about how PNES semiology might relate to etiology or mechanism, and whether some elements of it might have implications for choice of therapy. Drs. Duncan and Baslet will summarize published observations of PNES subjective and objective semiology in adults, will discuss the implication of these observations and will explore possibilities for future research. While PNES in children shares similar semiological features to those in adults, there are few studies assessing subjective experience and how this may inform treatment choice or treatment outcome. Dr. Doss will discuss PNES semiology in the pediatric population. 8:00 p.m. 10:00 p.m. Social Networking Groups Sheraton Madrona, Second Floor (registration is not required) Informal gathering and networking for SIG participants. Space is limited so participants are welcome on a first-come, first-served basis. Roundtable topics include: Adolescent Epilepsy and Transitional Clinics.

53 Sunday December 7, 2014 Poster Session 2 8:00 a.m. 6:00 p.m. Convention Center Hall 4B, Level 4 Authors Present: Noon 2:00 p.m. Poster Walking Tours begin at 12:15 p.m. (see page 15 for details) Behavior/Neuropsychology/ Language Adult Utility Of RBANS In Intractable Epilepsy Patients In A Arab Cohort/ N. A. Moussa, S. A. Al Jarrah, K. A. Siddiqui Quality Of Life And Mood Status Of New Patients In Outpatient Clinic For Epilepsy/R. Hanaya, Y. Kashida, H. Hosoyama, K. Iida, T. Otsubo, K. Arita Long-Term Follow-Up Of Memory Functions In Patients With Chronic Vagal Nerve Stimulation/I. Tyrlikova, Z. Hummelova, R. Kubikova, S. Telecka, M. Tyrlik, R. Kuba, M. Brazdil, J. Chrastina, J. Hemza, Z. Novak, I. Rektor Mapping The Cognitive Network In Adults With Temporal Lobe Epilepsy/T. Kellermann, J. Lin, L. Bonilha, B. Hermann Better Executive Function Associated With Higher Frontoparietal Functional Connectivity In The Spared Hemisphere In Left Mesial TLE/N. Kucukboyaci, K. Leyden, N. Kemmotsu, E. Tecoma, R. Q. Loi, D. Lee, C. McDonald The Social Experience Of Stigma In A Midwestern Epilepsy Population/J. L. Moore, C. Bosler Walton Mediators Of Quality Of Life In An Underserved Population Of Epilepsy Patients/D. Becker, A. Shallcross, D. Friedman, A. Singh, J. French, R. Jurd, T. Spruill, O. Devinsky Unprovoked Seizures In Patients Diagnosed With Dementia: Clinical And Neurophysiologic Characteristics/R. Sarkis, B. Dickerson, Z. Chemali A Randomized Efficacy Trial Of A Clinic-Based Decision Support System For Epilepsy Self-Management/ R. Shegog, C. Begley Reinstatement Of Distributed Spatiotemporal Patterns Of Oscillatory Power During Associative Memory/K. A. Zaghloul, R. B. Yaffe, M. S. Kerr, S. Damera, S. V. Sarma, S. K. Inati Relations Between Social Cognition And Quality Of Life In Epilepsy/K. Janke, Y. Cukier, S. Hwang, A. Mehta, C. Harden, S. Schaffer Pediatrics Neuropsychological Outcome In Children With Focal Cortical Dysplasia Following Surgical Resection For Intractable Epilepsy/R. Boada, G. Berrios-Siervo, D. L. Cohen, G. Wilkening, P. Laoprasert Memory And Executive Functioning In Monolingual And Bilingual Children With Epilepsy/ A. Veenstra, J. Riley, J. Romain, M. Muhonen, J. Lin, M. Zupanc, G. Mucci Language Localization In Pediatric Epilepsy: Comparison Between Functional Magnetic Resonance Imaging (fmri) And Electrical Stimulation Mapping (ESM)/C. M. Salinas, P. Chen, M. Korostenskaja, E. Castillo, J. Baumgartner, J. Seo, K. Lee, M. Westerveld Neurodevelopment In Preschool Children Of Fife And Lothian Epilepsy Study: Neuroprofiles A Population-Based Study/M. B. Hunter, K. Verity, R. Sumpter, A. McLellan, J. Shetty, M. Yoong, R. Chin Unexpected Subclinical Spikes: Clinical And Neurophysiological Correlations/M. Mintz, L. Szklarski, M. Chadehumbe, G. Alberts, S. Woldoff, M. Mohamadpour, J. Keating Neuropsychological Profiles Of Children With Benign Rolandic Epilepsy Highlight Vulnerability In Cognitive Efficiency, Learning And Memory/ K. Boyer, J. Girard, C. Vega, D. P. Waber, M. Takeoka Psychiatric Disturbance In Children With Epilepsy/F. Besag, A. Aldenkamp, R. Caplan, D. Dunn, G. Gobbi, M. Sillanpaa Computerized Training Of Working Memory In Children With Epilepsy Update/V. Terwilliger, M. Berl, E. Fisher, L. Sepeta Gender Differences And ADHD Among Children With Epilepsy/R. Trobliger, M. E. Lancman, M. Lancman Minnesota Epilepsy Group s Multidisciplinary Clinic for New Onset Pediatric Epilepsy (NOPE)/E. Adams, J. Doss, K. Berg, C. Opperman, F. Ritter Postoperative Neuropsychological Outcomes in Pediatric Patients Undergoing Temporal Lobe Epilepsy Surgery/ L. Bailey, T. Parsons, H. Blumenthal, A. Boals, M. Perry Psychiatric Comorbidity In Children With Recent-Onset Epilepsy: A 2-Year Prospective Controlled Investigation/J. Jones, D. Almane, D. Jackson, D. Hsu, L. Zawadzki, C. Stafstrom, M. Seidenberg, B. Hermann Left Centrotemporal Spikes Affect Language Function In BECTS/ J. Vannest, T. Maloney, J. Tenney, J. Szaflarski, K. Hibbard, D. Morita, T. Glauser All Ages Cognitive Consequences Of Interictal Spikes/L. Groomes, R. Madhavan, H. Tang, N. E. Crone, J. Madsen, A. Golby, F. Lenz, G. Kreiman, W. Anderson Use Of Magnetic Source Imaging Language Mapping To Predict Language Decline Following Left Temporal Lobe Epilepsy Surgery/ R. Doss, G. Risse, W. Zhang, R. Lyons Spatial Dissociation Between Phonological And Semantic Speech Processing In The Lateral Temporal Lobe/M. J. Hamberger, G. M. McKhann, II, M. Miozzo Pre- And Post-Neurosurgical Longitudinal Psychiatric Outcome In Intractable Mesial Temporal Lobe Epilepsy Patients Receiving Psychiatric Care/R. Pella, A. Velez, O. Lie, L. Morgan, K. Karkar, C. Szabo The Impact Of Mood On Memory Complaints And Memory Performance In Patients With Epilepsy/Y. Cukier, K. Janke, B. Rabinovitz, D. Hwang, D. Mehta, C. Harden, D. Schaffer Complication Rates During The WADA Test: One Center s Experience/N. J. Beimer, H. Buchtel, S. Glynn Health Services Delivery of Care Survey Of Online Patient Communities To Analyze Perceptions Of Healthcare Value/G. Cohen, B. Leymon-Porter, J. Fishman Epilepsy Surgery Trends In A Universal Health System: Ontario, Canada ( )/J. G. Burneo, K. Liu, S. Shariff, S. Leonard, A. Garg, G. Saposnik Antiepileptic Drug Therapy And Model Predictions Of Treatment Success/C. Dilley, M. Rozen-Zvi, J. Harrington, Y. Goldschmidt, C. Clark, P. Fritz, O. Devinsky Outpatient Education Reduces Emergency Room Use By Epilepsy Patients/F. T. Pascual, K. Hoang, C. Hollen, R. Swearingen, A. Hakimi, J. King, D. M. Thompson Time Elapsed From Onset Of Infantile Spasms To Diagnosis And Treatment/S. An, E. Nagarajan, I. Sánchez Fernández, C. Joshi, K. Knupp, I. Valencia, E. Wirrell, A. Berg, T. Loddenkemper Review Of Outpatient Home Clinical Video Telehealth (CVT) In Epilepsy And Pilot Experience Within The Veterans Health Administration (VHA)/T. T. Tran, P. Kelly, A. Husain Standardized Seizure Assessment In The EMU/O. Hope, M. Tapia, A. Balabanov Impact Of Psychogenic Non- Epileptic Seizure (PNES) Diagnosis On Acute Care Resource Utilization, Role For Psychiatric Consultation, And Follow-Up Within A Dallas County Hospital System/C. B. Culver, J. J. Konikkara, L. Howe-Martin, P. Van Ness, M. Agostini, R. Hays, P. Modur, K. Ding, P. Gupta 51 SUNDAY

54 Sunday December 7, 2014 Poster Session 2 8:00 a.m. 6:00 p.m. Convention Center Hall 4B, Level PACES In Epilepsy: Results Of A Self-Management Randomized Controlled Trial/R. T. Fraser, E. K. Johnson, S. Lashley, J. Barber, N. Chaytor, J. Miller, P. Ciechanowski, N. Temkin, L. Caylor A Survey Of Family Satisfaction Of Pediatric Epilepsy Care Via Telemedicine In British Columbia (BC)/A. Faber, S. Peinhof, S. Richards, Y. Pan, M. Connolly Yield Of Monitoring In An Adult Epilepsy Monitoring Unit/S. Agrawal, L. Turco, S. Goswami, M. Faulkner, S. P. Singh Reducing Urgent Hospital Re-Encounters Following Epilepsy Monitoring Unit Discharge/K. Secore, J. J. Chen, A. F. Van Straten, S. P. Wei, K. A. Birney, J. J. Harrington, B. Jobst, K. Bujarski, E. J. Kobylarz, V. Thadani, T. A. Caller Hospital Crossover Increases Utilization For People With Epilepsy: A Retrospective Cohort Study/ Z. Grinspan, J. S. Shapiro, E. L. Abramson, H. Jung, R. Kaushal, L. M. Kern Health Care Resource Utilization And Costs Of Immediate vs. Delayed Second-Line Treatment Initiation Among Patients With Epilepsy/V. Divino, V. Bollu, C. Makin, F. Velez Does Adherence To Epilepsy Quality Measures Predict Seizure Control?/L. V. Moura, D. Mendez, B. Vickrey, D. Hoch Quality Of Life Outcomes After Referral To A Tertiary Epilepsy Center/M. Tom, P. Penovich, R. Doss, A. Olson Improving The Standard Of Care For Patients With Epilepsy: Factors Influencing Hospitalization Rates/C. Begley, S. Helmers, D. Thurman, C. Dilley, C. Clark, P. Fritz, E. Faught Access to Care Leveraging Technology To Improve Access - Epilepsy Centers Of Excellence (ECoE) Capitalizes On The Telemedicine Opportunity/P. Kelly, R. Rehman, A. Husain Reduction Of ED Visits By Implementation Of An Urgent Clinic For Children With Established Epilepsy/D. Terry, J. Pacheco-Phillips The Michigan Pediatric Epilepsy Telemedicine Project- Innovative Subspecialty Care Within A Medical Home/S. Joshi, S. Clark, L. Fletcher, S. Jordan Patterns Of Neurological And Neurosurgical Care For Persons With Epilepsy/K. Sauro, S. Mah, B. Li, L. Svenson, C. DeCoster, S. Wiebe, N. Jetté Gaps In Medicaid Coverage Among Persons With Epilepsy/ P. Bakaki, S. Koroukian, J. Albert, K. Kaiboriboon Process Improvement To Reduce Time To Epilepsy Surgery/ C. Drees, R. DeBello, L. Frey, P. Korb, A. Shrestha, L. Strom, M. Spitz, C. O Brien Assessment Of Knowledge And Attitudes As Well As Patterns Of Referral About Epilepsy Surgery Among Family Doctors In Ontario, Canada/N. Cothros, J. G. Burneo, S. Brown, D. Steven Health Care Models Comorbidities Associated With Frequent Emergency Department Visits Among Children With Epilepsy/A. Patel, B. Haridas, Z. Grinspan Using The Measure Of Processes Of Care (MPOC-20) To Assess Family-Centred Care In Children With Epilepsy: Evaluating This Application/K. C. Joachim, P. Wilk, B. Ryan, K. Speechley Changing Practice Pattern Before And After The Modification Of EMU At UNC/R. Davis, N. Odom, S. Sutton, B. Vaughn, A. Hinn, E. Ryan, H. Ritchie, H. Shin The POEM Study: Patient Usage And Satisfaction With An Online Health Management Platform For Epilepsy/J. Hixson, D. Barnes, K. Parko, T. Durgin, S. Van Bebber, P. Wicks, A. Graham Mapping Epilepsy Subspecialty Care By Physician Networks/H. Hamid, J. Bates, M. Pugh, J. Neil, C. Brandt Developing An Effective Vocational Rehabilitation Model For Individuals With Epilepsy And Comorbid Disabilities In Japan: A New Hospital-Based Service Delivery System/Y. Namihisa, M. Sakata, M. Ohshima, M. Osako, M. Fujikawa Practice Resources Characteristics Of Pediatric Inpatients In Whom Clinical Decision Making Is Changed By Continuous Video EEG Monitoring/ M. C. Spiciarich, K. Ballaban-Gil, J. C. Beal Utility, Applications, Validity And Reliability Of The Inventory Of Neppe of Symptoms of Epilepsy and the Temporal Lobe (INSET) Compared With Ambulatory Electroencephalographic Parameters, Longitudinal Clinical Features, Anticonvulsant Responsiveness/ V. M. Neppe Frequency, Findings, And Comparisons Of Seizure Montage Polysomnography/A. Slansky, S. Manganaro, R. Ribot, L. Tornes Designing And Assessing Digital Patient Education Materials In An Outpatient Epilepsy Practice Setting/F. Blezin, H. Quinn, L. Ponticello, J. Richardson, J. Stribling SUDEP: What Do Patients Want To Know?/R. RamachandranNair, A. Rama Madhava, S. M. Jack, M. J. Shapiro Pregnancy And Seizures: Review Of Practice At George Washington University In The Past 5 Years/G. T. Que, C. Agha, U. Menon, R. Aly Epidemiology Epilepsy In The Elderly: A Distinct Entity?/C. Josephson, N. Jette, Y. Aghakhani, P. Federico, A. Hanson, W. Murphy, N. Pillay, S. Wiebe Mortality In Adult Epilepsy Patients Decreased Over 3 Decades: A Hospital-Based Cohort/ C. Granbichler, W. Oberaigner, G. Kuchukhidze, G. Bauer, J. Ndayisaba, K. Seppi, E. Trinka Research Project Management In Multi-Centre Long-Term Follow-Up Studies: Meeting The Challenges/ J. Terhaerdt, K. Speechley A Survey Of Medical Examiner Death Certification Of Vignettes On Death In Epilepsy: Gaps In Identifying SUDEP/D. Atherton, G. G. Davis, C. Wright, D. Hesdorffer Quality Of Life In Persons With Epilepsy/N. Jette, S. Patten, S. Wiebe, A. G. Bulloch, S. Macrodimitris, K. Fiest Epilepsy In Young Children: A Nationwide Population-Based Study/ K. Aaberg, P. Suren, C. Soraas, I. Bakken, M. Lossius, C. Stoltenberg, R. Chin Mortality In Patients With Epilepsy And Psychogenic Nonepileptic Seizures/ C. Garcia Gracia, K. Unnwongse, K. Shea, R. Burgess, I. Najm, L. Jehi Cause-Specific Mortality Among Children And Young Adults With Epilepsy: Results From The United States National Child Death Review Case Reporting System/ N. Tian, E. C. Shaw, M. Zack, R. Kobau, H. Dykstra, D. Thurman, T. M. Covington The Epidemiology, Management And Outcome Of Convulsive Status Epilepticus In Children/M. Uzun TBI Study In Moscow Predictors Of Seizures And Outcomes/A. Guekht, V. Krylov, N. Gulyaeva, E. Gusev, I. Kaimovsky, I. Trifonov, A. Talypov, S. Asratyan, A. Yakovlev, A. Lebedeva, A. Hauser Creation Of An Epilepsy Registry In The Veterans Health Administration/R. Rehman, P. Kelly, A. Husain A Community-Based Study Of The Sociodemographic Risk Factors Of Epilepsy Among Adults In The Province Of Alicante (Spain)/S. Palao-Duarte 52

55 Sunday December 7, 2014 Poster Session 2 8:00 a.m. 6:00 p.m. Convention Center Hall 4B, Level Prevalence And Risk Factors Of Peri-Ictal Autonomic Changes In Children With Temporal And Frontotemporal Lobe Seizures/ M. A. Whealy, E. Wirrell, L. Wong-Kisiel, K. Nickels Epileptic Seizures In Japanese Patients With Lacunar Infarction And Branch Atheromatous Disease/ K. Obata, M. Kinoshita, K. Sato, M. Chin, S. Yamagata, K. Shindo Evidence Mesial TLE Is Not Always Medically Refractory/P. Tseng, M. Liu, N. Fountain Resective Focal Epilepsy Surgery Has Selection Of Candidates Changed?/C. Kwon, J. Neal, J. Tellez-Zenteno, A. Metcalfe, W. Hader, S. Wiebe, N. Jetté The Clinical Characteristics Of Preschool-Aged Children Visited Emergency Room By Epileptic Seizures/B. Cha, G. Noh Public Health Effects Of Epilepsy In ADHD And Quality Of Life/M. Salam, K. Works A Mobile Health-Intensive Comprehensive Care Delivery Model For Amplifying Outreach For Refractory Epilepsy And Comorbid Mood Disorders/M. A. Rossi, N. Monica, K. Babiarz, L. Cendejas, R. Hanson, M. Tshionyi, J. Endres, M. Jain Attitude Of Neurologists In The United Arab Emirates Towards Epilepsy And Motor Vehicle Accidents/A. Shatila, O. Khaddam, N. O. Al Matrooshi, T. Alsaadi Trends In Healthcare Charges And Length Of Stay For People With Epilepsy, South Carolina, /D. A. Wilson, A. Selassie Engaging Primary Care Providers In Epilepsy Quality Measures/S. T. Arnold, R. R. Said, D. Sirsi, E. A. Burch BE- Beyond Epilepsy, Education, Awareness And Advocacy Program For Frontline Healthcare Providers In Tanzania/L. Jurasek, S. Mbelwa Premature Mortality In Poor Health And Low Income Adults With Epilepsy/K. Kaiboriboon, N. Schiltz, P. Bakaki, S. Lhatoo, S. Koroukian What Affects The Self-Stigma And Self-Esteem Of Persons With Epilepsy?/A. Tabata, K. Hara, S. Tohma, S. Tanaka, M. Hara, K. Ohta, M. Matsuura, M. Inaji, T. Maehara, Y. Sumi Do Drivers With Epilepsy Have Higher Rates Of Motor Vehicle Accidents Than Those Without Epilepsy?/P. Naik, M. Fleming, P. Bhatia, C. Harden The Effects Of Reports Of Car Accidents Caused By Persons With Epilepsy On Its Stigma In Japan/ K. Hara, S. Tanaka, Y. Hirose, S. Tohma, M. Matsuura, K. Ohta, M. Inaji, M. Hara, T. Maehara, Y. Sumi Antiepileptic Drug And Cardiovascular Risk In Patients With Epilepsy/C. Huang, C. Hsieh, Y. Yang Kao Epilepsy Transition: Challenges Of Caring For Adults With Childhood- Onset Seizures/F. Borlot, J. Tellez-Zenteno, A. Allen, A. Ali, O. Snead III, D. Andrade Epilepsy Knowledge And Understanding Among Parents/Caregivers Of Children With Epilepsy/L. Sanchez-Ortiz, R. Rios-Motta, M. Rios-Motta Implicit Attitudes Toward Epilepsy In Japan/S. Tohma, K. Hara, A. Tabata, S. Tanaka, M. Hara, M. Matsuura, K. Ohta, M. Inaji, T. Maehara, Y. Sumi History of Epilepsy Diet And Epilepsy A Historical Review / S. Goswami, S. P. Singh Otto Löwenstein ( ): The Forgotten Pioneer Of Video-Monitoring In Epilepsy/ G. Kraemer The Birth Of Stigma In Antiquity: Phaedrus As Disabling Text/A. Swenson Case Studies Refractory Partial Seizures As Manifestation Of Polymerase Gamma (POLG) Mutation In Pediatric Patients/N. Dalvi, L. Vargas, S. Karkare Pre- And Post-Ictal Body Positions In Patients With Generalized Convulsive Seizures/S. Graf, S. Wu, J. Liebenthal, S. Rose, J. Tao Alexia Without Agraphia In A Child An Unusual Complication Of Epilepsy Surgical Resection In The Left Posterior Head Region/ G. Wilkening, N. Stence, M. Handler, P. Laoprasert Resolution Of Seizures And Normalization Of EEG After Initiation Of CBD In A Patient With Doose Syndrome/J. Gold, S. Sattar, S. Wang, M. Nespeca EEG-Based Identification Of Command-Following After Cardiac Arrest In The Minimally Conscious State/P. B. Forgacs, N. Schiff Prolonged Propofol Infusion In Pregnant Women With Refractory Status Epileptics/N. O. Al Matrooshi, N. Ali, S. Sinha Super Refractory Status Epilepticus In An 8 Year Old Female With Congenital Brain Anomalies, Metabolic Myopathy, And Progressive Epilepsy Brain Autopsy And Genetic Testing Correlates/F. Khan, E. Ramsay, H. Dave, V. Sabharwal, L. Finger Photosensitive Epilepsy With OCD Type Behavior: A Case Series Report/N. Olney, R. Rajaraman, R. Sankar, S. A. Hussain Case Report: Seizure As The First Clinical Presentation In Adult With Childhood Genetic Disorder (Tuberous Sclerosis Complex)/T. Aung Use Of Nicotine Patch For Drug-Resistant ADNFLE In Children: A Case Study/C. Gonsalves, K. Lee, J. Seo, B. Pullum, J. L. Norman Surgical Treatment Of Recurrent Super-Refractory Status Epilepticus: A Case Report/U. Uysal, M. Mittal, N. Hammond Eye Closure Sensitivity In An Adult With Suspected Temporal Lobe Epilepsy/B. Chapman, J. Vidaurre Ischemic Epilepsia Partialis Continua And Age Of Onset: A Tale Of Two Patients And Review Of The Literature/T. Gholipour, M. Ng Baclofen Induced Non- Convulsive Status Epilepticus/ R. C. Martinez, W. Richeh, E. Mader Bizarre Visual Hallucinations In A Child With PRES Syndrome/ P. Maertens, M. Bramhall, M. Cobia Child Youth Epilepsy (CYE) TeleECHO Innovative Tele-Mentoring Clinic For Child & Youth Epilepsy Care/M. Yamada Small Temporal Encephaloceles: An Under-Recognized Cause Of Non- Lesional Temporal Lobe Epilepsy/ R. Azzam, P. Singh, A. Arain, V. Morgan, J. Neimat, B. Abou-Khalil The Ictal Guardian Angel: A Case Report Of An Ictal Spiritual Visual Hallucination/M. A. Kellogg, V. S. Wong Hemimegalencephaly In Tuberous Sclerosis Complex: Is Surgery The Only Treatment?/ P. B. Cerqueira, E. V. Caetano, M. G. Manreza, U. C. Reed, L. B. Sampaio, E. C. Miotto, F. A. Costa, P. S. Mendes, B. J. Correa Asynchronous Leg Jerking With Normal Sensorium As A Presentation Of Frontal Lobe Seizures/L. Vargas, N. Dalvi, S. Karkare Case Report Of A 24-Year-Old Patient Suffering From Seizures With G13513A Mutation In The ND5 Gene Of Mitochondrial DNA/M. Prieschl, W. Nachbauer, P. Lackner, B. Matosevic, I. Unterberger, U. Athing, G. Luef, B. Frauscher Are Interictal Epileptiform Discharges Always Subclinical? A Study Of Cognitive Function During Interictal Epileptiform Discharges/ A. Serafini, M. Gubernale, M. Da Rold, S. Negrin, P. Bonanni WITHDRAWN A Case Of Neonatal Epilepsy With KCNQ2 And SCN1A Mutations/ F. Baumer, L. Rodan, J. Heath, D. Harris, J. Soul Sudden Onset Alexia Without Agraphia Caused By A Reversible Splenial Lesion (RSL); Two Cases Of RSL In Non Epileptic Patients On Lamotrigine And Topomax/R. K. Gupta, P. Sofat, P. Li, T. Guttuso, R. Sawer, Jr Lesion Negative Anterior Cingulate Epilepsy/N. Lacuey Lecumberri, J. Chapa Davila, M. Pelayo, S. Amina, J. Turnbull, J. Miller, H. Luders, S. Lhatoo SUNDAY 53

56 Sunday December 7, 2014 Poster Session 2 8:00 a.m. 6:00 p.m. Convention Center Hall 4B, Level Refractory Focal-Onset Seizures As A Consequence Of Cerebral Amyloid Angiopathy-Related Inflammation: A Case Study/ B. Appavu, H. Seif Eddeine Desmoplastic Infantile Ganglioglioma Presenting With Neonatal Status Epilepticus/E. Ng, S. Karkare, M. Laureta, J. Maytal, S. Schneider Seizure After Laminectomy Associated With Pneumocephalus/ N. Cinar, M. Cakmak, S. Sahin, B. Kelten, S. Karsidag Insight Into The Precuneus: A Novel Seizure Semiology In A Child With Epilepsy Arising From The Mesial Parietal Region/J. A. Mailo Professionals in Epilepsy Care Nursing Quality Assurance In The Epilepsy Monitoring Unit: Time To Seizure Recognition And Intervention/D. Nelson, D. Briggs, J. Shen, K. Lovell, E. Harrell, E. Wedberg, P. Modur Seizure-Related Falls In The Epilepsy Monitoring Unit/E. Yagiri, H. Arai, H. Suzuki, K. Jin, M. Fujikawa, K. Kato, Y. Kakisaka, M. Iwasaki, K. Yamauchi, N. Nakasato Role Of A Nurse Program Coordinator: Comprehensive Epilepsy Clinic/M. Gustafson, K. Gugler To Coordinate Or Not To Coordinate?/K. Orton, G. R. Nelson, C. Van Orman Improving Quality Of Care Following EMU Discharge/R. Mealey, J. Pollard, K. Davis, C. Kohler, R. Shmuts, S. Chen, B. Oommen, C. Hill Creating A Standard Of Care For Epilepsy Patients: Starting with Nursing Staff in the Adult Epilepsy Monitoring Unit/R. Ward-Mitchell, M. Bensalem-Owen, G. Plank, R. Woodward Epilepsy Nurse Led Vagus Nerve Stimulator Program: Comprehensive Epilepsy Center/ K. J. Gugler, M. Gustafson Psychosocial Perception Of Happiness In Adults With Epilepsy/J. Cohen, D. F. Tovar Quiroga Driving Safety In People With Non-Epileptic Events/K. S. Ziemba, J. F. Drazkowski Education A Case Report - Importance Of Early Treatment In Anti-NMDA Receptor Encephalitis/T. Aung What s In A Year? EEGs Encountered In An ACGME-Accredited Clinical Neurophysiology Fellowship/ E. C. Lewis SUDEP Experience And Practice In A Large Group Of Child Neurologists/J. Reese, Jr, D. Friedman, W. Gaillard A Single Center Survery Of Pediatric Neurologists Views On Epilepsy Surgery And Medically Refractory Epilepsy/J. Bolton, G. Dabscheck Neurophysiology Video EEG Epilepsy-Monitoring Spread Of The Ictal Discharge From Hippocampus And Cortex To Scalp EEG Electrodes In Temporal Lobe Epilepsy/D. G. Vossler, A. J. Bell, D. L. Kraemer WITHDRAWN The Prognostic Value Of Early EEG Background During Hypothermia On MRI And Neurodevelopmental Outcome In Neonates With Hypoxic- Ischemic Encephalopathy/M. Balestri, M. Lispi, S. Pro, D. Longo, F. Vigevano, M. Cilio Microseizures Recorded With Clinical EEG Acquisition System/ L. Higdon, G. Ghearing, M. Richardson, C. Plummer Prevalence Of Ictal Infraslow Potentials (IISPs) In Scalp EEG/ N. Dorland, J. Lavingia, C. Carlson, M. Raghavan Right Temporal Lobe Seizure Frequently Induces Precipitous Heart Rate Increase/K. Kato, K. Jin, Y. Kakisaka, M. Iwasaki, M. Fujikawa, M. Aoki, N. Nakasato Intracranial Ictal EEG Patterns And Seizure Onset Zone: A Systematic Review/S. SINGH, S. Sandy, Y. Aghakhani, N. Pillay, S. Wiebe Evidence For A Multi-Night Improving Trend In Sleep During Intracranial EEG Monitoring/R. Joshi, N. Gaspard, I. Goncharova, M. Pavlova, R. Duckrow, J. Gerrard, D. Spencer, L. Hirsch, H. Zaveri Interictal Epileptiform Discharges Before And After A Generalized Tonic Clonic Seizure In A Patient With Generalized Epilepsy Case Report/D. Sabau, D. W. Harvey, M. Mehrizi Semiological Characterization And Clinical Profile Of Patients With Psychogenic Non-Epileptic Seizures/ S. Cieza, P. Amaro, I. Marcotegui, C. Viteri Torres, M. Alegre, J. Iriarte, E. Urrestarazu Cardiac Sympathetic Nerve Activity Is Abnormally Suppressed During Wakefulness In Patients With Epilepsy/N. Suzuki, K. Jin, K. Kato, Y. Kakisaka, M. Iwasaki, N. Nakasato Texting in Epilepsy: Activation or Distraction?/B. DiCaccio, K. H. Yelvington, W. Tatum ICU EEG High Frequency Oscillations Are Associated With Cognitive Processing In Human Recognition Memory/M. T. Kucewicz, J. Cimbalnik, J. Matsumoto, B. Brinkmann, M. Bower, V. Vasoli, V. Sulc, F. Meyer, R. Marsh, M. Stead, G. Worrell Misleading EEG Lateralization Associated With Midline Shift/ S. Abramovici, G. Ghearing The Adequacy Of Density Spectral Array (DSA) And Amplitude- Integrated EEG (aeeg) For Neonatal And Pediatric Seizure Identification/ H. Yamamoto, J. Natsume, H. Kidokoro The Application Of Conventional EEG For Early Prognosis In Infants Born With Hypoxic Ischemic Encephalopathy Undergoing Hypothermia/R. Obeid, M. Naik, M. Painter, R. Telesco, Y. Sogawa, S. Gedela, V. Lee, J. Wisnowski, A. Panigrahy Inter-Rater Agreement For Identification Of Electrographic Seizures And Periodic Discharges In Critically Ill Patients/D. Shiau, J. A. Desrochers, J. J. Halford, B. J. Kolls, G. U. Martz, S. R. Sinha, K. F. Haas, E. E. Kutluay, N. J. Azar, R. T. Kern, K. M. Kelly, J. C. Sackellares, S. M. LaRoche EEG Predictors Of Antiepileptic Drug Adjustments In Critically Ill Patients A Prospective Observational Study/G. Wang, A. M. Khawaja, G. Cutter, J. Szaflarski Skin Breakdown In Patients Undergoing EEG Monitoring In The NICU/S. Manganaro, E. Cruz, M. Andriola, A. Slansky, L. Manganas EEG Predictors Of Outcomes In Critically Ill Patients A Prospective Observational Study/ A. M. Khawaja, G. Wang, G. Cutter, J. P. Szaflarski Clinical Epilepsy Classification and Syndromes Clinical Characteristics Of Benign Convulsions With Mild Gastroenteritis/H. Kim, S. Kim, Y. Kim, J. Kim, W. Kim Ictal And Postictal Aphasia Are Most Common In Temporal Lobe Epilepsy/A. M. Loesch, H. Steger, C. Losher, C. Vollmar, J. Remi, E. Hartl, S. Noachtar Comparing EMU Staffing Models For Spell Classification Admissions/S. D. Spritzer, B. D. Pirotte, S. Agostini, K. Noe, J. Drazkowski Seizure Semiology In Pediatric Posttraumatic Epilepsy/J. T. Park, H. T. Chugani Incidence And Seizure Characteristics In Autoimmune Epilepsy Patients/J. Byun, J. Sunwoo, J. Moon, J. Shin, K. Jung, S. Lee, K. Jung, S. Lee, K. Chu, J. Jun Familial Ring Chromosome 20 Syndrome A Case Report/ I. Unterberger, H. Schober, D. Kotzot, C. Fauth 54

57 Sunday December 7, 2014 Poster Session 2 8:00 a.m. 6:00 p.m. Convention Center Hall 4B, Level SUDEP Awareness Among Pediatric Practitioners: A Descriptive Survey of United States Physicians/ S. Massey, D. Friedman, N. Berberi, O. Devinsky, S. Kothare Epilepsy Syndrome, MRI Pathologies and Treatment Response In Patients With First Seizure And New-Onset Epilepsy A Comparison Of Patients Of Middle Age (50-60 Years) Versus Elderly Patients (> Older 60 Years)/B. Pohlmann-Eden, C. Crocker, K. Legg, M. Schmidt Semiology Of Hypermotor Seizures/K. Alqadi, R. R. Sankaraneni, U. Thome Costa, P. Kotagal Participant Eligibility In The Human Epilepsy Project/S. Cristofaro, C. Freyer, V. Mays, O. HEP Investigators Not All But The Most Patients With CSWS Are Atypical Benign Partial Epilepsy In Childhood/ H. Shiraishi, K. Egawa, K. Otsuka, M. Nakajima, T. Ito, M. Narugami, S. Nakane, K. Takahashi Patterns Of Disease Progression In Epilepsy/D. Ekstein, M. Nassar, T. Ben Hur, R. Bar Yossef, M. Benifla, O. Bennett Delay To Initiation Of Treatment: Data From The Human Epilepsy Project/R. Hennessy, M. Mendoza, J. French, S. Haut, J. Hixson, K. Detyniecki, O. HEP Investigators Clinical Diagnosis Impact Of Specialty Epilepsy Consultation On Management And Outcomes Among Veterans/ A. Panduranga, E. Boudreau, M. Salinsky Radiological And Pathological Discordance Of Mesial Temporal Lobe Sclerosis In Pediatric Temporal Lobectomy/J. Kassiri, D. Sinclair, M. Wheatley Left Temporal Lobe Epilepsy Presenting As Apparent Life- Threatening Events In Infants/ J. Kassiri, R. Tang-Wai Longer Seizure Duration Terminates A Seizure Cluster During Epilepsy Monitoring/V. Ferastraoaru, S. R. Haut, R. B. Lipton, A. D. Legatt, J. Blumberg, M. Dumpelmann, A. Schulze-Bonhage Initial Involvement Of The Posterior Orbital Gyrus In Prolonged Panic Attack Associated With Simple Partial Status Epilepticus On Depth Electrodes/J. M. Chung, C. M. Reed, U. Rutishauser, A. N. Mamelak Seizure Types And Electrographic Patterns Of Angelman Syndrome In South Indian Children/ V. Puthenveettil, A. G. Roy, S. Nampoothiri Epileptic Pain As A Rare Symptom Of Seizures/N. Pazarci, N. Bebek, B. BAYKAN, C. Gurses, A. Gokyigit Bitemporal Epilepsy: Anatomo- Electro-Clinical Features And Comparison With Unitemporal Epilepsy/G. Didato, V. Chiesa, F. Villani, V. Pelliccia, F. Deleo, F. Gozzo, M. Canevini, R. Mai, R. Spreafico, M. Cossu, L. Tassi Predictors For Seizure Recurrence In 228 Developmentally And Neurologically Normal Children With A Newly Diagnosed, Unprovoked Seizure/H. Kim, A. Oh, X. de Grauw, A. de Grauw Drug-Resistant Epilepsy With Neurocysticercosis And Mesial Temporal Lobe Sclerosis/ L. M. Espaillat Solano, A. Martinez-Perez, M. Leon-Vazquez, J. Perez-Ruiz, R. Carrillo, M. Alonso-Vanegas, A. Fleury, I. E. Martinez-Juarez TOSCA Tuberous Sclerosis Registry To Increase Disease Awareness: First Interim Data On Epilepsy/R. Nabbout, C. Hertzberg, P. Curatolo, P. de Vries, M. Feucht, E. Belousova, M. Dahlin, J. Ferreira, J. lawson, A. Macaya, F. O Callaghan, M. Benedik, V. Sander, S. Youroukos, A. Jansen, S. Jozwiak Concordance Between History And Epilepsy Monitoring Unit Evaluation For Diagnosing Seizures/ K. Siddiqui, E. Khalid, R. S. Siddiqui, S. Sinha Autoimmune Epilepsy: Clinical Features, Management And Outcomes/D. Dubey, R. Hays, P. Gupta, K. Ding, M. Agostini, P. Van Ness, S. Vernino Electroclinical Correlation Of Typical Absence In Idiopathic Generalized Epilepsies (IGE)/ W. S. Sanchez Barrera Is Treatment-Resistant Focal Epilepsy Less Frequent In Veterans?/M. Lopez, A. Kanner New Onset Temporal Lobe Epilepsy And REM Sleep Behavior Disorder: Further Demonstration Of A Possible Association?/M. Junna, E. St. Louis, E. Duwell Rhythmic ictal Nonclonic Extremity Movements In Temporal Lobe Epilepsy: A Reappraisal/K. Ding, M. Agostini, P. Gupta, R. Hays, P. Van Ness, P. Modur Predictors Of Postneonatal Epilepsy And Sensitivity Of The First Hour Of EEG Monitoring In Predicting Risk Of Seizures In The Neonatal Period/A. J. Hani, K. Cornett, B. Smith, W. Gallentine Improving Long-Term Management Of Epilepsy Using Wearable Multi-Modal Seizure Detection System/S. Sabesan, K. Rose, G. Carlson, A. Mueller, R. Sankar, J. Wheless Ambulatory EEG In Children: When Is It Most Helpful?/S. Adhami, K. Singh, C. Harini Siblings with Juvenile Huntington s Disease having two different Seizure Types: A Case report/c. Srikanth Mysore, D. Madhavan, D. Mudugal, T. Jasinski Clinical Treatments Surgical Outcomes Of Patients With Focal Epilepsy Evaluated By Intracranial EEG Monitoring/S. Sandy, S. Singh, Y. Agha-Khani, N. Pillay, S. Wiebe Efficacy And Tolerability Of Intravenous Lacosamide In Daily Practice Results Of A Large Independent Registry/N. Lang, U. Stephani Successful Treatment Of Febrile Illness-Related Epilepsy Syndrome (FIRES) And New Onset Refractory Status Epilepticus (NORSE) With Plasma Exchange And Rituximab/J. Berkeley, P. Foreman, A. Foroughi, F. Tirol Efficacy And Safety Of Intravenous Lacosamide In Pediatric Status Epilepticus/K. Poddar, R. Sharma, Y. Ng Application Of A EEG To Severe Motor And Intellectual Disability (SMID) Utility In Control Of Seizures/T. Nagasawa, Y. Okoshi, S. Atsumi, N. Tanuma, M. Fukumizu, K. Tominaga Acetazolamide For Spike-Wave Index Reduction In Electrical Status Epilepticus In Slow Wave Sleep/ A. Fine, E. Wirrell, L. Wong-Kisiel, K. Nickels A Double-Blinded, Randomized Evaluation Of Neuropsychological And Behavioral Changes In Children With Benign Epilepsy With Centrotemporal Spikes Treated Either With Levetiracetam Or Sulthiame/ I. Borggraefe, M. Bonfert, L. Gerstl, F. Heinen, B. Neubauer Efficacy And Tolerability Of Modified Atkins Diet (MAD) And Low Glycemic Index Diet (LGID) Among Adults With Medically Intractable Epilepsy/A. Balabanov, K. Roehl Glioma Associated Epilepsy/ M. Fiol, M. Qureshi, M. Hunt, A. Malik Epilepsy And Bicycle: Observation In The Epilepsy Monitoring Unit/J. Kim, K. Hwang, E. Joo, S. Hong, D. Seo Outcomes Of Vagal Nerve Stimulation (VNS) For Intractable Epilepsy/V. S. Wasade, K. Mohanarangan, A. Gaddam, L. Schultz, J. Schwalb, M. Spanaki Responsive Neurostimulation In Patients With Periventricular Nodular Heterotopia (PNH)/P. Rutecki, A. Herekar, P. Van Ness, G. Bergey, C. Bazil, D. King-Stephens, F. Sun, R. Kapur, M. Morrell High Dose Oral Steroids For Treatment Of Infantile Spasms: The Wake Forest Baptist Medical Center (WFBMC) Experience/I. Khaytin, M. Silvia, G. Popli, A. Grefe, C. Lee SUNDAY 55

58 Sunday December 7, 2014 Poster Session 2 8:00 a.m. 6:00 p.m. Convention Center Hall 4B, Level Evaluation Of Clobazam Conversion Therapy Replacing Clonazepam In Patients With Medically Refractory Epilepsy/S. Marsh, S. S. Chung Responsive Stimulation Of Eloquent Cortex/R. Kapur, R. Duckrow, C. Heck, S. Eisenschenk, R. Gwinn, E. Geller, M. Smith, A. M. Murro, G. Worrell, R. Wharen, V. Salanova, G. L. Barkley, R. Gross, B. Jobst, C. Bazil, D. Nair, D. King-Stevens, E. Mizrahi, T. Crowder Skarpaas, M. Morrell Prognosis Electrodermal Activity During Complex Partial Seizures Is Dependent Of Age And MRI Lesions/ S. Thome-Souza, J. Klehm, R. Sarkis, K. kapur, E. Nagarajan, R. Picard, M. Jackson, C. Doshi, C. Papadelis, B. Dworetzky, C. Reinsberger, T. Loddenkemper Predictive Risk Factors Of Seizure-Related Injury And Postictal Behavioral Changes/C. Maideniuc, A. Stino, M. Basha Outcomes Of Genetic Generalized Epilepsy At A Comprehensive Epilepsy Center/ S. Maturu, T. Dayyoub, B. Assaad, L. Schultz, V. S. Wasade, E. Muma, T. Howard, J. Snyder, S. Gaddam, N. Mahmood, J. Constantinou, G. L. Barkley, M. Spanaki, A. Zillgitt Latency To Treatment Of Status Epilepticus: Long-Term Outcomes/J. Cheng Prognosis Of Idiopathic Generalized Epilepsy Patients Who Had At Least 10 Years Follow Up And Predictors Of At Least 5 Years Seizure Remission Off Medication/ H. Hosny Relationship Between Biomarkers Of Vascular And Metabolic Health And Cognition In Aging Persons With Chronic Epilepsy/B. Hermann, M. Sager, R. Koscik WITHDRAWN Comparison Between Febrile And Afebrile Convulsion With Mild Gastroenteritis/S. Kim, I. Lee, T. Eom Prediction of Future Epilepsy in Neonates Who Received Selective Head Cooling for HIE/T. McDonough, J. Paolicchi, L. A. Heier, N. Das, M. Engel, J. M. Perlman, Z. Grinspan Treatment Resistance Correlates With ECG Abnormalities In A Pilot Clinical Surveillance Of Epilepsy Patients/P. Zohrevand, M. Diaz, A. Amador, A. Goldman Detrimental Impact Of Convulsive Status Epilepticus On Health-Related Quality Of Life Apparent At 24 Months after Epilepsy Diagnosis In Children: A Longitudinal Population-Based Study/M. Ferro, S. Levin, S. Wiebe, R. Chin, C. Camfield, K. Speechley How Different Are Patients With Bilateral Hippocampal Sclerosis From The Unilateral Ones?/ E. Vanli- Yavuz, B. Baykan, S. Sencer, Z. Matur, N. Bebek, A. Gokyigit, O. Oktem, C. Gurses N20 Of Median Nerve SSEP Is An Early Predictor For Developmental Outcome After Hemispherotomy In Patients With Ohtahara Syndrome With Hemimegalencephaly/K. Sugai, R. Honda, T. Saito, E. Nakagawa, H. Komaki, M. Sasaki, A. Takahashi, T. Kaido, Y. Kaneko, T. Otsuki Risk Factors Of Postictal Generalized Electroencephalographic Suppression In Generalized Convulsive Seizures/V. Alexandre, B. Mercedes, L. Valton, L. Maillard, J. Petit, A. Biraben, F. Chassoux, P. Kahane, B. De Toffol, F. Bartolomei, P. Derambure, V. Navarro, E. Hirsch, A. Crespel, C. Marchal, P. Thomas, P. Ryvlin, S. Rheims Initial EEG Patterns As An Adjunctive Prognostic Indicator In Cardiac Arrest Patients Undergoing Therapeutic Hypothermia/ E. Tsimerinov, D. Maher, H. Tran, M. Nuno, D. Eliashiv, D. Palestrant, A. Moheet, W. Yu, J. Chung Women s Issues Improving The Prescription Of Folic Acid To Women Taking Antiepileptic Drugs/A. Sharma, J. Cavitt, M. Privitera, B. D. Moseley A Transdisciplinary Professional Clinic For Pregnant Adolescents And Young Adults With Epilepsy In A Midwest Children s Hospital/M. Turner, L. Garrity, K. Junger, S. Standridge Epilepsy And Reproductive Issues In Women With Epilepsy: Survey Of An Unselected Community Of Women With Epilepsy/ O. Laban-Grant, E. Fertig, M. Malik, C. B. de la Pena, M. Fleming, M. E. Lancman, P. Klein, M. Lancman Occurrence Of Obstetric Complications In Women With Epilepsy Results From The Oppland Perinatal Database In Norway/A. Farmen, T. Tomson, K. Nakken, M. Lossius Quality Of Life In Women With Epilepsy In Pregnancy: Experience At A Tertiary Care Centre/J. Qiang, E. Bui Menstrual Cycle Length In Women With Epilepsy Trying To Conceive Compared To Healthy Controls/C. Harden, C. Lau, P. Pennell, E. Bagliella, J. Huynh, R. Kashambwa, N. Llewellyn, B. Kaufman, A. Davis, J. French Seizure Control, Acceptability, And Drug Interactions During Use Of The Levonorgestrel Intrauterine System In Women With Epilepsy/ A. Davis, A. Pack, H. Saadatmand Neuroimaging Functional Imaging MSI/MEG And DTI Tractography In Tuberous Sclerosis Complex/ W. Zhang, D. Dickens, J. Doescher, T. Passe, F. Ritter, M. Dunn, M. Frost Individual-Subject Frontolimbic Neurocircuit Activations During Emotional Processing And Behavioral Inhibition In Psychogenic Non-Epileptic Seizures/D. L. Perez, B. A. Dworetzky, H. Pan, G. Baslet, D. R. Vago, L. Leung, J. Epstein, D. A. Silbersweig, E. Stern The Temporal Instability Of The Ventral Default Mode Network Connectivity In Intractable Epilepsy/ L. Robinson, P. Barnett, G. Doucet, D. Pustina, A. Ghani, J. Tracy In Vivo Optical Signal Changes Observed With Optical Coherence Tomography In A Focal Cortical Seizure Model/J. Szu, M. Eberle, C. Rodriguez, M. Hsu, B. Park, D. Binder Simultaneous EEG-NIRS (Near InfraRed Spectroscopy) Guided By MEEG And EEG-fMRI To Assess The Neurovascular Coupling In Focal Epilepsy: A New, Non-Invasive, Multimodal Approach/G. Pellegrino, A. Machado, S. Watanabe, N. Drouin, L. Allard, J. Lina, J. Hall, E. Kobayashi, C. Grova Computer-Automated Focus Lateralization Of Temporal Lobe Epilepsy Using fmri/s. Chiang, H. Levin, Z. Haneef Moving Towards New Techniques In The Evaluation Of The Ictal Onset Zone: Ratio Ictal SPECT (RISCOM) Using A 72-Detector Focused Collimator Ring SPECT Scanner System/M. Jain, K. Krug, P. Balaguera, C. M. Millan, A. Jalota, V. Pylypyuk, R. W. Byrne, M. A. Rossi Frequency Dependent Evolution Of Functional Networks Over Years Of Duration In Temporal Lobe Epilepsy/ V. L. Morgan, B. Abou-Khalil, B. P. Rogers Classification Of Individuals With Temporal Lobe Epilepsy Using Network Analysis Of Resting-State Functional MRI/D. Vaughan, M. Pedersen, C. Tailby, G. Jackson Components Of Epileptic Networks Show Pathological Coherent Fluctuations Even In The Absence Of Scalp Spikes/F. Pittau, G. Iannotti, E. Abela, F. Grouiller, M. Seeck, C. Michel, S. Vulliemoz Nonverbal Memory In Patients With Mesial Temporal Lobe Epilepsy And Amygdala Lesions/G. Kuchukhidze, L. Zamarian, E. Schmid, F. Koppelstaetter, C. Siedentopf, M. Delazer, H. Jokeit, E. Gizewski, G. Luef, I. Unterberger, E. Trinka Inter-Hemispheric Asymmetries In Resting-State fmri Activity For Identifying Seizure Onset And Irritative Zones/D. Groppe, P. Mégevand, Z. Fallil, S. Hwang, J. Hira, A. Abisogun, C. Yan, R. C. Craddock, M. Milham, S. Bickel, C. Harden, A. Mehta

59 Sunday December 7, 2014 Poster Session 2 8:00 a.m. 6:00 p.m. Convention Center Hall 4B, Level Brain Graph Theory Topology Changes Associated With Antiepileptic Drug Use/Z. Haneef, H. Levin, S. Chiang Real-Time Functional Mapping (RTFM) Of Language Function In Patients With Intractable Epilepsy/ B. Edmonds, M. Korostenskaja, P. Chen, A. Schaal, C. M. Salinas, M. Westerveld, E. Castillo, G. Schalk, P. Brunner, J. Baumgartner, K. Lee Comparing Four Connectivity Measures: From Simultaneous Direct Intracranial Stimulation And fmri, EEG, DWI, And rs-fmri/s. E. Jones, A. Alexopoulos, J. Bulacio, J. Gonzalez-Martinez, J. Mosher, D. Nair, I. Najm, M. Zhang Other Emerging Techniques Impact Of coregistered Multimodal Neuroimaging On Pediatric Epilepsy Surgery Planning And Postoperative Outcome/D. Freedman, L. Bailey, A. Hernandez, S. Malik, C. Keator, D. Donahue, M. Perry White Matter Compromise Modulates Verbal Fluency Performance In Patients With Atypical Language Dominance/N. Kemmotsu, K. Leyden, N. Kucukboyaci, V. Iragui-Madoz, E. Tecoma, C. McDonald Detection Of The Dominant Brain Network In Bitemporal Lobe Epilepsy With MEG/S. Bowyer, A. Zillgitt, M. Spanaki, K. Mason, V. S. Wasade Clinical Validity Of MEG-Guided Tractography (MEG-GT) To Characterize Networks Supporting Word Comprehension/E. Castillo, T. Kleineschay, C. M. Salinas, M. Korostenskaja, P. Chen, J. Baumgartner, J. Seo, K. Lee Regional Cerebral Hypoperfusion From Arterial Spin Labeling Correlates With EEG Lateralization In Patients With Epilepsy/H. Kadiwala, A. Verma, S. H. Fung Predicting Post-Surgical Language Outcome With ECoG-Based Real-Time Functional Mapping (RTFM)/M. Korostenskaja, P. Chen, C. M. Salinas, M. Westerveld, J. Seo, E. Castillo, A. Schaal, B. Edmonds, G. Schalk, P. Brunner, M. Elsayed, J. Baumgartner, K. Lee Stereotactic Laser Ablation: How Much Hippocampus And Amygdala Ablation Volume Optimizes Seizure Freedom?/A. Sharan, C. Wu, M. Sperling, R. Gross, J. Willie, D. Labiner, M. Weinand, R. Marsh, G. Worrell, G. Cascino, G. Popli, D. Couture, J. J. Shih, W. Tatum, A. Mehta, C. Harden, R. Patwardhan, B. Fernald, A. Shetty, A. Gowda Cormorbidity (Somatic and Psychiatric) Medical Conditions Mortality In Elderly Veterans With New And Chronic Epilepsy/ P. J. Foreman, A. VanCott, M. Pugh Post Ictal Headache Phenotype In Epileptic Seizures And Non- Epileptic Spells/S. Kapoor, A. Swaminathan Diagnosis Of Pnes In Childhood: Is It Possible To Suspect Of Non Epileptic Seizures In The First Standard Neurological Interview For Epilepsy?/R. Alessi, P. Rzezak, S. Vincentiis, K. Valente Delay In Diagnosis Of Psychogenic Non-Epileptic Seizures In Children And Adolescents: Age Matters/K. Valente, R. Alessi, S. Vincentiis Post Ictal Cardiac Asystole In A Series Of Pediatric Cases With Epilepsy Refractory To Medical Treatment/E. Andrade, Z. Liu Sleep Disorders And Circadian Rhythm In Epilepsy Revisited: A Prospective Controlled Study/G. Luef, B. Frauscher, D. Gabelia, M. Prieschl, K. Chea, M. Hofer, B. Hoegl, I. Unterberger Psychiatric Conditions ADHD In Childhood Epilepsy: Clinical Determinants Of Severity And Of Response To Methylphenidate/ S. Rheims, V. Herbillon, M. Milh, S. Auvin, S. Napuri, C. Cances, P. Berquin, P. Castelnau, S. N. Guyen, The Tich, F. Villega, H. Isnard, R. Nabbout, B. Kassai, A. Arzimanoglou Recognition Of Mood And Anxiety Disorders In Patients With Epilepsy By General Neurologists: A Comedy Of Contradictions/R. Ribot, A. Kanner Does Screening For Major Depressive Episodes And Generalized Anxiety Disorder By Epileptologists Translate In Their Remission?/ A. Kanner, J. Kozupsky Comorbidity Between Epilepsy And Psychiatric Disorders A Population-Based Study/ J. Christensen, C. Petersen, M. Vestergaard Stigma Is Uncommonly Reported By Adolescents With Epilepsy/J. Langer, M. Thompson, D. Taplinger Autism Spectrum Disorder And Neurocognitive Comorbidities In Patients With Epilepsy And ESES/ M. El-Hagrassy, R. C. Gunasekara, K. Mehrotra, C. Mohan, D. Francois, L. Probst, Y. Eksioglu Health Care Utilization Following Diagnosis Of Psychogenic Seizures In U.S. Veterans/M. Salinsky, C. Evrard, D. Storzbach, E. Goy, E. Boudreau Sleep Problems, Risk Factors, And Clinical Implications Among Children At A Tertiary Care Epilepsy Center/K. Fehr, E. Adams, K. Berg, M. Frost Depression Screening In Youth With Epilepsy: The NDDI-E-Y/ J. Wagner, G. Smith, B. Brooks, M. Mueller Subjective Forgetfullness In People With Epilepsy/I. Elmenshawi, M. A. Mohamed, A. Zaher Psychiatric Assessment Of Psychogenic Nonepileptic Seizures: A Comparison Of Approaches/ X. F. Jimenez, J. Bautista Psychosis In Temporal Lobe Epilepsy With Hippocampal Sclerosis: Corroborating The Relevance of Laterality/ K. Rodrigues Ximenes Goldberg, S. de Vincentiis, S. E. de Melo-Souza, F. J. Arruda, P. C. Ragazzo, H. van der Linden Jr., K. Dualibi Ramos Valente Predictors Of Major Depression In Multiplex Epilepsy Families/S. T. Sorge, J. O. Okeke, V. Tangel, S. Shostak, J. C. Phelan, J. Goldsmith, M. Winawer, D. Hesdorffer, W. K. Chung, R. Ottman Antiepileptic Drugs Clinical Trials Review Of Suicidality Events In Perampanel Clinical Studies/ A. B. Ettinger, C. Dobrinsky, H. Yang, B. Williams, D. Xing, R. Fain, A. Laurenza Safety Of Levetiracetam Among Infants Younger Than 12 months Results From A European Multicenter Observational Study/ A. Arzimanoglou, P. Berquin, C. Lösch, J. Bentz Analysis Of Psychiatric Adverse Events In Three Phase III Controlled Trials Of Eslicarbazepine Acetate As Adjunctive Therapy For Refractory Partial-Onset Seizures/ V. Biton, B. Shneker, M. Carreño, E. Ben-Menachem, F. Rocha, H. Gama, D. Blum, R. Claus Perampanel Discontinuation Is Not Associated With Self-Reported Withdrawal Symptoms in Patients Completing Phase III Clinical Studies/M. A. Rogawski, H. Yang, R. V. Fant, B. Williams, D. Xing, C. Dobrinsky, A. Laurenza Clinical And Quality Of Life Assessments Following Long-Term Treatment With USL255 (Qudexy XR; Extended-Release Topiramate) In Patients With Refractory Partial- Onset Seizures: PREVAIL OLE/ B. Anders, R. Hogan, S. S. Chung, A. M. Clark, I. Blatt SUNDAY 57

60 Sunday December 7, 2014 Poster Session 2 8:00 a.m. 6:00 p.m. Convention Center Hall 4B, Level Long-Term Safety And Tolerability Of USL255 (Qudexy XR; Extended-Release Topiramate) In Patients With Refractory Partial- Onset Seizures: PREVAIL OLE/I. Blatt, S. S. Chung, B. Anders, A. M. Clark, R. Hogan High Retention Rate In Patients With Refractory Epilepsy Treated With Eslicarbazepine Acetate/T. Svendsen, E. Brodtkorb, A. Reimers, E. Sætre, S. Johannessen, C. J. Landmark High Predictability Of Plasma Lacosamide And No Differences By Different Age And Gender Through Normalization Processes/C. Schaefer, W. Cawello, J. Andreas Is Half-Life A Clinically Relevant Measure For Extended-Release Drugs? Data Comparing IR Vs XR Topiramate (USL255; Qudexy XR)/ B. Gidal, A. M. Clark, B. Anders Patients Reporting Problems After Generic Antiepileptic Drug Switches Are Unlikely To Participate In A Generic Bioequivalence Trial D. Ficker, M. Berg, P. Bolger, F. Diaz, B. Dworetzky, E. Elder, B. Gidal, W. Jiang, R. Krebill, N. McBee, A. Paige, J. Pollard, M. Privitera, J. Szaflarski, T. Welty Subject-Unrecognized Medication Adherence Errors In The Equivalence Among Generic AED (EQUIGEN) Chronic Dose Trial/ D. Smith, M. Berg, N. Cohen, N. Llewellyn, M. Lozano, D. Schwieterman, J. Sieren, P. Bolger, F. Diaz, B. Dworetzky, E. Elder, B. Gidal, W. Jiang, R. Krebill, N. McBee, A. Paige, J. Pollard, M. Privitera, J. Szaflarski, T. Welty, D. Ficker Equivalence Among Generic AEDs (EQUIGEN) Single-Dose Study/M. Berg, F. Diaz, P. Bolger, B. Dworetzky, E. Elder, B. Gidal, W. Jiang, R. Krebill, N. McBee, A. Paige, J. Pollard, J. Szaflarski, T. Welty, D. Ficker, M. Privitera Aggression Adverse Events With Concomitant Levetiracetam Use In Perampanel Phase III Partial-Onset Seizure Clinical Studies/R. Fain, S. Chung, H. Yang, D. Xing, B. Williams, A. Laurenza Subgroup Analysis By Race In Perampanel Phase III Clinical Studies/A. Laurenza, H. Yang, B. Williams, S. Huang, M. Sperling Long-Term Safety And Efficacy Of Eslicarbazepine Acetate Monotherapy In Adults With Refractory Partial-Onset Seizures: A One-Year Open-Label Extension Study/M. R. Sperling, J. Rogin, J. H. Harvey, H. Cheng, D. Blum Placebo-Adjusted Estimation Of Treatment Effect Of Perampanel/ R. T. Wechsler, S. Mintzer, H. Yang, B. Williams, D. Xing, A. Laurenza Improvement In Seizure Control During Conversion To Eslicarbazepine Acetate Monotherapy: A Pooled Analysis Of Two Trials In Adults With Refractory Partial-Onset Seizures/G. Krauss, V. Biton, H. Cheng, D. Blum Effect Of Adjunctive Perampanel On Growth And Development In Adolescents With Inadequately Controlled Partial-Onset Seizures/J. E. Pina-Garza, H. Yang, B. Williams, D. Kumar, A. Laurenza Adjunctive Perampanel In Adolescents With Inadequately Controlled Partial-Onset Seizures: Efficacy And Safety Results From Study 235/B. Renfroe, L. Lagae, B. Williams, H. Yang, D. Kumar, A. Laurenza Pharmacokinetic, Pharmacodynamic And Cognitive Effects Of Adjunctive Perampanel In Adolescents With Inadequately Controlled Partial-Onset Seizures/ Z. Hussein, B. E. Gidal, H. Yang, B. Williams, D. Kumar, A. Laurenza, J. Ferry, K. J. Meador Cohort Studies Changes In Antiepileptic Drug Prescribing Patterns In A Large, Tertiary-Care Epilepsy Center ( )/J. Moeller, A. Legge, K. Detyniecki, L. Hirsch, R. Buchsbaum, H. Choi Lacosamide Monotherapy Treatment Pathways In Epilepsy Patients In A U.S. Managed Care Population/T. Durgin, R. Wade, C. Chen, D. Hines, C. Makin Analysis Of Real-World Rufinamide Utilization In The Treatment Of Epilepsy: Demographic And Socioeconomic Factors/ R. L. Knoth, J. H. Lasley, S. A. Field, J. Kerrick Walker, S. Mendes Beyond Lennox-Gastaut Syndrome: A Retrospective Study Of Clobazam In Pediatric Refractory Epilepsy/S. Reddy, C. Lopez, M. Messinger, D. Elledge, A. Wilfong Experience With Lacosamide In Galicia, Spain (GALACO Study): Results At 12 Months/X. Rodriguez Osorio, F. López González, A. Pato, M. Saavedra Piñeiro, E. Rubio-Nazábal, I. Cabo López, N. Raña Martínez, M. Sobrido, M. Aguado Valcárcel Efficacy Of Clobazam Add On Treatment Of Refractory Focal Epilepsy In Adults/P. Klein, A. Barber, I. Tyrlikova, J. Janousek, A. Azarion, L. Goldman, D. Gorelik Lacosamide Effectiveness In Pediatric Epilepsy: Effect Of Concomitant NA Channel Medications/E. Robbins, J. W. Cohen, S. Kessler Clinical Outcomes Of Treatment With Oxtellar XR Or Immediate-Release Oxcarbazepine (OXC-IR) In Typical Care Settings: A Standardized Case Record Review/W. O Neal, E. E. Hur, K. Stringer, T. Resnick Long-Term Follow-Up Of Lacosamide As Add-On Therapy In Refractory Partial Onset Epilepsy In Adults In Real Clinical Practice Of University Hospital, Bratislava/ G. Timarova, S. Mehešová Analysis Of Real-World Rufinamide Utilization In The Treatment Of Epilepsy: Dosing, Titration, And Concomitant Antiepileptic Drugs/S. Mendes, S. A. Field, J. H. Lasley, J. Kerrick Walker, R. L. Knoth Valproate And Lamotrigine: Is Clobazam More Effective Than Other Drugs As Adjunctive Therapy?/ V. Moraes, S. Vincentiis, K. Valente Drug Interaction Interaction Study Between Brivaracetam And Ethanol In Healthy Subjects/A. Stockis, A. C. Kruithof, J. M. van Gerven, M. L. de Kam, S. Watanabe, P. A. Peeters Pharmacokinetic Variability Of Clobazam And Its Metabolite Desmethylclobazam In Clinical Practice Impact Of Comedication/ M. Burns, S. Johannessen, C. J. Landmark The Effect Of Epidiolex (Cannabidiol) On Serum Levels Of Concomitant Anti-Epileptic Drugs In Children And Young Adults With Treatment-Resistant Epilepsy In An Expanded Access Program/ D. Friedman, M. Cilio, N. Tilton, J. Sullivan, J. Hedlund, E. Rosenberg, J. Bluvstein, O. Devinsky In Vitro Pharmacokinetic Profile Of Brivaracetam Reveals Low Risk Of Drug-Drug Interaction And Unrestricted Brain Permeability/ H. Chanteux, S. Kervyn, B. Gerin, M. Rosa, N. Latour, A. Stockis, J. Nicolas Seizure Control In Patients Initiated On Clobazam Who Use Frequent 1,4-Benzodiazepines/ G. Russo, T. Vollaro, R. Davis, N. Le Drug Side Effects Adverse Visual Side Effects Of Antiepileptic Drugs In Adults With Epilepsy/B. Chen, K. Detyniecki, L. Hirsch, R. Buchsbaum, H. Choi Antiepileptic Use And Dyslipidemia: A Systematic Review/ M. Vyas, J. Costel, L. Escalaya, J. G. Burneo Anti-Epileptic Drugs And Vitamin D Deficiency In Children With Epilepsy/J. Yu, S. Lee, J. Koh 58

61 Sunday December 7, 2014 Poster Session 2 8:00 a.m. 6:00 p.m. Convention Center Hall 4B, Level Adverse Drug Reactions To Antiepileptic Drugs In Children With Epilepsy/J. Kim, H. Park, W. Kim, H. Kim, J. Kang, S. Kim, J. Yu, Y. Kim The Pediatric Epilepsy Side Effects Questionnaire : Establishing Minimal Clinically Important Difference Scores/K. Junger, D. Morita, A. Modi Adverse Effects Of Antiepileptic Drug Treatment: The Patients View/V. K. Kjærvik, M. A. Mevåg, A. Villagran, S. Johannessen, O. Henning, C. J. Landmark Pigmentary Abnormalities (Discoloration) Associated With Ezogabine/Retigabine Treatment: Clinical Aspects/S. Evans, A. Alio Saenz, C. Harrington, D. Kelly, N. Walsh, S. McDonald, W. Lee, N. Brickel Unusual Case Of Drug Rash With Eosinophilia And Systemic Symptoms (DRESS) With Ethosuximide/S. Paudel, A. Patel, P. Kandel, P. Rawal Randomized Crossover Study Comparing Neuropsychological Effects Of Lacosamide Versus Carbamazepine Immediate Release In Healthy Subjects/K. J. Meador, D. W. Loring, A. Boyd, W. Byrnes, D. Dilley, E. Webster, S. Borghs, M. De Backer, T. Story, P. Dedeken An Interesting Case Of Sinus Nodal Dysfunction Following Use Of Lacosamide/M. Gurme, C. M. Reed, D. Eliashiv Beyond Efficacy: Focus On Safety And Effectiveness Of Antiepileptic Drugs (AEDs)/M. Wen, V. Nguyen, Y. Bukovskaya, S. Dergalust Effect Of Long-Term Administration Of Low Dose Of Rapamycin On Development And Immunity In Young Rats/L. Zeng Pigmentary Abnormalities (Discoloration) Associated With Ezogabine/Retigabine Treatment: Nonclinical Aspects/J. S. Prescott, C. Evans, A. Alio Saenz Other Generic Antiepileptic Drugs, Mood Disorders And Pharmacovigilance: Case Analyses And Literature Review/K. R. Kaufman, A. M. Zimmerman, S. Wong, N. D. Kaufman, P. J. Struck Adherence Concerning Antiepileptic Medication: The Patients View/A. Villagran, M. A. Mevåg, V. Kjærvik, S. Johannessen, C. J. Landmark, O. Henning Effectiveness And Tolerance Of Clobazam Used As Adjunctive To A Sodium-Blocker Antiepileptic Drug In Maximum Tolerated Doses In Focal Seizures/E. A. Seraphim, L. Rodrigues, J. T. Corso, P. Naves, G. Bienes, E. Yacubian An In Vitro Screen For Antiepileptogenic Compounds Utilizing Organotypic Hippocampal Slice Cultures/Y. Saponjian, Y. Berdichevsky, W. Swiercz, K. Staley Topiramate (TPM) And Impaired Verbal Fluency: Observations From Three Formulations With Different Input Rates/S. E. Marino, S. T. Brittain, S. V. Pakhomov Individual Pharmacokinetic Profile Analysis From An Average Bioequivalence Study Of Lamotrigine In Generic-Brittle Patients: What Can Be Learned About Patients With Switchability Issues/T. Ting, W. Jiang, X. Jiang, J. Polli Use Of Computer Simulations To Test The Concept Of Dose Forgiveness In The Era Of Extended- Release (XR) Drugs/S. T. Brittain Brivaracetam Achieves Brain SV2A Occupancy Faster Than Levetiracetam/J. Mercier, D. Holden, A. K. Deo, K. Fowles, S. Kervyn, N. Nabulsi, J. Nicolas, H. Klitgaard, Y. Huang, J. D Souza, R. E. Carson, J. Hannestad Evaluation Of Weight-Based Dosing Of Fosphenytoin In Obese Pediatric Patients/M. M. Messinger, S. J. Bork, B. S. Moffett, G. G. Burgess, A. Wilfong Surgery Adult Neurological And Medical Complications Of Epilepsy Surgery At A Tertiary Level Hospital In A Developing Country/M. Leon-Vazquez, F. Chavez-Hassan, L. M. Espaillat Solano, J. Villeda Hernandez, M. Alonso-Vanegas, D. Crail Melendez, A. Ruiz Chow, I. E. Martinez-Juarez Preoperative Evaluation Of Speech And Memory Dominance Estimated By Intracarotid Propofol Test/T. Kunieda, N. Mikuni, T. Kikuchi, R. Inano, T. Inada, Y. Takahashi, S. Nishida, T. Nakae, S. Shibata, Y. Yamao, Y. Arakawa, R. Matsumoto, A. Ikeda, S. Miyamoto Failed Epilepsy Surgery Deserves A Second Chance/ C. M. Reed, S. Dewar, D. Eliashiv Stereotactic Laser Ablation: How Much Hippocampal Atrophy Optimizes Seizure Freedom?/G. Popli, D. Couture, A. Laxton, R. Gross, J. Willie, A. Sharan, M. Sperling, D. Labiner, M. Weinand, R. Marsh, G. Worrell, G. Cascino, J. J. Shih, R. Wharen, W. Tatum, R. Patwardhan, B. Fernald, A. Shetty Outcomes After Temporal Lobectomy After Invasive Monitoring Versus No Monitoring/A. Romeo, B. Agee, L. Ver Hoef, K. Riley Stereotactic Laser Amygdalo- Hippocampotomy For Mesial Temporal Lobe Epilepsy: Collective Experience From Seven Single-Center, Prospective, Investigator-Initiated Studies Objectives/R. Gross, J. Willie, S. Helmers, K. J. Meador, S. Laroche, R. Faught, E. Gedzelman, A. Sharan, M. Sperling, R. Marsh, G. Cascino, G. Worrell, J. J. Shih, R. Wharen, W. Tatum, G. Popli, A. Laxton, D. Couture, M. Weinand, D. Labiner, A. Mehta, C. Harden, D Robotic-Assisted MRI-Compatible Stereoelectroencephalography: Technique And Complications/J. Hall Pediatrics WITHDRAWN Pediatric Epilepsy Surgery Strategy And Complications: Inter- Center Worldwide Variability/ B. Rydenhag, A. Cukiert, W. Harkness, I. Panel Pediatric Epilepsy Surgery Techniques General Issues: Inter- Center Worldwide Variability/ A. Cukiert, B. Rydenhag, W. Harkness, T. International Pediatric Epilepsy Surgery Panel Seizure Outcome After Battery Depletion In Patients With Secondary Generalized Epilepsy Submitted To Vagus Nerve Stimulation/A. M. Lima, J. A. Burattini, C. M. Cukiert, A. Cukiert Subtotal Hemispherectomy In Children With Intractable Focal Epilepsy/H. Chugani, E. Asano, C. Juhasz, A. Kumar, W. Kupsky, S. Sood MR-Guided Laser Interstitial Thermal Therapy For Drug-Resistant, Lesional Epilepsy in Children/ E. C. Lewis, J. Ragheb, M. Duchowny, I. Miller Corpus Callosotomy With Stereotactic Laser Ablation In A Pediatric Patient/A. Dolce, D. Curry, A. Wilfong Usefulness Of Intraoperative Insular Electrocorticography During Modified Functional Hemispherectomy/ G. Kim, J. Seo, J. Baumgartner, K. Lee The Ultimate Case Of Curative Focal Heterotopia Resection: Resolution Of Lennox-Gastaut Syndrome And Epileptic Encephalopathy/J. R. Fesler, S. Kanaan, T. B. Mapstone, Y. Ng Surgical Outcome In Adolescents With Mesial Temporal Sclerosis (MTS): Is It Different Than Adults?/P. Farooque, L. Hirsch, S. Levy, F. Testa, R. Mattson, H. Zaveri, J. Bonito, D. Spencer Repeat Epilepsy Surgery For Children With Refractory Seizures: Profiles And Outcomes/J. Ziobro, D. Depositario-Cabacar, K. Havens, J. Conry, S. Weinstein, T. Zelleke, A. Kao, T. Tsuchida, M. Kolodgie, A. Yaun, C. Oluigbo, W. Gaillard 59 SUNDAY

62 Sunday December 7, 2014 Poster Session 2 8:00 a.m. 6:00 p.m. Convention Center Hall 4B, Level The Spectrum Of Sleep Disorders In Children Undergoing Pre- Surgical Evaluation For Refractory Epilepsy/S. Jain, P. Horn, H. Greiner REM Sleep EEG Indicates Epileptogenic Hemisphere For Successful Epilepsy Surgery In Children With Generalized Interictal Epileptiform Discharges/K. Okanari, S. Baba, H. Otsubo, E. Widjaja, S. Sakuma, C. Go, K. Jones, K. Nishioka, S. Oba, T. Matsui, M. Ueno, S. Ukitsu, J. Rutka, J. Drake, E. Donner, S. Weiss, O. Snead, A. Ochi Thermal Ablation For Patients Who Failed Surgery Or Would Seldom Be Considered As Surgical Candidate/ D. F. Clarke, J. B. Titus, N. Nussbaum, F. F. Perkins, K. C. Keough, M. R. Lee Complete Resection Of Fast Ripples Is A Superior Predictor Of Seizure-Freedom After Epilepsy Surgery In Comparison To Conventional Intraoperative Electrocorticography Findings/ S. A. Hussain, G. Mathern, R. Sankar, J. Wu All Ages Predictive Power Of Presurgical Studies For Temporal Lobectomy Seizure Freedom/ O. I. Khan, D. M. Goldenholz, A. Jow, W. Theodore Frameless Image-Guided Stereotactic Implantation Of Depth Electrodes Via Craniotomy For Presurgical Evaluation Of Pharmacoresistant Epilepsy/H. Khoo, H. Kishima, S. Oshino, N. Tani, T. Maruo, T. Yanagisawa, K. Edagawa, Y. Inoue, M. Hirata, T. Yoshimine Surgical Removal Of High Frequency Oscillations Correlates With Postsurgical Outcome A Prospective Multi-Center Study/ J. Jacobs, J. Y. Wu, P. Perucca, R. Zelmann, M. Mader, F. Dubeau, A. Schulze-Bonhage, G. Mathern, J. Gotman Appropriating Surgical Intervention In Mesial Temporal-Lobe Epilepsy (MTLE) Patients: Comparison Of Parameters Influencing Timing Of Surgery In Patients With Epilepsies With Different Evidence Levels For Surgery/K. Iida, K. Kagawa, M. Kartagiri, A. Hashizume, K. Kurisu Laser Ablation Therapy For The Management Of Medically-Resistant Epilepsy After Age 50/F. Vale, H. Waseem, M. Schoenberg, V. Kelley, A. Bozorg, S. Benbadis, D. Cabello Temporal Lobe Epilepsy With Bilateral Features: Prognostic Factors And Outcomes/H. Waseem, K. E. Eichstaedt, M. Schoenberg, V. Kelley, A. Bozorg, S. Benbadis, F. Vale Electrical Stimulation Of The Centromedian Nucleus Of The Thalamus For The Treatment Of Intractable Epilepsy/Y. Shon, S. Lim, W. Kim Acute Intraoperative Entropy Rise During Hippocampal Deep Brain Stimulation Surgery/A. Marin, H. Carmona, N. Sinisterra, A. Liscano, C. M. Cukiert, A. Cukiert Safety And Efficacy Of Complete Corpus Callosotomy As A Localization Tool For Catastrophic Unlocalizing Epilepsy/J. Seo, K. Lee, J. Baumgartner, B. Pullum Does Seizure Outcome Influence Nonseizure Outcome, Long- Term Outcome After Surgery For MTS/M. Tripathi, K. Garg, A. Garg, A. Wadhawan, M. Goel, C. Bal, C. Sarkar, V. Kumar, P. Madakasira, S. Chandra Health Services Incidence And Prevalence Of Epilepsy In Low-Income Children: Preliminary Analysis/A. Chandran Pillai, K. Kaiboriboon, S. Koroukian, E. Pestana Knight 60

63 AES 68 TH ANNUAL MEETING Seattle, WA MONDAY December 8, :00 a.m. 8:30 a.m. Special Interest Group Meetings Location listed under each session Ketogenic Diet: Does the Ketogenic Diet Offer a Cure for Epilepsy? Convention Center Room 613, Level 6 Coordinators: Susan Masino, Ph.D., Christina A. Bergqvist, M.D. Speakers: Detlev Boison, Ph.D., Sudha Kessler, M.D., Renee A. Shellhaas, M.D., Timothy A. Simeone, Ph.D. We have an arsenal of treatments for epilepsy, but do we have any cures? More specifically, could the time-honored treatment of a ketogenic diet also be an anti-epileptogenic treatment and offer insight into a cure? What proof do we have that this is, or is not, the case? This year the discussion will be organized into a pro/con debate of clinical evidence and basic science evidence with ample time for rebuttal and audience participation. Our invited speakers are expected to take a side as we explore this hot topic. We hope to have fun and inspire the community to share their thoughts, suggest experiments and put forth provocative ideas to help move the field forward. Neuropsychology: Can We Spare Memory with Newer Surgical Approaches for Temporal Lobe Epilepsy? Emergent Outcome Data from Laser Ablation, Multiple Hippocampal Transection, and Fornix DBS Convention Center Room 609, Level 6 Coordinators: Philip S. Fastenau, Ph.D., Gail L. Risse, Ph.D. Speakers: Daniel L. Drane, Ph.D., Robert Gross, M.D., Philip Fastenau, Ph.D., Jonathan P. Miller, M.D. Emergent neuropsychological outcome data will be presented on three novel surgical techniques and will be critically evaluated and discussed with the audience. The topic (neuropsychology, surgery, temporal lobe) and the neuropsychologist-neurosurgeon paired presentations are expected to draw a diverse multidisciplinary audience. NINDS and Non-Profit Research Resources Convention Center Room 620, Level 6 Coordinators: Brandy Fureman, Ph.D., Randall Stewart, Ph.D., William Benzing, Ph.D., Steve Roberds, Ph.D., Ilene Miller, J.D., Seth Wohlberg Speakers: Abigail Hemani, Scott C. Baraban, Ph.D. The purpose of this SIG is to generate focused two-way discussion between government and non-profit funders and basic and clinical researchers attending the AES annual meeting. This discussion will educate researchers on how government and non-profits set their priorities and fund research or make other resources available, and it will educate non-profit leaders on what else they could do to support basic and clinical researchers in the epilepsies. The ultimate goal of this group is to accelerate research on the epilepsies by more effectively making valuable resources available to the research community. Nursing Convention Center Room 608, Level 6 Coordinators: Tara Myers, CPNP, Wendy Miller, Ph.D., RN, CCRN Speakers: Nurse Travel Award Winners The Nurse Travel Award winners will present their poster topics in a 10-minute synopsis with audience discussion and question session. In addition, we will hold a discussion on an epilepsy certificate program and feasibility of epilepsy certification in nursing. Status Epilepticus: Are We Over-Treating Status Epilepticus, and Especially, Nonconvulsive Status Epilepticus? Convention Center Room 612, Level 6 Coordinators: Frank W. Drislane, M.D., Howard Goodkin, M.D., Ph.D. Speakers: Peter Kaplan, M.B.B.S., Lawrence J. Hirsch, M.D., Howard Goodkin, M.D., Ph.D. Neurologists agree readily that generalized convulsive Status Epilepticus (SE) is a neurologic emergency and that it should be halted immediately and the patient kept from having recurrence of seizures. There is no consensus, however, that all forms of SE (particularly nonconvulsive SE) need be treated so aggressively. Even after interruption of convulsive SE, there is disagreement on how long seizures need be suppressed, and on which EEG abnormalities signify seizures that require re-treatment. Prolongation of medically-induced coma with highly sedating drugs keeps patients at risk of prolonged ICU stays and of new medical complications. Dr. Peter Kaplan, who has written on the risks of overtreatment (including a paper this year on worsened outcome for aggressively treated SE patients) will make the case that much of current treatment is excessive. Dr. Larry Hirsch, who has studied the treatment of ICU patients with refractory SE, as well as the deleterious consequences of SE itself, will speak in favor of vigorous seizure suppression. Finally, Dr. Howard Goodkin, with both a clinical and basic science perspective, will discuss what evidence from basic and clinical research can guide us in determining how aggressively to treat NCSE. 8:45 a.m. Noon Merritt-Putnam Symposium: Stress, Cannabinoids and Epilepsy: The Science Behind the Buzz (3.0 CME Credits) Convention Center Ballroom 6C, Level 6 Presentation: Hans O. Lüders, M.D., Ph.D., William G. Lennox Award Overview The impact of stress on seizure control has long been recognized but the neurobiology of stress impact on neurophysiology is not widely known. Similarly, cannabinoids have been considered as potentially effective adjunctive treatment for epilepsy as an alternative to traditional medications but here, too, the neurobiology requires further elucidation. There is evidence of shared mechanisms between stress impact on neurologic function and the neurobiology of cannabinoids. These topics will be explored, providing information necessary for improved management of patients with pharmacoresistant epilepsy. Presentations on basic science related to stress and to cannabinoids, and clinical data regarding both will be presented. Research on how cannabinoid receptors alter the brain s immune system will be presented, as well as progress that has been made in identifying cannabinoid agents devoid of drug of abuse properties that may provide treatment for diverse neurological disorders. Learning Objectives u Identify a patient for whom stress is contributing to difficulties in management of seizures and develop treatment strategies to address the role of stress u u Query patients regarding use of cannabinoids and address the impact of such use in developing treatment plans Identify a patient who is using cannabinoids for treatment of epilepsy and discuss the impact of the use of cannabinoids MONDAY 61

64 MONDAY December 8, 2014 u u u Assist clinicians in developing treatment plans that account for the impact of cannabinoids and their interaction with traditional medications Counsel patient regarding the need for stress management in treatment of epilepsy Counsel patients regarding the impact of stress on seizure control and develop plans for managing stress u Evaluate the possible adverse effects of cannabinoids on cognitive function in patients using cannabinoids for seizure treatment. Target Audience Basic, Intermediate and Advanced (see page 120 for details) Program Chair: Amy Brooks-Kayal, M.D. 9:00 a.m. Introduction Amy Brooks-Kayal, M.D. 9:15 a.m. The Neurobiology of Stress: How Stress and Epilepsy Intersect at the Synapse Tallie Z. Baram, M.D., Ph.D. 9:45 a.m. Stress and Epilepsy: What Are the Clinical Data? Sheryl Haut, M.D. 10:15 a.m. Stress and Cannabinoids: What Is the Link? Jaideep Bains, Ph.D. 10:45 a.m. Cannabinoids and Epilepsy: What Are the Clinical Data? Allen Hauser, M.D. 11:10 a.m. Cannabinoids in Treatment of Neurological and Psychiatric Disorders: Is There a Potential Role in Epilepsy? Nephi Stella, Ph.D. 11:40 a.m. Panel Discussion and Conclusions Amy Brooks-Kayal, M.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 3.0 contact hours for this session. Nurse Practitioners may claim 3.0 hours of pharmacology for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 3.0 contact hours (0.3 CEUs). UAN L01-P. Initial Release Date: 12/8/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Merritt-Putnam Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Professionalism, Medical Knowledge, Practice-based Learning and Systems-based Practice Acknowledgment This program is supported in part by CURE. 9:00 a.m. 10:30 a.m. Special Interest Group Meetings Location listed under each session NEW Epilepsy and Aging Convention Center Room 620, Level 6 Coordinators: Bruce P. Hermann, Ph.D., Kimford J. Meador, M.D., Helen E. Scharfman, Ph.D. Speakers: Carrie McDonald, Ph.D., David Loring, Ph.D., Ilo Leppik, M.D., R. Eugene Ramsay, M.D., Helen Scharfman, Ph.D., Manisha Patel, Ph.D. This SIG will focus on neurological, neuropsychological, imaging and basic science aspects of the relationship between epilepsy and aging. This includes the complications of aging with chronic epilepsy and the issue of new onset epilepsy with advancing chronological age. The initial meeting will include brief invited presentations and discussants from clinical neurology, neuropsychology, and basic science. Surgery: Surgical Failure in Pediatric and Adult Epilepsy: The Slam Dunk Case That Wasn t! Convention Center Room 609, Level 6 Coordinators: Saadi Ghatan, M.D., Gerald Grant, M.D. Speakers: TBA We will solicit cases from pediatric and adult surgical epilepsy programs and select 3-5 cases for presentation, reviewing cases in advance and sticking to a strict timeline. Presenters are asked to provide a case that was predicted to be an unequivocal success but resulted in a failure to adequately treat the patient s epilepsy or realize the goal of the operation. Audience participation is then solicited to generate discussion and suggestions about approaches and recommendations, with moderators polling the audience. Tuberous Sclerosis: Thinking Outside the Tuber in TSC Convention Center Room 612, Level 6 Coordinator: Peter E. Crino, M.D., Ph.D. Speakers: Peter Crino M.D., Ph.D., Delia Talos Ph.D., Juurian Peters M.D. This SIG will focus on the role of non-tuberal cortex and sub-cortical structures in epilepsy and neurobehavioral disabilities in TSC. 2:15 p.m. 3:00 p.m. Lennox and Lombroso Lecture: Priorities in Pediatric Epilepsy Research Convention Center Ballroom 6C, Level 6 Presentation: Karen Gale, Ph.D., Extraordinary Contributions Award Lecturer: Anne Berg, Ph.D. The past several decades of clinical and epidemiological research have provided a wealth of knowledge about the diversity within the pediatric epilepsies and greatly clarified the sometimes reassuring but still too often devastating prognosis of many of these disorders. The tremendous advances in neuroimaging, molecular cell biology, and therapeutics hold the promise of prevention, more effective targeted treatment, and even disease modification for these epilepsies with the possibility of ameliorating what can otherwise be moderate to severe lifelong disability. The challenge is to learn how -when and in whom- to utilize these techniques and therapies in an optimal manner to assure the best patient outcomes. Stakeholder identified and endorsed priorities can help develop a series of research priorities for accomplishing this goal. 62

65 MONDAY December 8, :00 p.m. 4:30 p.m. Investigators Workshop This workshop is an AES Research Grant funded study Convention Center Room 607, Level 6 Modeling Epilepsies with Patient-Derived Induced Pluripotent Stem Cells Moderator: Jack M. Parent, M.D. Speakers: Kevin Ess, M.D., Ph.D., Jack Parent, M.D., Lori Isom, Ph.D. 3:00 p.m. 5:00 p.m. FDA Town Hall Update: SUDEP and Clinical Trials (2.0 CME Credits) Convention Center Room 612, Level 6 Overview In 2011, a meta-analysis published in Lancet Neurology suggested that patients randomized into placebo-controlled add-on studies of antiepileptic drugs had a higher likelihood of having SUDEP if they were randomized to the placebo arm compared to addition of an active drug. This analysis was recently repeated by the FDA using data requested from the companies performing the trials. This symposium will discuss the following issues: 1) How do the findings impact the design of add-on studies of antiepileptic drugs? 2) What do these findings mean for clinical practice? The session will include a long interactive audience discussion session, as specifically requested by the FDA, to provide community input to the regulatory process. Learning Objectives u Define patient-specific risk/benefit ratios related to treatment interventions vs absence of intervention in treatment resistant patients u Counsel patients regarding risks and benefits related to treatment interventions vs absence of intervention in treatment resistant patients u Understand and counsel patients regarding risks and benefits related to treatment interventions vs absence of intervention in treatment resistant patients. Target Audience Intermediate and Advanced (see page 120 for details) Program Co-Chairs: Jacqueline A. French, M.D. and Billy Dunn, M.D. 3:00 p.m. Introduction Billy Dunn, M.D. 3:05 p.m. Review of 2011 Analysis Philippe Ryvlin, M.D., Ph.D. 3:20 p.m. Presentation of FDA Analysis Mary Doi, M.D., M.S. 3:40 p.m. Potential Impact on Clinical Trial Design and Practice Jacqueline A. French, M.D. 4:00 p.m. Interactive Panel/Audience Discussion Eric Bastings, M.D. Norman Hershkowitz, M.D., Ph.D. Mary Doi, M.D., M.S. Alice Hughes, M.D. Billy Dunn, M.D. Sally Jo Yasuda, Pharm.D., M.S. 4:55 p.m. Conclusions Jacqueline A. French, M.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Town Hall FDA Update and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competency: Professionalism 3:00 p.m. 5:15 p.m. Pediatric Epilepsy Highlights Session Convention Center Ballroom 6E, Level 6 Note: Number below refers to poster assignment This session will showcase selected scientific abstracts focused on topics in clinical care and research in pediatric epilepsy. Authors will present a six-minute overview of their work. Presentations are chosen from all submitted abstracts. Participants will be able to view posters and meet the authors at the end of the program Diminished Antiepileptogenic Effects Of Neurosteroids In Mice Lacking Delta-Subunit Extrasynaptic GABA-A Receptors/Bryan Clossen Early-Life Clonazepam Exposure Leads To Persistent Alteration Of Seizure Susceptibility/Hana Kubova Behavioral Co-Morbidities In Pediatric Epilepsy: What Is The Role Of Cognition?/Soyong Eom Temporal Lobe Epilepsy With Hippocampal Sclerosis: The Role Of 5HT1A and 5HT2A Receptos In Human Epileptogenesis/Kette Valente Surgical Versus Medical Treatment For Children With Epileptic Encephalopathy In Infancy And Early Childhood An Observational Cohort Study By Far-East Asia Catastrophic Epilepsy (FACE) Study Group/ Taisuke Otsuki Psychiatric Comorbidity In Children With Recent-Onset Epilepsy: A 2-Year Prospective Controlled Investigation/Jana Jones Familial Ring Chromosome 20 Syndrome A Case Report/ Iris Unterberger Left Temporal Lobe Epilepsy Presenting As Apparent Life-Threatening Events In Infants/Richard Tang-Wai Inflammatory Mechanisms Of Epileptogenesis In The Genetic Epilepsy, Tuberous Sclerosis Complex/Bo Zhang A Brain-Machine Interface For Burst Suppression Control in Pediatric Status Epilepticus/Christos Papadelis MONDAY 63

66 MONDAY December 8, :00 p.m. 5:15 p.m. Platform Sessions: 3 Concurrent Sessions See page 120 for locations There will be three concurrent sessions consisting of selected key scientific abstracts. Authors will present a 10-minute overview of their work followed by a five-minute Q & A. 5:30 p.m. 8:00 p.m. Pediatric State of the Art Symposium: Long-term Outcomes of Neonatal Seizures (2.5 CME Credits) Convention Center Ballroom 6C, Level 6 Overview Seizures occur in a significant number of neonates, yet many critical questions remain regarding their diagnosis, treatment, and long-term prognosis. Modern neurophysiological monitoring indicates that the scope of the neonatal seizure problem may be more extensive than previously appreciated. Although contemporary neuroprotective strategies have led to improved short-term outcomes, the impact of both seizures and the medications used to treat them are now being explored more rigorously in both animal models and humans. There is a need for clinicians who treat infants, children, adolescents, and even adults to become familiar with the long-term sequelae of neonatal seizures. Importantly, these sequelae include not only seizures cognitive, neuropsychological and social outcomes are affected, as well. This State of the Art Symposium will address the long-term outcomes of neonatal seizures, with a focus on both epilepsy and non-epilepsy factors. Learning Objectives u Recognize long-term sequelae of neonatal seizures from information provided by outcome studies Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.5 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.5 contact hours (0.25 CEUs). UAN L01-P. Initial Release Date: 12/8/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Pediatric State of the Art Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Patient Care and Systems-based Practice Acknowledgment This program is supported in part by an educational grant from Mallinckrodt Pharmaceuticals. u Choose appropriate medications used to treat neonatal seizures based on information from follow up studies regarding long-term sequelae u Utilizing information provided regarding long-term sequelae of neonatal seizures and medications used to treat them, counsel families about seizure- and development related outcomes after neonatal seizures. Target Audience Intermediate and Advanced (see page 120 for details) Program Co-Chairs: Adam Hartman, M.D. and Renée A. Shellhaas, M.D., M.S. 5:30 p.m. Introduction and Case Presentation Adam Hartman, M.D. 5:45 p.m. Introduction to Neonatal Seizures Geraldine Boylan, Ph.D. 6:10 p.m. Clinical and EEG Predictors of Prognosis Renée A. Shellhaas, M.D., M.S. 6:35 p.m. Are Neonatal Seizures So Bad? Rodney Scott, M.D. 7:00 p.m. Are Seizure Medicines So Bad? Timothy Benke, M.D., Ph.D. 7:25 p.m. Neonatal Seizure Management 2014 Janet Soul, M.D. Get Your Annual Meeting CME / CE Credit Online Go to See page 120 for details 7:50 p.m. Conclusions Renée A. Shellhaas, M.D., M.S. 64

67 Monday December 8, 2014 Platform Sessions 3:00 p.m. - 5:15 p.m. A. Clinical Convention Center Room 608, Level 6 Moderators: Amy Crepeau, M.D., Nicholas Abend, M.D. B. Treatment / Imaging Convention Center Room 609, Level 6 Moderators: Jacquelyn Bainbridge, Pharm.D., Jeffrey Ojemann, M.D. C. Translational Convention Center Room 603, Level 6 Moderators: Suzanne Bausch, Ph.D., Lori Isom, Ph.D. 3:00 p.m. A.01 The Not So Simple Course Of Childhood Epilepsies/A. Berg, K. Rychlik B.01 Neural Mechanism Of Impaired Consciousness In Typical Childhood Absence Seizures/J. Guo, R. Kim, W. R. Xiao, E. Feeney, X. Bai, M. Negishi, M. J. Crowley, L. C. Mayes, T. Constable, H. Blumenfeld C.01 Synaptic Impairment Of Frontal Cortical Fast- Spiking Basket Cells Induces Cognitive And Behavioural Deficits In Mice With A Cacna1a Loss-Of-Function Mutation./A. Lupien-Meilleur, I. Riebe, L. Damaj, C. Vanasse, G. Louise, A. M. Van den Maagdenberg, J. Lacaille, E. Rossignol 3:15 p.m. A.02 Factors Influencing Driving Impairment In Persons With Refractory Epilepsy/V. Punia, P. Farooque, W. Chen, L. Hirsch, A. Berg, H. Blumenfeld selected for the Fritz Dreifuss Honor B.02 Safety And Pharmacokinetics Of IV Loading Dose Of Lacosamide In The ICU/R. E. Ramsay, V. Sabharwal, F. Khan, H. Dave C.02 Dravet Syndrome Patient-Derived Induced Pluripotent Stem Cell Cardiac Myocytes Have Increased Sodium Current Density And Increased Beating Rate/C. R. Frasier, H. Zhang, K. Collon, J. Parent, L. L. Isom 3:30 p.m. A.03 Terminal Seizure Remission 45 Years After Onset Of Absence Epilepsies/M. Holtkamp, A. Kirschbaum, A. Kowski, D. Janz B.03 Field Potential Imaging: A New Paradigm For Focal Epilepsy/G. P. Kalamangalam, R. E. Gabr, P. A. Narayana C.03 Cerebellar Control Of Spontaneous Seizures In A Mouse Model Of Temporal Lobe Epilepsy/ E. Krook-Magnuson, C. Armstrong, G. G. Szabo, M. Oijala, I. Soltesz 3:45 p.m. A.04 Children With Epilepsy And Mild Intellectual Disability Do Not Have A High Risk Of Long-Term Resistant Epilepsy; However, Moderate Or Severe/Profound Intellectual Disability Is Ominous: A Population-Based Study With >20 Years Of Follow-Up/P. Camfield, C. Camfield B.04 Automated Detection Of Cortical Dysplasia In MRI-Negative Epilepsy: Class II Diagnostic Evidence/ S. Hong, B. Bernhardt, D. Schrader, N. Bernasconi, A. Bernasconi C.04 (1-3)Insulin-Like Growth Factor 1 Suppresses Seizures And Hypsarrhythmia In An Animal Model Of Infantile Spasms./C. L. Lee, J. D. Frost, Jr., J. T. Le, R. A. Hrachovy, J. W. Swann 4:00 p.m. 4:15 p.m. A.05 Management Of Children With Refractory Epilepsy. A Decision Analysis Comparing Medical Versus Surgical Treatment/I. Sánchez Fernández, S. An, T. Loddenkemper A.06 Pulmonary Edema Occurs In Nearly One-Third Of Monitored Patients With Convulsive Seizures And Is Directly Associated With The Duration Of The Preceding Seizure/J. Kennedy, P. Parikh, K. Hardin, M. Seyal B.05 Increased Cerebral Oxygenation Precedes Generalized Tonic Clonic Seizures/B. D. Moseley, J. Britton, E. So B.06 Continuous Infusions In Refractory Convulsive Status Epilepticus. Results From The Pediatric Status Epilepticus Research Group (pserg)./t. Loddenkemper, I. Sánchez Fernández, N. Abend, R. Arya, R. Basu, N. Brenton, J. Carpenter, K. Chapman, J. Condie, N. Dean, W. Gaillard, T. Glauser, J. Goldstein, H. Goodkin, A. J. Hani, M. Jackson, K. Kapur, T. Kebede, J. Klehm, M. Mikati, K. Peariso, M. Sacco, K. Schmidt, A. Topjian, D. Turner, A. Wilfong, K. Williams, M. Wainwright, R. Tasker C.05 Development Of Glutamatergic Transmission Onto Transplanted MGE Interneurons/M. Howard, S. Baraban C.06 A Novel Mouse Model Of Chromosome Xq22.1 Deletion Syndrome Displays Epilepsy And Cortical Circuit Dysfunction/E. M. Goldberg, J. Zhou, C. Yue, P. Wang, D. Coulter MONDAY 4:30 p.m. A.07 Temporal Lobe Epilepsy In Patients With Nonlesional MRI And Normal Memory: An SEEG Study/J. Miller, J. Sweet, S. Suresh, P. Landazuri, H. Lüders B.07 The Johns Hopkins Hospital Adult Epilepsy Diet Center: Results And Experience In Four Years/ M. Cervenka, E. Kossoff, B. Henry, J. Barnett, R. Fisher C.07 Neuron Subset-Specific-PTEN Deletion Induces Abnormal Skeletal Activity In Mice/J. Lugo, M. Thompson, P. Huber, G. Smith, A. Holley, S. Bain, E. Gardiner, R. Kwon 4:45 p.m. A.08 A Diagnostic Blood Test For Epilepsy: A Soluble ICAM-5-Based Panel/J. R. Pollard, P. B. Crino, G. P. Mueller, O. Eidelman, C. Dalgard, E. Brand, C. T. Anderson, P. Cai, M. Wamil, M. C. Strauman, E. Burakgazi-Dalkilic, K. A. Davis, H. B. Pollard B.08 Long-Term Memory And Language Outcomes With Responsive Cortical Stimulation Do Not Differ By Stimulation Localization/D. W. Loring, R. Kapur, K. J. Meador, M. Morrell selected for Goldberg Kaufman Honor C.08 Hippocampal DBS Affects Disease Development In The KA Rat Model For TLE/B. Van Nieuwenhuyse, R. Raedt, J. Delbeke, M. Sprengers, I. Dauwe, S. Gadeyne, W. Wadman, P. Boon, K. Vonck 5:00 p.m. A.09 Predictive Model For Early Posttraumatic Seizures In The PICU/R. Rajaraman, J. Lerner, D. Arndt, D. McArthur, J. Fischer, M. Zeiger, M. Choe, C. Giza B.09 Structural Connectivity Of Limbic Brain Regions In Patients With Psychogenic Non-Epileptic Seizures (PNES)/K. Hernando, J. Allendorfer, S. Lee, L. Ver Hoef, J. Szaflarski C.09 Seizures And SUDEP In A Mouse Knock-In Model Of SCN8A Related Epileptic Encephalopathy/J. Wagnon, M. Korn, R. Parent, J. Jones, G. Murphy, J. Parent, M. Meisler The Fritz Dreifuss Honor is awarded to the highest ranking abstract in the outstanding patient care topic category and is sessioned as Platform A.02. The abstract honored is selected by the Scientific Program Committee from all submitted abstracts. The Rebecca Goldberg Kaufman Honor is awarded to the highest ranking abstract in the psychiatric topic category and is sessioned as Platform B.08. The abstract honored is selected by the Scientific Program Committee from all submitted abstracts. 65

68 Monday December 8, 2014 Poster Session 3 8:00 a.m. 3:00 p.m. Convention Center Hall 4B, Level 4 Authors Present: Noon 2:00 p.m. Poster Walking Tours (see page 15 for details) Translational Research Mechanisms Increase In Dendritic Spines Correlates With Increased Synapses In Hippocampal CA1 Following Hypoxia- Induced Neonatal Seizures/ J. Lippman-Bell, S. Francomacaro, F. Jensen Using CRISPR In Utero Electroporation To Study The Function Of PCDH19/Y. Wang, F. Chen, J. loturco, J. Parent Targeting The JAK/STAT Pathway For Disease Modification In Epilepsy/A. J. Carrel, H. L. Grabenstatter, J. Carlsen, Y. Cruz Del Angel, S. Russek, M. F. Wempe, A. Brooks-Kayal Topology Of Network Synchronization During Early Epileptogenesis/K. Lillis, Z. Wang, G. Q. Zhao, B. Bacskai, K. Staley Retrograde Monosynaptic Tracing Of Inputs To Neonatal- Vs. Adult-Born Dentate Granule Cells In A Rodent Temporal Lobe Epilepsy Model/X. Du, A. L. Althaus, H. Zhang, E. G. Wolf, J. Parent Disabled 1-Deficient Mice Exhibit Hippocampal Structural Abnormalities And A Reduced Seizure Threshold/M. J. Korn, J. Parent Hippocampal Metaplasticity Induced By Early Life Hypoxic Seizures In Rats/H. Sun, F. E. Jensen Extracellular And Intracellular K+ Accumulation And Buffering During Focal Cortical Epilepsy: A Spatiotemporal Study In Vivo/ S. Dufour, P. Bazzigaluppi, O. Levi, P. Carlen Ceftriaxone Treatment In A Rat Posttraumatic Epilepsy Model Preserves Cortical Inhibitory Interneuron Function And Parvalbumin Expression/M. Q. Hameed, T. Hsieh, J. Morales-Quezada, G. S. Goodrich, A. Rotenberg Mifepristone Treatment Post- Status Epilepticus Normalizes Basal Corticosterone Levels, Increases Calretinin Positive Cell Number In The Dentate Gyrus And Reduces Hilar Cell Proliferation In Mice/A. C. Wulsin, J. P. Herman, S. Danzer ProBDNF Levels Increase Rapidly After Seizures In The Mouse/ A. X. Thomas, Y. Cruz Del Angel, S. J. Russek, B. L. Hempstead, A. R. Brooks-Kayal Preventive Effect Of Levetiracetam Against The Pathological Changes In Hippocampus Of Temporal Lobe Epilepsy Model Mice/T. Higo, H. Sugano, M. Nakajima, Y. Iimura, H. Arai Inflammatory Mechanisms Of Epileptogenesis In The Genetic Epilepsy, Tuberous Sclerosis Complex/B. Zhang, N. Rensing, J. Zou, M. Yang, M. Wong Functional Evaluation Of A De Novo GRIN2A Mutation In A Patient With CSWSS, Continuous Spike And Waves During Slow-Wave Sleep Syndrome/H. Yuan, A. Tankovic, S. F. Traynelis A Juvenile Myoclonic Epilepsy GABAA Receptor Mutation Causes The Developmentally-Dependent Expression Of Seizures And Cortical Disinhibition/M. Gallagher, F. Arain, C. Zhou, L. Ding, S. Zaidi Mechanisms Of Epilepsy And Epileptic Encephalopathy Due To KCNT1 Mutations/I. H. Quraishi, G. E. Kim, J. K. Kronengold, R. L. Couture, M. L. Schwartz, G. Barcia, R. Nabbout, L. K. Kaczmarek A KCNQ2/3 Mutation Causing Severe Epilepsy Disrupts Channel Targeting To The Axon Initial Segment/B. Tran, M. Xu, E. C. Cooper Prenatal Valproic Acid Exposure Impairs Interneuron Proliferation And Migration/ R. F. Martin, E. Powell The Effects Of TRPV1 Ligands On Blood Brain Barrier Permeability In A Rodent Model Of Experimental Febrile Seizures/L. Scott, K. B. Rivard, K. Barrett, S. Nakanishi, M. Scantlebury HT6 Receptor Ligands Modulate Seizure Thresholds And Inhibitory Synaptic Transmission In The Dentate Gyrus/G. J. Remigio, G. W. Saunders, P. J. West The Effect Of Vitamin D On The Pentylenetetrazol-Kindling And The Seizure-Induced Neuronal Damage In The Mouse Hippocampus/S. Lim, Y. Shon, W. Kim Modulation Of NKCC1 And KCC2 Co-Transporters For Control Of Drug-Resistant Seizures/V. Dzhala, Y. Saponjian, Y. De Koninck, K. Staley Time Course Of The Neuronal Sodium Concentration In PosttTraumatic Epileptogenesis In Vitro/T. Balena, K. Staley A Novel Therapy For Status Epilepticus Using Biodegradable Immune-Modifying Nanoparticles/ D. Xu, S. Miller, S. Koh Hypothalamus On The Horizon Of The Seizure Control/T. Chachua, C. Chern, I. Lilja, J. Veliskova, L. Velisek Models Use Of Ethosuximide To Improve Outcome In The Kainic Acid Model Of Temporal Lobe Epilepsy/ S. S. Iyengar, J. J. LaFrancois, H. E. Scharfman Unravelling The EEG Footprints That Develop Into Spontaneous Recurrent Seizures (SRS) During Epileptogenesis In C57BL6/J Mouse Model Of Temporal Lobe Epilepsy (TLE)/S. Puttachary, S. Sharma, T. Thippeswamy The Piriform Cortex In The Intrahippocampal Kainic Acid Model: Effects Of Lesions And Deep Brain Stimulation On Spontaneous Seizures/M. Sprengers, R. Raedt, R. Siugzdaite, B. Descamps, B. Van Nieuwenhuyse, I. Dauwe, J. Delbeke, W. Wadman, P. Boon, K. Vonck Effect Of A Conventional Antiepileptic Strategy On Seizure Activity And Neuroprotection In A Rat Model Of Human Cortical Dysplasia: Data From A Pilot Study/G. Battaglia, P. Nobili, A. Finardi, F. Colciaghi New Model Of Focal Cortical Dysplasia Associated Epilepsy/ L. S. Hsieh, J. H. Wen, G. Buchanan, K. Claycomb, H. Zhan, A. Bordey Electrographic Spiking And Frequency Power Analysis In Mouse CCI Models Of TBI Compared With Memory And Motor Deficits/J. Carlsen, D. Raible, L. Frey, A. Brooks-Kayal Oxidative Stress-Mediated Mitochondrial Dysfunction And Neuronal Loss Contribute To Cognitive Deficits In Experimental Temporal Lobe Epilepsy/J. Pearson, S. Rowley, L. Liang, B. Day, M. Patel Aberrant Diurnal And Circadian Rhythms In Epileptic Mouse Model/ R. Maganti, E. Wallace, J. Williams Microelectrode Array Neuronal Recordings From Intact Larval Zebrafish/ M. Meyer, A. Poduri, A. Rotenberg Enhancing KCC2 By Acute TrkB Inhibition Rescues Phenobarbital- Resistant Seizures In A Model Of Neonatal Ischemia/S. Kadam, S. Kang, M. Johnston Cardiac Consequences Of Repeated Brief Seizures In Chronic Experimental Temporal Lobe Epilepsy/ J. Jefferys, A. Ashby-Lumsden, T. Lovick, K. Qing, S. Lee, P. Irazoqui Spike-Wave Discharges Before And After The Induction Of Epilepsy In Rats/ J. LaFrancois, K. Bermudez-Hernandez, H. E. Scharfman Pattern Recognition And Quantification Of Spike-And-Wave Discharge In Normal And Brain-Injured Sprague-Dawley Rats/D. Barth, F. Dudek, K. Rodgers Flupirtine Is More Efficacious Than Phenobarbital In The Treatment Of Hypoxia-Ischemia Induced Neonatal Seizures In A Rodent Model/ D. Sampath, A. White, Y. Raol EEG Analysis After Ketamine Induction Mechanistic Similarities To Anti-NMDA Receptor Encephalitis/ C. N. Braun, L. UnCheol, S. Glynn, M. George Increased Neuroinflammation In A Mouse Model Of Tuberous Sclerosis/A. A. Coley, H. Sun, S. S. Soldan, F. E. Jensen, D. M. Talos 66

69 Monday December 8, 2014 Poster Session 3 8:00 a.m. 3:00 p.m. Convention Center Hall 4B, Level In Vivo Modulation Of Synaptic Noise: A Novel Model Of Ictogenesis/ H. Luna-Munguia, P. Starski, W. Stacey Lithium-Pilocarpine And DFP- Induced Status Epilepticus In Immature Rats: Behavioral, Electrographic, And Neuropathological Characteristics/E. A. Scholl, N. Simon, M. Lehmkuhle, J. Ekstrand, F. E. Dudek Epilepsy In A Novel Tuberous Sclerosis Mouse Model/S. C. Dhamne, E. Chadwick, S. Lammers, M. Q. Hameed, D. Kwiatkowski, A. Rotenberg, M. Sahin First In-Vivo Model For Electrically Induced Seizures An Electroclinical Characterization/ A. Y. Kitay, M. Brosch, F. Marquardt, L. Buentjen, C. Kluge, J. Mylius, E. Selezneva, K. Kopitzki, J. Voges, H. Heinze, H. Scheich, F. Schmitt Identifying Gene Pathways Activated After Audiogenic Atimulus In Wistar Audiogenic Rats/A. Matos, A. S. Schwambach Vieira, V. Pascoal, C. S. Rocha, D. Nascimento, S. Martins, C. Maurer Morelli, A. Martins, A. Godard, I. Lopes-Cendes Comparison Of Spike-Wave Discharges And Other Oscillatory Activity In Normal Animals With Spontaneous Recurrent Seizures Across Several Animal Models Of Acquired Epilepsy/F. Dudek, K. M. Rodgers, W. A. Pouliot, S. Kadam, E. H. Bertram, D. S. Barth Rapamycin Normalizes Total EEG Power In Neuron Subset-Specific PTEN Knock-Out Mice/ A. Regnier-Golanov, L. Nguyen, A. Brewster, V. Patil, A. Anderson Early EKG Changes And Cardiac Activation Of Intracellular Signaling Cascades In A Model Of Acquired Epilepsy/A. Brewster, A. Anderson, Y. Lai Late Inhibition Of mtor Suppresses Fully Established Epilepsy And Associated Neuropathology In The NS-Pten KO Mouse Model Of Cortical Dysplasia/L. Nguyen, A. Brewster, M. Clark, A. Regnier-Golanov, C. Sunnen, V. Patil, A. Anderson Neonatal Stroke And Phenobarbital Treatment: Improved T-Maze Function And Impact On Post- Stroke Hilar Neurogenesis/A. Comi, M. Mateo, S. George, A. Garson, K. Fisk, H. Miao Gender Differences In Cerebrospinal Fluid Levels Of Monamine Metabolites In The Baboon/M. Patel, J. Rogers, C. Szabo, M. Leland, M. A. Javors Human Studies Does Valproate Increase Levels Of Folate Receptor Autoantibodies In Women?/C. Lau, C. Harden, A. Palacios, R. Finnell Characteristics Of Seizure Termination In Focal And Generalized Seizures/M. Borzello, A. Maheshwari, C. Chu, M. Westover, M. Kramer, S. Cash Looking For Complexity In Quantitative Semiology Of Frontal And Temporal Lobe Seizures Using Neuroethology And Graph Theory/ N. Garcia-Cairasco, P. Bertti, J. Tejada, A. Pinheiro Martins, M. Cleto Dal-Cól, V. Terra, J. Cortes de Oliveira, T. Rodrigues Velasco, A. Ceiki Sakamotob Quantitative Proteomic Profiling Reveals Repression Of Epilepsy Risk Genes Due To Aberrant MicroRNA Activity In Epileptogenic TSC Tubers/A. A. Dombkowski, D. Cukovic, N. J. Carruthers, P. M. Stemmer, H. T. Chugani, D. C. Chugani The North American SUDEP Registry/B. Kaufman, D. Hesdorffer, E. Donner, G. Lapham, J. Buchhalter, D. Friedman, O. Devinsky Deep Brain Stimulation For Focal Epilepsy How Do Changes Of Interictal Epileptic Discharges Correspond To Outcome?/H. Lee, C. Kluge, F. Marquardt, J. Voges, L. Buentjen, S. Rampp, A. Kowski, M. Holtkamp, H. Heinze, F. Schmitt The Safety, Efficacy And Dosing Of Barbiturate Coma In Pediatric Sustained Refractory Status Epilepticus/E. Payne, C. Griffiths, H. Frndova, A. Trope, C. Hahn Whole Brain Networks Of Visual Object Recognition/ C. Kadipasaoglu, C. Conner, V. Baboyan, N. Tandon Ventricular Repolarization Instability In Children With Epilepsy/ W. Ali, B. Bubolz, A. Anderson, Y. Lai Multiple Functions Of The Pre- Central Frontal Eye Field/E. C. Brown, O. Muzik, R. Rothermel, C. Juhasz, A. Shah, D. Fuerst, S. Mittal, S. Sood, E. Asano Biomarkers Tracking Inflammation In Epileptogenic Brain Tissue In The Rat By Nanoparticles/S. Eyal, E. Portnoy, B. Polyak, D. Inbar, A. Mann, A. Rai, A. Bishara, M. Shmuel, S. Magdassi, T. Ben Hur, D. Ekstein High Frequency Oscillations Deviate From Neuronal Avalanche Dynamics In The Ictal Onset Zone/ E. Gireesh, C. Jouny, N. Crone The Role Of Physiologic Biomarkers During A Taurine Trial For Succinic Semialdehyde Dehydrogenase Deficiency/J. Schreiber, P. Pearl, I. Dustin, E. Wiggs, E. Barrios, E. Wassermann, K. M. Gibson, W. Theodore Mass Spectrometry-Based Metabolomics Approach For Uncovering Epileptogenic Mechanisms And Biomarker Discovery/ S. Heischmann, L. B. Gano, K. Quinn, C. Cruickshank-Quinn, N. Reisdorph, M. Patel Generalized, Automated Algorithm For Detecting HFOs And The Extent Of The Seizure Onset Zone/S. Gliske, W. Stacey Occurence Of Ictal High Frequency Oscillations Mirrows Seizure Strength In Rats/N. Birk, K. Somerlik-Fuchs, T. Stieglitz, A. Schulze-Bonhage, J. Jacobs How Reliable Are The High- Frequency Oscillations And Delayed Responses As Epileptogenicity Biomarkers? A Study Based On Intracranial Stimulation/A. Barborica, C. Donos, M. Maliia, J. Ciurea, A. Rasina, I. Mindruta Early Seizure Detection Using Relative Gamma And Ripple Band Phase Decoherence/Z. Nadasdy, D. Benites, J. Shen, D. Briggs, D. F. Clarke, R. Buchanan, M. Lee, D. Nelson, P. Modur High Frequency Oscillations In Patients With Nonlesional Class I Outcomes In Seizure Onset Channels Versus Non Seizure Onset Channels In Temporal And Neocortical Structures/N. D. Child, J. Cimbalnik, V. M. Vasoli, V. Svehlik, B. H. Brinkmann, M. Stead, G. Worrell Spectroscopic Imaging In Early Post-Status Epilepticus In A Rodent Model/P. S. Pearce, N. de Lanerolle, A. Rapuano, T. Hitchens, J. W. Pan Automated High-Frequency Oscillation Detection From Tripolar Concentric Ring Electrode Scalp Recordings/M. Abtahi, I. E. Martínez-Juárez, O. Makeyev, A. Medvedev, J. Gaitanis, R. Fisher, W. Besio Modulating Epileptogenesis In The Glutamine-Synthetase Deficient Model Of MTLE/E. Perez, H. Zaveri, R. Joshi, H. Wang, E. Damisah, R. Dhaher, T. Eid Behavior/Neuropsychology/ Language Adult Development And Field-Testing Of An Epilepsy Self-Management Instrument For Adults With Epilepsy/C. Escoffery, Y. Bamps, W. LaFrance, S. Stoll, R. Shegog, J. Buelow, P. Shafer, N. Thompson Distinct Domains Of Impulsivity Are Impaired In Juvenile Myoclonic Epilepsy, But Not In Temporal Lobe Epilepsy/P. Rzezak, S. Moschetta, E. Lima, C. X. Castro, A. Coan, C. Guerreiro, G. Busatto, K. Valente Stability And Variability Of Cognitive Performance In Patients With Epilepsy/M. T. Lutz, T. Mayer MONDAY 67

70 Monday December 8, 2014 Poster Session 3 8:00 a.m. 3:00 p.m. Convention Center Hall 4B, Level Depression And Isolation In People With Epilepsy/N. Thompson, Y. A. Bamps, L. Selwa, S. Stoll, C. Begley, E. K. Johnson, R. Fraser PHQ-9 And GAD-7 As Reliable Screening Tools For Mood Disorders In People With Epilepsy (PWE)/ I. Ahmed, S. Nair, A. Riaz, I. Ali The Impact Of Disease Variables And Standard Cognitive Measures On Social Cognition In Epilepsy/K. Bujarski, L. Flashman, R. M. Roth Felt Stigma In Families Containing Multiple Individuals With Epilepsy/M. Sabatello, S. T. Sorge, J. O. Okeke, V. Tangel, S. Shostak, J. C. Phelan, J. Goldsmith, M. Winawer, D. Hesdorffer, W. K. Chung, R. Ottman Depression And Seizure Frequency Predicts Worse Social Functioning In Patients With Juvenile Myoclonic Epilepsy (JME)/ S. C. Moschetta, C. A. Guerreiro, C. Lima Castro, A. Coan, P. Rzezak, K. Valente Unique Characteristics Of Patients With Comorbid Epileptic And Psychogenic Nonepileptic Seizures/ J. J. Konikkara, J. Pacheco, P. Van Ness, M. Agostini, R. Hays, L. Howe-Martin, C. B. Culver, J. Munoz, K. Ding, P. Modur, P. Gupta Preoperative Hippocampal Volume And Neuropsychological Outcomes/S. C. Germeyan, E. Wiggs, L. Sepeta, E. Emery, I. Dustin, K. zaghloul, S. Inati, W. Theodore Comparison Of Common Data Elements From The Managing Epilepsy Well (MEW) Integrated Database And A Well Characterized Sample With Nonepileptic Seizures/W. LaFrance, Jr, Y. Bamps, S. Stoll, S. S. Sahoo, E. Welter, J. Sams, C. Tatsuoka, M. Sajatovic Genetics Human Studies Screen For Somatic Mosaic Mutations In Unexplained Dravet Syndrome Patients/C. Myers, J. McMahon, I. Scheffer, H. Mefford The Phenotypic Spectrum Of SCN2A Encephalopathy: A Diagnosis With Treatment Implications/ K. Howell, J. McMahon, G. L. Carvill, A. Poduri, M. T. Mackay, M. V. Rodriguez Casero, R. Webster, D. Clark, J. L. Freeman, S. Calvert, S. Mandelstam, H. Mefford, A. S. Harvey, I. Scheffer Are Mutations Of The Respiratory Control Gene PHOX2B Associated With Sudden Unexpected Death In Epilepsy (SUDEP)?/ B. M. Regan, R. D. Bagnall, D. E. Crompton, C. Cutmore, S. Berkovic, I. E. Scheffer, C. Semsarian Whole-Exome Sequencing In 84 Cases Of Unsolved Progressive Myoclonus Epilepsy/M. Muona, S. Berkovic, L. M. Dibbens, K. L. Oliver, S. Maljevic, T. Joensuu, M. A. Bayly, S. Petrou, H. Lerche, A. Palotie, A. Lehesjoki Familial Adult Myoclonic Epilepsy: A New Family Consistent With Linkage To Chromosome 2/ K. Klein, M. Pendziwiat, R. Straussberg, I. Blatt, C. E. Kim, P. S. Reif, S. von Spiczak, A. Korczyn, H. Muhle, F. Rosenow, H. Hakonarson, G. Kuhlenbäumer, H. Goldberg-Stern, U. Stephani, Z. Afawi, I. Helbig Genetic Determinants Of Common Epilepsies: A Meta-Analysis Of Genome-Wide Association Studies/G. Na CHD2 Myoclonic Encephalopathy: Self-Induced Seizures, Photosensitivity And Variable Cognitive Outcome/ R. Thomas, L. Zhang, G. L. Carvill, J. Archer, S. Mandelstam, D. Craiu, S. Berkovic, D. Gill, H. Mefford, I. Scheffer Whole-Exome Sequencing And Targeted Re-Sequencing In Pediatric Epileptic Encephalopathies/ J. L. Michaud, M. Lachance, F. F. Hamdan, S. Dobrzeniecka, H. Mefford, R. G. Lafrenière, B. Minassian, P. Cossette, E. Rossignol CACNA1A-Related Hemiplegic Migraine Mimicking Psychogenic Non-Epileptic Seizures (PNES)/ M. Chadehumbe, M. Mintz, R. Boles Epilepsy Genetics Initiative (EGI)/D. Goldstein, E. Heinzen, D. Lowenstein, S. Berkovic, T. Dixon-Salazar, J. Milder, H. White, O. Devinsky, D. Dlugos, W. Gallentine, M. Mikati, A. Poduri, I. Scheffer, J. Sullivan Copy Number Variants Are An Important Cause Of Unexplained Epilepsy Plus Other Neurological Abnormalities/S. E. Buerki, E. Sade, P. Eydoux, M. Connolly, M. Demos Severe Multi-Organ Involvement Including Pancreatic Neuroendocrine Tumor In A 51-Year- Old Female With Tuberous Sclerosis Complex/F. Andermann, D. Amrom, M. Heshmati Moghaddam, P. Zanelli, E. Andermann Regional Variation Of SLC7A11 Expression In Glioblastoma Associated Seizures/J. Lee, J. Snyder, T. Mikkelsen, P. Wen Uncovering New Genetic Loci For Infantile Spasms Syndrome/ E. D. Marsh, J. Glessner, X. Bozarth, W. Dobyns, H. Hakonarson, I. Helbig Utilizing Brain Expression Networks To Prioritize Candidate Epileptic Encephalopathy Genes/ K. L. Oliver, V. Lukic, N. P. Thorne, S. F. Berkovic, I. E. Scheffer, M. Bahlo Association Between Polymorphisms In Genes Involved In P-Glycoprotein Regulation And Pharmacoresistance In Childhood- Onset Epilepsy/J. Montalvo, M. Rios-Motta, S. Gonzalez-Crespo, L. Gonzalez-Sepulveda, K. Acevedo, M. Vazquez, I. Pita Whole Exome Sequencing In Intractable Paediatric Epilepsy Patients In Calgary/L. Bello-Espinosa Copy Number Variants In Children With Epilepsy/ S. J. Mackenzie, Y. Eksioglu Natural History Of Seizures In Rett Syndrome And MECP2-Related Disorders/D. Tarquinio, J. B. Lane, W. Hou, W. Kaufmann, S. A. Skinner, K. J. Motil, J. L. Neul, D. Glaze, A. K. Percy Animal Studies Superimposing Status Epilepticus On NS-PTEN Haploinsufficient And Wild Type Mice Results In Long-Term Changes In Behavior/G. Smith, J. White, J. Nicoletti, A. Pandian, J. Lugo Selective Targeting Of Scn8a Expression Confers Seizure Resistance In Two Mouse Models Of Refractory Epilepsy/J. Wong, C. Makinson, H. Zafar, A. Escayg Scn2a-null Heterozygosity Improves Survival And Modifies Neurocardiac Interaction In The Kcna1-Null Mouse Model Of SUDEP/ E. Glasscock, N. Gautier, B. Karumuri, R. Liu, I. Vlachos, L. Iasemidis Neuropathology of Epilepsy Human Studies Oligodenderoglia-Like Cells In White Matter Recruiting The Extensive Epileptogenic Zones In Pediatric Intractable Focal Epilepsy/ S. Sakuma, W. Halliday, K. Okanari, S. Baba, M. Nakajima, Y. Sato, A. Ochi, H. Otsubo Hippocampal Changes In Refractory Status Epilepticus: Autopsy Findings/K. M. Ikeda, L. Ang, G. Young Neuroinflammatory Processes, Acute Neuronal Injury And Blood Brain Barrier In SUDEP/Z. Michalak, D. Obari, M. Thom, S. Sisodiya Cerebral Glucose Hypometabolism Is Associated With Mitochondrial Dysfunction In Patients With Intractable Epilepsy And Cortical Dysplasia/J. Tenney, L. Rozhkov, P. Horn, L. Miles, M. Miles The Serum Levels Of Sodium And Uric Acid In Children With Benign Convulsion With Mild Gastroenteritis/ S. Kim, J. Kang, H. Bang, T. Kim, H. Kim, J. Kang, J. Kim, Y. Kim 68

71 Monday December 8, 2014 Poster Session 3 8:00 a.m. 3:00 p.m. Convention Center Hall 4B, Level Gene Expression Profiling In Dentate Granule Cells Of Mesial Temporal Lobe Epilepsy Patients With And Without Hippocampal Sclerosis/ N. G. Griffin, Y. Wang, L. Hong, C. Hulette, M. Haglund, R. Radtke, P. Skene, S. Sinha, E. Heinzen A Case Of Glioneuronal Tumor With Focal Cortical Dysplasia Type IIb/T. Saito, S. Sukigara, S. Hanai, A. Takahashi, M. Sasaki, T. Otsuki, M. Itoh Animal Studies NMDA Receptor Activation Contributes To Benzodiazepine Refractoriness By Enhancing Ampa Receptor Mediated Transmission During Status Epilepticus/S. Joshi, K. Rajasekaran, J. Williamson, J. Kapur Circulating Ccr2+ Monocytes Display Delayed Brain Infiltration After Chemoconvulsant-Induced Status Epilepticus/N. Varvel, J. J. Neher, R. J. Miller, M. Jucker, R. Dingledine Deletion Of Micro-RNA-146a Leads To Fewer Animals Developing Acute Behavioral Seizures Following Viral Encephalitis/M. F. Cusick, J. E. Libbey, R. M. O Connell, R. S. Fujinami Effects Of Neuronal Nitric Oxide Synthase Inhibition In A Neonatal Mouse Model Of Acute Hypoxic Seizures/S. A. Zanelli, P. Wagley, J. Kapur Regulation Of Hippocampal Glutamate Transporter-1 (GLT1) Expression In The Intrahippocampal Kainic Acid Model Of Epileptogenesis/ J. A. Hubbard, J. Szu, D. Binder Impact Of Targeted Ablation Of Developing Dentate Granule Cells On Temporal Lobe Epileptogenesis/ B. Hosford, J. Liska, S. Danzer Do Ripples Change After Pilocarpine-Induced Status Epilepticus?/C. Behr, M. Lévesque, C. Pack, J. Gotman, M. Avoli Sex- And Brain Region-Specific Regulation Of Brd2 In GABAergic Neurons In A Juvenile Myoclonic Epilepsy Mouse Model/J. A. Miller, F. Mohammad, D. S. Chandler, J. Veliskova, L. Velisek, D. A. Greenberg Evaluation Of The Inflammatory Process In Focal Cortical Dysplasia Model By Freeze Lesion/A. Donatti, A. Fernandes, N. Garcia-Cairasco Effects Of Postnatal Inflammation On Brain Excitability In A Mouse Model Of Autism Spectrum Disorder/M. L. Lewis, L. Qulu, S. A. Candy, J. M. Rho, Q. J. Pittman In Vitro Studies Laser Scanning Photostimulation Reveals Altered Astrocyte Maturation In A Model Of Developmental Cortical Malformation/ M. Armbruster, C. Dulla Epidemiology Real-World Assessment Of The Burden Of Epilepsy In Tuberous Sclerosis Complex (TSC) Patients In The United Kingdom (UK)/P. Crawford, C. Shepherd, D. Demuth, P. Nasuti, L. Lucchese, Z. Haider, E. Gray, M. Magestro Managing Information Well: Towards An Ontology-Driven Informatics Platform For Data Sharing And Secondary Use In Epilepsy Self-Management Research Centers/S. D. Lhatoo, S. S. Sahoo, G. Zhang, Y. Bamps, R. Fraser, S. Stoll, C. Tatsuoka, E. Welter, M. Sajatovic Sudden Unexpected Death In Epilepsy. A Population-Based Study/ A. Einarsdottir, O. Sveinsson, E. Olafsson Using Routine Data To Investigate Secular Trends In Hospital Admission Amongst Children With Epilepsy: A Nationwide Study/ O. Ajetunmobi, C. Weir, R. Wood, R. Chin A Study Of Epilepsy Prevalence And Incidence In The U.S. Using Administrative Claims Data/ S. Helmers, D. Thurman, T. Durgin, A. Kalsanka Pai, A. Patel, E. Faught Epidemiology Study Of Association Between Onset Of Chronic Headache And Epilepsy/ T. Chen Long QT Mutations And QT Prolongation Are Linked With An Increased Risk Of Seizures/ D. S. Auerbach, M. Ruwald, M. Andrews, A. Moss Retrospective Review Of Seizures Associated With Posterior Reversible Encephalopathy Syndrome (PRES)/N. Dike, S. Rana Trajectories Of Emotional Well-Being In Children With Newly Diagnosed Epilepsy/S. W. Goodwin, P. Wilk, M. Campbell, K. N. Speechley Fertility In Epilepsy: Effects Of Estimated Offspring Risk And Genetic Attribution/V. Tangel, S. T. Sorge, J. O. Okeke, S. Shostak, J. C. Phelan, J. Goldsmith, M. Winawer, D. Hesdorffer, W. K. Chung, R. Ottman Defining The Prevalence And Characteristics Of Seizure Clusters/ T. Choezom, S. Zhang, S. Radhakrishna, J. Bonito, H. Zaveri, R. Joshi, L. Hirsch, K. Detyniecki Sudden Unexpected Death In Dravet Syndrome: A Case-Control Study/E. Donner, D. Friedman, B. Kaufman, D. Hesdorffer, G. Lapham, J. Buchhalter, J. Thaler, S. Rai, A. Thaler, O. Devinsky Predictors Of Seizure Clusters/B. Chen, H. Choi, L. Hirsch, R. Buchsbaum, K. Kato, A. Legge, K. Detyniecki The Clinical And Social Impact Of The Post-Ictal State/C. Josephson, N. Jette, Y. Aghakhani, P. Federico, A. Hanson, W. Murphy, N. Pillay, S. Wiebe The Elixhauser Index In Incident Epilepsy And First Unprovoked Seizure: Means And Reliability Of Patient Or Parent Report And Hospital Medical Record/E. Leaffer, A. Hauser, A. Pack, E. Baldin, C. I. Akman, D. Hesdorffer How Do Caregivers Determine Seizure Severity In Their Child With Epilepsy?/S. Shih, M. Ardini, B. Kroner, W. Gaillard, S. Cushner-Weinstein, J. Salpekar, K. Havens, A. Kao, T. Zelleke, D. Depositario-Cabacar Patterns Of Comorbidity In Pregnant Women with Epilepsy/ A. M. Malek, D. A. Wilson, B. Wannamaker, R. B. Newman, J. E. Vena, A. Selassie Tuberous Sclerosis Does Regional Differences In Clinical Features Exist?/E. V. Caetano, P. B. Cerqueira, M. G. Manreza, U. C. Reed, L. B. Sampaio, E. C. Miotto, F. A. Costa, P. S. Mendes, B. J. Correa Parental Worry About Nocturnal Seizures And Utilization Of Methods For Monitoring/B. Kroner, S. Shih, M. A. Ardini, W. Gaillard Etiologies And Yield Of Investigations For Infantile Spasms: Results Of A U.S. Multicenter, Prospective Study/E. Wirrell, C. Joshi, R. Shellhaas, C. Keator, S. Kumar, W. Mitchell Neurophysiology Other Clinical EEG Pharmacologically Induced Burst Suppression In Pediatric And Adult Patients Varying But Predictable Pattern?/L. M. Sorin, B. Jabo, T. Losey Completely Lateralized Vertex Waves Of Sleep Are A Normal Phenomenon: A Retrospective, Blinded, Case Control Study/ J. N. Brenton, J. R. Mytinger Posterior Rhythmic Delta Activity In Patients With Absence Epilepsy/R. Fabris, L. Wong-Kisiel, K. Nickels Multifocal Electrographic Seizures Recorded By 128 Channel Dense Array High-Resolution EEG In Outpatient EEG LAB/H. Hasegawa EEG Focal Interictal Epileptiform Transients (FIET) & Their Correlation With Clinical Diagnosis/ F. Matsuo How Much Does Sleep Deprivation EEG Useful For Detecting Epileptiform Abnormalities?/D. Ozbek, I. Midi, K. Agan MONDAY 69

72 Monday December 8, 2014 Poster Session 3 8:00 a.m. 3:00 p.m. Convention Center Hall 4B, Level Generalized Onset Seizures With Focal Evolution Should Be Recognized As A Seizure Type/ A. Linane, B. Abou-Khalil, A. Lagrange Preictal Failure Of Post-Spike Slow Waves To Control Spike-Related High-Frequency Oscillations Is Associated With Seizure Initiation In Focal Cortical Dysplasia Type II/ Y. Sato, S. M. Doesburg, S. M. Wong, A. Ochi, H. Otsubo Correlation Between Bispectral Index And Electrocorticography During Epilepsy Surgery/D. San Juan Orta, M. Gómez Ramírez, L. R. Rodríguez Arias, A. Osorio Santiago, A. López Pizano, R. Llerenas Zamora, R. Vázquez Gregorio, A. Espinoza López, C. Trenado, A. Hernandez Ruiz, J. Delgado-delaMora, M. Alonso-Vanegas, D. Anschel Diagnostic Utility And Yield Of Routine Electroencephalogram Study In Patients Referred By Epileptologists And Carrying A Diagnosis Of Epilepsy/A. Gudlavalleti, B. B. Allen, N. K. Sethi, G. Solomon Diagnosis Of Electrical Status Epilepticus In Sleep Made By A Clinician Versus Computerized Spike Detection Software: A Comparison/ T. Bryant, M. Guess, L. Wenzel, D. Tadlock, C. Joshi Validation Of The M-Score, An EEG Grading Scale For Infantile Spasms/J. R. Mytinger, S. A. Hussain, J. J. Millichap, N. Ryan, G. L. Heyer Minute Versus Extended Outpatient Eeg For The Detection Of Epileptiform Abnormalities In New Referrals/D. Burkholder, J. Britton, V. Rajasekaran, R. Fabris, J. C. Perumpillichira, K. Kelly, E. So, K. Nickels, L. Wong-Kisiel, T. Lagerlund, G. Cascino, G. Worrell, E. Wirrell High-Rate REM Sleep High Frequency Oscillations (HFOs) Are Specific To Epileptogenicity/ R. Sakuraba, M. Iwasaki, E. Okumura, K. Jin, Y. Kakisaka, K. Kato, T. Tominaga, N. Nakasato The Dynamic Changes Of Ictal High Frequency Oscillations During Temporal Lobe Seizures Recorded By Stereo-Electroencephalography/ S. Wu, J. Tao, S. Rose, S. Lhatoo, H. Lüders Detectability Of Fast Ripples On The Scalp EEG: A Preliminary Study With Subdermal Electrodes/ F. Pizzo, B. Frauscher, T. Ferrari-Marinho, F. Dubeau, J. Gotman Fixation-Off Sensitivity (FOS)- Like Phenomenon After Embolic Strokes Of The Parietal And Occipital Regions/F. Tirol, A. Foroughi, P. Foreman The Intracerebral EEG Pattern Of Focal Cortical Dysplasia Changes During The Different Stages Of Sleep/I. Menezes Cordeiro, N. von Ellenrieder, F. Dubeau, J. Gotman, B. Frauscher Changes In Scalp EEG Spectral Content During Deep Temporal Lobe Seizures Lacking A Scalp Ictal Correlate/A. D. Lam, S. S. Cash Quantitative Analysis Of Interictal Discharges In Mesial Temporal Lobe Epilepsy/L. A. Oliveira, A. D. Borges, S. Yamashita, L. Betting The Epileptiform Abnormalities In Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcus (PANDAS) Patients/X. Zhou, A. Buckley, S. Swedo, S. Inati How High Is High Enough? Do Faster EEG Sampling Rates Lead To Improved Seizure Onset Localization?/ S. P. DeVries, K. A. Davis, J. B. Wagenaar, W. C. Stacey Changes In Intracranial Electroencephalography (ieeg) In Five Patients During WADA/S. Le, K. J. Meador Increased Left Hemisphere Interictal Epileptiform Discharges Are Associated With Language Based Knowledge And Learning In Benign Rolandic Epilepsy/M. Takeoka, J. Girard, C. Harini, C. Vega, K. Boyer EEG Photic Driving: Clinical Significance Of Asymmetric Responses/M. T. Kendirli, H. Tekeli, E. Togrol, F. Ozdag The Utility Of Ambulatory Electroencephalography (aeeg)/ K. AbdeleRahman, R. Mahajan, M. Grigg-Damberger Prevalence Of Epileptiform Activity In Children Less Than 1 Year Of Age Referred For Polysomnography/ A. W. Ho, A. Adeleye, A. Nettel-Aguirre, V. Kirk, J. Buchhalter Differences In The Yield Of Routine EEG Studies In Patients 60 Years Or Older As Compared To Patients Less Than 60-Years-Old Presenting With Transient Loss Of Consciousness/N. Gupta, C. Christodoulou, J. Miller-Horn Broadband Intracranial Ictal EEG Analysis In Lesional And Non- Lesional Pharmacoresistant Epilepsy/M. Dhakar, A. Shah Characteristic Electrographic Findings In Fraternal Twins With Sialidosis/A. Sheikh, J. Menon, V. Ramsey-Williams, D. Cameron, H. Li Fun Finding Artifacts This Is An Interactive Poster Showing Some Common And Uncommon Artifacts. The Goal Is To Challenge All Levels Of EEG Knowledge. See The Artifact And You Guess What You Think That It Is, Once You Have An Idea You Can Check Your Answer/C. L. Riley Intracranial Recording: A Glimpse On White Grey Matter Differences/M. Mercier, S. Bickel, P. Megevand, D. Groppe, A. Mehta, F. Lado Visual-Evoked Responses As A Biomarker For Neural Hyper- Excitability In Childhood Absence Epilepsy/R. Holt, F. Pei, B. Porter, J. Tsai, A. Norcia Eletroencephalographic Profile Of Outpatients Presenting Seizures During Routine EEG on a Tertiary Teaching Hospital/R. Alessi, C. N. Alencar, P. B. Lima, M. R. Silveira, J. Q. Andrade, E. Garzon Photic Stimulation: Get More Information From An Old Test; Can We Do Better? Utility Of Change In SPR As A Marker Of Chronc Efficacy/ P. Timmings Computational Analysis & Modeling Of EEG Accuracy Of EEG Interpretation Without A Reference Standard/J. Slater, A. C. Grant, A. Omurtag On Seizure Dynamics And Propagation/C. Bernard, V. Jirsa, W. Stacey, F. Bartolomei, T. Proix Spectral Analysis Of Intracranial Interictal Bursts May Localize Seizure Onset/H. Ung, K. Davis, D. Wulsin, B. Litt Epileptic Spikes And High Frequency Oscillations Are More Frequent During Generalized Slow Oscillations Than During The Rest Of NREM Sleep/B. Frauscher, N. von Ellenrieder, T. Ferrari-Marinho, F. Dubeau, M. Avoli, J. Gotman Ripple (80-250Hz) Characterization In Nonepileptic Brain Regions/N. von Ellenrieder, B. Frauscher, T. Ferrari-Marinho, F. Dubeau, J. Gotman Interictal Localization Of The Seizure Onset Zone Using High Frequency Oscillations And Visibility Graphs/A. M. Spring, R. A. Bessemer, D. J. Pittman, Y. Aghakhani, P. Federico Interictal Phase Clustering Of High Frequency Oscillations Derived From 256-Channel Scalp EEG Correlates With The Epileptogenic Zone/M. D. Holmes, C. Ramon MRI And Electrical Source Analysis In Patients With Temporal Lobe Encephaloceles: Localization And Clinical Correlation/M. Quach Index Of HFO Cross-Frequency Coupling For Assessing The Seizure Onset Zone/C. Jouny, U. Malinowska, M. Cervenka, G. Bergey Investigation Of HFO In Human Intracranial EEG With A Semi-Supervised X-means Clustering/S. Liu, N. Ince, A. Abosch, T. Henry, Z. Sha 70

73 Monday December 8, 2014 Poster Session 3 8:00 a.m. 3:00 p.m. Convention Center Hall 4B, Level Co-Occurrence Of High Frequency Oscillations For Identification Of The Seizure Onset Zone/U. Malinowska, G. Bergey, M. Cervenka, C. Jouny Integrating 3D Source Localization And Connectivity Maps For Guiding Pre-Surgical Subdural Grid Placement/A. Pinzon-Ardila, M. Cabrerizo, N. Rojas, P. Jayakar, G. Sergio, M. Adjouadi Validating Individual Head Models In Electrical Source Imaging Of Spikes And Seizures/K. Jenson, D. Tucker, P. Luu, M. D. Holmes Source Localization Techniques Are Essential In More Accurate Determination Of Target Tuber Conglomerates For MRI-Guided Laser- Induced Thermal Ablation For Treatment Of Intractable Epilepsy And Neurocognitive Comorbidities In Pediatric Tuberous Sclerosis/ Y. Eksioglu, Z. Tovar-Spinoza, F. Duffy Frequency-Frequency Coupling Of Brain Oscillations In Studying Ictal EEG Activity/Y. Hsin Clinical Epilepsy Clinical Diagnosis Clinical Manifestations Of The Patients With Caspr2 Encephalitis/ J. Sunwoo, J. Byun, J. Moon, J. Shin, J. Jun, S. Lee, K. Jung, K. Jung, K. Chu, S. Lee Asystole In The Epilepsy Unit/A. Honig, S. Chen, F. Benninger, R. Bar Yossef, R. Eichel, S. Kipervasser, I. Blatt, M. Neufeld, D. Ekstein Electroclinical Features Of Ring Chromosome 20 Syndrome In Children/H. Ikeda, H. Ikeda, K. Imai, Y. Takahashi, Y. Inoue Referral Delay For Epilepsy Surgery Centers In Patients With Temporal Lobe Epilepsy And Hippocampal Sclerosis: Why We Should Educate Neurologists In First And Secondary Care Centers/ S. de Vincentiis, K. Rodrigues Ximenes Goldberg, S. E. de Melo-Souza, F. J. Arruda, P. C. Ragazzo, H. van der Linden J.r., K. Dualibi Ramos Valente Increased Cerebrovascular Reactivity In The Epileptogenic Temporal Lobe In Mesial Temporal Lobe Epilepsy Patients/K. Alhadid, O. Sobczyk, G. Montandon, J. Poublanc, L. Venkatraghavan, A. Crawley, J. Fisher, D. Mikulis, T. Valiante Ictal EEG Yield In Newly- Treated Focal Epilepsy: Interim Findings From The Human Epilepsy Project (HEP)/R. Singh, M. Hegde, V. Mays, D. Dlugos, on behalf of the HEP EEG Core and HEP Investigators A Brain-Machine Interface For Burst Suppression Control In Pediatric Status Epilepticus/ C. Papadelis, C. Doshi, S. Thome-Souza, E. Grant, R. Tasker, T. Loddenkemper New-Onset Refractory Status Epilepticus: Etiology And Outcome In A Retrospective Series Of 121 Cases/N. Gaspard, B. Foreman, V. Alvarez, C. M. Cabrera Kang, J. Probasco, A. Jongeling, E. Meyers, K. Haas, A. Espinera, S. Schmitt, E. Gerard, T. Gofton, P. Kaplan, J. Lee, B. Legros, J. Szaflarski, M. Westover, S. Laroche, L. Hirsch Clinical Correlates And Outcome Of Cyclic Seizures In Critically Ill Patients: A Case-Control Study/L. F. Pinto, E. Gilmore, O. Petroff, N. Rampal, L. Hirsch, N. Gaspard Eyewitnesses Of Seizures Are More Accurate Historians Than The Patients/M. Spitz, S. Moreland, K. Horiuchi, K. Lervik, P. Korb, C. Drees, R. DeBello, L. Strom, L. Frey, A. Shrestha, C. O Brien Automated EMG Based Seizure Detection And Quantification For The Home And The EMU, A Prospective Multicenter Study/ J. Cavazos, M. Girouard, L. Whitmire Jeavons Syndrome: Seizing The Light A Compulsive Epilepsy Disorder?/A. Yadav, I. Tuxhorn The Proportion Of Time Spent In The Tonic Phase Of A Convulsive Seizure Predicts Postictal Hypopnea/E. Acton, A. Thaler, A. Krause, C. Anderson, A. Esfahanizadeh, J. Pollard Associated Cardiac Findings In Children With Down Syndrome And Infantile Spasms/D. Daniels, K. Knupp, T. Benke, F. Hickey, K. Wolter-Warmerdam, D. L. Cohen KCNQ2-Deficiency: Clinical Spectrum Of Epilepsy, Encephalopathy, And Response To Ezogabine/K. Park, J. Millichap, E. C. Cooper Temporal IEDs In Extratemporal Lobe Epilepsy Are Associated With Temporal Hypometabolism On PET Imaging/ E. Hartl, J. Rémi, A. Loesch, C. Vollmar, S. Noachtar Co-Oscillation Of Spikes, Spindles And K Complexes: A Useful Biomarker Of Epileptogenicity And Outcome In Children With Epilepsy?/ A. Zrik, I. Tuxhorn, A. Yadav, P. Rai Clinical And Intracranial EEG Features After Secondarily Generalized Seizures/L. M. Bateman, C. Schevon Characteristics Of Other Seizure Types Associated With Infantile Spasms/J. Millichap, L. Wong-Kisiel, E. Yozawitz, J. Sullivan Electrographic And Hemodynamic Changes In Patients With Focal Seizures/K. Hecox, J. Zemblis, C. Sauer, H. Whalen, P. Monrad Clinical Course of Seizures In Ring Chromosome 20 Syndrome/ H. Ikeda, H. Ikeda, T. Hiyoshi, E. Yamazaki, K. Yoshimura, Y. Inoue Clinical Treatments The Application Of An Explanatory Model Of Treatment Decision- Making In A Patient With Medically Refractory Focal Epilepsy/ S. Dewar, H. Pieters Protective Effects Of Vagus Nerve Stimulation On Cardiac Electrical Instability In Patients With Drug-Resistant Epilepsy/A. Schomer, B. D. Nearing, S. Schachter, E. Bachman, P. Shafer, D. Sundstrom, R. L. Verrier Pyridoxine Deficiency In Adult Status Epilepticus Patients/H. Dave, R. Ramsay, F. Khan, V. Sabharwal, I. Iwuchukwu Outpatient Initiation Of The Ketogenic Diet: The BC Children s Hospital Experience/A. Michoulas, M. Connolly, K. Selby, E. Anghelina, A. Ferguson, C. Simonson, F. Zanotto, K. Farrell Electrical Stimulation Of The Hippocampus For Medically Refractory Mesial Temporal Lobe Epilepsy: A Long-Term Follow-Up Study/S. N. Lim, C. Y. Lee, S. T. Lee, P. H. Tu, B. L. Chang, C. H. Lee, C. W. Chang, W. E. Tseng, T. Wu A Lack Of Clinically Significant Vision Loss Among Vigabatrin-Treated Patients With Infantile Spasms: The UCLA Experience/M. Schwarz, M. Li, J. Tsao, R. Zhou, Y. W. Wu, S. A. Hussain The National Infantile Spasms Consortium (NISC): Moving Towards Standardization Of Care And Improved Treatment And Outcomes In Infantile Spasms/N. Ryan, J. Coryell, J. R. Mytinger, K. Nickels, K. Knupp Improving Efficiency In Management Of Status Epilepticus Using A Specific EMR Order Set/ J. Boggs, R. Bolen, L. Bishop, M. Bailey, M. Bennett Management Of Super Refractory Status Epilepticus With Ketamine And/Or Propofol/V. Sabharwal, H. Dave, R. Lancaster, M. Almualim, F. Khan, H. McGrade, E. Ramsay New-Onset Refractory Status Epilepticus: Immune Modulatory Therapy And Outcome/C. M. Cabrera Kang, S. M. Laroche, B. Foreman, V. Alvarez, J. Probasco, A. Jongeling, E. Meyers, K. Haas, S. E. Schmitt, E. Gerard, T. Gofton, P. W. Kaplan, J. Lee, B. Legros, J. P. Szaflarski, M. Westover, L. J. Hirsch, N. Gaspard MONDAY 71

74 Monday December 8, 2014 Poster Session 3 8:00 a.m. 3:00 p.m. Convention Center Hall 4B, Level Lightning Strike Induced Vagus Nerve Stimulator Malfunction/P. Shah, G. Ghearing Ketamine In Refractory Status Epilepticus A Two Year Retrospective Study On 26 Patients/J. Höfler, A. Zerbs, J. Dobesberger, G. Pilz, M. Leitinger, H. Novak, E. Trinka Frequency And Predictors Of Rescue Medication Use In Children Admitted To The Epilepsy Monitoring Unit/L. AHMADI, K. Nickels, L. Wong-Kisiel, E. Wirrell Use Of Clobazam In Pediatric Epilepsy At A Tertiary Care Center/ N. McNamara, S. Joshi Clinical Characterization Of The Pre-Ictal State In The Pediatric Population: A Caretaker s Perspective On Seizure Prediction/P. Patel, R. Jehle, D. Gold, S. Haut Spectrum Of Autoimmune Epilepsy With Glutamic Acid Decarboxylase Antibody/A. Shah, M. Dhakar Early Complications Of Subdural Electrode Placement In Pediatric Epilepsy Surgery/ P. Pojomovsky, A. Mandel, D. McBrian, M. Giordano, L. Goldenstein, N. Feldstein, G. McKhann, C. Akman Efficacy Of Ketogenic Diet: An Experience Of King Fahd Specialist Hospital-Dammam (KFSH-D)/ R. S. Al-Baradie Prognosis Electrodermal Sleep Storm Activity As A Biomarker In Epilepsy Patient/K. Kapur, S. Thome-Souza, J. Klehm, R. Sarkis, E. Nagarajan, M. Jackson, R. Picard, C. Doshi, C. Papadelis, B. Dworetzky, C. Reinsberger, T. Loddenkemper Mortality In Children Evaluated For Epileptic Spasms At A Tertiary Care Center/C. Harini, E. Nagarajan, A. Bergin, K. Kapur, C. Marti, M. Takeoka, T. Loddenkemper, M. Libenson Predictors Of Refractory Status Epilepticus/M. Gonzalez, E. Santamarina, M. Toledo, S. Sarria, M. Sueiras, L. Guzman, J. Salas Puig Ictal Vital Signs In Epilepsy/ W. O. Tatum, M. L. Langston, E. Acton, K. H. Yelvington, C. Bowman, J. J. Shih, W. Cheshire EEG Prior To Weaning Antiepileptic Therapy In Seizure-Free Children: A Cost-Effectiveness Analysis/B. McCoy, E. Donner Correlation Of EEG Findings And Prognosis In Patients On Therapeutic Hypothermia After Cardiac Arrest/Y. Krutoshinskaya, S. Manganaro, R. Krel, L. Bello Outcome Of Early Successful Seizure Control Or Aggressive Seizure Management In Presumed Childhood Encephalitis/N. Rismanchi, J. Gold, S. Sattar, C. Glaser, H. Sheriff, A. Mower, J. Crawford, M. Nespeca, S. Wang Clinical Phenotypes Within Patients With Non-Lesional Temporal Lobe Epilepsy Based On Response To Antiepileptic Drugs/J. Kim Epilepsy With Onset Within 3 Years Of Age: Electro-Clinical Characterization And Long-Term Outcome/A. Vignoli, G. F. Scornavacca, F. La Briola, K. Turner, V. Chiesa, E. Zambrelli, V. Fergnani, M. Canevini Adaptive Function In Dravet Syndrome/S. Kim, D. Nordli, L. Laux Diagnosis, Treatment, And Outcomes Of Infantile Spasms In The Trisomy 21 Population/C. Beatty, J. Wrede, H. Blume Clinical And Electroencephalographic Characteristics Of Neonates Who Underwent Continuous Electroencephalographic Monitoring/ A. J. Sansevere, I. Sánchez Fernández, J. Klehm, E. Nagarajan, L. St. Louis, P. Pearl, J. Neil, T. Loddenkemper Long-Term Seizure Outcome In Response To Carbamazepine In Children With Newly Diagnosed Partial Onset Epilepsy/G. Aungaroon, S. Standridge, K. Holland Sudden Unexpected Death In Epilepsy, Peri-ictal Physiology And The SUDEP-7 Inventory/N. Odom Interictal Background Is Associated With Survival And Neurodevelopmental Outcome In Term Infants Undergoing Hypothermia For Hypoxic-Ischemic Encephalopathy/ L. Rao, J. Wu, T. Chanlaw, H. Wang, M. Garg EEG Monitoring In Patients With Hypothermia Post Cardiac Arrest A Comparison Of Evolving Patterns And Outcomes/K. Suchdev, S. Rao, L. Avedian, S. Thadur, D. Zutshi Praxis Induction In Juvenile Myoclonic Epilepsy. Significance In Prognosis/C. P. Uchida, K. Carvalho, M. B. Guaranha, L. M. Guilhoto, E. Yacubian Sudden Unexpected Death In Epilepsy (SUDEP) Vanderbilt University Experience/ S. Bandyopadhyay, N. Azar, A. Arain Seizure Outcomes After Glioma Resection/A. C. Jongeling, P. D. Canoll, C. Schevon, S. Srinivasan Neuroimaging Structural Imaging Relationship Between Cortical Thickness And Sulcal Depth In Pediatric Focal Epilepsy/S. Gurbani, P. Siddarth, D. Tosun, J. Levitt, R. Caplan MRI Characterization Of Cerebellar Tubers In Tuberous Sclerosis Complex: Longitudinal Follow Up And Associations With Clinical Manifestations/A. Yogi, Y. Hirata, J. Wu, P. Pan, G. Mathern, N. Salamon Brain Morphometry On Multi- Modal Imaging For The Detection Of Epileptogenic Cortical Dysplasias/ L. Kini, S. Das, K. Davis, B. Litt Transient Focal Lesion In Corpus Callosum After First Episode Of Generalized Seizure: A Case Report/R. Vakili, M. M. Donohue, T. Emch Are There Neuroanatomical Differences In New Onset Focal Epilepsy? Preliminary Results From The Human Epilepsy Project/ H. R. Pardoe, R. Kuzniecky, A. HEP MRI Core Disrupted Modular Architecture Of Brain Structural Network In Temporal Lobe Epilepsy/ Z. Chen, C. Yasuda, G. C. Beltramini, T. M. Lopes, M. Morita, A. Coan, F. Bergo, F. Cendes, C. Beaulieu, D. Gross Disrupted Brain Volumetric Network In Temporal Lobe Epilepsy/ C. Yasuda, C. Zhang, G. C. Beltramini, M. Morita, A. Coan, P. Araujo, F. Bergo, C. Beaulieu, F. Cendes, D. Gross Contralateral Hippocampal Atrophy Following Temporal Lobe Surgery For Temporal Lobe Epilepsy/ C. A. Elliott, C. Yasuda, L. Concha, M. Liu, D. Gross, T. Sankar, M. Wheatley, C. Beaulieu Correlation Between Brainstem Rotation After Hemispherectomy And The Occurrence Of Clinical Symptoms In Hemimegalencephaly Patients/A. Yogi, Y. Hirata, J. Wu, P. Pan, G. Mathern, N. Salamon Volumetric And Shape Analyses Of Hippocampal Subfields In Temporal Lobe Epilepsy With Hippocampal Sclerosis/J. Kim Reduced Right Hippocampal Volume In Patients With Left Hippocampal Atrophy Is Associated With Anxiety And Depression/ T. Stoub, C. L. Grote, A. Kanner Biometric Correlations With Diffusion Tensor Data Of Temporal Lobe Epilepsy Mcd Patients At 3.0T/S. Nikolova, R. Nikolov, R. Bartha, J. G. Burneo Reversible Brain MRI Changes Associated With Periodic Lateralized Epileptiform Discharges (PLEDs)/ A. B. Memon, A. Shah, M. Basha Cortical Thickness And Cognition In Children With ECTS: A Longitudinal Study/D. Jackson, C. Garcia-Ramos, K. Dabbs, J. Jones, D. Hsu, C. Stafstrom, L. Zawadzki, M. Koehn, M. Seidenberg, B. Hermann Hippocampal Subregion Analysis In Adults With Mesial Temporal Lobe Epilepsy/L. Sepeta, S. C. Germeyan, M. Berl, J. Ostuni, W. Gaillard, W. Theodore 72

75 Monday December 8, 2014 Poster Session 3 8:00 a.m. 3:00 p.m. Convention Center Hall 4B, Level Magnetic Resonance Imaging Abnormalities Associated With Status Epilepticus: A Case Report And Literature Review/A. M. Feyissa, L. Ponce Mejia, T. Masel Disrupted Brain Network Topology In New-Onset Pediatric Epilepsy: A Controlled Prospective Study/J. Lin, R. Rajyaguru, J. Riley, G. Gulsen, K. Dabbs, J. Jones, D. Jackson, D. Hsu, C. Stafstrom, M. Seidenberg, L. Bonilha, B. Hermann To Evaluate Original Diffusion Properties Of Neural Pathways Of Patients With Partial Seizures And Secondary Generalization By Individual Anatomic Reference Atlases/S. Peng, T. Harnod, C. Huang, Y. Hsin Increased Fractional Anisotropy In Children With Epilepsy/M. Berl, V. Terwilliger, L. Sepeta, W. Gaillard Quantitative Analysis Of Fiber Density From Diffusion Tensor Imaging Identifies Structural Changes In Cryptogenic Focal Epilepsy/J. Joc, N. Khalilieh, E. Hartl, S. Noachtar, C. Vollmar Functional Imaging EEG-fMRI Study Of Operculo- Insular Epilepsy/P. Pouliot, T. Tran, M. robert, A. Bouthillier, D. Nguyen Decreased Functional Interactivity In Patients With Temporal Lobe Epilepsy And Normal MRI/ A. Coan, B. M. Campos, F. Cendes Additive Potential Of Real-Time Functional Mapping (RTFM) To Electrical Stimulation Mapping (ESM) Results For Epilepsy Surgery Candidates/M. Elsayed, M. Korostenskaja, E. Castillo, P. Chen, A. Schaal, B. Edmonds, C. M. Salinas, M. Westerveld, J. Seo, G. Schalk, P. Brunner, J. Baumgartner, K. Lee T Mrs In Medically Refractory Temporal Lobe Epilepsy Patients With Normal 1.5T/M. jones, S. Nikolova, J. G. Burneo, R. Bartha Language fmri And Post- Operative Language Decline/E. Emery, S. C. Germeyan, L. Sepeta, E. Wiggs, M. Berl, I. Dustin, D. Goldenholz, W. Gaillard, W. Theodore Significance Of FDG-PET Hypermetabolism In Focal Cortical Dysplasia (FCD)/P. Laoprasert, R. W. Dudley, S. Koh, M. Handler, N. Stence, D. Mirsky, A. White Voxel-Mirrored Homotopic Connectivity Analysis Of Pediatric Epilepsy Patients With Mesial Temporal Sclerosis/A. V. Poliakov, E. J. Novotny, S. L. Poliachik, S. D. Friedman, G. E. Ishak, J. N. Nixon, D. W. Shaw, J. G. Ojemann Identification Of A Pre-Spike Network In Mesial Temporal Lobe Epilepsy/N. L. Faizo, H. Burianová, M. Gray, J. Hocking, G. Galloway, D. Reutens FMRI Mesial Temporal Activation Paradigm For Children With Epilepsy/H. Shurtleff, J. Nixon, M. Warner, A. V. Poliakov, D. W. Shaw, E. Novotny, J. Ojemann Altered Functional Connectome For Fearful Face Processing In Temporal Lobe Epilepsy/J. Riley, R. Rajyaguru, G. Gulsen, J. Lin Resting State fmri Lateralizes Seizure Onset But Fails To Predict Cognitive Change After Anterior Temporal Lobectomy In Temporal Lobe Epilepsy/M. Gelfand, K. Davis Altered Resting-State Networks In Psychogenic Nonepileptic Seizures And Idiopathic Generalized Epilepsy/D. An, C. Luo, S. Chen, B. Yan, D. yao, D. Zhou Ictal Perfusion Pattern With And Without Secondarily Generalized Tonic-Clonic Seizure: A Voxel-Based ECD-SPECT Analysis In Temporal Lobe Epilepsy/X. Chen, C. H. Wong, R. McCredie, M. L. Bartley, D. C. Farlow, Z. Zhao, E. Somerville, A. Bleasel Abnormal Functional Organisation Of Default-Mode And Task-Positive Networks In Lennox- Gastaut Syndrome/A. Warren, J. Archer, D. Abbott, G. Jackson Antiepileptic Drugs Clinical Trials FDA OGD s Post-Marketing Studies To Ensure Therapeutic Equivalence Of Generic Antiepileptic Drugs In Epilepsy Patients/X. Jiang, N. Zheng, T. Ting, J. Polli, M. Privitera, M. Berg, W. Jiang Open Label Trial Of Add-On Lacosamide Versus High Dose Monotherapy In Patients With Breakthrough Seizures/J. Alam, N. Llewellyn, B. Dworetzky, R. Sarkis, P. Pennell, E. Bubrick, J. Lee Immediate Steady State Concentrations In Plasma After Oral Or Intravenous Lacosamide Loading Dose/W. Cawello, J. Andreas, C. Schaefer Focal Seizure Frequency By Study Phase And Seizure Type In Conversion To Lacosamide Monotherapy Study: A Post-Hoc Analysis/J. Stern, M. Sperling, S. S. Chung, P. Ryvlin, R. Wechsler, S. Dimova, M. De Backer, T. Story, M. Brock, C. McShea, K. J. Werhahn Conversion To Lacosamide Monotherapy: Post-Hoc Analysis On Responder And Seizure Freedom Rates/P. Ryvlin, M. Sperling, S. S. Chung, J. Stern, R. Wechsler, S. Dimova, M. De Backer, T. Story, M. Brock, C. McShea, K. J. Werhahn Lacosamide Added To A Baseline Monotherapy In Patients With Partial-Onset Seizures (POS): Efficacy And Safety Across Center Types In The VITOBA Study/C. Brandt, M. Noack-Rink, T. Mayer, U. Runge, F. Ramirez, T. Lauterbach, P. Dedeken Safety And Tolerability Of Lacosamide Monotherapy In Elderly: A Subgroup Analysis From Lacosamide Trials In Diabetic Neuropathic Pain/ J. Sirven, E. Faught, M. De Backer, K. Eckhardt, F. Tennigkeit, S. Bongardt, D. Rudd, D. Sen, K. Werhahn Efficacy and Safety Of Lacosamide As Adjunctive Treatment For Partial-Onset Seizures In Hispanic/Latino Patients From Mexico: Post Hoc Analysis Of An Open-Label Trial/H. Ceja Moreno, P. Tzvetanov, W. Waldman Zadeh, A. Escartin, I. Wild, W. Byrnes, F. Tennigkeit, S. Borghs, C. McShea, P. Dedeken, M. De Backer WITHDRAWN Lacosamide Added To An Existing Monotherapy In Epilepsy Patients With Partial-Onset Seizures: A Subgroup Analysis Of The Elderly Population In The VITOBA Study (VImpat Added To One Baseline AED)/U. Runge, T. Mayer, M. Noack - Rink, F. Ramirez, M. De Backer, F. Tennigkeit, K. Werhahn An Open-Label Trial Evaluating The Efficacy And Safety Of Lacosamide As First Add-On Treatment Of Partial-Onset Seizures/P. Tzvetanov, W. Waldman, A. Escartin, W. Byrnes, F. Tennigkeit, P. Dedeken, M. De Backer, S. Borghs, T. Li Tolerability Of Lacosamide 200 Mg/Day Starting Dose: Post-Hoc Analysis Of Conversion To Lacosamide Monotherapy Study/K. J. Werhahn, S. Dimova, C. McShea, M. Brock, W. Byrnes, M. De Backer, E. Faught Reduction Of Treatment- Limiting Non-Psychotic Behavioral Adverse Events Associated With Levetiracetam: An Open-Label, Prospective Study Of Patients With Epilepsy Switching From Levetiracetam To Brivaracetam Treatment/S. Yates, T. Fakhoury, W. Liang, K. Eckhardt, J. D Souza Impact Of Adding Perampanel To Existing Anti-Epileptic Drug (AED) Therapy On Health-Related Quality Of Life (HRQL) As Measured By The Quality Of Life In Epilepsy Inventory (QOLIE-31-P) In A Pooled Population Of Patients With Partial-Onset Seizures (POS) f/w. Tsong, S. Hudgens, A. Forsythe, R. Muniz Vigabatrin For Treatment Of Complex Partial-Onset Seizures In Patients With Tuberous Sclerosis: Prospective Trial And Retrospective Case Series/B. Oommen, E. Brand, A. Volpe, A. Krause, P. Crino, J. Pollard MONDAY 73

76 Monday December 8, 2014 Poster Session 3 8:00 a.m. 3:00 p.m. Convention Center Hall 4B, Level Efficacy And Safety Of Epidiolex (Cannabidiol) In Children And Young Adults With Treatment- Resistant Epilepsy: Initial Data From An Expanded Access Program/ O. Devinsky, J. Sullivan, D. Friedman, E. Thiele, E. Marsh, L. Laux, J. Hedlund, N. Tilton, J. Bluvstein, M. Cilio Retrospective Study Of Lacosamide In The Elderly (> 60 years Of Age)/J. Bainbridge, P. Wong, M. Spitz, L. Frey, C. Drees, C. O Brien, L. Strom, A. Shrestha, J. Sirven, S. Benbadis, E. Maa, S. S. Chung, B. Phillips The Initial Results Of Adjunctive Lacosamide For Uncontrolled Partial-Onset Seizures in Eskisehir, Turkey/O. O. Erdinc, G. Akdag, G. Uzuner, D. Ilhan Algin Vigabatrin In The First Line Treatment Of Infantile Spasms/ K. Jones, J. Boyd, C. Go, A. Ochi, B. McCoy, K. Puka, O. Snead Prospective, Controlled Trial Of Cannabadiol In A Case Of FIRES/ C. Lopez, A. Wilfong, T. P. Ngo, M. R. Jenner Initial Therapy Outcomes In Absence Epilepsy : Ethosuximide, Valproic Acid, Lamotrigine And The Combination Of Valproic Acid And Lamotrigine/B. Eun Other Efficacy And Tolerability Of Lacosamide As An Adjunctive Treatment In Vascular Epilepsy: 3 Months Study/F. L. Gonzalez, X. Rodriguez Osorio, M. Toledo, M. Saavedra Piñeiro, E. Santamarina, I. Lopez Dequit, A. Pato, D. Campos Blance, P. Bellas, J. Salas Puig, J. Poza Aldea Classification Of Phenytoin As A Narrow Therapeutic Index Drug/ N. Zheng, L. Fang, W. Jiang A Preliminary Analysis Of The Effect Of Lacosamide On Seizure Control And Neuropsychological Performance: Anxiety, Depression And Quality Of Life/M. Romero Acebal, C. Sánchez Ortiz, F. Villalobos Chávez, G. Rubio Esteban, L. Redondo Verge, J. Romero-Godoy, E. Calzado Rivas, P. Quiroga Subirana, R. Hervas Navidad, P. Martínez Agredano, C. Pedraza Benitez Efficacy And Tolerability Of Lacosamide In The Treatment Of Children With Refractory Generalized Epilepsy/C. Miskin, D. Khurana, I. Valencia, A. Legido, D. Hasbani, K. Carvalho Therapeutic Use Of Lacosamide Does Not Alter Its Distribution Between Serum And Cerebrospinal Fluid/A. Shah, S. Michelhaugh, S. Mittal VPA Retains Suppressive Ppr Effect At Steady-State With Less Variability Than CBZ: Retrospective Analysis Of 239 Photosensitive Clinic Patients/D. G. Kasteleijn-Nolst Trenite, R. Reed Efficacy Of Clobazam On Patients With Failed Resective Surgery Aparna Sarma DO, Carolina Restrepo, Janice Jordan, C. Akos Szabo M.D./A. Sarma, C. Restrepo, J. Jordan, C. Szabo Resistance To Rectal Diazepam In Dravet s Syndrome/P. McGoldrick, S. Wolf Commonly Prescribed Antiepilepsy Drugs In Nursing Home Residents/A. Birnbaum, S. Bathena, I. Leppik Non-AED / Non-Surgical Treatments (Hormonal, Ketogenic, Alternative, Etc.) Adult An Evaluation Of Catamenial Seizure Patterns And The Relationship Between The Menstrual Cycle, Seizures, And Ketosis In Women On The Modified Atkins Diet For Treatment For Epilepsy/E. Felton, E. Kossoff, B. Henry, M. Cervenka Auricular Acupuncture For The Treatment Of Nonepileptic Seizures: NADA4NES Pilot Study/E. Maa LORETA z-score Neurofeedback Training In Patients With Drug- Refractory Epilepsy/L. Frey, C. O Brien The Impact Of An Art Therapy Program On Self-Esteem And Quality Of Life In People With Epilepsy/ J. M. Buelow, L. R. Vitko, J. M. Gattone, J. R. Kakacek Pediatrics Predictors Of Ketogenic Diet Efficacy In Children Based On The Electroencephalogram/I. M. Walker, R. Said Intravenous Methylprednisolone For Intractable Childhood Epilepsy/M. M. Jan Therapeutic Plasma Exchange (TPE) In Children With Antibody- Mediated Neurologic Disease/ M. Oldham, M. Sweeney, P. Horn, L. Peglar, E. Rompies, K. Wesselkamper, B. Hallinan, S. Goldstein Preliminary Overview Of Social Stressors And Social Work Support Of Patients And Caregivers In The Ketogenic Diet Program At Boston Children s Hospital/C. Ryan, F. Chris, K. Costas, S. Tarrant, P. Lora, P. Pearl, A. Bergin Ketogenic Diet Initiation: Step By Step For Sweet Success/L. Pixley, S. Tarrant, K. Costas, K. Kapur, A. Bergin Blood Beta-Hydroxybutyrate Levels Correlate With Seizure Frequency In Epileptic Patients Treated With The Ketogenic Diet/ J. Buchhalter, J. D. Smith, S. D Alfonso, R. Singer, M. Connolly, A. Michoulas, E. Fung, D. Sinasac, J. M. Rho Evaluation Of Patients Right And Left Ventricular Functions Who Treated With Ketogenic Diet/ O. Dokgoz, K. celegen, O. Guzel, U. Yilmaz, R. Isgüder, M. Celegen, T. Mese A Chef Educator s Role In The Ketogenic Diet Program At Children s Mercy Hospital/R. Finn Lack Of Efficacy Of The Ketogenic Diet In The Treatment Of Highly Refractory Infantile Spasms/ J. Shin, K. Murata, J. Matsumoto, S. A. Hussain Complications Of Vagus Nerve Stimulation For Epilepsy In Children: How Can We Do Better?/B. Sitwat, S. Williams, C. Patterson, S. Gedela, E. Tyler-Kabara, M. Tamber, Y. Sogawa New Onset Super-Refractory Tonic Status Epilepticus In Child With Down Syndrome: Successful Treatment With Ketogenic Diet/ L. P. Sampaio, C. L. Moreira, L. Caboclo Clinical Characteristics Of Children Less Than 3 Years Of Age Who Elected Vns As An Adjunctive Therapy For Medically Intractable Epilepsy/L. D. Fernandez, S. Gedela, Y. Sogawa Pentobarbital, Propylene Glycol, And Ketosis In Refractory Status Epilepticus/K. Costas, R. Tasker, J. Soul, N. Lamb, L. Li, A. Bergin Use Of The Ketogenic Diet In The Neonatal Intensive Care Unit Safety and Tolerability/A. Hall, M. Gustafson, L. Thompson All Ages Benefits Of Exercise in Patients With Epilepsy: A Literature Review/F. Gilliam, R. Hogan, G. Gilmet Safety And Tolerability Of 1 Hz Deep Repetitive Transcranial Magnetic Stimulation (rtms) For Treatment Of Temporal Lobe Epilepsy/L. Oberman, R. Gersner, A. Zangen, A. Rotenberg Animal Antidepressants Have Different Effects On The Vesicular Glutamate Transporter 1 And EEG Spectrum In The Rat Hippocampus/ D. Shin, H. Song Non-Invasive Low Frequency Sensory Stimulation Suppresses Seizures In Two Rodent Models Of Epilepsy/N. Couturier 74

77 Monday December 8, 2014 Poster Session 3 8:00 a.m. 3:00 p.m. Convention Center Hall 4B, Level Beta-hydroxybutyrate And Docosahexaenic Acid Suppress Seizures And Hippocampal Network Hyperexcitability In A Mouse Model Of Dravet Syndrome/Y. Abdulkadir, T. Scheuer, W. Catterall, F. Kalume Regulation Of Brain PPARγ Mediates Ketogenic Diet Anti-Seizure Efficacy/T. A. Simeone, S. A. Matthews, K. K. Samson, K. Simeone A 35% Triheptanoin Diet Reduces Spontaneous Electrographic Seizures in Pilocarpine-Induced Epileptic Mice/A. Fernandez, J. Stoll Surgery Adult Super-Selective Amygdalohippocampotomy Using Real- Time Magnetic Resonance Guided Laser Ablation In Patients With Mesial Temporal Lobe Epilepsy/ J. W. Yoon, W. Tatum, J. J. Shih, V. Gupta, P. Vibhute, R. Wharen Cognitive Outcome Of Patients Undergoing Stereotactic Laser Ablation Of Cavernous Malformations To Control Chronic Seizures/ D. L. Drane, J. Willie, D. W. Loring, N. Voets, A. M. Saindane, M. Ivanisevic, R. Brewster, R. Jayakar, R. Faught, K. J. Meador, R. Gross A Case Report Of A Patient With Refractory Temporal Lobe Epilepsy Suffered Ischemic Stroke After The Wada Test Had Good Outcome/H. Gong, M. Kim-Tenser, D. Ko Modulating Cortico-Cortical Evoked Potentials And Their Connectivity Maps With Differing Stimulation Parameters/S. Bickel, M. Mercier, P. Megevand, D. Groppe, A. Mehta, F. Lado Frontal Topectomy May Be Palliative In Difficult To Localize Intractable And Disabling Frontal Epilepsy/J. Oster Assessment Of Driving Outcomes After Epilepsy Surgery/ R. Dawkins, N. Omar, B. Agee, B. Walters, K. Riley Stimulation Of Ncl. Accumbens In Intractable Partial Epilepsy Possible Candidates/F. C. Schmitt, A. Kowski, L. Buentjen, H. Stefan, H. B. Straub, T. Mayer, T. Zaehle, F. Oltmanns, H. Heinze, M. Holtkamp, J. Voges Pediatrics Pediatric Epilepsy Surgery Techniques Specific Issues: Inter- Center Worldwide Variability/ W. Harkness, B. Rydenhag, A. Cukiert, I. Panel Epilepsy Related Characteristics Of Children Less Than Five Years Of Age Who Underwent Epilepsy Surgery/E. Thompson, J. Walker, W. Chlon, S. LeSure, D. F. Clarke Surgical Treatment Of Patients With Rasmussen Encephalitis (34 Cases)/Y. Guan, G. Luan SEEG-Based Tailored Laser Ablation For Lesional Epilepsy/ T. P. Ngo, C. Lopez, D. Curry, A. Wilfong Review Of Extended Multi-lobar Epilepsy Surgery In Pediatric Patients/R. Yu, H. Kang, J. Lee, D. Kim, H. Kim Follow Up EEG, MRI And Frequency Of Relapse In Children Status Post Resection Of Focal Cortical Dysplasia/K. Havens, C. Oluigbo, S. Magge, W. Gaillard, G. Vezina, D. Depositario-Cabacar Special Needs Of Autistic Patients Undergoing Epilepsy Surgery: Review Of Inpatient Management In 57 Cases/S. Ghatan, M. Kokoszka, P. McGoldrick, M. La Vega-Talbott, H. Raynes, R. Prince, J. Kim, H. Kang, S. Wolf Acute, Mid-And Long-Term Outcomes Of Medically Refractory Epilepsy And Neurocognitive Difficulties Following Staged MRI- Guided Thermal Laser Ablation In Pediatric Patients With Tuberous Sclerosis Complex/Y. Eksioglu, Z. Tovar-Spinoza Outcomes Of Stereotactic Laser Ablation For Treatment- Resistant Epilepsy In The Pediatric Population With 1-Year Follow-Up/ D. Curry, A. Shetty, A. Wilfong MEG In Pediatric Presurgical Evaluation: Comparative Study With Intracranial EEG Recordings In Children With Focal Cortical Dysplasia/U. Thome, N. Agarwal, Z. I. Wang, H. Murakami, B. Krishnan, R. Burgess, A. Alexopoulos, A. Gupta Acute Intralesional Recording In Hypothalamic Hamartoma: Description Of 4 Cases/N. Specchio, M. Rizzi, M. Trivisano, L. Fusco, E. Rebessi, S. Cappelletti, F. Villani, A. Savioli, A. De Benedictis, C. Marras, O. Delalande, F. Vigevano PET And SPECT Concordance With EEG And MRI In Pre-Surgical Evaluation For Pediatric Epilepsy/ C. Moufawad El Achkar, M. Takeoka Surgical Management Of Patients With CSWS: The Detroit Experience/R. Agarwal, A. Kumar, E. Asano, R. Rothermel, S. Sood, H. Chugani MRI-Guided Laser-Induced Thermal Ablation: A Promising Tool With Favorable Acute, Mid And Long- Term Outcomes For Intractable Seizures And Neurocognitive Comorbidities In Cortical Dysplasias/ Y. Eksioglu, K. Ogden, S. Huckins, Z. Tovar-Spinoza Deep Focal Cortical Dysplasia And Surgical Outcomes In Children/ D. Depositario-Cabacar, K. Havens, C. Oluigbo, S. Magge, G. Vezina, W. Gaillard All Ages VNS (Vagus Nerve Stimulation) Is A Useful Tool To Promote The Epilepsy Surgery/I. Takumi, T. Nozaki, Y. Kishi, A. Morita Epilepsy Surgery In Or Close To Eloquent Cortex New Methods Open For Surgery In More Patients/A. Egge, M. Stanisic, P. Larsson Spontaneous Improvement In Seizure Control After Intracranial Electrode Implantation/C. Morris, J. Boggs, V. Woodard, C. O Donovan, G. Popli Radiographic Changes Following Laser Interstitial Thermal Therapy For Medically Intractable Epilepsy/R. Buckley, J. Ojemann Temporopolar Grey/White Matter Abnormalities In Temporal Lobe Epilepsy With Hippocampal Sclerosis And Long-Term Prognosis After Epilepsy Surgery/P. V. Naves, L. Caboclo, H. Carrete. Jr., R. Centeno, B. V. Kelmann, E. Yacubian Magnetoencephalography Localization Can Guide Reoperation After Unsuccessful Neocortical Epilepsy Surgery/I. Mohamed, A. Pooladian, Y. T. Tran, M. Robert, A. Bouthillier, D. Nguyen Stereotactic Laser Ablation For Epilepsy: An Analysis Of The Safety Profile From Peer-Reviewed Reports/A. Wilfong, A. Shetty, D. Curry Seizure Outcome After Battery Depletion In Patients Submitted To Deep Brain Stimulation For Epilepsy./J. A. Burattini, A. M. Lima, C. M. Cukiert, A. Cukiert Epilepsy Surgical Outcomes : The USC Experience With Standard Temporal Lobectomy And Selective Amygdalohippocampectomy/ Y. Marquez, M. N. Zubair, B. Lee, D. Millett, L. Kalayjian, D. Ko, S. Shaw, C. Heck, C. Liu Results Of A Drug Withdrawal Protocol After Temporal Lobe Epilepsy Surgery/R. S. Centeno, M. D. Guimaraes, L. Caboclo Speed And Precision Of Robotic Depth Electrode Placement For Stereotactic EEG/N. Tandon, G. Kalamangalam, B. Seignot MONDAY 75

78 THE EPILEPSY RESEARCH BENCHMARKS 2014 NINDS Benchmarks for Epilepsy Research Beginning in 2000, the National Institute of Neurological Disorders and Stroke (NINDS) has hosted a series of Curing the Epilepsies conferences in partnership with epilepsy advocacy and professional organizations to assess progress in epilepsy research and help set an agenda for future years. As an outcome, these conferences have led to the development of Benchmarks for Epilepsy Research, which reflect shared priorities across the epilepsy community. The current 2014 Benchmarks are: I. Understand the causes of the epilepsies and epilepsy-related neurologic, psychiatric, and somatic conditions A. Identify new genes and pathways associated with epilepsies and epilepsy-related conditions. B. Identify new infectious, immune, age-related, environmental, or other causes and risk factors associated with the epilepsies and epilepsy-related conditions. C.Determine whether factors related to age, gender, race / ethnicity, socioeconomic status, and other features of specific populations affect risk and mechanisms of epilepsy and epilepsy-related conditions. D. Determine whether the bi-directional relationships that exist between the epilepsies and several co-occurring conditions (e.g., neuropsychiatric or neurodevelopmental disorders) result from the same underlying causal II. mechanisms, interacting mechanisms, or are a consequence of the first presenting condition. Prevent epilepsy and its progression A. Understand epileptogenic processes involved in epilepsies with neurodevelopmental origins, including those due to genetic or presumed genetic causes. B. Understand epileptogenic processes involved in the development of epilepsy following traumatic brain injury, stroke, brain tumor, infections, neurodegeneration, or other insults to the brain. C.Identify biomarkers that will aid in identifying, predicting, and monitoring epileptogenesis and disease progression, including markers early after injury / insult that identify those people at risk for epilepsy. D. Develop or refine models aligned with the etiologies of human epilepsies to enable improved understanding of epileptogenesis and rigorous preclinical therapy development for epilepsy prevention or disease modification. E. Identify new targets and develop interventions to prevent or modify epileptogenesis and the progression of epilepsy and epilepsy-related conditions. III. Improve treatment options for controlling seizures and epilepsy-related conditions without side effects A. Understand the initiation, propagation, and termination of seizures at the network level in different forms of epilepsy. B. Identify biomarkers for assessing or predicting treatment response, including markers that may identify specific populations that are likely to have good outcomes or develop adverse responses. C.Develop or refine models that are aligned with etiologies and clinical features of human epilepsies, especially treatment resistant forms, to enable improved understanding of ictogenesis and preclinical development to improve seizure control with fewer side effects. Establish the sensitivity and specificity of these models with regard to current therapies. D. Identify, develop, and improve interventions to detect, predict, prevent, or terminate seizures, including approaches suitable for use in the home and other non-medical settings. E. Identify, develop, and improve anti-seizure therapies that target (either alone, or in combination) novel or multiple seizure mechanisms. F. Develop, improve, and implement interventions for effective self-management, including treatment adherence. G.Develop and validate objective patient-centered outcome metrics for clinical studies. IV. Limit or prevent adverse consequences of seizures and their treatment across the lifespan A. Understand and limit adverse impacts of seizures on quality of life, including effects on neurodevelopment, mental health, intellectual abilities, and other neurological and non-neurological functions. B. Understand and limit adverse impacts of anti-seizure treatments (medical, surgical, or other interventions) on quality of life, including effects on neurodevelopment, mental health, intellectual abilities, and other neurological and non-neurological functions. C.Understand risk factors and mechanisms involved in non-epileptic seizures (NES). Develop effective approaches for earlier and accurate diagnosis and treatment. D. Identify causes, risk factors, and potential preventive strategies for sudden unexpected death in epilepsy (SUDEP) and other epilepsy-related mortality (for example, suicide) in people with epilepsy. E. Identify the impact of pharmacological treatment of the epilepsies on fetal and neonatal development. Develop strategies to control seizures in pregnancy without causing harm to either the mother or child. Walter Koroshetz, M.D. Acting Director, NINDS Daniel H. Lowenstein, M.D. Chair, Benchmarks Stewards University of California, San Francisco Raymond J. Dingledine, Ph.D. Vice-Chair, Benchmarks Stewards Emory University Brandy Fureman, Ph.D. Co-Chair, Benchmark Stewards NINDS For more information about the Benchmarks and to view Steward s previous reports, please visit: 76

79 AES 68 TH ANNUAL MEETING Seattle, WA TUESDAY December 9, :00 a.m. 8:30 a.m. Special Interest Group Meetings Location listed under each session Critical Care (ICU EEG Monitoring) Controversies in ICU EEG Interpretation and Management Convention Center Room 612, Level 6 Coordinators: Suzette M. LaRoche, M.D., Cecil Hahn, M.D. Speakers: Tammy Tsuchida, M.D., Ph.D., Courtney Wusthoff, M.D., William Gallentine, D.O., Eric Payne, M.D., M.P.H., FRCPC, Sarah Schmitt, M.D., Lawrence J. Hirsch, M.D. We will present three controversial cases (one neonatal, one pediatric, one adult) that demonstrate controversial EEG patterns and approach to management. Speakers will utilize a pro / con format, debating the merits of aggressive vs. non-aggressive treatment. Genetics: Personalized Epilepsy Diagnosis and Treatment Convention Center Room 613, Level 6 Coordinators: Tara L. Klassen, Ph.D., Eric Marsh, M.D., Ph.D. Speakers: Tara L. Klassen, Ph.D., Eric Marsh, M.D., Ph.D., Stephen Traynelis, Ph.D., Elizabeth K. Ruzzo, Ph.D. This SIG will discuss the use of genome sequencing for individual diagnosis and its implication for treatment. The speakers will review exome application on an individual level, present cases that highlight the possibilities and limitations of personalized genetic medicine, and then discuss how to apply genetic data for individualized therapeutics. NEW Global Health in Epilepsy: How Can You Get Involved? Convention Center Room 603, Level 6 Coordinator: Sheryl Haut, M.D. Speakers: Jose Cavazos., M.D., Ph.D., Lionel Carmant, M.D. Participation in epilepsy-related global health projects is exciting, productive and important! Many people are still unaware of the possible avenues to pursue global health. This SIG will focus on opportunities for international collaborations, professorships and partnerships around the world, both in person and via telemedicine. The speakers will discuss challenges across different regions, successes and lessons learned. Areas to be highlighted as examples include ILAE supported activities such as the PECA (Partnering Epilepsy Centers in the Americas) program of the North American Commission of the ILAE and visiting professorship programs in Africa, and the ILAE/WFN supported epilepsy demonstration project in Haiti. Practice Management Convention Center Room 618, Level 6 Coordinator: Gregory Barkley, M.D. Annual update on ICD and CPT coding plus an open forum to discuss Electronic Health Record (EHR) issues, tips, and tricks. Participants are encouraged to submit suggestions of problems or tips from their own practices ahead of time. Submit to barkley@neuro.hfh.edu. Sleep and Epilepsy: Sleep Polygraphy Monitoring in the EMU: Are We Missing a Diagnostic / Therapeutic Opportunity? Convention Center Room 606, Level 6 Coordinators: Mark S. Quigg, M.D., Erik K. St. Louis, M.D. Speakers: Milena Pavlova, Terence J. O Brien, M.D., FRACP, Erik K. St. Louis, M.D. Comorbid sleep disturbances such as obstructive sleep apnea, insomnia, and restless legs syndrome are frequent in persons with epilepsy, and epileptologists are increasingly recognizing the importance and value of diagnosing and treating sleep comorbidities in epilepsy patients. Approximately 15-40% of patients with refractory epilepsy have comorbid sleep apnea, and treatment of sleep apnea in epilepsy patients may improve seizure burden, in addition to improving alertness and well-being and modifying future health risk. However, identification of sleep apnea remains challenging, and most epilepsy centers have separate clinical infrastructures for the evaluation of epilepsy and sleep disorders, despite obvious intuitive, practical, and logistical advantages of employing sleep polygraphy techniques directly in the epilepsy monitoring setting. This year s Sleep and Epilepsy SIG will feature three expert epileptologists addressing the timely issue of utilizing polysomnography in the differential diagnosis of epilepsy and spells, and the importance of identifying sleep apnea in epilepsy monitoring inpatients. Temporal Lobe Club: The Thalamus in Epilepsy Player or Bystander? Convention Center Room 620, Level 6 Coordinators: John Huguenard, Ph.D., Robert S. Fisher, M.D., Ph.D. Speakers: Robert S. Fisher, M.D., Ph.D., John Huguenard, Ph.D., Hal Blumenfeld, M.D., Ph.D. The thalamus has been called the gateway to the cortex. Do seizures travel through the gate, and if so, in which direction? The role of the thalamus in seizures has been debated for decades. In this temporal lobe club session, we will consider whether the thalamus is a player or bystander in epilepsy. Time is set aside for a lively group discussion. Tumor Induced Epilepsy Meningiomas Convention Center Room 604, Level 6 Coordinators: Jeffrey Politsky, M.D., FRCP(C), Theodore Schwartz, M.D., FACS Speakers: Sandeep Mittal, M.D., Jeffrey Politsky, M.D., FRCP(C), Jeffrey G. Ojemann, M.D. The focus of the 2014 Tumor-Related Epilepsy SIG will be meningiomas. Dr. Sandeep Mittal and Dr. Jeffrey Politsky will be present clinical data. There will be a third presenter to discuss pathologic basis of meningioma-related epilepsy. We will also invite members to submit cases in advance and will reserve the final minutes of the SIG for an open forum discussion. Women s Issues: Controversies in Caring for Women with Epilepsy Convention Center Room 615, Level 6 Coordinators: Danielle Andrade, M.D., M.Sc., Mona Sazgar, M.D. Speakers: Samuel F. Berkovic, M.D., Terence J. O'Brien, M.D., FRACP, Andrew G. Herzog, M.D., M.Sc., Sanjeev V. Thomas, M.D., D.M. Caring for women with epilepsy poses significant challenges to healthcare professionals. Despite a growing wealth of knowledge, many issues remain controversial and we lack evidence-based guidelines and consensus for many difficult management issues in this field. This SIG targets four major controversial issues in counseling and caring for women with epilepsy and intends to bring together expert opinion and best available evidence in addressing these difficult areas. 1. Controversies about inheritance of epilepsy 2. Controversies about teratogenicity of new AEDs and prenatal counseling 3. Controversies regarding contraception and epilepsy 4. Controversies in hormonal and non-hormonal treatment of catamenial epilepsy. TUESDAY 77

80 TUESDAY December 9, :45 a.m. 10:45 a.m. Hot Topics Symposium: Epilepsy Updates (2.0 CME Credits) Convention Center Ballroom 6C, Level 6 Overview The Hot Topics symposium will present information about newly developed approaches to epilepsy diagnosis and management. Faculty will discuss how MRI can be used to facilitate understanding the pathophysiology of epilepsy and interictal functional disturbances through study of the default mode network. In addition, new MRI analyses evaluate disease progression with important implications for both diagnosis and treatment. How generic drug use impacts seizure control will be discussed, presenting data from a new study. Lastly, a new less invasive surgical treatment for epilepsy, thermal ablation, will be discussed. This potpourri of topics covers the most recent advances in epilepsy, and should be valuable to both clinicians and basic scientists. Learning Objectives u u Recognize when to use generic anticonvulsant drugs when appropriate, based on the potential impact on treatment efficacy and tolerability and assists patients in understanding the pros and cons of utilizing generic medications Utilizing current understanding of the pathophysiology of epilepsy, including progression of disease, learner utilizes new diagnostic and treatment approaches u Educate patients on how new diagnostic and treatment approaches can be used to manage refractory epilepsy. Target Audience Intermediate (see page 120 for details) Program Co-Chairs: R. Edward Hogan, M.D. and Michael R. Sperling, M.D. 8:45 8:50 a.m. Introduction Michael R. Sperling, M.D. 8:50 9:15 a.m. The Default Mode and Networks in Epilepsy Jean Gotman, Ph.D. 9:15 9:40 a.m. Progression of Disease in Epilepsy Andrea Bernasconi, M.D. 9:40 10:05 a.m. Generic Drug Update Michael D. Privitera, M.D. 10:05 10:30 a.m. Thermal Ablation Robert Gross, M.D., Ph.D. 10:30 10:45 a.m. Conclusions R. Edward Hogan, M.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.0 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.0 contact hours (0.2 CEUs). UAN L01-P. Initial Release Date: 12/9/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Hot Topics Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competency: Medical Knowledge 8:45 a.m. 10:45 a.m. Scientific Symposium: The Epidemiology, Pathophysiology & Prevention of SUDEP (2.0 CME Credits) Convention Center Ballroom 6E, Level 6 Overview This symposium will review the basic and clinical science of Sudden Unexpected Death in Epilepsy (SUDEP). Specific areas that will be addressed include epidemiology, clinical risk factors, potential role of preventive strategies, gaps in how physicians educate patients and families, current biomarkers of SUDEP and the evidence for the role of devices in seizure detection and their potential role in preventing SUDEP. In addition, two leading models used to understand the mechanisms underlying SUDEP in animals and humans will be discussed: the role of the serotonergic system and respiration and insights into human SUDEP from a mouse model of Dravet syndrome. Learning Objectives u u u u Apply understanding of the clinical risk factors, epidemiology, educational gaps, and basic mechanisms of SUDEP, to developing treatment plans focused on potential role of preventive strategies Counsel patients and families regarding utility of devices to detect seizures Counsel patients / families regarding clinical risk factors, epidemiology, educational gaps, and potential role of preventive strategies underlying SUDEP Understand and advice practitioners and patients / families regarding issues of medication adherence and therapeutic levels as prevention strategy for SUDEP prevention u Assist patients / families to develop cognitive skills and strategies to improve medication adherence that could be life saving for some patients. Target Audience Basic, Intermediate, and Advanced (see page 120 for details) Program Chair: Orrin Devinsky, M.D. 8:45 a.m. Introduction Orrin Devinsky, M.D. 8:55 a.m. Risk Factors and Prevention of SUDEP Dale C. Hesdorffer, Ph.D. 9:15 a.m. Serotonin, Adeonsine and Respiration George B. Richerson, M.D., Ph.D. 9:35 a.m. Insights from Dravet Syndrome William A. Catterall, Ph.D. 9:55 a.m. Biomarkers of SUDEP and the Role of Devices Daniel Friedman, M.D. 78

81 TUESDAY December 9, :15 a.m. Pediatric SUDEP and Patient / Family Education Elizabeth J. Donner, M.D. 10:35 a.m. Conclusions Orrin Devinsky, M.D. Credit Designation The American Epilepsy Society designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses may claim up to 2.0 contact hours for this session. Pharmacy Credit AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based activity for 2.0 contact hours (0.2 CEUs). UAN L01-P. Initial Release Date: 12/9/2014. ABPN Core Competencies The American Board of Psychiatry and Neurology has reviewed the Scientific Symposium and has approved this program as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification. Core Competencies: Patient Care, Practice-based Learning, Interpersonal and Communication Skills Seven on-demand audio webinars introducing the core elements of seizures, epilepsy, and epilepsy care. This program will assist nurses and other health care professionals to provide appropriate care and support to patients and families in any health care setting. Audio Webinars include: Basics of Epilepsy Recognition and Care of Seizures and Emergencies: Parts 1-2 Overview of Treatment Options: Parts 1-2 Patient and Family Education and Self-Management Approaches TUESDAY 79

82 See you in Philadelphia! 2015 ANNUAL MEETING December 4-8 PHILADELPHIA, PA Pennsylvania Convention Center CME Symposia and Lectures Platform Sessions Informative Exhibitors Special Interest Group Meetings Skills Workshops FUTURE ANNUAL MEETING DATES 2016 Houston, TX George R. Brown Convention Center December Washington, D.C. Washington Convention Center December New Orleans, LA Ernest N. Morial Convention Center November 30 - December Baltimore, MD Baltimore Convention Center December

83 EXHIBITOR FLOOR PLAN GES EXHIBITOR LOUNGE Exhibit Manager Office 936 FOOD & BEVERAGE EXIT EXIT PE PE POSTER BOARDS ESCALATOR DOWN TO LEVEL PE PE 1 2 SOUTH GALLERIA MAIN ENTRANCE ESCALATOR UP TO LEVEL 6 OFFICE #1 OFFICE # WF MEDIA WALL PAVILION B PAVILION A FOOD & BEVERAGE PAVILION D PAVILION C AES 519 EPILEPSY RESOURCE CENTER BAG DISTRIBUTION REGISTRATION SOUTH LOBBY - LEVEL 4 Poster Information Table* WF CYBER CAFE Elevators Elevators Poster Session Entrance When Exhibits are Closed Coat Check *Poster Walking Tours begin at the Poster Information Table Exhibit Hall Hours: Saturday, December 6...Noon - 6:00 p.m. Sunday, December :00 a.m. - 6:00 p.m. Monday, December :00 a.m. - 3:00 p.m. 81

84 EXHIBITOR LOCATIONS Booth ABRET Neurodiagnostic Credentialing & Accreditation*...3 Ad-Tech Medical Instrument Corp AED Pregnancy Registry Ambry Genetics Ambu Inc American Board of Clinical Neurophysiology, Inc. (ABCN)*..2 American Board of Psychiatry and Neurology American Clinical Magnetoencephalography Society* (ACMEGS)...5 American Clinical Neurophysiology Society (ACNS)*...4 American Epilepsy Society Angel Wings Foundation*...16 Anita Kaufmann Foundation, The*...1 ANT North America Ark Diagnostics, Inc ASET The Neurodiagnostic Society*...15 Athena Diagnostics, Inc Aurora Health Care B. Braun CeGat, LLC BIOPAC Systems, Inc Blackrock NeuroMed Brain Vision LLC Cadwell Laboratories, Inc captureproof Charlie Foundation, The and Ice Epilepsy*...19 Child Neurology Foundation Clever Sys, Inc Compumedics Limited Courtagen Diagnostics Lab CorTechs Lab, Inc CURE (Citizens United for Research in Epilepsy)*...6 Cyberonics, Inc Department of Veterans Affairs, Epilepsy Centers of Excellence*...9 DigiTrace EEG Services Dravet Syndrome Foundation*...11 Eisai Inc Electrical Geodesics, Inc...717, 816 ELEKTA Elsevier, Inc Emfit Corp emka TECHNOLOGIES Inc Emory Genetics Laboratory Epilepsy Foundation*...8, 513 GeneDx GlaxoSmithKline GW Pharmaceuticals IEEG.org*...17 International Epilepsy Congress INSYS Therapeutics Jack Pribaz Foundation, The John Libbey EUROTEXT Booth LGS (Lennox-Gastaut Syndrome) Foundation*...10 Lifelines Neurodiagnostic Systems, Inc Lundbeck...405, 511 Mallinckrodt Pharmaceuticals...217, 316 Medical Neurogenetics, LLC MediKidz Medtech Surgical Medtronic Moberg Research Monteris Medical Multi Channel Systems National Association of Epilepsy Centers National Institute of Neurological Disorders & Stroke (NINDS) Natus Neurology Incorporated Neuralynx, Inc Neurology Reviews NeuroPace, Inc NeuroQuest LLC Neurotech Nexstim Nihon Kohden America, Inc Novartis Pharmaceuticals Optima Neuroscience, Inc Oxford University Press PCDH19 Alliance*...7 Persyst Development Corporation Physicians Insurance Pinnacle Technology, Inc PMT Corporation PreventionGenetics Rhythmlink International, LLC Ring14 USA Outreach*...12 Ripple LLC Rogue Research Inc RosmanSearch, Inc SeizureTracker.com*...21 Smart Monitor Corp SUDEP Aware*...20 Sunovion Pharmaceuticals Inc Supernus Pharmaceuticals, Inc Texas Children s Hospital Transgenomic, Inc Triangle BioSystems, Inc Tuberous Sclerosis Alliance*...22 UCB, Inc...135, 205 UCSF Medical Center Upsher-Smith Laboratories, Inc...625, 823 Vitaflo USA Wiley Wolters Kluwer Health *Please see Epilepsy Resource Center Participants on page 83

85 Stop by the EPILEPSY RESOURCE CENTER at the Entrance of the Exhibit Hall 2014 Epilepsy Resource Center Participants Table # ERC Participants: ENTRANCE ENTRANCE Presentation Area ENTRANCE ENTRANCE 1 The Anita Kaufmann Foundation 2 American Board of Clinical Neurophysiology, Inc. (ABCN) 3 The American Board of Registration of EEG and EP Technologies (ABRET) 4 American Clinical Neurophysiology Society (ACNS) 5 American Clinical MEG Society (ACMEGS) 6 CURE (Citizen s United for Research in Epilepsy) 7 PCDH19 Alliance 8 Epilepsy Foundation 9 Epilepsy Centers of Excellence, Department of Veterans Affairs 10 LGS Foundation 11 Dravet Syndrome Foundation 12 Ring14 USA Outreach 14 North American SUDEP Registry 15 ASET The Neurodiagnostic Society 16 Angel Wings Foundation 17 IEEG.org 18 British Paediatric Neurology Association 19 The Charlie Foundation and ICE Epilepsy 20 SUDEP Aware 21 SeizureTracker.com 22 Tuberous Sclerosis Alliance Many of the ERC participants will be offering mini-workshops dedicated to the education, awareness and research for people with epilepsy worldwide. All participants of AES, including exhibitors, are invited to attend the mini-workshops. The schedule will be posted daily outside the ERC. The Epilepsy Resource Center is a comprehensive one-stop resource for patients, researchers and clinicians specializing in the area of epilepsy. 83

86 EXHIBITORS as of October 21, 2014 Saturday, December 6: Noon-6:00 p.m. Lunch: Noon-1:00 p.m. Symposia Break: 5:00 p.m.-6:00 p.m. Prize Drawing: 5:30 p.m. Exhibit Schedule Sunday, December 7:10:00 a.m.-6:00 p.m. Lunch: Noon-1:00 p.m. Suds for Science: 5:00 p.m.-6:00 p.m. Prize Drawing: 5:30 p.m. Monday, December 8: 10:00 a.m.-3:00 p.m. Lunch: Noon-1:00 p.m. Prize Drawing & Grand Prize Drawing: 2:30 p.m. ABRET Neurodiagnostic Credentialing & Accreditation Booth # Greenbriar Dr - Ste A Springfield IL Phone: Fax: abreteo@att.net Website: Contact: Ms. Janice Walbert ABRET Neurodiagnostic Credentialing & Accreditation offers five credentials (R. EEG T., R. EP T., CNIM, CLTM, CAP) and manages three laboratory accreditation programs, LAB-EEG, LAB-NIOM, and LAB- LTM. Learn more about laboratory accreditation, view resources for technologists and receive assistance in recruiting neurodiagnostic technologists. Ad-Tech Medical Instrument Corp. Booth # William St Racine WI Phone: Fax: abouwma@adtechmedical.com Website: Contact: Ms. Angie Bouwma For over 25 years, Epilepsy Centers have made Ad-Tech their choice for invasive electrodes for brain mapping and epilepsy monitoring. We offer a large variety of electrodes and accessories to meet you and your patient s needs. Visit our Booth to discover why Ad-Tech is your best choice. AED Pregnancy Registry Booth # Innerbelt Rd - Ste 220 Massachusetts General Hospital Somerville MA Phone: Fax: crsmith1@partners.org Website: Contact: Ms. Caitlin Smith The North American AED Pregnancy Registry is dedicated to determine the safety of anticonvulsant medications that can be taken by women during pregnancy. The primary goal is to determine the frequency of major malformations in the infants exposed during pregnancy to anticonvulsant drugs. Please visit our booth to learn more about our findings, and to obtain materials for use in your office. Ambry Genetics Booth # Argonaught Aliso Viejo CA Website: Contact: Colleen Garcia Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)- certified commercial clinical laboratory with headquarters in Orange County, California. Ambry is a leader in providing genetic services focused on clinical diagnostics and genomic services, and has established a reputation for unparalleled customer satisfaction. Ambu Inc. Booth # Baymeadow Dr Glen Burnie MD Phone: meha@ambu.com Website: Contact: Megan Hasson Ambu is dedicated to the development of innovative products that help save lives and simplify workflow of the anesthetists to the benefit of the patients.within the field of anesthesia Ambu offers a wide range of products from resuscitators, face masks and laryngeal masks to the highly innovative single use flexible intubation scope. American Board of Clinical Neurophysiology, Inc. (ABCN) Booth # Greenbriar Dr Ste A Springfield IL Phone: Fax: abcn@att.net Website: Contact: Ms. Janice Walbert The ABCN has a 65 year history of promoting excellence in Clinical Neurophysiology and offers examinations with added competency in Epilepsy Monitoring or Neurophysiologic Intraoperative Monitoring. A General Clinical Neurophysiology Track is also available. A Critical Care EEG Track will be offered in fall International testing is available. American Board of Psychiatry and Neurology Booth # E Lake Cook Rd - #900 Buffalo Grove IL Phone: Fax: questions@abpn.com Website: Contact: Ms. Karen Back The American Board of Psychiatry and Neurology serves the public interest and the professions of psychiatry and neurology by promoting excellence in practice through its certification and maintenance of certification processes. ABPN also oversees the certification process for physicians seeking certification in child and adolescent psychiatry. American Clinical Magnetoencephalography Society (ACMEGS) Booth #5 555 E. Wells Street Ste 1100 Milwaukee WI Phone: mkelley@acmegs.org Website: Contact: Ms. Megan Kelley ACMEGS is a non-profit association whose membership includes clinical MEG facilities in the U.S. Founded by physicians committed to high-quality care of patients with epilepsy, ACMEGS now advocates for patients with neurological conditions who may benefit from MEG by educating policymakers about recommended standards of care, reimbursement, and provider regulations. American Clinical Neurophysiology Society (ACNS) Booth #4 555 E. Wells Street Ste 1100 Milwaukee WI Phone: Fax: info@acns.org Website: Contact: Ms. Megan Kelley The American Clinical Neurophysiology Society (ACNS) is a professional association dedicated to fostering excellence in clinical neurophysiology and furthering the understanding of central and peripheral nervous system function in health and disease through education, research, and the provision of a forum for discussion and interaction. 84

87 EXHIBITORS American Epilepsy Society Booth # N Main St West Hartford CT Phone: Fax: ctubby@aesnet.org Website: Contact: Ms. Cheryl-Ann Tubby Visit the AES booth for information on membership, publications, and research funding opportunities. Stop by to watch interviews being taped with member experts on some of the hottest topics at the meeting. Recognize a mentor or colleague by purchasing a Community of Caring pin, and support AES research and awareness programs. Get a personal tour of AES online resources including the Epilepsy Learning Institute, EMU Caring, and the AES website. AES logo scarves, ties and bowties will also be available for purchase. Angel Wings Foundation Booth # Baldwin Ct Hanover Park IL Phone: dflader@angelwingsfoundation.net Website: Contact: Ms. Debbie Flader Angel Wings Foundation is dedicated to enhancing the lives of adults with epilepsy, allowing them to reach their full potential through independent living in the community. Angel Wings will create home where adults with epilepsy can lead person-centered lives, with supports in place. Angel Wings will offer recreational, vocational and educational opportunities for adults with epilepsy. Anita Kaufmann Foundation, The Booth #1 PO Box 751 Livingston NJ Phone: debra@akfus.org Website: Contact: Ms. Debra Josephs AKF, global sponsor of Purple Day, is a 501(c)(3) public charity with a grassroots mission to educate the public not to fear people with epilepsy. Visit purpledayeveryday.org and akfus.org to learn about our Heads Up For Vets and Lace Up For Epilepsy Programs, or to register for our Purple Day Mall of America Walk for Epilepsy in conjunction with the CNF Brain Carnival on 3/21/15. ANT North America Booth # S. Yellowstone Dr #216 Madison WI Phone: myuchtman@ant-neuro.com Website: Contact: Moshe Yuchtman Ark Diagnostics, Inc. Booth # Fremont Blvd Fremont CA Phone: Fax: ryan@ark-tdm.com Website: Contact: Mr. Ryan Olandria Ark Diagnostics Inc. designs, manufactures, and distributes in vitro diagnostic products. ARK s proprietary assays accurately measure drug levels in biological fluids. Clinicians use these measurements to guide dosing decisions for safe, effective, and personalized drug therapy. Anti-epileptic drug assays (FDA 510k Cleared): Levetiracetam, Lamotrigine, Topiramate, Gabapentin, and Zonisamide. ASET The Neurodiagnostic Society Booth # E Bannister Rd Ste A Kansas City MO Phone: Fax: sarah@aset.org Website: Contact: Ms. Sarah Ecker ASET The Neurodiagnostic Society represents more than 4,500 allied health professionals who perform neurodiagnostic procedures. ASET provides education and advocacy, creates greater awareness of the profession, and establishes standards and best practices to ensure quality patient care. Stop by the ASET booth to see our newest publications and educational offerings. Athena Diagnostics, Inc. Booth #612 Ms. Lorri Harrell 200 Forest Street 2nd Floor Marlborough MA Phone: lorri.l.harrell@questdiagnositics.com Website: Athena Diagnostics is a leader in diagnostics testing for neurological diseases. Our comprehensive test menu includes over 400 tests for epilepsy, muscular dystrophy, peripheral neuropathy, stroke, and other neuromuscular and developmental disorders. Aurora Health Care Booth # West Forest Home Ave Milwaukee WI Phone: chris.mccarrier@aurora.org Website: Contact: Christine McCarrier Aurora Health Care is the largest healthcare system in eastern Wisconsin and extends into northern Illinois. Our integrated delivery model helps us coordinate and simplify quality care, minimize costs and improve our patients overall health care experience. Our 15 hospitals and 90+ clinics support neurologists who believe that better health care leads to stronger communities. B. Braun CeGat, LLC Booth # Twelfth Ave Bethlehem PA Phone: genetics.us@bbraun.com Website: Contact: Mitch Nemcek B. Braun CeGaT is a genetic diagnostic laboratory that offers an extensive menu of single-gene sequencing tests and over 150 multi-gene diagnostic panels for a wide variety of genetic diseases, including 19 panels that analyze 400+ genes associated with epilepsies, migraines, and related disorders. BIOPAC Systems, Inc. Booth # Aero Camino Goleta CA Phone: Fax: frontdesk@biopac.com Website: Human and animal wireless EEG systems with AcqKnowledge analysis automation & scoring: small animal seizure detection, EPOCH 2-ch long-term wireless EEG/neural signals, B-Alert X10 wireless EEG & Cognitive State Metrics, Mobita 32-ch wireless EEG system with water electrodes, BioNomadix Wireless Physiology amplifiers, Stellar telemetry interface for multiple animals, Developer Scripting, and more! Blackrock NeuroMed Booth # Komas Dr - Ste 200 Salt Lake City UT Phone: Fax: sryan@blackrockneuromed.com Website: Contact: Ms. Shanna Ryan Blackrock NeuroMed s Cervello EEG/LTM systems provide physicians and clinicians an advanced EEG monitoring system with up to 256 channels, remote monitoring capabilities, Bluetooth wireless connectivity and a full HD 1080 PTZ video camera. All systems include comprehensive service and support with start to finish integration and IT consultation. Brain Vision LLC Booth # Gateway Centre Blvd Ste 100 Morrisville NC Phone: Fax: travel@brainvision.com Website: Brain Vision LLC offers full service solutions for customized neurophysiological related research including epilepsy related on infants and adults that include EEG/ERP as well as fnirs software and hardware, fmri 85 EXHIBITORS

88 EXHIBITORS compatible equipment, stimulation devices (TMS, tdcs, tacs), wireless system applications for passive, active, dry electrodes and accessories. Cadwell Laboratories, Inc. Booth # N Kellogg St Kennewick WA Phone: Fax: lorik@cadwell.com Website: Contact: Ms. Lori Kaufman Cadwell introduces a new concept in Ambulatory and Clinical EEG. Come bybooth 811 to see the new ARC Alterna EEG system. Completely new software designed with the EEG specialist in mind, you will appreciate the clean, simple look and feel of this new system. The addition of an all new Photic Stimulator allows for clinical EEGs with the Ambulatory hardware while still providing Ambulatory EEGs. captureproof Booth # th St. Ste 4 San Francisco CA Phone: info@captureproof.com Website: Do your patients send you videos? CaptureProof is the HIPAA secure photo and video solution that organizes events chronologically. Videos are uploaded by the patient and shown at the next appointment or shared online. You can also share images with peers for consults. See-and-know what your patients are talking about. Sign-up free at captureproof.com using invite code: AES2014. Charlie Foundation, The and Ice Epilepsy Booth # Victoria Circle S Elm Grove WI Phone: Fax: ketogenicseminars@wi.rr.com Website: Contact: Ms. Beth Zupec-Kania The Charlie Foundation advocates ketogenic diet therapies through education programs and offers KetoCalculator, a web-based diet tool designed to manage ketogenic therapies. ICE Alliance provides drug information, advocacy support for appropriate medical treatment and education, a patient registry and funding of research for intractable childhood epilepsies:ice-epilepsy.org Child Neurology Foundation Booth # Chicago Ave - Ste 200 Minneapolis MN Phone: Fax: amiller@cnsmail.org Website: Contact: Ms. Amy Brin Miller 86 CNF improves lives of families battling one or more of the 450+ childhood neurologic disorders through our web resources, by supporting affiliate organizations, public policy initiatives, and the hope derived from our annual scholarships and awards. Clever Sys, Inc. Booth # Isaac Newton Sq - Ste 202 Reston VA Phone: Fax: nzhang@cleversysinc.com Website: Contact: Ms. Naili Zhang Headquartered in the metropolitan D.C. area, Clever Sys. Inc. sells products and services for lab animal behavior analysis including rodents, drosophila, zebra fish, primates, etc.. Our products utilize information of animal full body as well as animal body parts, providing measurements of novel behavioral paradigms and new parameters, which are more revealing of the intrinsic of animal behaviors. Compumedics Limited Booth # W WT Harris Blvd - Ste F Charlotte NC Phone: Fax: marketing@compumedicsusa.com Website: Contact: Ms. Marjie Cummings Compumedics provides solutions for Epilepsy monitoring. NEUVO LTM and Grael EEG Systems with CURRY 7 Neuroimaging Suite meet requirements for routine and ambulatory recordings as well as LTM / Neuro-ICU monitoring. Compumedics addresses ultra-high density recordings, source localization and source imaging. See more and do more with Compumedics. CorTechs Labs, Inc. Booth # Executive Dr - Ste 250 San Diego CA Phone: Fax: sadams@cortechslabs.com Website: Contact: Ms. Shelly Adams Courtagen Diagnostics Lab Booth # Gill St - Ste 3700 Woburn MA Phone: Fax: john.geanacopoulos@courtagen.com Website: Contact: Mr. John Geanacopoulos Courtagen is a diagnostic sequencing and molecular information company that converts NGS sequencing data into actionable clinical information for neurological and metabolic disorders such as mitochondrial disorders (mtseek and nucseek ), epilepsy (episeek ), and intellectual disability, including autism spectrum disorders (devact and devseek ). CURE (Citizens United for Research in Epilepsy) Booth #6 430 W Erie Ste 210 Chicago IL Phone: Fax: liz@cureepilepsy.org Website: Contact: Ms. Tracy Dixon-Salazar CURE (Citizens United for Research in Epilepsy) is a nonprofit organization dedicated to finding a cure for epilepsy by raising funds for research and by increasing awareness of the prevalence and devastation of the disease. Since its inception in 1998, CURE has raised over $28 million to fund epilepsy research and other initiatives that will lead the way to a cure. Cyberonics, Inc. Booth # Cyberonics Blvd Houston TX Phone: Fax: renee.adams@cyberonics.com Website: Contact: Ms. Renee Adams Cyberonics, Inc. is the leader in device solutions for epilepsy and is committed to consistently delivering innovative and effective solutions for physicians, caregivers and people with epilepsy. Cyberonics VNS Therapy is available in more than 70 countries for the treatment of drugresistant epilepsy, with more than 80,000 patients implanted worldwide. Department of Veterans Affairs, Epilepsy Centers of Excellence Booth # Clement St (127E) San Francisco CA Phone: Fax: ryan.rieger@va.gov Website: Contact: Mr. Ryan Rieger The Department of Veterans Affairs, Epilepsy Centers of Excellence's mission is to improve the health and well-being of Veteran patients with epilepsy and other seizure disorders through the integration of clinical care, outreach, research, and education.

89 EXHIBITORS DigiTrace EEG Services Booth # Corporate Pl - Ste 5B Peabody MA Phone: Fax: dmartin@sleepmedinc.com Website: Contact: Mr. Dan Martin DigiTrace EEG products and services are used by dozens of comprehensive epilepsy centers throughout the U.S. In addition, there are over 40 SleepMed Service Centers around the country where physicians can refer their patients for ambulatory EEG testing. We are noted for unique capabilities including our lightweight head-mounted preamplifier that minimizes motion artifact. Dravet Syndrome Foundation Booth #11 PO Box West Haven CT Phone: Fax: maryanne.m@dravetfoundation.org Website: Contact: Ms. Mary Anne Meskis The mission of Dravet Syndrome Foundation (DSF) is to aggressively raise research funds for Dravet syndrome and related epilepsies; to increase awareness of these catastrophic conditions; and to provide support to affected individuals and families. Eisai Inc. Booth # Tice Blvd Woodcliff Lake NJ Phone: Fax: shirley_hunt@eisai.com Website: Contact: Ms. Shirley Hunt As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer s disease, epilepsy and metabolic disorders). Electrical Geodesics, Inc. Booth #717, East 4th Ave Ste 200 Eugene OR Phone: Fax: daguilar@egi.com Website: Contact: Ms. Diana Aguilar EGI brings next-generation clinical EEG systems, tools, and workflows to hospitals and clinics worldwide. EEG Systems feature EGI s Geodesic Sensor Net for rapid application and unprecedented comfort. Your choice of routine EEG systems or dense array systems for source estimation. Visit EGI s booth to see this in action! ELEKTA Booth # Perimeter Center Terrace Suite 50 Atlanta GA Phone: Fax: doris.aubuchon@elekta.com Contact: Doris AuBuchon Elekta is the global leader in advanced magnetoencephalography (MEG) instrumentation. MEG is a highly sensitive and completely non-invasive technology increasingly used for localizing the epileptogenic zone(s) and adjacent eloquent cortex in pre-surgical evaluation of epileptic patients. Elsevier, Inc. Booth # JKF Blvd - Ste 1800 Philadelphia PA Phone: Fax: j.francis@elsevier.com Website: Contact: Mr. Jeffrey Francis Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries, that advance the boundaries of knowledge and human progress. Visit our booth to find out about our Neurology journals. Emfit Corp. Booth #909 PO Box Austin TX Phone: Fax: christine.ocean@emfit.com Website: Contact: Ms. Christine Ocean Emfit is a pioneer and world-leading manufacturer of movement activity and discreet vitals monitoring systems. We will be demonstrating the Emfit Movement Monitor for monitoring and detecting abnormal, nighttime movements, along with the newly released Emfit QS Sleep Monitor for tracking and recording essential sleep statistics, including heart rate, respiration rate, and movement activity. emka TECHNOLOGIES Inc. Booth # Annandale Rd - Ste 203 Falls Church VA Phone: Fax: vb@emkatech.com Website: Contact: Ms. Virginie Brechet Stop by booth#701 to discover the all new non-invasive and tether-less monitoring system: rodentpack v2. An affordable, headmounted, radio-telemetry device for recording EEG, EMG, ECG, temperature, and/or activity from up to 32 subjects simultaneously! Weighs only 4.5g with batteries, 5 meters transmission range, 150 hours continuous recording, no refurbishment, just replace batteries. Emory Genetics Laboratory Booth # N Decatur Rd Decatur GA Phone: Fax: derek.stevens@emory.edu Website: Contact: Mr. Derek Stevens Emory Genetics Laboratory (EGL) features fully integrated molecular genetics, cytogenetics, and biochemical genetics laboratories, making it a "one-stop shop" for genetic testing. EGL benefits from its affiliation with Emory University, but EGL is not the typical, highly specialized academic laboratory. EGL offers a full range of test options, with more than 900 tests available. Epilepsy Foundation Booths #8, Professional Pl Ardmore MD Phone: taregbesola@efa.org Website: Contact: Ms. Temi Aregbesola The Epilepsy Foundation is a communitybased, family-led organization dedicated to improving the lives of people impacted by seizures. We provide programs, services, support, and encourage innovation in accelerating new treatments and therapies.we educate about proper seizure awareness, recognition and first aid.we advocate for improved rights and regulations involving people living with epilepsy. GeneDx Booth # Edward H Ross Dr Elmwood Park NJ Phone: Fax: msansing@bioreference.com Website: Contact: Ms. Marianne Sansing GeneDx is highly respected laboratory, specializing in genetic testing for rare Mendelian disorders. GeneDx offers sequencing and deletion/duplication testing for inherited cardiac disorders, mitochondrial disorders, neurological disorders, inherited cancer disorders, prenatal disorders and other rare genetic disorders. GeneDx also offers whole exome sequencing, next-generation and microarray-based testing. EXHIBITORS 87

90 EXHIBITORS GlaxoSmithKline Booth #336 Ms. Laura Byrne Five Moore Dr Research Triangle Park NC Phone: Website: GlaxoSmithKline is a leading research-based pharmaceutical company with a powerful combination of skills to discover and deliver innovative medicines. We offer a number of program resources to support effective health management strategies and improve patient care. Please visit our exhibit to learn more about our products and resources. GW Pharmaceuticals Booth #133 1 Cavendish Pl London W1G 0QF United Kingdom Phone: sschultz@gwpharm.com Website: Contact: Kelly Simontacchi With 15 years of cannabinoid research experience, GW is the world leader in development of novel cannabinoid prescription medicines to address unmet patient needs across a range of therapeutic areas. Our portfolio includes the world s first plantderived cannabinoid prescription drug, Sativex, as well as Epidiolex, currently in development for treatment of Dravet and Lennox-Gastaut syndromes. IEEG.org Booth #17 Room 301 Hayden Hall, 240 S. 33rd St Philadelphia PA Phone: wilkinsc@seas.upenn.edu Website: eeg.org Contact: Carolyn Wilkinson IEEG.org: A Scientific Platform for collaborative science. The International Epilepsy Electrophysiology Portal is a collaborative initiative funded by the NIH/NINDS. This initiative seeks to advance research towards the understanding of epilepsy by providing a platform for sharing data, tools and expertise between researchers. ( NIH Grant #1 U24 NS ) International Epilepsy Congress Booth #234 7 Priory Office Park, Stillorgan Rd Co. Dublin 18 Ireland Phone: Fax: Website: Contact: Mr. Fergus Egan The ILAE is the world's preeminent association of physicians and other health professionals working towards a world where no person s life is limited by epilepsy. The IBE 88 exists to improve the quality of life of people with epilepsy and their families and carers through national epilepsy organizations around the world. INSYS Therapeutics Booth # S Spectrum #100 Chandler AZ Phone: amarzahl@insysrx.com Website: Contact: Anna Marzahl INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules, including its proprietary sublingual spray technology, to help improve patient quality of life. Focused on pharmaceutical cannabinoids development, the company is evaluating its pharmaceutical cannabidiol (CBD) for epilepsy treatment. Jack Pribaz Foundation, The Booth #332 PO Box 813 Wheaton IL Phone: angelacherry86@gmail.com Website: Contact: Angela Cherry The Jack Pribaz Foundation is a 501(c)(3) charity established in Illinois in Named for a boy diagnosed with one of the first known cases of KCNQ2 epileptic encephalopathy in North America, its mission is to support research for this condition by raising funds and awareness. To learn more visit and. John Libbey EUROTEXT Booth # Avenue de la Republique Montrouge France Phone: Fax: gilles.cahn@jle.com Website: Contact: Mr. Gilles Cahn For decades, JOHN LIBBEY EUROTEXT has been THE Publisher of both worldrenowned specialists and new authors in Epilepsy. Through Epileptic Disorders, the Educational Journal of the ILAE, and moreover through our huge book series, we provide first-class knowledge in the field of Epilepsy. Visit The Real Forum for The Worldwide Epilepsy Community. LGS (Lennox-Gastaut Syndrome) Foundation Booth # Lexington Ave Ste 216 New York NY Phone: christina@lgsfoundation.org Website: Contact: Ms. Christina San Inocencio The LGS Foundation is a non-profit organization dedicated to providing information about Lennox-Gastaut Syndrome while raising funds for research, programs and services for individuals living with LGS, and their families. Lifelines Neurodiagnostic Systems, Inc. Booth # Edwardsville Rd Ste A Troy IL Phone: Fax: sales@lifelinesneuro.com Website: Cloud-based technology is the next step in the evolution of EEG, and LifeLines Neurodiagnostic Systems is leading the industry with innovative, new products. ieeg Cloud is a complete, home video solution. Record and upload the EEG/video data to the Cloud for review over the Internet in nearreal time. We maintain servers with our hosted solution. Stop by booth #921 to see how EEG is evolving! Lundbeck Booth #405, 511 Four Parkway North Deerfield IL Phone: Fax: lerr@lundbeck.com Website: Contact: Ms. Lisa Berry Headquartered in Deerfield, Illinois, with a portfolio specialty central nervous system (CNS) therapies and a robust pipeline of promising CNS compounds, Lundbeck is committed to providing innovative therapies that fulfill unmet medical needs of people with CNS disorders, including rare diseases, for which few, if any, effective treatments are available. Mallinckrodt Pharmaceuticals Booth #217, Research Rd Hayward CA Phone: Fax: jt.thomas@mallinckrodt.com Website: Contact: J.T. Thomas Mallinckrodt is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and a Global Medical Imaging segment.

91 EXHIBITORS Medical Neurogenetics, LLC Booth # Glenridge Dr NE Atlanta GA Phone: Fax: Website: Contact: Juliann Kowalski MNG provides expert diagnostics through clinical services, biochemical testing and Next Generation Sequencing. Our panels are the most cost effective and comprehensive available, particularly for cellular energetics, muscular dystrophies, and epilepsy. A major focus is to provide rapid sequencing /metabolic diagnostics. Now available is an Anticonvulsant-Resistant Epilepsy Rapid Evaluation Kit. MediKidz Booth # West 46th St New York City NY Phone: ryanmulcock@medikidz.com Website: Contact: Ryan Mulcock Medikidz is an exciting initiative in children s health education, which aims to provide accurate and relevant medical information for young people. Medikidz believes that every child deserves access to medical information they can understand. We are creating a global community of young people that are informed, empowered and health-aware. Medtech Surgical Booth # Warren St - Ste 306 Newark NJ Phone: Fax: e.caille@medtechsurgical.com Website: Contact: Mr. Eric Caille ROSA is a FDA approved Neurosurgery robot to offer a touchless Laser Registration that has been in use for several years in leading Epilepsy programs in North America and abroad. With over 1600 procedures to date ROSA is on the forefront of SEEG Invasive monitoring. We offer a complete program including training, case observations, consultation and innovative webinars and referral programs. Medtronic Booth # El Rio St Houston TX Phone: Fax: amarquette@visualaseinc.com Website: Contact: Mr. Andre Marquette The Visualase Thermal Therapy System is an MRI-guided, minimally invasive laser ablation system which allows for continuous monitoring of an ablation in real-time. The system is FDA-cleared for the ablation of soft tissue, including for use in neurosurgical procedures. More than 45 U.S. centers have performed more than 900 neurosurgical cases. Moberg Research Booth # S Maple Way Ambler PA Phone: Fax: kfitzgerald@moberg.com Website: Contact: Ms. Kathleen Fitzgerald The Moberg CNS Monitor continuously records EEG and processed EEG trends, time-synchronized with other physiology. Multimodal monitoring with integrated video, EEG trends and physiology helps you evaluate patients' neurological statuses. View correlations between EEG and parameters from other devices including vital signs, ICP, brain oxygen, cerebral blood flow, and more. Monteris Medical Booth # th Ave N - Ste 200 Plymouth MN Phone: Fax: marketing@monteris.com Website: Contact: Ms. Lisa Bichsel Monteris Medical manufactures minimallyinvasive devices for MR-guided neurosurgery including: The NeuroBlate System for precise controlled laser ablation therapy of epilepsy and brain lesion targets; AxiiiS Stereotactic Miniframe skull-mounted platform for imageguided trajectory alignment; AtamA System, an MR-compatible transport and head stabilization system. Multi Channel Systems Booth # Marine St Farmingdale NY Phone: Fax: margaret@alascience.com Website: Contact: Ms. Margaret Badon Multi Channel Systems develop precision scientific measuring instrumentation & equipment for research groups at universities & the pharmaceutical industry, in the field of electrophysiology. We provide solutions for extracellular recordings with microelectrode arrays in vitro & in vivo with the MEA-System & the ME-System as well as for electrical stimulation with the STG series. National Association of Epilepsy Centers Booth # Maryland Ave SW - Ste 835W Washington DC Phone: jgray@dc-crd.com Website: Contact: Ms. Johanna Gray The National Association of Epilepsy Centers is a non-profit 501(c)(6) trade association with a membership of more than 210 specialized epilepsy centers in the United States. With the goal of no seizures and no side effects, NAEC strives to make high quality healthcare available to and affordable for epilepsy patients across the country. National Institute of Neurological Disorders & Stroke (NINDS) Booth # Center Dr - Bldg 31 - Rm 8A07 Bethesda MD Phone: Fax: frazinn@ninds.nih.gov Website: Contact: Ms. Natalie Frazin The National Institute of Neurological Disorders and Stroke (NINDS) supports basic, translational, and patient-oriented research on epilepsy prevention, diagnosis and treatment, including mechanisms underlying seizures and epileptogenesis, gene discovery and targeted therapeutics, epidemiology, psychosocial and behavioral consequences, and development of new therapies. Free patient information. Natus Neurology Incorporated Booth # Pleasant View Road Middleton WI Phone: Fax: madison.info@natus.com Website: Neuralynx, Inc Booth # Commercial Dr Bozeman MT Phone: Fax: sales@neuralynx.com Website: Contact: Ms. Kathy Walsh Neuralynx ATLAS systems record the entire range of human electrophysiology from surface EEG to single units via micro-wires. Features include DC capability, flexible referencing, and 40 KHz acquisition across all channels. ATLAS provides complete integration with Nihon Kohden EEG systems for a seamless clinical workflow. This functionality makes ATLAS the logical choice for clinical research. Neurology Reviews Booth #101 7 Century Dr - Ste 302 Parsippany NJ Phone: Fax: lkalish@frontlinemedcom.com Website: Contact: Ms. Lynne Kalish EXHIBITORS 89

92 EXHIBITORS NEUROLOGY REVIEWS is a clinical news publication with articles and timely department features that keep neurologists, primary care physicians, and other healthcare professionals informed of the latest news affecting their practice. NEUROLOGY REVIEWS covers major medical conferences and monitors the peer review literature to report the latest research findings. NeuroPace, Inc. Booth # N. Bernardo Ave Mountain View CA Phone: Fax: info@neuropace.com Website: Contact: Ms. Kathy Miller NeuroPace, Inc. develops and produces medical device solutions for the treatment of neurological disorders. NeuroPace, Inc. has FDA approval for the RNS System, the world s first and only neurostimulator that provides targeted, responsive therapy for patients with medically refractory epilepsy. NeuroQuest LLC Booth #834 S75 W17317 Janesville Rd Muskego WI Phone: Fax: mgersonde@neuroquestllc.com Website: Contact: Ms. Mindy Gersonde There's no place like home to have your EEG(SM), especially since we make house calls. NeuroQuest LLC is the premiere provider of extended ambulatory video EEGs. Our technologists travel into your patient's home, a clinic, office or institution to meet the goal of providing the highest quality, most convenient, cost-effective EEGs. Neurotech Booth # Watertown Plank Rd Ste 2 Elm Grove WI Phone: vwolfe@neurotecheeg.com Website: Contact: Vickie Wolfe Neurotech EEG Telemedicine In Home Tests, 24/7 Remote Monitoring Neurotech provides 24+ hour EEG tests to diagnose seizures. With prompt scheduling, technologists hookup patients in their homes. R EEG T remotely monitors patients continuously, any problems resolved by technologist returning to patient if necessary; ensuring quality test results. Physicians have live online access to data. Nexstim Booth # Union Hill Rd Ste 5B Alpharetta GA Phone: Website: Contact: Sydney Bridger Nexstim s Navigated Brain Stimulation (NBS) System integrates TMS, EMG, & MRI guided navigation to noninvasively map the motor cortex with the accuracy of DCS. Nexstim holds FDA clearances for (NBS) Pre- Procedural Planning and (NexSpeech) for Mapping Language Function. Future FDA applications: Stroke Rehabilitation*, Depression, and TBI. *currently in clinical trials. Nihon Kohden America, Inc. Booth # Barranca Pkwy Irvine CA Phone: Fax: jeannie_callahan@nkusa.com Website: Contact: Ms. Jeannie Callahan For over 60 years Nihon Kohden has been the trusted Neurology solution for Epilepsy Monitoring, Electroencephalography, EEG & PSG Wireless & Ambulatory Recording, Polysomnography, Out of Center Sleep Testing/PSG, Electromyography, Evoked Potentials, Intra-operative and ceeg ICU monitoring. Serving the Best Minds in Neurology for Over Sixty Years. Novartis Pharmaceuticals Booth #137 One Health Plaza East Hanover NJ Phone: Website: Contact: Marianne LaRosa Novartis Oncology has emerged as a global leader in oncology through targeted research and open partnership in the pursuit of new therapies capable of transforming outcomes for people with cancer. Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways. Optima Neuroscience, Inc. Booth # Research Circle Alachua FL Phone: Fax: rrojas@tdt.com Website: Optima Neuroscience is a medical device company developing innovative technologies for the diagnosis and treatment of neurological disorders. Optima's initial product lines feature neurological status monitoring technologies designed to directly address these needs. Oxford University Press Booth # Madison Ave New York NY Phone: Fax: meagan.burnett@oup.com Website: Contact: Ms. Meagan Burnett PCDH19 Alliance Booth #7 6 Wisteria Ct Novato CA Phone: julie@pcdh19info.org Website: Contact: Ms. Julie Walters The PCDH19 Alliance focuses on raising and directing funds to scientific research with the goal of finding better, more effective treatments and, ultimately, a cure; providing information and support to affected families; and assisting the efforts of the medical community, so that no family suffers without a diagnosis and the most appropriate medical treatment. Persyst Development Corporation Booth # High Bluff Dr - Ste 213 San Diego CA Phone: Fax: sales@persyst.com Website: For more than twenty years Persyst has produced the most trusted and innovative EEG analysis products. Today, Persyst is the world s leading supplier of artifact reduction, seizure detection, spike detection, and quantitative analysis software to every leading EEG manufacturer for continuous EEG monitoring, LTM and ambulatory EEG. Physicians Insurance Booth # Second Ave Ste 2700 Seattle WA Phone: Fax: Liz@phyins.com Website: Contact: Catherine Kunkel Physicians Insurance A Mutual Company is the largest medical professional liability insurance company in the Northwest, with 7,000 members in Oregon, Washington, Idaho, and Wyoming. Owned and operated by its insured physicians and clinics, Physicians Insurance offers broad protection at a reasonable cost, focusing on patient safety and claims management. 90

93 EXHIBITORS Pinnacle Technology, Inc. Booth # Oregon St Lawrence KS Phone: Fax: Website: Contact: Ms. Linda Lane Pinnacle provides preclinical research tools. New this year is optogenetics technology integrated into our seizure monitoring systems. Biosensors can be added to the core EEG/EMG units to measure neurotransmitters along with seizure activity. Our analysis software finds, identifies, marks and analyzes seizure events. Synchronized video and precision timing can be added to any system. PMT Corporation Booth # Park Rd Chanhassen MN Phone: Fax: Website: Contact: Ms. Amanda Bammert PMT Corporation is the premier supplier of an extensive line of neurosurgical products, offering Cortac, cortical surface electrodes, Depthalon, depth electrodes and seeg depth electrodes for epilepsy monitoring and microsurgical instruments. PMT also offers high-end neck braces, including halo systems and orthotic vests for cervical, thoracic and lumbar spinal immobilization. PreventionGenetics Booth # South Business Park Ave Marshfield WI Phone: Website: Contact: Danielle Krohn PreventionGenetics is a leader in providing comprehensive clinical DNA testing offering NextGen Sequencing, Sanger sequencing and deletion/duplication testing via array CGH for over 1000 genes. Our highly experienced team of geneticists provide fast turnaround times, outstanding personalized service, and the highest quality testing at the lowest prices possible. We are CLIA/CAP accredited. Rhythmlink International, LLC Booth # First St S Columbia SC Phone: Fax: gbutler@rhythmlink.com Website: Contact: Mr. Garrett Butler Rhythmlink International is a medical device manufacturing company specializing in devices that help connect patients to machines to record or elicit physiologic information. Rhythmlink offers an array of monitoring devices including the first and only FDA cleared disposable MR Conditional EEG products on the market. Ring14 USA Outreach Booth # Wood Dr. Midland TX Phone: yssa@ring14usa.org Website: Contact: Yssa DeWoody Ripple LLC Booth # S 1100 E Salt Lake City UT Phone: Fax: mitch@rppl.com Website: Contact: Mr. Mitch Frankel Ripple provides high performance electrophysiology data acquisition systems for neuromuscular recording and stimulation. Our systems are compact, portable, and heavily optimized for real-time, closed-loop control applications with up to 512 channels of EMG, EEG and microelectrode data. Our software is cross platform, and can be run on Windows, Mac OS X, and Linux. Rogue Research Inc. Booth # St-Laurent Ste 206 Montreal QC H2W 1Z5 Canada Phone: Fax: diane@rogue-research.com Website: Contact: Mrs. Diane Gariepy Rogue Research develops the Brainsight family of neuronavigation products, including Brainsight TMS, the first and most popular neuronavigation system designed specifically for TMS. Brainsight NIRS is a unique fnirs system designed specifically for multimodality applications, allowing fnirs acquisition during TMS and simultaneous fnirs acquisition along with EEG, fmri or MEG. RosmanSearch, Inc. Booth # Pinetree Rd Ste 250 Pepper Pike OH Phone: Fax: bdery@rosmansearch.com Website: Contact: Mrs. Beth Dery RosmanSearch is a dual-specialty, truly expert, high integrity neurosurgical and neurology recruiting service you can trust. We specialize exclusively in neurosciences permanent placement, and our recruitment methodology is data driven and unique in the industry. SeizureTracker.com Booth #21 PO Box Alexandria VA Phone: Fax: rob@seizuretracker.com Website: Contact: Mr. Robert Moss Seizure Tracker provides free tools to help patients and doctors better understand seizure activity and surrounding treatments. The site provides patients with resources to log their seizures along with medication, diet, VNS settings and much more. Reports generated on SeizureTracker.com include graphs that illustrate trending in treatment efficacy and can be easily shared with care providers. Smart Monitor Corp. Booth # San Ignacio Ave #112 San Jose CA Phone: Fax: sheri.becker@smart-monitor.com Website: Contact: Ms. Sheri Becker Smart Monitor provides monitoring solutions for people with chronic health conditions. Founded in 2009 and headquartered in San Jose, CA, Smart Monitor fuses together sensor, mobile and cloud technologies with big-data analytics in a seamless environment. Our patent protected solutions foster autonomy and enhance safety,while offering significant peace-of mind to their families and care providers. SUDEP Aware Booth # Danforth Ave Ste 350 Toronto ON M4K 1N2 Canada Phone: tcjeffs@gmail.com Website: Contact: Ms. Tamzin Jeffs SUDEP Aware is a not-for-profit organization that has worked since 2007 to bring more awareness and better understanding to Sudden Unexpected Death in EPilepsy (SUDEP). It provides support to families and researchers through its co-founder partnership between Dr Elizabeth Donner (Pediatric Neurologist at Sick Kids Hospital, Toronto) & Tamzin Jeffs (who has epilepsy and lost her sister to SUDEP). Sunovion Pharmaceuticals Inc. Booth # Waterford Dr Marlborough MA Phone: Fax: susan.mahoney@sunovion.com Website: Contact: Ms. Susan Mahoney EXHIBITORS 91

94 EXHIBITORS Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the Psychiatry, Neurology and Respiratory disease areas and improve the lives of patients and their families. Sunovion is a subsidiary of Sumitomo Dianippon Pharma Co., Ltd. Supernus Pharmaceuticals, Inc. Booth # E Gude Dr Rockville MD Phone: tconner@supernus.com Website: Contact: Mr. Tilton Conner Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of CNS diseases. The company has two marketed products for epilepsy, Oxtellar XR (oxcarbazepine) extendedrelease tablets and Trokendi XR (topiramate) extended-release capsules. Texas Children s Hospital Booth # S Braeswood Ste 6226 Houston TX Phone: Fax: kcwilkin@texaschildrens.org Website: Contact: Ms. Karen Wilkinson The Neuroscience Center at Texas Children s Hospital, located in Houston, Texas is committed to creating a healthier future for children and women by leading in patient care, education and research. Utilizing Neurology, Neurosurgery and the Jan and Dan Duncan Neurological Research Institute, we are able to identify, monitor and surgically correct the full continuum of neurological conditions. Transgenomic, Inc. Booth # Emmet St Omaha NE Phone: Fax: sstremick@transgenomic.com Website: Contact: Mr. Scott Stremick Transgenomic, Inc. specializes in genetic testing for cardiology (FAMILION), neurology, mitochondrial disorders and oncology. Transgenomic develops assays and offers testing with the goal to overall improve medical diagnosis and outcomes for patients. 92 Triangle BioSystems, Inc. Booth # Page Rd Ste 108 Durham NC Phone: Fax: jmorizio@trianglebiosystems.com Website: Contact: Mr. James Morizio Miniaturized stimulation and recording solutions for rodent and other animal models. Wireless Stim headstage (2-16ch). Recording headstages for single unit, EEG and other signals: tethered, multiplexed or signature wireless headstages (5 128Ch). Software: Neuroware acquisition, Optimap video tracking, StimWare. Custom electrophysiology engineering solutions. Tuberous Sclerosis Alliance Booth # Roeder Rd Ste 750 Silver Spring MD Phone: Fax: info@tsalliance.org Website: Contact: Ms. Katie Smith Founded in 1974, the TS Alliance is the only national voluntary health agency dedicated to finding a cure for TSC, while improving the lives of those affected. TSC is a genetic disorder characterized by seizures and tumor growth in vital organs such as the brain, heart, kidneys, lungs and skin. UCB, Inc. Booth #135, Lake Park Dr Smyrna GA Phone: Fax: dave.tappan@ucb.com Website: Contact: Mr. Dave Tappan At UCB, we have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe immunological diseases and central nervous system disorders. With 8,500 employees in 40 countries, we invest more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. UCSF Medical Center Booth # Geary Blvd Ste 301 San Francisco CA Phone: Cheryl.Hardin@ucsfmedctr.org Website: jobs.ucsfmedicalcenter.org Contact: Cheryl Hardin If you are looking to take your career in the END field to the next level then UCSF Medical Center Neurodiagnostics Program is for you! UCSF has one of the largest, most comprehensive epilepsy surgery programs in the western United States. Upsher-Smith Laboratories, Inc Booth #625, Evenstad Dr Maple Grove MN Phone: Fax: becky.bouley@upsher-smith.com Website: Contact: Ms. Becky Bouley Upsher-Smith Laboratories, Inc., founded in 1919, is a growing pharmaceutical company dedicated to its mission of Advancing Pharmacotherapy. Improving Life. With capabilities ranging from early-stage research to delivering on-market products, Upsher- Smith is committed to developing quality products that enable people to live life to its greatest potential. Vitaflo USA Booth # Montgomery St Alexandria VA Phone: katrina.bellan@vitaflousa.com Website: Contact: Ms. Katrina Bellan Vitaflo is at the forefront of developing innovative specialized medical foods for Metabolic Disorders, Nutrition Support and other areas of disease specific nutrition. Our aim is to create nutritional products that combine the best of cutting edge research with the lifestyle demands of modern living, ensuring the most acceptable products are available for the patient. Wiley Booth # River Street Hoboken NJ Phone: Fax: info@wiley.com Website: Wiley is the leading society publisher. We publish on behalf of more societies and membership associations than anybody else, and offer libraries and individuals 1,250 online journals, thousands of books and e-books, reviews, reference works, databases, and more. For more information, or our online resource: onlinelibrary.wiley.com. Wolters Kluwer Health Booth #400 Two Commerce Sq 2001 Market St Philadelphia PA Phone: Fax: customerservice@wolterskluwer.com Website: Contact: Ms. Joey-Rose Jester Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Clinicians rely on Wolters Kluwer Health s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice.

95 ABSTRACT AUTHOR INDEX A Aaberg, K Abbott, D Abdel-Latief, O AbdeleRahman, K Abdulkadir, Y Abel, T.J Abela, E Abend, N , 1.182, B.06 Abibullaev, B Abisogun, A Abosch, A Abou-Khalil, B , 1.280, 1.321, 1.327, 1.338, 2.117, 2.242, Abramovici, S Abramson, E.L Abtahi, M Abu Abthan, M Abubakr, A Acevedo, K Aceves, J Ackley, M , Acton, E , Adams, E , 2.021, Adeleye, A Adhami, S Adjouadi, M Adkins, A Afawi, Z Afra, P Agadi, S , Agan, K Agarwal, M Agarwal, N , Agarwal, R Agee, B , Agha, C Agha-Khani, Y Aghakhani, Y , 2.067, 2.150, 3.139, Agostini, M , 2.189, 2.193, Agostini, S Agrawal, S Aguado Valcárcel, M Ahishali, B Ahmadi, L Ahmed, I Ahmed, O.J Ajetunmobi, O Akasaka, N Akdag, G Akiyama, M Akiyama, T Akman, C Akman, C.I Al Ghamdi, S Al Jarrah, S.A Al Matrooshi, N.O Al matrooshi, N.O Al-Baradie, R.S Alagapan, S Alam, J Alareddy, A Albert, J Alberts, G Aldenkamp, A Alegre, M Alencar, C.N Alessi, R , 2.260, Alexandre, F.P Alexandre, V Alexopoulos, A , 1.144, 1.149, 1.240, 2.249, Alhadid, K Alhashem, A Alhusaini, S Ali, A Ali, I , Ali, N , Ali, W Alio Saenz, A , Alkawadri, R Allard, L Allen, A Allen, B.B Allen, V Allendorfer, J , 1.257, B.09 Almane, D Almualim, M Almutairi, F Alonso-Vanegas, M , 2.334, Alqadi, K Alsaadi, T Alshafai, L Althaus, A.L Altura, C Alvarez, V , Aly, R Amador, A Amaro, P Amina, S Amiri, M Amrom, D , An, D An, S , A.05 Anastassopoulos, K.P , Andermann, E , 1.317, 1.319, Andermann, F , Anders, B , 1.308, 2.280, 2.281, Anderson, A , 3.048, 3.049, 3.050, Anderson, C Anderson, C.T. A.08 Anderson, M Anderson, W , 1.061, Anderson, W.S Ando, N , Ando, T Andrade, D , Andrade, E Andrade, J.Q Andreas, J , Andrews, J Andrews, M Andriola, M , 1.142, Ang, L Anghelina, E Anschel, D Antony, A Aoki, M Appavu, B Appleton, R Aracri, P Arai, H , 1.363, 1.370, 2.132, Arain, A , 2.117, Arain, F Arakawa, Y , Araujo, P Archer, J , Ardini, M , Arican, N Arita, K , Arkilo, D Armbruster, M Armstrong, C. C.03 Arndt, D , A.09 Arnedo, V Arnett, A , Arnold, S.T Arrigoni, E Arruda, F.J , Arya, R , B.06 Arzimanoglou, A , Asadi-Pooya, A Asano, E , 2.345, 3.062, Ashby-Lumsden, A Asratyan, S Assaad, B , Ates, N Atherton, D Athing, U Atsumi, S Auerbach, D.S Auguste, K.I Aung, T , Aungaroon, G Auvin, S , 1.056, Avallone, J Avedian, L Avoli, M , 3.121, Ayasoufi, K Azar, N , 1.327, 2.160, Azarion, A Azuma, J Azuma, Y , 1.235, Azzam, R , B Baba, H , 1.361, Baba, K Baba, S , 1.145, 2.353, Babiarz, K Baboyan, V Babtain, F Bachman, E , Backofen-Wehrhahn, B Bacskai, B , Badesch, B Bagliella, E Bagnall, R.D Bahlo, M Bai, X. B.01 Bailey, L , Bailey, M Bain, S. C.07 Bainbridge, J Bakaki, P , Baker, D Baker, E Baker, M Baker, S Bakken, I Bal, C Balabanov, A , Balaguera, P Baldeweg, T Baldin, E Balena, T , Balestri, M Ball, T Ballaban-Gil, K Bamps, Y , 3.078, 3.085, Bandt, S Bandyopadhyay, S Bang, H Banks, G Bar Yossef, R , Baraban, S. C.05 Baram, T , Barba, C Barber, A Barber, J Barborica, A , Barbosa-Nunez, C Barcia, G Barisic, N , Barker-Haliski, M Barkley, G.L , 2.212, Barnard, M.E Barnes, D Barnett, J. B.07 Barnett, P , Barrett, K , Barrios, E Barritt, S.E Barth, D , Bartha, R , Bartley, M.L Bartolomei, F , 2.226, Basha, M , Baslet, G Bastar, J Basu, I Basu, R. B.06 Bateman, L , Bates, J Bathena, S Battaglia, G Baudry, M Bauer, G Baulac, M Baumer, F Baumgartner, J , 2.014, 2.248, 2.253, 2.255, 2.348, 2.364, Bautista, J Baxter, R Baykan, B , Baykan, B Baykara, Y Bayly, M.A Baysal Kirac, L Bazil, C , ABSTRACT AUTHOR INDEX 93

96 ABSTRACT AUTHOR INDEX 94 Bazzigaluppi, P , Beal, J.C Beatty, C Beaulieu, C , 3.260, Bebek, N , 2.183, Becchetti, A Bechstedt, S Becker, D Beers, C Begley, C , 2.047, Behr, C , Beimer, N.J Belfort, G , Bell, A.J Bellas, P Bello, L , 1.142, Bello-Espinosa, L , Belousova, E Beltramini, G.C , Ben Hur, T , Ben Salem, Z Ben-Menachem, E Benbadis, S , 1.315, 1.317, 1.322, 1.340, 2.360, 2.361, Bendrups, N Benedik, M Beniczky, S Benifla, M Benites, D Benke, T Bennett, M Bennett, O Benninger, F Bensalem-Owen, M , Bentz, J Berberi, N Berdichevsky, Y Berg, A , 1.206, 2.035, A.01, A.02 Berg, K , Berg, M , 2.285, 2.286, 2.287, Berg, R Bergey, G , 1.216, 2.209, 3.189, Bergin, A , 3.325, 3.326, Bergo, F , Berkeley, J Berkovic, S , 3.088, 3.089, 3.092, 3.095, Berl, M , 3.268, 3.272, Bermudez-Hernandez, K Bernard, C Bernardo,, D Bernasconi, A , 1.244, B.04 Bernasconi, N , 1.244, B.04 Bernhardt, B , 1.244, B.04 Berquin, P , Berrios-Siervo, G Bertram, E.H Bertti, P Besag, F Besio, W Bessemer, R.A Betting, L Betts, K Bevot, A Bhatia, H Bhatia, P Bickel, S , 2.246, 3.177, Bienes, G Bilir, E Binder, D , Bingaman, W , 1.093, 1.099, 1.240, 1.347, 1.362, Biraben, A , Birk, N Birnbaum, A , Birney, K.A Bishara, A Bishop, L Biton, V , Blatt, I , 1.308, 2.280, 2.281, 3.090, Bleasel, A Blezin, F Block, S.C Blum, D , 1.287, 1.312, 1.314, 1.315, 1.316, 1.317, 1.318, 1.319, 1.320, 1.321, 1.322, 1.323, 1.342, 2.278, 2.290, Blumberg, J Blumcke, I Blume, H Blumenfeld, H , 1.062, 1.076, 1.164, A.02, B.01, Blumenfeld, J Blumenthal, H Bluvstein, J , Boada, R Boals, A Boelman, C , Bogaarts, G Boggs, J , Bolen, R Boles, R Bolger, P , 2.285, 2.286, Bollu, V , Bolton, J Bonanni, P Bond, T.C , Bonfert, M Bongardt, S Bonilha, L , 2.004, Bonito, J , Bonno, D.M Boon, P , 1.067, 3.028, C.08 Bordey, A Borges, A.D Borggraefe, I Borghs, S , 2.320, 3.295, Bork, S.J Borlot, F , Borzello, M Bosler Walton, C Boudreau, E , Bouthillier, A , 3.274, Bowden, S.C Bower, M Bower Baca, C Bowman, C Bowyer, S , Boychuk, J Boyd, A Boyd, J Boyer, K , Boyle, M Bozarth, X Bozorg, A , Braesch, C.T Bragin, A Bramhall, M Brand, E , A.08 Brandt, C , Braun, C.N Brazdil, M Brennan, G.P Brenton, J.N Brenton, N. B.06 Brewster, A , 3.049, Brewster, R Brickel, N Briggs, D , Brima, T Brinkmann, B , 2.156, Brittain, S.T , 1.343, 2.329, Britton, J , 3.158, B.05 Brock, M , 3.292, Brodie, M , 1.334, 1.335, Brodtkorb, E Brooks, B Brooks-Kayal, A , 3.003, 3.011, Brosch, M Brouhard, G Brown, E.C Brown, M Brown, S , Brunner, P , 2.255, Brusco, S Bryant, T Bubolz, B Bubrick, E Buchanan, G , 1.164, 3.030, Buchanan, R Buchfelder, M , Buchhalter, J , 3.057, 3.137, 3.172, Buchsbaum, R , 2.312, Buchtel, H Buckley, A Buckley, R Buckley, S Buckmaster, P Budech, C.B Buelow, J , Buentjen, L , 3.058, Buerki, S.E Bui, E Bujarski, K , 1.286, 2.042, Bukovskaya, Y Bulacio, J , Bulloch, A.G , Bunker, M.T Bunnenberg, A Burakgazi-Dalkilic, E. A.08 Burattini, J.A , Burch, E.A Burdette, D Burgess, G.G Burgess, R , 1.144, 1.149, 1.240, 2.073, Burgos, J Burianová, H Burkholder, D , Burn, S Burneo, J.G , 2.032, 2.054, 2.313, 3.265, Burns, M Burns, S Buroker, J Busatto, G Busch, R.M , 1.099, Butler, C Byars, A.W Byerman, B Byrne, R.W Byrnes, W , 3.295, 3.296, 3.298, Byun, J , Bzymek, K C Cabello, D Cabo López, I Caboclo, L , 3.369, Cabrera Kang, C.M , Cabrerizo, M Caetano, E.V , Cai, P. A.08 Cakmak, M Caller, T , 1.286, Calvert, S Calzado Rivas, E Cameron, D Cameron, J Camfield, C , 2.223, A.04 Camfield, P , A.04 Campbell, M Campos, B.M Campos Blance, D , Cances, C Candy, S.A Canevini, M , Canoll, P.D Caplan, R , 1.252, 1.254, 2.018, Cappelletti, S Cara, L Carbone, L Carlen, P , 1.016, Carlsen, J , Carlson, C Carlson, G , Carlson, H Carmona, H Carpenter, J , B.06 Carrel, A.J Carrete Jr., H Carreño, M , CarrilloCarrillo, R Carruthers, N.J Carson, R.E Carvalho, K Carvalho, K Carver, C Carvill, G.L , 3.087, Cascino, G , 2.337, 2.339, 3.158

97 ABSTRACT AUTHOR INDEX Cash, S Cash, S.S , Castelnau, P Castillo, A Castillo, E , 2.014, 2.248, 2.253, 2.255, Castillo, R Castro, C Castro, C.X Catterall, W Cavalleri, G Cavaretta, J Cavazos, J Cavitt, J Cawello, W , Caylor, L Ceiki Sakamotob, A Ceja Moreno, H Celegen, K Celegen, M Cendejas, L , Cendes, F , 1.377, 3.259, 3.260, Centeno, R , Cerqueira, P.B , Cerven, S , 1.199, 1.200, Cervenka, M , 3.189, 3.191, 3.318, B.07 Cha, B Chabardes, S , Chabrol, T Chachua, T Chadehumbe, M , Chadwick, E Chae, J , Chagin, K Chan, S Chan, V Chandler, D.S Chandra, S Chang, B.L Chang, B.S Chang, C.W Chang, E Chang, T , Chanlaw, T Chansard, M Chanteux, H Chapa Davila, J Chapman, B Chapman, K , 1.182, 1.326, 1.345, B.06 Charpier, S Chassoux, F Chauvel, P Chavez, G Chavez-Hassan, F Chaytor, N Chea, K Chekhovtsov, I Chemali, Z Chen, B , 2.312, Chen, C Chen, D.K Chen, E Chen, F Chen, H Chen, J.J , Chen, P , 2.014, 2.248, 2.253, 2.255, Chen, S , 2.135, 3.197, Chen, T Chen, W , 1.076, 1.164, A.02 Chen, X Chen, Y Chen, Z Cheng, H , 1.322, 2.290, Cheng, J Chern, C Cheshire, W Chevalier-Riffard, C Chez, M Chiang, S , Chiba, Y Chiesa, V , Chikako, O Child, N.D Chin, M Chin, R , 2.072, 2.223, Chin, R.F Chiti, L Chiyonobu, T Chlon, W Cho, K Cho, S Cho, Y , 1.218, Choe, M. A.09 Choezom, T Choi, H , 2.312, Choi, J Choi, S Choi, Y Chow, E Chrastina, J Chris, F Christensen, J Christian, E Christodoulou, C Christodoulou, J Chu, C , Chu, J Chu, K , Chuang, S Chugani, D.C Chugani, H , 2.167, 2.345, 3.056, Chung, H Chung, J , Chung, J.M Chung, S , 1.316, 1.319, Chung, S.S , 1.199, 1.200, 1.201, 1.307, 1.308, 1.334, 1.335, 1.336, 2.211, 2.280, 2.281, 3.291, 3.292, Chung, W.K , 3.081, Ciechanowski, P Cieza, S Cilio, M , 2.309, Cimbalnik, J , 2.156, Cinar, N Ciricillo, S Ciurea, J , Clark, A.M , 1.308, 2.280, 2.281, Clark, C , Clark, D Clark, M Clark, S Clarke, D.F , 3.070, Claus, R , 1.316, 1.317, 1.323, Claycomb, K , Cleto Dal-Cól, M Clossen, B Coan, A , 3.082, 3.259, 3.260, Cobia, M Cohen, D.L , Cohen, G Cohen, J Cohen, J.W Cohen, M.S Cohen, N , Colciaghi, F Cole, A.J Coleman, M Coley, A.A Collon, K. C.02 Colón-Zimmermann, K Coman, D Comi, A Concha, L Condie, J. B.06 Congedo, B.A Conner, C Connolly, M , 3.096, 3.220, Connors, R Conry, J Constable, T. B.01 Constantinou, J , Conti, V Cook, M , Cooper, E.C , Corallo, K Cordeiro, M Cornett, K Correa, B.J , Corso, J.T Cortes de Oliveira, J Coryell, J Cossette, P , Cossu, M Costa, F.A , Costas, K , 3.326, Costel, J Cothros, N Cotten, J Coulter, D. C.06 Couture, D , 2.337, Couture, R.L Couturier, N Covington, T.M Craddock, R.C Crail Melendez, D Craiu, D Cramer, J.A , Crawford, J Crawford, P Crawley, A Crespel, A Crino, P , Crino, P.B. A.08 Cristofaro, S Crocker, C Crompton, D.E , Crone, N , 1.353, 2.025, Cross, J Crowder Skarpaas, T , Crowley, M.J. B.01 Cruickshank-Quinn, C Cruz, E , 1.142, Cruz Del Angel, Y , 3.003, Cukier, Y , Cukiert, A , 2.343, 2.344, 2.363, 3.350, Cukiert, C.M , 2.363, Cukovic, D Culver, C.B , Cummins, T.R Cunningham, C Cunningham, C.E Curatolo, P Curry, D , 3.353, 3.358, Cushner-Weinstein, S Cusick, M.F Cutmore, C Cutter, G , Czech, T D D Alfonso, S , D Ambrosio, R D Souza, J , 2.332, D Souza, W , 1.232, Da Rold, M Dabbs, K , 3.267, Dabscheck, G Dagam, J Dahlin, M Dalgard, C. A.08 Dalvi, N , Damaj, L. C.01 Damera, S Damiano, J.A Damisah, E Daniels, D Danny, L Danzer, S , Danzer, S.C Das, N Das, S Dauwe, I , C.08 Dave, H , 3.219, 3.225, B.02 Davis, A , Davis, A.M Davis, E.C Davis, G.G Davis, K , 2.135, 3.183, 3.256, Davis, K.A , 3.167, A.08 Davis, R , Dawe, R Dawkins, R ABSTRACT AUTHOR INDEX 95

98 ABSTRACT AUTHOR INDEX Day, B Dayyoub, T Dazzo, E De, G De Backer, M , 3.291, 3.292, 3.294, 3.295, 3.296, 3.297, 3.298, De Benedictis, A de Grauw, A de Grauw, X De Jonghe, P de Kam, M.L De Koninck, Y de la Pena, C.B de Lanerolle, N de Melo-Souza, S.E , de Paula, V.D De Toffol, B de Vincentiis, S , de Vries, P Dean, N. B.06 DeBello, R , DeCoster, C Dedeken, P , 3.293, 3.295, 3.296, del Prete, A Delalande, O Delanty, N Delazer, M Delbeke, J , C.08 Deleo, F Delgado-delaMora, J DeLorenzo, R Demos, M Demuth, D Denny, D , 1.199, 1.200, Deo, A.K Depaulis, A Depienne, C Depondt, C Depositario-Cabacar, D , 2.351, 3.141, 3.355, Derambure, P Dergalust, S Derry, R Descamps, B Deshpande, L Desnous, B , Desrochers, J.A DeStefino, V Detyniecki, K , 2.296, 2.312, 3.136, 3.138, Devinsky, O , 1.133, 1.262, 2.007, 2.033, 2.170, 2.309, 3.057, 3.095, 3.137, 3.303, DeVries, S.P Dewar, S , Dhaher, R , Dhakar, M , Dhamne, S.C Diaz, F , 2.285, 2.286, Diaz, M Diaz-Medina, G Dibbens, L.M DiCaccio, B Dickens, D Dickerson, B Dickstein, L Didato, G Diehl, B Dike, N Dilley, C , Dilley, D Dimova, S , 3.292, Ding, K , 2.189, 2.193, Ding, L Ding, Y.S Dingledine, R Dionisio, A , Divino, V Dixon-Salazar, T Dlugos, D , 3.095, 3.201, Dobesberger, J Dobrinsky, C , Dobrzeniecka, S Dobyns, W , Doesburg, S Doesburg, S.M Doescher, J Doggett, K Doherty, C Doherty, J , Dokgoz, O , Dolce, A Dombkowski, A.A Donahue, D Donatti, A Donner, E , 3.057, 3.137, Donner, E.J Donohue, K.D Donohue, M.M Donos, C Dorland, N Doshi, C , 3.202, Doss, J , Doss, R , 2.026, Doucet, G , Dove, C Drake, J , Drane, D , Drazkowski, J , Drees, C , 3.205, Drouin, N Du, X du Plessis, D Dualibi Ramos Valente, K , Dubeau, F , 1.259, 2.358, 3.161, 3.163, 3.184, Dubey, D Dubroff, J.G Duchowny, M Duckrow, R , 1.156, 1.216, 2.151, Dudek, F , 1.166, 3.038, 3.043, Dudley, R.W , Duempelmann, M , Duffy, F Dufour, S , Dulla, C , Dumpelmann, M Duncan, R Dunn, D Dunn, M Dupuis, N , Durand, D , Durgin, T , 2.297, Dustin, I , 3.065, 3.084, Duveau, V Duwell, E Dworetzky, B , 1.324, 2.213, 2.236, 2.285, 2.286, 2.287, 3.235, Dykstra, H Dzhala, V , E Eb, A Eberle, M Eberly, L.E Ebril, M Eckhardt, K , Edagawa, K Edakawa, K Edmonds, B , 2.255, Egawa, K , Egge, A Eichel, R Eichstaedt, K.E Eid, T , Eidelman, O. A.08 Einarsdottir, A Eisenschenk, S Eksioglu, Y , 3.103, 3.194, 3.357, Ekstein, D , 2.175, 3.063, Ekstrand, J Ekstrom, A El Tahry, R El-Hagrassy, M Elder, E , 2.285, 2.286, Elger, C , 1.316, Eliashiv, D , 2.321, Eliassen, J.C Elledge, D Ellingson, B , 1.245, Elliott, C.A Elmenshawi, I Elmoufti, S Elsayed, M , Emch, T Emerson, R , Emery, E , Enatsu, R Endres, J Engel, J Engel, M Englot, D.J Enoki, H Entz, L Eom, S Eom, T Epi4K/EPGP, C Epstein, J Erdinc, O.O Escalaya, L Escartin, A , Escayg, A , Escoffery, C Esfahanizadeh, A Eskandar, E.N Eslamy, H Espaillat Solano, L.M Espaillat Solano, L.M Espinera, A Espinoza López, D.A Ess, K. Ettinger, A.B Eun, B Euroepinomics-Res, C Evans, C Evans, J Evans, S Evrard, C Eyal, S Eydoux, P F Faber, A Fabo, D Fabris, R , Fain, R , Faingold, C , 1.034, Faizo, N.L Fakhoury, T , Fallil, Z , Fang, L Fant, R.V Farah, J Faria, L Farlow, D.C Farmen, A Farooque, P , A.02 Farrell, K Farwell Gonzalez, K.D Fasano, A Faught, E , 2.219, 3.130, 3.294, Faught, R , Faulkner, M Fauth, C Fayed, N Federico, P , 2.067, 3.139, Feeney, E. B.01 Fehr, K Feldstein, N Felton, E Feng, H Feoli, E Ferastraoaru, V Fergnani, V Ferguson, A Ferguson, L , 1.099, Ferguson, R.J Fernald, B , Fernandes, A Fernandez, A , Fernandez, G Fernandez, L.D Ferrari-Marinho, T , 3.184, Ferrazzano, P Ferreira, J , Ferro, M Ferrrari, L Ferry, J Fertig, E , 1.140, Fesler, J.R Fessler, A

99 ABSTRACT AUTHOR INDEX Feucht, M Feyissa, A.M Ficker, D , 2.286, Fiedler-Kelly, J , 1.314, 1.319, 1.320, Field, S.A , Fiest, K Fiest, K.M Filippi, C Finardi, A Fine, A Finger, L Finn, C Finn, R Finnell, R Fiol, M Fischer, J. A.09 Fisher, E Fisher, J Fisher, R , 3.073, B.07 Fishman, J Fisk, K Fitzsimons, M Flanagan, P Flashman, L Fleming, M , Fletcher, L Fleury, A Flores, J Fonseca, N Ford, L Foreman, B , Foreman, P , Foreman, P.J Forgacs, P.B Forman, S Forman, S.D Foroughi, A , Forsythe, A Fountain, N , Fowles, K Franaszczuk, P Francois, D Francomacaro, S François, C , 1.335, Fraser, R , Fraser, R.T Frasier, C.R. C.02 Frauscher, B , 2.262, 3.161, 3.163, 3.184, Freedman, D Freeman, J.L French, C French, J , 2.007, 2.176, Frey, L , 3.031, 3.205, 3.304, Freyer, C Fried, I Friedman, D , 2.142, 2.170, 2.309, 3.057, 3.137, Friedman, K Friedman, S.D , Frigerio, F Fritz, P , Frndova, H Frohlich, F Frost, M , Frost, Jr., J.D. C.04 Fu, A , 1.199, 1.200, Fuerst, D Fujikawa, M , 2.132, Fujimoto, A Fujinami, R.S Fujita, K Fujita, M Fujita, S Fujiwara, H , Fukasawa, T Fukumizu, M Fuller, P.M Funck, V Fung, E Fung, S.H Furman, M Fusco, L G Gabelia, D Gabr, R.E. B.03 Gabrieli, J.D Gaddam, A Gaddam, S Gadeyne, S. C.08 Gadhoumi, K Gaik-Siew, C Gaillard, W , 2.142, 2.351, 3.141, 3.144, 3.268, 3.272, 3.278, 3.355, 3.364, B.06 Gaitanis, J Galanopoulou, A.S , 1.305, Galimberti, C Gallagher, M Gallentine, W , 2.194, Galloway, G Gama, H , 1.316, 1.317, 1.323, Gandomi, S Gangisetty, O Gano, L.B Gao, J Garces, M Garcia, P Garcia, R Garcia Gracia, C Garcia-Cairasco, N , Garcia-Ramos, C Gardella, E Gardiner, E. C.07 Garg, A , Garg, K Garg, M Garrido, E Garrity, L Garson, A Garzon, E Gaspard, N , 2.151, 3.203, 3.204, Gaston, T Gaston, T.E , Gattaz, W.F Gattone, J.M Gautier, N Gavrilovici, C Gaxiola Valdez, I Gebre, R Gedela, S , 3.331, Gedzelman, E Gelfand, M Geller, E Geng, B Genov, R George, M George, S Gerard, E , Gerin, B Germeyan, S.C , 3.268, Gernert, M , Gerrard, J , Gersner, R , 1.302, Gerstl, L Gey, L Ghani, A , Ghassemi, A Ghatan, S Ghearing, G , 2.157, Gholipour, T Giarratano, M Gibson, K.M Gibson, M Gidal, B , 2.284, 2.285, 2.286, Gidal, B.E Gilbert, T Gilby, K Gill, D Gilliam, F Gilmet, G Gilmore, E , Giordano, M Girard, J , Gireesh, E Girouard, M Giza, C , A.09 Gizewski, E Glaser, C Glass, H.C Glasscock, E Glauser, T , B.06 Glaze, D Glessner, J Glielmi, C Gliske, S Glykys, J Glynn, S , Go, C , 1.172, 1.189, 2.353, Gobbi, G Godard, A Goel, M Gofton, T , Gokyigit, A , 2.183, Golby, A Gold, D Gold, J , Goldberg, E.M. C.06 Goldberg-Stern, H Goldenholz, D , Goldenholz, D.M Goldenstein, L Goldie, J Goldman, A Goldman, L Goldschmidt, Y Goldsmith, J , 3.081, Goldstein, D Goldstein, J , B.06 Goldstein, S Gómez Ramírez, M Gommer, E Goncharova, I Gong, H Gonsalves, C Gonzales, E , Gonzalez, F.L Gonzalez, M Gonzalez-Crespo, S Gonzalez-Martinez, J , 1.063, 1.153, 1.240, 1.347, 1.362, 1.377, Gonzalez-Sepulveda, L González de la Aleja, J Good, L Goodkin, H , B.06 Goodrich, G.S Goodwin, S.W Gordon, C.M Gorelik, D Gospe, S.M Goswami, S , Gotman, J , 1.178, 1.259, 2.358, 3.121, 3.161, 3.163, 3.184, 3.185, Gowda, A Goy, E Goyal, A Gozzo, F Grabenstatter, H.L , Graf, S Graham, A Granbichler, C Grant, A.C , Grant, E Gray, E Gray, M Greenberg, D.A Grefe, A Greiner, H , 1.353, Griffin, N.G Griffiths, C Grigg-Damberger, M Grinspan, Z , 2.055, Groomes, L Groppe, D , 2.246, 3.177, Gross, D , 3.260, Gross, D.W Gross, R , 2.212, 2.256, 2.337, 2.339, Grote, C.L Grouiller, F Grova, C , Gu, B Gu, F Guan, Y Guaranha, M.B Gubernale, M Gudbranson, E , Gudlavalleti, A ABSTRACT AUTHOR INDEX 97

100 ABSTRACT AUTHOR INDEX Guekht, A Guenot, M Guerreiro, C , Guerrini, R Guess, M Gugler, K , Guilfoyle, S , Guilhoto, L.M Guimaraes, M.D Guiraud-Diawara, A , 1.335, Gulsen, G , Gulyaeva, N Gummadavelli, A , Gunasekara, R.C Guo, A Guo, D Guo, J. B.01 Gupta, A , 1.362, Gupta, N Gupta, P , 2.189, 2.193, Gupta, R.K Gupta, V Gupta, Y.K Gurbani, S , 1.254, Gurkoff, G Gurme, M Gurses, C , 1.128, 2.183, Gusev, E Gustafson, M , 2.137, Guttuso, T Guzel, O Guzman, L Gwinn, R H Haas, K , 2.160, 3.203, Hader, W , Haginoya, K Haglund, M Hahn, C , Haider, Z Hajek, M.A Hakami, T Hakimi, A Hakonarson, H , Halford, J.J Hall, A Hall, J , Halliday, W Hallinan, B Halvorsen, M.B , Hamano, S Hamberger, M.J Hamdan, F.F Hameed, M.Q , Hamer, H , Hamid, H Hammond, N Hammond, R , Han, H Han, J Han, R Han, S Hanai, S Hanaya, R , Handler, M , 2.103, Handreck, A Haneef, Z , Hani, A.J , B.06 Hannestad, J Hanson, A , Hanson, M Hanson, R Hanusa, B.H Hanáková, H Haque, O Hara, K , 2.093, Hara, M , 2.093, Harada, Y Harden, C , 2.011, 2.029, 2.092, 2.233, 2.246, 2.256, 2.339, Hardin, K. A.06 Haridas, B Harini, C , 2.196, 3.169, Harkness, W , 2.343, Harnod, T Harrell, E Harrington, C Harrington, J , 2.033, Harris, D Harris, K Harris, R , Hart, S Hartl, E , 3.211, Hartman, A. Harvey, A.S Harvey, D.W Harvey, J , 1.312, 1.319, Harward, S.C Hasbani, D Hasegawa, H Hashizume, A , Hastings, W Hauser, A , Haut, J , Haut, S , Haut, S.R Havens, K , 3.141, 3.355, Hawasli, A.H Hawkins, C Hays, R , 2.189, 2.193, He, B Heath, J Heck, C , 2.212, Hecox, K , Hedlund, J , Hedrick, N.G Heers, M Hegde, M Heier, L.A Heinen, F Heinze, H , 3.058, Heinzen, E , Heischmann, S Heiss, J Helbig, I , 3.090, Helmers, S , 2.339, Helmstaedter, C Hempstead, B.L Hemza, J Henegan, P.L Hennessy, R Henning, O , Henry, B , B.07 Henry, T Heo, K , HEP Investigators 2.173, 2.176, HEP MRI Core Herbillon, V Herekar, A , Herman, J.P Herman, S Hermann, B , 2.004, 2.023, 2.218, 3.267, Hernandez, A Hernandez Ronquillo, L Hernandez Ruiz, A Hernando, K , B.09 Hertzberg, C Hervas Navidad, R Hesdorffer, D , 2.275, 3.057, 3.081, 3.135, 3.137, Heshmati Moghaddam, M Hevner, R Heyer, G.L Heyse, H Hibbard, K Hickey, F Higdon, L Higo, T , 1.370, Hildebrand, M.S Hilkman, D Hill, C , Hines, D Hinn, A Hino-Fukuyo, N Hira, J Hirai, S Hirata, M , Hirata, Y , 1.245, 1.261, 3.255, Hirose, S Hirose, Y Hirsch, E Hirsch, L , 1.135, 1.156, 2.151, 2.296, 2.312, 2.350, 3.136, 3.138, 3.203, 3.204, 3.226, A.02 Hirvonen, J Hitchens, T Hixson, J , Hiyoshi, T Hjalgrim, H Ho, A.W Hoang, K Hoch, D Hochberg, L.R Hocking, J Hoegl, B Hoerth, M Hofer, M Höfler, J Hoffmann, D , Hogan, R , 1.308, 1.376, 2.280, 2.281, Holden, D Holland, K , Hollen, C Holley, A , C.07 Holmes, M.D , 3.187, Holt, R Holtkamp, M , 3.349, A.03 Homa, K.A Honda, R , 1.359, 1.361, 2.225, Hong, J Hong, L Hong, S Hong, S , 1.365, 2.207, B.04 Honig, A Hope, C Hope, O Hori, J.M Horiuchi, K Horn, P , 3.111, Hosain, S.A Hosford, B Hosny, H Hosoyama, H Hou, W Howard, M , C.05 Howard, T Howe-Martin, L , Howell, K Hrachovy, R.A. C.04 Hsieh, C Hsieh, L.S Hsieh, T Hsin, Y , Hsu, D , 2.023, 3.267, Hsu, M , Hsu, S Huang, C , Huang, S Huang, Y , 1.041, 1.253, Hubbard, J.A Huber, P. C.07 Huckins, S Hudgens, S Huiskamp, F Hulette, C Hummelova, Z Hunt, M Hunter, M , Hur, E.E Husain, A , 2.048, Hussain, S.A , 2.355, 3.157, 3.222, Hussein, Z Huynh, J Hwang, D Hwang, E.S Hwang, H , 1.195, Hwang, K , Hwang, S , 2.011, Hwang, Y , 1.195, Hyder, F

101 ABSTRACT AUTHOR INDEX I Iannotti, G Iasemidis, L Iida, K , 2.002, Iijima, K Iimura, Y , 1.370, Ikeda, A , 1.350, Ikeda, H , Ikeda, K.M Ikeda, T Ikegaya, N Ilhan Algin, D Imai, K Inaba, Y Inada, T Inaji, M , 2.093, Inano, R , Inati, S , 1.150, 3.084, Inati, S.K Inbar, D Ince, N Innis, R Inoue, N Inoue, Y , 1.365, 2.357, 3.198, International Pediatric Epilepsy Surgery Panel, T Iragui-Madoz, V Irazoqui, P Iriarte, J Isaacs Lebeau, K Iseki, H Isgüder, R Ishak, G Ishak, G.E , Ishihara, N , 1.235, Ishihara, Y Isnard, H Isnard, J Isojarvi, J , 1.335, Isom, L.L. C.02, Ito, T Ito, Y , 1.235, Itoh, K Itoh, M Ivanisevic, M Iwaki, T Iwasaki, K Iwasaki, M , 2.132, 2.149, 2.154, Iwasaki, T Iwuchukwu, I Iyengar, S.S Iyer, S Izadi, A J Jabo, B Jack, S.M Jackson, D , 2.023, 3.267, Jackson, G , Jackson, G.D Jackson, M , 2.213, 3.235, B.06 Jacobs, J , 1.167, 2.358, Jacobson, M Jaffe, D.B Jähn, J Jain, M , Jain, S Jaisani, Z Jalota, A Jan, M.M Jang, S Janio, E.A Janke, K , Janousek, J Jansen, A Janz, D. A.03 Jasinski, T Javors, M.A Jayabal, V Jayakar, P Jayakar, R Jefferys, J Jehi, L , 1.347, 1.362, 1.377, Jehle, R Jenko, K Jenner, M.R Jensen, F , 3.007, Jensen, J Jenson, K , Jeon, J Jeong, J Jepsen, B Jetté, N , 2.051, 2.067, 2.071, 2.082, Ji, K Jiang, W , 2.285, 2.286, 2.287, 2.330, 3.288, Jiang, X , Jiang, Y Jih, J Jimenez, X.F Jin, K , 2.132, 2.149, 2.154, Jin, X Jirsa, V Joachim, K.C Joaquim, H.P Job, A Jobst, B , 1.209, 1.286, 2.042, Joc, J Joensuu, T Johannessen, S , 2.308, 2.317, Johnson, E.K , Johnson, J.K , Johnson, M Johnston, L.A Johnston, M Jokeit, H Jones, A Jones, D , 1.335, Jones, J , 2.023, 3.267, 3.270, C.09 Jones, K , Jones, M Jones, S.E , Jongeling, A Jongeling, A.C Jongeling, A Joo, E , 1.130, 1.218, Jordan, J Jordan, S Jorgensen, A Josan, V Josephson, C , Joshi, C , 2.035, 3.145, Joshi, R , 3.074, Joshi, S , 2.050, 3.115, Jouny, C , 3.064, 3.189, Jow, A Jozwiak, S Jucker, M Juhasz, C , 2.345, Jun, J , Jung, D Jung, H Jung, K , Jung, S Junger, K , 1.091, 2.229, Junna, M Jurasek, L Jurd, R K Kaczmarek, L.K Kadam, S , Kadipasaoglu, C Kadish, N.E Kadiwala, H Kagawa, K , Kahane, P , 1.348, 2.226, Kahle, K.T Kaiboriboon, K , Kaido, T , 1.365, 2.225, Kaimovsky, I Kakacek, J.R Kakisaka, Y , 2.149, 2.154, Kalamangalam, G , 1.168, 3.375, B.03 Kalayjian, L Kalsanka Pai, A Kalume, F , Kameyama, S Kaminski, R Kamson, D Kanaan, S Kandel, P Kaneko, Y , 2.225, Kang, H , 3.354, Kang, J , Kang, K Kang, S Kankirawatana, P Kanner, A , 2.264, 2.265, Kao, A , Kaplan, L.R Kaplan, P Kaplan, P.W Kapoor, S Kapur, J , 3.115, Kapur, K , 3.235, 3.236, 3.326, B.06 Kapur, R , 2.212, B.08 Karaarslan, U Karavaeva, E , Karkar, K Karkare, S , 2.120, Karsidag, S Kartagiri, M , Karumuri, B Kashambwa, R Kashida, Y Kassab, A Kassai, B Kassiri, J , Kasteleijn-Nolst Trenite, D.G Kato, K , 2.149, 2.154, 3.138, Kato, M , Kattan, M Katus, L Kaufman, B , 3.057, Kaufman, K.R Kaufman, N.D Kaufmann, W Kaushal, R Kavak, K Kawasaki, H Kaya, M Kayani, S Keating, J Keating, R Keator, C , Kebede, T. B.06 Keller, C Kellermann, T Kelley, V , Kellogg, M.A Kelly, D , Kelly, K , Kelly, K.M Kelly, P , 2.048, Kelmann, B.V Kelten, B Kemmotsu, N , Kempapura, M Kendirli, M.T Kennedy, J. A.06 Keough, K.C Kern, L.M Kern, R.T Kerr, M.S Kerr, W.T Kerrick Walker, J , Kervyn, S , Kessler, S Khaddam, O Khalid, E Khalilieh, N Khan, F , 3.219, 3.225, B.02 Khan, I Khan, O Khan, O.I Khawaja, A.M , Khaytin, I Khoo, H , Khurana, D Khusiwilai, K Kidokoro, H , 1.235, 1.243, Kikuchi, T , Kim, B ABSTRACT AUTHOR INDEX

102 ABSTRACT AUTHOR INDEX Kim, C.E Kim, D , 1.204, 1.218, Kim, E , Kim, G , Kim, G.E Kim, H , 1.195, 1.211, 1.212, 1.244, 1.365, 2.164, 2.185, 2.315, 3.112, Kim, J Kim, J , 1.218, 2.164, 2.207, 2.315, 3.112, 3.242, 3.263, Kim, K , 1.119, 1.195, 1.212, Kim, M , 1.218, Kim, R. B.01 Kim, S , 1.218, 1.221, 2.164, 2.220, 2.315, 3.112, Kim, T Kim, W , 2.164, 2.315, 2.362, Kim, Y , 2.164, 2.315, Kim-Tenser, M Kimura, S King, J King-Stephens, D , King-Stevens, D Kini, L Kinoshita, M , Kipervasser, S Kirk, V Kirkpatrick, M Kirmani, B Kirschbaum, A. A.03 Kishi, Y Kishima, H , Kitay, A.Y Kiura, Y Kjærvik, V , Klaas, P , Kleen, J Klehm, J , 1.197, 1.329, 1.345, 2.213, 3.235, 3.246, B.06 Klein, K Klein, P , 2.230, Kleineschay, T Kleinfeld, K Klitgaard, H , Klooster, D Kloosterman, F Kluge, C , Kluger, D Klus, C Knopf, L Knoth, R.L , Knowlton, R.C , Knupp, K , 2.035, 3.209, Ko, D , Ko, T , Kobau, R Kobayashi, A Kobayashi, E Kobayashi, J Kobayashi, K , Kobayashi, M Kobylarz, E , Koehn, M Kogure, S Koh, E Koh, J Koh, S , 1.222, 1.267, 3.024, Kohler, C Kohli, S Kokoszka, M Kolls, B.J Kolodgie, M Komaki, H Kommajosyula, S.P Kondo, T Konikkara, J.J , Kopitzki, K Koppelstaetter, F Korb, P , Korczyn, A Korgaonkar, A.A Korn, M , C.09 Koroma, M Korostenskaja, M , 2.014, 2.248, 2.253, 2.255, Koroukian, S , Korzeniewska, A Koscik, R Kossoff, E , B.07 Kotagal, P Kothare, S Kotloski, R Kotzot, D Kowacs, P Kowski, A , 3.349, A.03 Kozupsky, J Kraemer, D.L Kraemer, G Kramer, M Krause, A , Krauss, G , 1.320, Krebill, R , 2.285, 2.286, Kreiman, G Kreisl, W Krel, R Krishnan, B , 1.144, 1.240, Krishnan, V Kronengold, J.K Kroner, B , Krook-Magnuson, E. C.03 Krueger, A Krug, K Kruithof, A.C Krutoshinskaya, Y Krylov, V , Kuba, R Kubikova, R Kubota, M Kubota, T , Kubota, Y Kubova, H Kucewicz, M.T , Kuchibhotla, K Kuchukhidze, G , Kucuk, M Kucukboyaci, N , Kudela, P Kuhlenbäumer, G Kumada, S Kumada, T Kumar, A , Kumar, D , 2.294, Kumar, R Kumar, S Kumar, U Kumar, V Kunieda, T , Kunnakkat, S.D Kuo, C Kupsky, W Kuratani, J Kurisu, K , Kurlemann, G Kuruba, R , Kutluay, E.E Kuzniecky, R , Kwan, P Kwiatkowski, D Kwon, C Kwon, H Kwon, O , Kwon, R. C.07 L La Briola, F La Vega-Talbott, M Laban-Grant, O , Labiner, D , 2.256, 2.337, Lacaille, J. C.01 Lach, L Lachance, M Lachhwani, D , 1.099, Lackner, P Lacuey Lecumberri, N Ladino, L.D Lado, F , LaFrance, W , LaFrancois, J , Lafrenière, R.G Lagae, L Lagerlund, T Lagrange, A Lai, Y , 3.049, Lam, A.D Lamanna, I Lamar, T Lamartine Sabido Monteiro, M Lamb, N Lambrakis, C Lammers, S Lancaster, R Lancman, M , 1.131, 2.020, Lancman, M.E , 2.020, Landazuri, P. A.07 Landmark, C.J , 2.308, 2.317, Lane, J.B Lang, A.E Lang, N Langer, J Langston, M.L Lantz, G Lanyon, R Laoprasert, P , 2.012, 2.103, LaPalme-Remis, S Lapham, G , Lapointe, V Laroche, S , LaRoche, S.M , Larsen, J Larsson, P LaSarge, C.L Lashley, S Lasley, J.H , Latour, N Lau, C , Laura, W Laurenza, A , 2.276, 2.279, 2.288, 2.289, 2.291, 2.293, 2.294, Laureta, M Lauterbach, T Laux, L , Lavingia, J Lawson, J Laxton, A , Le, J.M Le, J.T. C.04 Le, N Le, S Leaffer, E Leanage, G Lebedeva, A Leclercq, K Lee, B , Lee, C Lee, C.H Lee, C.L. C.04 Lee, C.Y Lee, D , Lee, E , Lee, H Lee, I , Lee, J , 1.218, 3.098, 3.203, 3.226, 3.289, Lee, K , 1.196, 1.234, 2.014, 2.110, 2.248, 2.253, 2.255, 2.348, 2.364, Lee, M , Lee, M.R Lee, S , 1.219, 1.236, 2.168, 2.314, 3.036, 3.196, B.09 Lee, S.T Lee, V Lee, W Lee, Y , 1.230, Lega, B , Legatt, A.D Legendre, A Legg, K Legge, A , Legido, A Legros, B , 3.203, Lehesjoki, A Lehmkuhle, M Leijten, F Leitinger, M Leland, M Lemesiou, A Lenz, F Leon, Y.C Leon-Vazquez, M , Leonard, S

103 ABSTRACT AUTHOR INDEX Leppik, I , 1.325, Lerche, H Lerner, J , A.09 Lervik, K Lesage, F , LeSure, S Leung, L Leuthardt, E Leventer, R.J Lévesque, M , Levi, O Levin, H , Levin, S Levitt, J , 1.254, Levy, S Lewis, E Lewis, E.C , Lewis, M.L Leyden, K , Leymon-Porter, B Lhatoo, S , 2.126, 3.127, Li, B Li, H Li, L Li, M Li, N Li, P , Li, S Li, T , Li, W Li, Y Liang, L Liang, W Libbey, J.E Libenson, M Lie, O Liebenthal, J Ligot, N Lilja, I Lillis, K , Lim, B , 1.195, Lim, S , Lim, S.N Lima, A.M , Lima, E Lima, P.B Lima Castro, C Lin, C Lin, J , 2.004, 2.013, 3.270, Lina, J , Linane, A , Lindsay, K Lineweaver, T , Liow, J Lippman-Bell, J Lipski, W.J Lipton, R.B Liscano, A Lisicki, D Liska, J Lispi, M Litt, B , Liu, C Liu, G Liu, K Liu, M , 2.081, Liu, R , Liu, S Liu, Y.C Liu, Z Llerenas Zamora, R Llewellyn, N , 2.286, Locke, D Loddenkemper, T , 1.182, 1.197, 1.329, 1.345, 2.035, 2.213, 3.202, 3.235, 3.236, 3.246, A.05, B.06 Loeb, J Loesch, A , Loi, R.Q Long, X Longo, D Longo, F.M Lopes, T.M Lopes-Cendes, I Lopez, C , 3.307, Lopez, M Lopez Dequit, I López-Gomáriz, E López González, F , López Pizano, A Lopez-Trigo Picho, F Lora, P Loring, D.W , 3.344, B.08 Lösch, C Loscher, W Losey, T Losher, C Lossius, M , Loturco, J Loughman, A Louise, G. C.01 Love, T.E Lovell, K Lovick, T Lowden, A Lowe, H Lowen, K Lowenstein, D Lozano, M Lu, Y Luan, G , 1.365, Lucchese, L Luczak, A Lüders, H , 3.160, A.07 Ludmir, E.B Ludwig, E , 1.314, 1.319, 1.320, Luef, G , 2.245, Lugo, J , 3.105, C.07 Lukic, V Luna-Munguia, H Lundstrom, B Luo, C Lupien-Meilleur, A. C.01 Lushbough, C Lutz, M.T Luu, P , 1.263, Ly, C Lyons, R , M Ma, Y Maa, E , Macaulay, D Macaya, A Machado, A Maciag, C Mackay, M.T Mackenzie, S.J Mackie, E.J Macrodimitris, S , Madakasira, P Mader, E Mader, M , Madhavan, D Madhavan, R Madsen, J Madsen, J.R Maehara, T , 2.093, Maertens, P Maganti, R Magdassi, S Magestro, M Magge, S , 3.355, Mah, S Mahajan, R Maher, D Maheshwari, A Mahmood, N Mai, R Maideniuc, C Maillard, L Mailo, J.A Majmudar, S Makeyev, O Makin, C , Makinson, C Malek, A.M Maliia, M Malik, A Malik, M Malik, S Malinowska, U , Maljevic, S Mall, E.M Maloney, T Malykhin, N.V Mamelak, A , Mandadi, S Mandel, A Mandelstam, S , Mandrekar, J Manganaro, S , 1.142, 2.063, 2.162, Manganas, L , 1.135, Mangano, F Manitpisitkul, P Mann, A Mann, K Manreza, M.G , Mapstone, T.B Marchal, C Marcotegui, I Mares, P , Mari, F Marin, A Marini, C , Marino, S.E Mariyappa, N Marquardt, F , Marquez, Y Marras, C Marsh, E Marsh, E.D Marsh, R , 1.374, 2.156, 2.256, 2.337, Marsh, S Marsh, S.T Marson, A Marti, C Martin, R.F Martinez, G Martinez, J Martinez, R.C Martinez-Juarez, I.E , Martinez-Perez, A Martins, A Martins, S Martz, G.U Martínez Agredano, P Martínez-Juárez, I.E Maruo, T , Maruyama, A Masel, T Mason, K , Mason, S Massaro, A Massey, S Massot-Tarrús, A Matagne, A Mateo, M Mathern, G , 1.357, 2.355, 2.358, 3.255, Matkovic, Z Matos, A Matosevic, B Matsui, T Matsumoto, H Matsumoto, J , 1.182, 2.156, Matsumoto, N , Matsumoto, R , Matsuo, F Matsuo, T Matsuura, M , 2.093, Matthews, S.A Mattson, R Matur, Z Maturu, S Maurer Morelli, C Mauri, J Mavroudakis, N Maxwell, C Mayer, T , 3.293, 3.297, Mayes, L.C. B.01 Mays, V , Maytal, J Mazarati, A , 1.056, Mbelwa, S McArthur, D. A.09 McAuley, J McBee, N , 2.285, 2.286, McBrian, D McCarthy, A McCarthy, D McCoy, B , 3.239, McCredie, R McDonald, C , ABSTRACT AUTHOR INDEX

104 ABSTRACT AUTHOR INDEX 102 McDonald, S McDonough, T McGoldrick, P , McGrade, H McGuire, R McIntosh, A McKee, H.R McKhann, II, G.M , McLachlan, R McLellan, A , McMahon, J , 3.086, McNamara, J , 1.038, McNamara, N McNaughton, B.L McPhillips, M McShea, C , 3.292, 3.295, Meador, K.J , 2.320, 2.339, 3.168, 3.344, B.08, Mealey, R Mecchella, J.N Medvedev, A Mefford, H , 3.086, 3.087, 3.092, Megevand, P , 3.177, Mégevand, P Mehešová, S Mehrizi, M Mehrotra, K Mehta, A , 2.011, 2.246, 2.256, 2.339, 3.177, Mehta, D Meisler, M. C.09 Melaiki, B Melanson, D Memon, A.B Mendes, P.S , Mendes, S , Mendez, D Mendoza, L , Mendoza, M Menezes Cordeiro, I Menon, J Menon, U Mercan, M Mercedes, B Mercier, J Mercier, M , Mesad, S Mese, T , Messinger, M , Metcalfe, A Mevåg, M.A , Meyer, F , 1.374, Meyer, K Meyer, M Meyers, E , Miao, H Michalak, Z Michaud, J.L Michel, C Michelhaugh, S Michelucci, R Michoulas, A , Midi, I Midura, M Mikati, M , B.06 Mikkelsen, T Mikulis, D Mikuni, N Milder, J Miles, L Miles, M Milh, M Milham, M Millan, C.M Millen, K.J Miller, I Miller, J , 2.039, 2.126, A.07 Miller, J.A Miller, R.J Miller, S Miller-Horn, J Millett, D Millichap, J , 3.157, Milligan, C.J Minassian, B Mindruta, I , Minotti, L , Mintz, M , Mintzer, S Miotto, E.C , Miozzo, M Mirchandani, N Mirro, E Mirsattari, S Mirsky, D , Mirza, N Misajon, J Miskin, C Misra, S.N Mitchell, W Mittal, M Mittal, S , Miura, K , 1.235, Miyama, S Miyamoto, S , Mizrahi, E Modi, A , 1.091, Modur, P , 2.038, 2.131, 2.193, 3.070, Moeller, J Moffett, B.S Mohamadpour, M Mohamed, I , Mohamed, M.A Mohammad, F Mohammadi, M Mohan, C Mohanarangan, K Mohanraj, R Moheet, A Molins, A Møller, R.S , Monica, N Monrad, P Montalvo, J Montandon, G , Montoya, J Moon, C Moon, H Moon, J , Moore, J.L Moorley, N , 1.199, 1.200, Moraes, V Morales-Quezada, J Moran, J Morawo, A Moreira, C.L Moreland, S Morgan, L Morgan, V Morgan, V.L Morisada, N Morita, A Morita, D , 2.024, Morita, M , 3.259, Morrell, M , 2.209, 2.212, B.08 Morris, C Morris, G Morse, C Moschetta, S Moschetta, S.C Moseley, B.D , B.05 Moseley, M Mosher, J , 1.149, Moshé, S Moss, A Moss, R Motamedi, G Motelow, J , Motika, P Motil, K.J Moufawad El Achkar, C Moura, L.V Moussa, N.A Mower, A Mowrey, W , Mrelashvili, A Mucci, G Mudugal, D mueller, A Mueller, G.P. A.08 Mueller, M Muhle, H , Muhonen, M Mullatti, N Mullins, J.G Muma, E Muniz, R Munoz, J , Muona, M Murakami, H , Murata, K Murphy, G. C.09 Murphy, M Murphy, W , Murro, A.M Muzik, O Myers, C Myers, L , Mylius, J Myseros, J Mytinger, J.R , 3.157, N N Guyen The Tich, S Na, G Nabatame, S Nabbout, R , 2.263, Nabors, L.B Nabulsi, N Nachbauer, W Nadasdy, Z Naduvil Valappil, A , 1.192, Naeije, G Nagarajan, E , 2.035, 2.213, 3.235, 3.236, Nagasawa, T Nagase, H Naik, M Naik, P Nair, D , 1.153, 1.216, 2.212, Nair, S Najimipour, B Najm, I , 1.012, 1.040, 1.058, 1.063, 1.240, 1.362, 1.377, 2.073, Nakae, T , Nakagawa, E , 1.147, 2.225, Nakagawa, T Nakajima, M , 1.363, 1.370, 2.174, 3.012, Nakamura, K Nakane, S Nakanishi, S Nakano, H Nakasato, N , 2.132, 2.149, 2.154, Nakashima, M , Nakayama, T Nakhutina, L Nakken, K Nam, H Namihisa, Y Nampoothiri, S Napuri, S Narayana, P.A. B.03 Narayanan, M Narugami, M Nascimento, D Nash, K Nassar, M Nasuti, P Natsume, J , 1.235, 1.243, Navarro, V Naves, P , Navratilova, Z Ndayisaba, J Neal, J Nearing, B.D Negishi, M. B.01 Negoro, T , 1.235, Negrin, S Neher, J.J Neil, J , Neimat, J Nelson, D , Nelson, E.B Nelson, G.R Nemes, A , 1.012, Nemoto, M Neppe, V.M Nespeca, M , Nettel-Aguirre, A Neubauer, B , 2.204

105 ABSTRACT AUTHOR INDEX Neufeld, M Neul, J.L Neumann, A Neveux, M Newman, R.B Ng, E Ng, M Ng, Y , Ngo, T.P , Nguyen, D , 3.274, Nguyen, D.K , Nguyen, D.V Nguyen, L , Nguyen, M , Nguyen, V Ni, J Nick, S Nickels, K , 1.355, 1.364, 2.079, 2.203, 3.148, 3.158, 3.223, Nicolas, J , Nicoletti, J Niemann, H Nikanorova, M Nikolov, R Nikolova, S , Nishida, S , Nishioka, K Nishiyama, M Nita, D.A Nixon, J , Noachtar, S , 2.165, 3.211, Noack - Rink, M , Nobile, C Nobili, P Noe, K Noebels, J. Noh, G Nonoda, Y Norcia, A Nordli, D , Norman, J.L Nourski, K.V Novak, H Novak, Z Noviawaty, I Novotny, E , 3.280, Nowell, M Nozaki, T Nuno, M Nussbaum, N O O Brien, C , 3.205, 3.304, O Brien, T O Brien, T.J , O Callaghan, F O Connell, R.M O Day, K O Donovan, C O Hara, B.F O Neal, W O Neill, B Oba, S Obari, D Obata, K Obeid, R Oberaigner, W Oberman, L Ochi, A , 1.145, 1.172, 1.189, 2.353, 3.108, 3.153, Odom, N , Ogawa, C Ogden, K Oguni, H Oh, A Oh, M Ohshima, M Ohta, K , 2.093, Oijala, M. C.03 Ojemann, J , 3.280, 3.282, 3.368, Okanari, K , 1.145, 2.353, Okanishi, T , 1.172, Okeke, J.O , 3.081, Okoshi, Y Oktem, O Okumura, A Okumura, E Olafsson, E Oldham, M Oliveira, L.A Oliver, K.L , Olney, N Olson, A Olson, L Oltmanns, F Oluigbo, C , 2.351, 3.355, Omar, N Omurtag, A Ono, T , Onomura, A Oommen, B , Opperman, C Orhan, N Orii, K Orozco-Suarez, S Orton, K Osaka, H Osako, M Osawa, S Osborn, M Oshino, S , Osorio Santiago, A Oster, J Ostuni, J Otsubo, H , 1.145, 1.172, 1.189, 2.353, 3.108, Otsubo, T Otsuka, K Otsuki, T , 1.365, 2.225, 2.341, Ottman, R , 3.081, Otáhal, J Oya, H Ozbek, D Ozdag, F P Pacheco, J Pacheco, L Pacheco-Phillips, J Pack, A , Pack, C Paige, A , 2.285, 2.286, Painter, M Pakhomov, S.V Palacios, A Palao-Duarte, S Palat Chirakkara, S Palestrant, D Palmquist, M Palotie, A Pan, H Pan, J.W Pan, P , Pan, Y Pandey, R Pandian, A Panduranga, A Panel, I , Pang, T , Panigrahy, A Paolicchi, J Papadelis, C , 3.202, Papale, L Parada, I Pardoe, H.R Paredes Saenz, C.F Parent, J , 3.005, 3.006, C.02, C.09, Parent, R. C.09 Parikh, P. A.06 Park, B Park, C Park, E Park, H Park, J.T Park, K , 1.218, Park, S , 1.081, 1.218, 1.282, Parker, P Parko, K Parra, M Parsons, K Parsons, T Parthasarathy, S Pascoal, V Pascual, F.T Pascual, J Pascual-Leone, A , Passarell, J , 1.314, 1.319, Passe, T Passen, N Passmore, C Patel, A , 2.319, Patel, A.B Patel, M , 3.052, Patel, P , Patel, R Pathmanathan, J Patil, V , Pato, A , Patten, S Patten, S.B Patterson, C Patterson, E Patterson, K.P Patwardhan, R , 2.337, Paudel, S Pavlova, M Payne, E , Pazarci, N Pazdera, L Pearce, P.S Peariso, K. B.06 Pearl, P , 1.225, 3.065, 3.246, Pearson, J Pedersen, M Pedersen, N.P Pedraza Benitez, C Peeters, P.A Peglar, L Pei, F Peinhof, S Pelayo, M Pella, R Pellegrino, G Pelliccia, V Peltier, A Pendziwiat, M , Peng, K Peng, S Pennell, P , 3.289, Penovich, P , 1.320, Perchyonok, Y Percy, A.K Perez, D.L Perez, E Perez Velazquez, J Perez-Ruiz, J Perkins, F.F Perlman, J.M Pernot, F Perry, L , Perry, M , Perucca, P Perumpillichira, J.C Perven, G Perzynski, A.T Peters, J Peters, P.A Petersen, B Petersen, C Petit, J Petroff, O , Petrou, S , Petty, S.J Phelan, J.C , 3.081, Phillips, B Phillips, K Picard, R , Pickrell, W.O Pieters, H , Pike, V Pillai, A Pillay, N , 2.150, 2.198, Pilli, V Pilz, G Pina-Garza, J.E Ping, X ABSTRACT AUTHOR INDEX

106 ABSTRACT AUTHOR INDEX 104 Pinheiro Martins, A Pinto, L.F Pinzon-Ardila, A Pirmohamed, M Pirotte, B.D Pita, I Pittau, F Pittman, D.J , Pittman, Q.J Pixley, L Pizzo, F Plank, G Platel, J Plegue, M Plummer, C Poddar, K Poduri, A , 3.087, Pohlmann-Eden, B Pojomovsky, P Polack, P Poliachik, S , 1.250, Poliakov, A.V , 1.250, 3.280, Politsky, J , Pollard, H.B. A.08 Pollard, J , 2.135, 2.285, 2.286, 2.287, 3.208, Pollard, J.R. A.08 Polli, J , Polster, T Polyak, B Ponce Mejia, L Ponticello, L Pooladian, A Popli, G , 2.256, 2.337, 2.339, Porter, B Portnoy, E Poublanc, J Pouliot, P , Pouliot, W.A Powell, E Powell, K.L Poza Aldea, J , Prayson, R , Prescott, J.S Press, C Prieschl, M , Prince, D.A Prince, R Privitera, M , 2.228, 2.285, 2.286, 2.287, 3.288, Pro, S Probasco, J , Probst, L Proix, T Prusa, C Pugh, M , Puka, K , Pullum, B , Punia, V. A.02 Pushchinska, G Pustina, D , Puthenveettil, V Puttachary, S Pylypyuk, V Q Qiang, J Qing, K Quach, M Que, G.T Quelen, C , 1.335, Quigg, M Quinn, H Quinn, K Quiroga Subirana, P Qulu, L Quraishi, I Quraishi, I.H Qureshi, M R Rabinovitz, B Rabinowicz, A.L Radhakrishna, S Radtke, R Raedt, R , 3.028, C.08 Ragazzo, P.C , Raghavan, M Ragheb, J Rai, A Rai, P Rai, S Raible, D Rajaraman, R , A.09 Rajasekaran, K , Rajasekaran, V , Rajyaguru, R , Rama Madhava, A RamachandranNair, R Raman, K.R Ramey, P Ramirez, C Ramirez, F , Ramon, C Rampal, N , Rampp, S , 1.346, Ramsay, E , Ramsay, R Ramsay, R.E. B.02 Ramsey, R.K Ramsey-Williams, V Rana, S Randall, M Rankin, S Ransom, C Rao, L Rao, S Raol, Y Rappoport, D.A Rapuano, A Rasina, A Rau, S Rawal, P , Rayer, K Raygor, K Raynes, H Raña Martínez, N Rebessi, E Reck-Peterson, S Reddy, D , 1.031, 1.032, Reddy, J Reddy, S Redondo Verge, L Reed, C.M , 2.321, Reed, R Reed, U.C , Rees, M.I Reese Jr, J Regan, B.M Regnier-Golanov, A , Rehman, R , Reid, C. Reif, P.S Reimers, A Reinsberger, C , Reisdorph, N Rektor, I Remi, J , Rémi, J Remigio, G.J Rener Primec, Z Renfroe, B Rensing, N , Resnick, T Restrepo, C Reutens, D , Rheims, S , 2.226, Rho, J.M , 3.124, Rhone, A.E Riaz, A Ribot, R , Richards, S Richardson, J Richardson, M , Richardson, Z Richeh, W Richerson, G Riebe, I. C.01 Riley, C.L Riley, J , 3.270, Riley, K , Rios-Motta, M , Rios-Motta, R Rismanchi, N Risse, G , Ritacco, D.G Ritchie, H Ritter, F , Rivard, K.B , Rizzi, M Robbins, E Robert, M , Roberts, H Roberts, J Robichaud, A Robichaud, A.J Robinson, L Robinson, S Rocha, C.S Rocha, F , 1.287, 1.315, 1.316, 1.319, 1.320, 1.322, Rocha, L Rodan, L Rodgers, K Rodgers, K.M Rodgers, P Rodrigues, L Rodrigues Velasco, T Rodrigues Ximenes Goldberg, K , Rodriguez, C Rodriguez, J Rodriguez Casero, M.V Rodriguez Osorio, X , Rodriguez Uranga, J Rodriguez-Osorio, X Rodríguez Arias, L.R Roehl, K Roers, E Roessler, K , Rogawski, M.A Rogers, B.P Rogers, J Rogin, J , Rojas, N Romain, J Romatoski, K , Romeo, A Romero Acebal, M Romero-Godoy, J Romigi, A Rompies, E Ronen, G Rosa, M Rose, D , Rose, K , Rose, S , Rosenbaum, P.L Rosenberg, E Rosenfeld, W Rosenow, F Rossi, M.A , 2.085, Rossignol, E , C.01 Rotenberg, A , 1.302, 3.009, 3.034, 3.044, Roth, R.M , Rothermel, R , Rothman, S Roucard, C Rowley, S Roy, A Roy, A.G Rozen-Zvi, M Rozhkov, L Rubio Esteban, G Rubio-Nazábal, E Rudd, D Rudoinov, R Rueda, C.H Ruiz Chow, A Runge, U , Russek, S , Russo, G Rutecki, P Rutishauser, U , Rutka, J , 1.189, Ruttle-Soon, L Ruvalcaba, N Ruwald, M Ryan, B Ryan, C Ryan, E Ryan, N , Rychlik, K. A.01 Rydenhag, B , 2.343, Ryu, H

107 ABSTRACT AUTHOR INDEX Ryvlin, P , 2.226, 3.291, Rzezak, P , 3.076, S Saadatmand, H Saavedra Piñeiro, M , Sabatello, M Sabau, D Sabesan, S , Sabharwal, V , 3.219, 3.225, B.02 Sabri, J Sacco, M. B.06 Sackellares, J.C Sade, E Saenz, J Safi, D Sager, M Sahin, D Sahin, M Sahin, S Sahoo, S.S , Said, R , Said, R.R Saindane, A.M Sainju, R , Saito, T , Saito, Y Saitsu, H , Saiz-Diaz, R Sajatovic, M , 3.085, Sakaguchi, Y , Sakata, M Sakuma, S , 1.145, 2.353, Sakuraba, R Salam, M Salam, T Salamon, N , 1.245, 1.261, 1.278, 3.255, Salanova, V Salas Puig, J , 3.237, Salinas, C.M , 2.248, 2.253, 2.255, Salinsky, M , Salituro, F Salpekar, J Sampaio, L.B , Sampaio, L.P Sampath, D Sams, J Samson, K.K San Juan Orta, D Sanchez Barrera, W.S Sánchez Fernández, I , 1.182, 1.197, 1.329, 2.035, 3.246, A.05, B.06 Sánchez Ortiz, C Sanchez-Ortiz, L Sander, T Sander, V Sandy, S , Saneto, R Sankar, R , 2.108, 2.195, Sankar, T Sankaraneni, R.R Sansevere, A Sansevere, A.J Santamarina, E , Santana-Gomez, C Santaniello, S Santhakumar, V Santos, V.R Saper, C.B Saponjian, Y , 2.328, Saposnik, G Sarkar, C Sarkis, R , 2.213, 3.235, Sarma, A Sarma, S.V , Sarode, A Sarria, S Sasaki, M , 2.225, 2.341, Satishchandra, P Sato, K Sato, S Sato, Y , 3.108, Sattar, S , Sauer, C Saunders, G.W Sauro, K Savioli, A Sawan, M , Sawchuk, T Sawer Jr, R Scantlebury, M , 1.030, 1.217, Schaal, A , 2.255, Schachter, S , 1.302, Schaefer, C , Schaffer, D Schaffer, S Schalk, G , 2.255, Scharfman, H.E , Scheffer, I , 1.115, 1.120, 3.086, 3.087, 3.088, 3.092, 3.095, Scheich, H Scheuer, T Schevon, C , 3.213, 3.253, Schiemann, J Schiff, N , Schildt, C Schiltz, N Schmid, E Schmidt, K. B.06 Schmidt, M Schmidt, S Schmiedel, G Schmitt, F , Schmitt, F.C Schmitt, S , Schmitt, S.E Schneider, S Schober, H Schoedel, K.A Schoenberg, M , Scholl, E.A Schomer, A Schooley, D.E Schrader, D. B.04 Schreiber, J Schultz, L , Schulze-Bonhage, A , 1.129, 1.167, 2.180, 2.358, Schwabe, M.J Schwalb, J Schwambach Vieira, A.S Schwartz, M.L Schwarz, M Schwieterman, D Schönherr, M Scornavacca, G.F Scott, J Scott, L , Scullion, K Secore, K Secore, K.L Seeck, M Seidenberg, M , 3.267, Seidl, S Seif Eddeine, H Seignot, B Selassie, A , Selby, K Selezneva, E Selwa, L Semah, F Semsarian, C Sen, D Sencer, S Seneviratne, U Seo, D , Seo, J , 1.179, 2.014, 2.110, 2.253, 2.255, 2.348, 2.364, Sepeta, L , 3.084, 3.268, 3.272, Seppi, K Serafini, A Serafini, R Seraphim, E.A Sergio, G Serioli, E Serout, F Sethi, N.K , Seyal, M. A.06 Sha, Z Shafer, P , Shafi, M , Shah, A , 1.321, 3.062, 3.174, 3.232, 3.266, Shah, P Shahlaie, K Shallcross, A Shandra, O Shapiro, J.S Shapiro, M.J Shapiro, M.S Sharan, A , 1.349, 2.256, 2.337, Shariff, S Sharma, A Sharma, B Sharma, P Sharma, R Sharma, S Shatila, A Shaw, D.W , 3.280, Shaw, E.C Shaw, S Shea, K Shegog, R , Sheikh, A Shellhaas, R , 1.136, 3.145, Shen, A Shen, J , Shen, S.C Shen, V , 1.335, Shepherd, C Sheriff, H Sherman, E Shetty, A , 2.337, 3.358, Shetty, J , Shi, Y Shiau, D Shibata, S , Shields, D Shih, J.J , 2.256, 2.337, 2.339, 3.238, Shih, S , Shih, Y Shimoda, Y Shimono, M Shin, D , 1.289, Shin, H , Shin, J , 2.168, Shin, W Shindo, K Shinpoo, M Shiraishi, H Shmuel, M Shmuts, R Shneker, B , Shon, Y , Shostak, S , 3.081, Shrestha, A , 3.205, Shults, J Shurtleff, H Shutter, L.A Si, Y , Siddarth, P , 1.254, Siddiqui, K , Siddiqui, R.S Sidovar, M Siebert, R Siedentopf, C Sieren, J Silbersweig, D.A Sillanpaa, M Sills, G Silveira, M.R Silvia, M Simeone, K , Simeone, T Simeone, T.A Simon, N Simonson, C Sinasac, D Sinclair, D Singer, R Singh, A Singh, K Singh, M Singh, P Singh, R Singh, S , Singh, S.P , ABSTRACT AUTHOR INDEX 105

108 ABSTRACT AUTHOR INDEX 106 Sinha, S , 1.148, 1.239, 2.106, 2.188, Sinha, S.R Sinisterra, N Sirsi, D Sirven, J , Sisodiya, S Sitwat, B Siugzdaite, R Sivaraju, A Skene, P Skibo, J Skidmore, C , Skinner, S.A Slansky, A , Slater, J , Slick, D Smith, B , Smith, D Smith, E Smith, G , 3.105, C.07 Smith, J.D , Smith, M , Smith, N Smith, P.E Smyth, M Snead, C Snead, O , 2.353, Snead III, O.C , Snyder, J , So, E , B.05 Sobczyk, O Sobrido, M Soderblom, E.J Sofat, P Sogawa, Y , 3.331, Sohn, Y Sohrabpour, A Soldan, S.S Solomon, G Solt, K Soltesz, I. C.03 Somerlik-Fuchs, K Somerville, E Sommer, B Song, H Soni, N Sonmezturk, H , Sood, S , 2.345, 3.062, Soraas, C Sorge, S.T , 3.081, Sorin, L.M Soucy, A Soul, J , Sousa, R , 1.287, 1.317, 1.319, 1.320, 1.322, Sozzani, S Spain, W Spampanato, J , Spanaki, M , 2.215, Specchio, L Specchio, N Speechley, K , 2.069, 2.223, Spencer, D , 1.209, 1.216, 2.151, Sperling, M , 1.318, 1.320, 1.323, 1.349, 2.290, 2.256, 2.289, 2.337, 2.339, 3.291, 3.292, Spiciarich, M.C Spitz, A Spitz, M , 3.205, Spreafico, R Sprengers, M , 3.028, C.08 Spring, A.M Spritzer, S.D Spruill, T Squillacote, D Srikanth Mysore, C Srinivasan, S St. Louis, E St. Louis, L , Staba, R Stacey, W , 3.067, 3.167, Stafstrom, C , 2.023, 3.267, Staley, K , 1.021, 2.328, 3.004, 3.022, Stamatoyannopoulos, J Stamboulian-Platel, S Standridge, S , Stanisic, M Stanslaski, S Stanton, P Starski, P Stead, M , 2.156, Steenland, H Stefan, H , 3.349, Steger, H Stemmer, P.M Stence, N , Stephani, U , 2.199, Stephen, L Stern, E Stern, J , 3.291, Steve, T.A Steven, D Stieglitz, T Stino, A Stockis, A , Stocks, J.D , Stoll, J Stoll, S , 3.078, 3.085, Stoltenberg, C Storrs, J.M Story, T , 3.291, Storzbach, D Stoub, T Straub, H.B Strauman, M.C. A.08 Straussberg, R Streiner, D.L Striano, P , Striano, S , 1.320, Stribling, J Stringer, K Strode, D Strom, L , 2.053, 3.205, Struck, P.J Stufflebeam, S , Suchdev, K Sudo, A Sueiras, M Sugai, K , 1.365, 2.225, Sugano, H , 1.363, 1.370, Sukigara, S Sulc, V Sullivan, J , 2.309, 3.095, 3.214, Suls, A Sumi, Y , 2.093, Sumpter, R Sun, F , Sun, H , 3.007, Sun, P.Y Sunderam, S , Sundstrom, D Sunkaraneni, S , 1.314, 1.319, 1.320, Sunnen, C Sunwoo, J , Suren, P Suresh, S. A.07 Sutton, S Suwanpakdee, P , Suzuki, H Suzuki, N , 1.258, Svehlik, V , Sveinsson, O Svendsen, K.H Svendsen, T Svenson, L Swaminathan, A Swann, J , C.04 Swearingen, R Swedo, S Sweeney, M Sweet, J. A.07 Swenson, A Swiercz, W , Sylvester, C Szabo, C , 3.052, Szabo, G.G. C.03 Szaflarski, B.A Szaflarski, J , 1.257, 1.281, 1.310, 1.324, 1.330, 2.024, 2.161, 2.163, 2.285, 2.286, 2.287, 3.203, 3.226, B.09 Szaflarski, M , Szklarski, L Szu, J , Sætre, E T Tabata, A , Taccone, F Tadlock, D Tailby, C Takada, S Takagi, Y Takahashi, A , 1.365, 2.225, 2.341, Takahashi, K Takahashi, R , Takahashi, Y , Takami, Y Takeoka, M , 2.017, 3.169, 3.236, Takeshita, S Takeuchi, T , Takumi, I Talib, L.L Talos, D.M Talypov, A , Tamber, M Tampieri, D Tan, M Tanaka, N , Tanaka, S , 2.093, Tanaka, T Tandon, N , Tang, H Tang-Wai, R Tangel, V , 3.135, Tani, N Tankovic, A Tanuma, N Tao, J , Tao, W Tapia, M Taplinger, D Tarquinio, D Tarrant, S , Tasker, R , 3.202, 3.334, B.06 Tassi, L , Tatsuoka, C , Tatum, W , 2.155, 2.256, 2.337, 2.339, Tatum, W.O Tayah, T Taylor, C.T Taylor, D Tecoma, E , Tejada, J Tekeli, H Telecka, S Telesco, R Tellez-Zenteno, J , 2.082, Temkin, N Tenney, J , 2.024, Tennigkeit, F , 3.295, 3.297, Terashima, H Terhaerdt, J Terra, V Terrill, M Terry, D Terwilliger, V , Teskey, G , 1.217, Testa, F Teter, B Tezer-Filik, F Thadani, V , Thadur, S Thaker, A.A Thakur, D.S Thaler, A , Thaler, J Thamattoor, A Theodore, W , 1.065, 1.150, 1.225, 2.356, 3.065, 3.084, 3.268, Thibert, R Thiele, E Thippeswamy, T Thom, M Thomas, A.X

109 ABSTRACT AUTHOR INDEX Thomas, G.P Thomas, P Thomas, R Thome, U Thome Costa, U , Thome-Souza, S , 1.329, 2.213, 3.202, Thompson, A.L Thompson, D Thompson, D.M Thompson, E Thompson, L Thompson, M , C.07 Thompson, N , Thomson, J Thomson, K Thorne, N.P Thurman, D , 2.074, Tian, N Tilton, N , Timarova, G Timmings, P Ting, T , Tippin Davis, B Tirol, F , Titus, J.B Toda, K , Todaro, M , Togrol, E Tohma, S , 2.093, Tohyama, J , Toledo, M , 3.237, Toler, J Tom, M Tominaga, K Tominaga, T , Tominaga, Y Tomson, T Topjian, A , B.06 Torello, A Tornes, L Toropova, K Torres-Barba, D Torrez-Corzo, J Tosun, D , 1.254, Toth, E Tovar Quiroga, D.F Tovar-Spinoza, Z , 3.357, Toyoda, I Toyoshima, D Tracy, J , Tran, B Tran, H Tran, P.T Tran, T Tran, T.T Tran, Y.T Tranel, D Traynelis, S.F Treiman, D.M Treiman, L.J Tremblay, J , Trenado, C Trent, C Trifonov, I , Trinka, E , 1.319, 2.068, 2.245, Tripathi, M Trivisano, M Trobliger, R Troncoso, L Troncoso, M Trope, A Tropea, T Tsai, J Tsao, J Tseng, P Tseng, W.E Tsenov, G Tshionyi, M Tsimerinov, E Tsong, W Tsuchida, T , 1.137, Tsuchiya, K Tsuji, T Tu, P.H Tucker, D , 1.263, Turco, L Turnbull, J Turner, D. B.06 Turner, K Turner, M Tuxhorn, I , Tyler-Kabara, E Tyrlik, M Tyrlikova, I , Tzvetanov, P , U Uchida, C.P Uchio, H Ueda, Y Uematsu, M Ueno, M , Ugorec, I Ugur Yilmaz, C Ukitsu, S Ullmann, J Umezu, M Ünalp, A UnCheol, L Ung, H Unnwongse, K Unterberger, I , 2.169, 2.245, Upchurch, K Upreti, C Urrestarazu, E Uysal, U Uzun, M Uzuner, G V Vago, D.R Vajjala, V.S Vakili, R Vale, F , Valencia, I , 2.035, Valente, K , 2.259, 2.260, 2.306, 3.076, Valiante, T , Valle-Dorado, M Valton, L Valujskikh, A Van Bebber, S Van Cott, A.C Van den Maagdenberg, A.M. C.01 van der Linden, Jr., H , van Gerven, J.M Van Grunderbeek, W Van Kampen, A van Kranen-Mastenbroek, V Van Ness, P , 2.038, 2.189, 2.193, 2.209, Van Nieuwenhuyse, B , C.08 Van Orman, C van Rijckevorsel, K Van Straten, A.F Vanasse, C. C.01 VanCott, A VanHaerents, S , Vanli- Yavuz, E Vannasing, P , Vannest, J , Vargas, L , Varni, J Varvel, N Vasoli, V , 2.156, Vater, I Vaughan, D Vaughn, B Vazquez, B Vazquez, M Vázquez Gregorio, R Veenstra, A Vega, C , 3.169, Velez, A Velez, F , 1.344, Velez, F.F , Velisek, L , Veliskova, J , Velmurugan, J Velmurugan, M Vena, J.E Venkatesan, C Venkatraghavan, L Venkatraman, K Ver Hoef, L , 1.247, 1.249, 2.338, B.09 Verity, K Verma, A Vernet, M Vernier, E Vernino, S Verpillat, P , 1.335, Verrier, R.L Vestergaard, M Vezina, G , Vezzani, A Vibhute, P Vickrey, B , Vidaurre, J Vigevano, F , Vignoli, A Villagran, A , Villalobos, R , Villalobos Chávez, F Villani, F , Villanueva, V Villeda Hernandez, J Villega, F Vincent, J Vincentiis, S , 2.259, 2.260, Virta, J Viteri Torres, C Vitko, L.R Vitkovskiy, P , 1.076, Vlachos, I Voets, N Voges, J , 3.058, Vollaro, T Vollmar, C , 3.211, Volpe, A von Deimling, M von Ellenrieder, N , 3.184, von Spiczak, S , Vonck, K , 1.067, 3.028, C.08 Vossler, D.G Vulliemoz, S Vyas, M W Waber, D.P Wada, T Wade, A.G , 1.335, Wade, R Wadhawan, A Wadman, W , C.08 Wagenaar, J.B Wagley, P Wagner, G Wagner, J Wagnon, J. C.09 Wainwright, M. B.06 Waldman, W Waldman Zadeh, W Walker, I.M Walker, J Walker, M Wallace, E Waller, K Walsh, N Walters, B Wambacq, I Wamil, M. A.08 Wang, G , Wang, H , 1.103, 3.074, Wang, J.L Wang, L Wang, P. C.06 Wang, S , Wang, X , 1.273, Wang, Y , Wang, Z , Wang, Z.I , Wannamaker, B Ward-Mitchell, R Wark, J.D Warner, M Warren, A Warren, C Warren, P Wasade, V.S , 2.215, ABSTRACT AUTHOR INDEX 107

110 ABSTRACT AUTHOR INDEX Waseem, H , Washington III, J Wassermann, E Watanabe, K , 1.235, Watanabe, S , 2.239, Watanabe, T Watson, R Weaver, K. Weber, Y Webster, E , Webster, R Wechsler, R , Wechsler, R.T , Weckhuysen, S Wedberg, E Wei, S.P Weinand, M , 2.256, 2.337, Weinstein, S Weinstock, A Weir, C Weiss, S Weiss, S.A Welter, E , 3.085, Welty, T , 2.285, 2.286, Wempe, M.F Wen, J.H Wen, M Wen, P Wenzel, L Werhahn, K , Werhahn, K.J , 3.292, Wesselkamper, K West, P.J Westerveld, M , 2.248, 2.255, Weston, M Westover, M , 3.054, 3.203, Wetjen, N Whalen, H Whalley, B.J. Wharen, R , 2.212, 2.337, 2.339, Whealy, M.A Wheatley, M , Whelan, P Wheless, J White, A , 3.039, White, H , White, J Whitehead, M Whitfield-Gabrieli, S Whitmire, L Wicks, P Widjaja, E , 1.189, Wiebe, S , 2.051, 2.067, 2.071, 2.082, 2.150, 2.198, 2.223, Wiggs, E , 3.084, Wild, I Wilfong, A , 2.333, 2.347, 3.307, 3.353, 3.358, 3.371, B.06 Wilk, P , Wilkening, G , 2.012, Williams, B , 2.276, 2.279, 2.288, 2.289, 2.291, 2.293, 2.294, Williams, J Williams, K , B.06 Williams, P Williams, S Williamson, J , Willie, J , 2.256, 2.337, 2.339, Willmore, L Wilman, A.H Wilner, A Wilson, D.A , Wilson, J.A Winawer, M , 3.081, Wirrell, E , 1.206, 1.355, 1.364, 2.035, 2.079, 2.203, 3.145, 3.158, Wise, C.A Wisnowski, J Wlodek, M.E Woldoff, S Wolf, E.G Wolf, S , Wolff, M Wollack, J.B Wolter-Warmerdam, K Wong, C.H Wong, J , Wong, M , 3.013, Wong, P Wong, S , Wong, S.M Wong, V.S , 1.277, Wong-Kisiel, L , 1.355, 1.364, 2.079, 2.203, 3.148, 3.158, 3.214, Woo, D Woo, Y Wood, R Woodard, V Woodrum, D Woodward, R Works, K Worrell, G , 1.175, 1.374, 1.377, 2.156, 2.212, 2.256, 2.337, 2.339, 3.071, Wrede, J Wright, C Wu, C Wu, E Wu, J , 2.355, 3.249, 3.255, Wu, J.Y Wu, R Wu, S , Wu, T Wu, X , 1.031, Wu, Y.W Wulsin, A.C Wulsin, D Wusthoff, C , Wyatt, K Wyllie, E , X Xiao, W.R. B.01 Xie, J Xing, D , 2.276, 2.279, 2.288, Xiong, W Xu, D Xu, M Y Yacubian, E , 3.251, Yadav, A , Yaffe, R.B Yaghouby, F , Yagiri, E Yakovlev, A Yamada, M Yamagata, S Yamaguchi, T Yamamoto, H , 1.243, 1.365, Yamamoto, T , Yamao, Y , Yamashita, H Yamashita, S Yamauchi, K Yamazaki, E Yamazoe, T Yan, B Yan, C Yanagisawa, T , Yang, A Yang, G Yang, H , 2.276, 2.279, 2.288, 2.289, 2.291, 2.293, 2.294, Yang, M Yang, T Yang, X Yang Kao, Y Yao, D Yarbrough, C Yardi, R Yardi, R , Yasuda, C , 3.260, Yasuda, R Yates, S Yaun, A Ye, S Yelvington, K.H , Yeom, J Yerra, S Yildirim Capraz, I Yilmaz, C Yilmaz, U Ying, Z , 1.012, Yogi, A , 1.245, 1.261, 3.255, Yokoi, S , Yokota, T Yoon, J Yoon, J.W Yoong, M , Yoshimine, T , Yoshimura, K Young, G Youroukos, S Yozawitz, E Yu, H Yu, J , Yu, R Yu, W Yuan, H Yudovin, S Yue, C. C.06 Yum, M , Z Zack, M Zadeh, N Zaehle, T Zafar, H Zaghloul, K zaghloul, K Zaghloul, K.A Zaher, A Zaidi, S Zak, M Zamarian, L Zambrelli, E Zanelli, P Zanelli, S.A Zangen, A Zanotti-Fregonara, P Zanotto, F Zaveri, H , 1.156, 2.151, 2.350, 3.074, Zawadzki, L , Zeft, A Zeiger, M. A.09 Zelleke, T , Zelmann, R Zemblis, J Zeng, C Zeng, L Zeng, R Zerbs, A Zeuthen, T Zhan, H Zhan, Q , Zhang, B Zhang, C Zhang, G Zhang, H , C.02 Zhang, L Zhang, M Zhang, S Zhang, W , Zhao, B Zhao, G.Q Zhao, J Zhao, Z Zheng, N , Zhou, C Zhou, D Zhou, J. C.06 Zhou, R Zhou, X Ziemba, K.S Zillgitt, A , 2.215, Zimmerman, A.M Ziobro, J Zoghbi, S Zohrevand, P Zou, J Zrik, A Zubair, M.N Zupanc, M Zutshi, D

111 COMMERCIAL SUPPORTER RECOGNITION All as of October 21, 2014 Benefactor Level Special thanks to: Sunovion Pharmaceuticals Inc. for supporting: Exhibit Program Book Ad Media Wall Spots (3 days) Footprints virtualtote Bag Banner Ad virtualtote Bag Insert Suds for Science Reception Lunch in Exhibit Hall (3 days) Poster Session Breakfast (2 days) Coffee Break in Exhibit Hall (3 days) Innovation Pavilion (Saturday / Sunday) Cyber Café (3 days) Cell Phone Charging Station (3 days) Networking Massage Lounge (3 days) Airport Baggage Carousel Display AD Passport to Prizes Door Drops Scientific Exhibit Office Rental in Exhibit Hall Epilepsy Currents Ads Educational Grant - Annual Fundamentals Symposium, AET Symposium AES Fellows / EpiPORT SIGs (2) SUPPORTER LEVELS 109

112 Leader Level Special thanks to: Eisai, Inc. for supporting: Exhibit Program Book Ad Innovation Pavilion (Monday) virtualtote Bag Banner Ad Passport to Prizes Door Drops Epilepsy Currents Ads Named Fellowship (Sustained) Nurse / Young Investigator Awards AES Fellows / EpiPORT Educational Grant Epilepsy Specialist Symposium, Annual Fundamentals Symposium, AET Symposium, Professionals in Epilepsy Care Symposium 110

113 Leader Level Special thanks to: UCB, Inc. for supporting: Exhibit Program Book Ad Scientific Exhibits Educational Grant Epilepsy Specialist Symposium, Annual Fundamentals Symposium, AET Symposium AES Fellows / EpiPORT Cyber Café (3 days) Media Wall Spot (3 days) Coffee Break in Exhibit Hall (2 days) SUPPORTER LEVELS 111

114 Partner Level Special thanks to: Lundbeck Pharmaceuticals, Inc. for supporting: Exhibit Program Book Ad Media Wall spot (2 days) Innovation Pavilion (Saturday / Sunday) Passport to Prizes Door Drops Scientific Exhibit Epilepsy Currents Ads Educational Grant AET Symposium, Annual Fundamentals Symposium 112

115 Partner Level Special thanks to: Upsher-Smith Laboratories, Inc. for supporting: Exhibit Hoyer Lecture Program Book Ad Passport to Prizes Door Drops Scientific Exhibits Epilepsy Currents Ads Seed Grant AES Fellows / EpiPORT Year Round Education SUPPORTER LEVELS 113

116 Supporter Level Special thanks to: Cyberonics, Inc. for supporting: Exhibit Innovation Pavilion (Saturday / Sunday) Scientific Exhibit Named Fellowship (Sustained) Educational Grant Annual Fundamentals Symposium Supporter Level Special thanks to: Natus Neurology Incorporated for supporting: Exhibit Auction of XLTEK LTM System 114

117 Supporter Level Special thanks to: Supernus Pharmaceuticals, Inc. for supporting: Exhibit Program Book Ad Passport to Prizes Door Drop AES Fellows / EpiPORT Educational Grant Annual Fundamentals Symposium Supporter Level Special thanks to: Mallinckrodt Pharmaceuticals for supporting: Exhibit Epilepsy Currents Ads Educational Grant Pediatric State of the Art Symposium SUPPORTER LEVELS 115

118 Supporter Level Special thanks to: Acorda Therapeutics for supporting: Investigator Workshop SIGs (2) Program Book Ad virtualtotebag Banner Ad Epilepsy Currents Ads AES Fellows / EpiPORT 116

119 Contributor Level Special thanks to: Nihon Kohden America, Inc. for supporting: Exhibit Auction of EEG-1200 Contributor Level Special thanks to: Cadwell Laboratories, Inc. for supporting: Exhibit Media Wall Spot (2 days) Footprints Passport to Prizes Epilepsy Currents Ads Contributor Level Contributor Level Special thanks to: Compumedics Limited for supporting: Exhibit Epilepsy Currents Ad Special thanks to: Pfizer Inc. for supporting: General Conference Grant SUPPORTER LEVELS 117

120 Advocate Level Special thanks to these companies for supporting: NeuroPace, Inc. Exhibit Innovation Pavilion (Saturday/Sunday) Epilepsy Currents Ad ELEKTA Exhibit Electrical Geodesics, Inc. Exhibit Epilepsy Currents Ad Educational Grant Annual Course Medtronic, Inc. Exhibit Nurse/Young Investigator s Awards GW Pharmaceuticals Exhibit Investigator s Workshop (1) SIG (1) Blackrock Microsystems, LLC Exhibit 118

121 Patron Level Special thanks to these companies for supporting: Rhythm Link Exhibit Epilepsy Currents Ad Ad-Tech Medical Instrument Corp. Exhibit Monteris Medical, Inc. Exhibit Medical Neurogenetics, LLC Exhibit PMT Corporation Exhibit Ripple LLC Exhibit Lifelines Neurodiagnostics Systems, Inc. Exhibit The Jack Pribaz Foundation Exhibit Passport to Prizes Media Wall Spot (3 days) Nexstim, Inc. Exhibit Neurolynx, Inc. Exhibit SUPPORTER LEVELS 119

122 GENERAL INFORMATION AES 2014 Annual Meeting The American Epilepsy Society (AES) is one of 108 Chapters of the International League Against Epilepsy (ILAE). The Annual Meeting of the American Epilepsy Society is the largest meeting and exhibition in the world for those who share the common scientific and clinical interests of epilepsy and clinical neurophysiology. The meeting attracts more than 4,000 attendees dedicated to improving the quality of life for those dealing with epilepsy. This meeting is the top forum to examine common concerns and to gain insight from leading authorities. Mission Statement The American Epilepsy Society advances research and education for professionals dedicated to the prevention, treatment and cure of epilepsy. Target Audiences Basic: Those new to epilepsy treatment or whose background is limited, e.g., students, residents, general physicians, general neurologists and neurosurgeons, other professionals in epilepsy care, administrators. Intermediate: Epilepsy fellows, epileptologists, epilepsy neurosurgeons, and other providers with experience in epilepsy care (e.g., advanced practice nurses, nurses, physician assistants), neuropsychologists, psychiatrists, basic and translational researchers. Advanced: Symposia will address highly technical or complex topics (e.g., neurophysiology, advanced imaging techniques or advanced treatment modalities, including surgery). Policy on Commercial Support and Conflict of Interest The American Epilepsy Society maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the AES provide in-depth presentations that are fair, balanced, independent and scientifically rigorous. All faculty, planning committee members, editors, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to the activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentations. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. This information will also be made available through syllabus materials and faculty presentations. Disclosure of Unlabeled / Unapproved Uses This educational program may include references to the use of products for indications not approved by the FDA. These discussions are noted on the faculty s disclosure forms as well as during their presentations. Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals. Abstracts Abstracts from the 2014 Annual Meeting are available on the AES website and will also be available as an online supplement to Epilepsy Currents. Accreditation The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to offer continuing medical education for physicians. Credit Designation Physicians: The American Epilepsy Society designates this live activity for a maximum of AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physician Assistant: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of hours of Category 1 credit for completing this program. Nursing: Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and American Epilepsy Society. AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center s Commission on Accreditation. This activity is awarded contact hours. Nurse Practitioners: Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and American Epilepsy Society. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number: This program is accredited for contact hours which includes 7.0 hours of pharmacology. Program ID #21424 This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards. Pharmacy: Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and American Epilepsy Society. AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Select portions of this Annual Meeting are approved for pharmacy CE credit. Specific hours of credit for approved presentations and Universal Activity Numbers assigned to those presentations are found elsewhere in program materials. Criteria for success: Credit is based on documented program attendance and online completion of a program evaluation / assessment. If you have any questions about this CE activity, please contact AKH Inc. at service@akhcme.com. International Credits: The American Medical Association has determined that non-u.s. licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credits TM. CME / CE Certificates The Medical Education Evaluator is an online system that allows attendees to complete course evaluations, track educational credits and print out the appropriate certificate. Once you have accessed the Medical Education Evaluator, you will be asked to enter your myaes number and password that you created. The certificate(s) are saved to your personal account page and are cumulative. You may print the certificate(s) at any time. The following fees apply for obtaining educational credits: Member Fees: $50 through January 16, 2015 $75 January 17 February 27, 2015 Non-member Fees: $75 through January 16, 2015 $100 January 17 February 27, 2015 The online Evaluator will be open through February 27, You must complete the evaluations and credit tracking by that date. Completing this information online also assists the Council on Education and Annual Meeting Committee with important needs assessment data so AES can further plan and address educational gaps to meet the needs of our learners. Attendance Certificate / International Attendees A meeting attendance certificate will be available at the registration desk for international meeting attendees on Tuesday, December 9. Handouts Handouts for the educational symposia will be available via the virtualtotebag. For instructions: please refer to the flyer provided in your meeting bag or go to the AES website for details at Questions? Please contact virtualtotebag Support Desk at support@virtualtotebag.com 120

123 GENERAL INFORMATION Audience Response System AES will be utilizing the Audience Response System (ARS) in several of the symposia. Faculty will have ARS questions throughout their presentations with multiple choice answers. To participate, you will use your cell phone to text your reply. When a question appears in a presentation, simply text your answer (a 5 or 6 digit code) to Standard text rates will apply. The ARS will allow for interactive audience participation as well as real time, immediate feedback to enhance the learning environment and ensure that we are meeting the learning objectives set forth by each symposium. Commercial Exhibits (page 82) The Exhibit Hall is an integral part of the learning experience. Meeting participants will have an ideal opportunity to learn about the latest in pharmaceuticals, publications, scientific equipment, and technology relevant to the fields of epilepsy and neurophysiology. Please check the AES website for an updated listing of exhibiting companies and organizations. To ensure safety and security, no children under 12 years of age, strollers, carriages, wheeled luggage or wheeled briefcases will be allowed in the Exhibit Hall during exhibit hours. Saturday, December 6 Noon - 6:00 p.m. Sunday, December 7 10:00 a.m. - 6:00 p.m. Monday, December 8 10:00 a.m. - 3:00 p.m. Scientific Exhibits (page 23) AES has approved guidelines for industry-sponsored Scientific Exhibits at the Annual Meeting. Scientific Exhibits differ from traditional poster presentations in that a broad range of material can be presented as a collection of topics, such as results of various clinical trials, or a thematic presentation of one aspect of drug development. Scientific Exhibits will be displayed on Sunday, December 7 and Monday, December 8. An application to register for a Scientific Exhibit was ed to interested companies in June. Reservations will be reviewed and accepted on a first-come, first-served basis until space is sold out. Send inquiries of interest to JoLynn Amsden at jamsden@aesnet.org. Cyber Café Convention Center Exhibit Hall 4B, Level 4 Open during Exhibit Hall hours The Cyber Café will be available during Exhibit Hall hours at the Convention Center with and Internet access. You will also be able to complete the course evaluations and obtain your CME certificate online. For your convenience, Wi-Fi will also be available in the Convention Center. Photography and Recording of Programs AES strictly prohibits all photography (flash, digital, or otherwise), audio and / or videotaping during the Annual Meeting. Equipment will be confiscated. Material presented at the AES Annual Meeting is not to be reproduced in any format without the express written consent of the AES. Attendees acknowledge and agree that commercial or promotional distribution, publishing or exploitation of speaker sessions, content, or materials from the AES Annual Meeting is strictly prohibited unless you have received the express prior written permission from AES or the otherwise applicable rights holder. When you attend an approved AES event or program, you enter an area where photography, audio, and video recording may occur. By entering the event premises, you consent to photography and its release, publication, exhibition, or reproduction to be used for news, newsletters, promotional purposes, advertising, inclusion on websites, or any other purpose by AES and representatives. You release AES, its officers and employees, and each and all persons involved from any liability connected with the taking, digitizing, or publication of photographs and computer images. You have been fully informed of your consent, waiver of liability, and release before entering the event. Business Centers Two full-service FedEx Office business centers are conveniently located in Seattle for Annual Meeting attendees. Both offer a variety of services which include shipping, mailing, faxing and photocopying. Please contact the office directly for details. Washington State Convention Center, Level 1 (Suite 11-13) Phone: Sheraton Seattle Hotel, Level 2 Phone: Press Room Convention Center Room 304, Level 3 AES offers meeting information and assistance for journalists reporting on epilepsy studies, educational presentations, and special reports at this meeting. The AES on-site Press Room staff works with journalists to develop stories, research facts and information, and connect with experts and presenters. The on-site Press Room is also available to sponsors and exhibitors for the display and distribution of relevant press releases and media kits. For more information, contact Ellen Cupo at (203) and ellen@bigvoicecomm.com, or Natalie Judd at (203) and natalie@bigvoicecomm.com. Friday, December :00 a.m. - 6:30 p.m. Saturday, December :30 a.m. - 6:30 p.m. Sunday, December :30 a.m. - 6:30 p.m. Monday, December :30 a.m. - 6:30 p.m. Tuesday, December :30 a.m. - 1:00 p.m. A series of media briefings on a select number of topics will be held in the press room from Friday, December 5 through Monday, December 8. Details will be posted in Room 304, Level 3 at the Washington State Convention Center and in advance on the AES website Press Room after December 1. Hotel Information Early Departure Policy Guests who check out of the hotel prior to their scheduled departure date will be charged a penalty of one night s room rate and tax. Sheraton Seattle Hotel (Headquarters Hotel) 1400 Sixth Avenue, Seattle, Washington Telephone: Crown Plaza Hotel Seattle 1113 Sixth Avenue, Seattle, WA Telephone: Grand Hyatt Seattle 721 Pine Street, Seattle, WA Telephone: Hyatt at Olive 8 Seattle th Avenue, Seattle, WA Telephone: Hilton Seattle 1301 Sixth Avenue, Seattle, WA Telephone: Mayflower Park Hotel 405 Olive Way, Seattle, WA Telephone: Motif Seattle Hotel (formerly the Red Lion) 1415 Fifth Avenue, Seattle, WA Telephone: Renaissance Seattle Hotel 515 Madison Street, Seattle, WA Telephone: The Fairmont Olympic Seattle 411 University Street, Seattle, WA Telephone: The Paramount Hotel 724 Pine Street, Seattle, WA Telephone: The Roosevelt Hotel th Avenue, Seattle, WA Telephone: Warwick Seattle Hotel 401 Lenora Street, Seattle, WA Telephone: Meeting Location Washington State Convention Center 800 Convention Place, Seattle, WA GENERAL INFORMATION

124 GENERAL INFORMATION Program Changes AES cannot assume liability for any changes in the program due to external or unforeseen circumstances. Language The official language of the Annual Meeting is English. Meeting Attire Dress for the Annual Meeting is business casual. Consider bringing a light jacket or sweater with you since meeting room temperatures and personal comfort levels vary. No Smoking Policy For the comfort and health of all attendees, smoking is not permitted at any AES function. This includes educational sessions, meetings and all food functions. Both the Convention Center and the Sheraton Seattle are smokefree facilities. Also, smoking is not permitted in public buildings, restaurants or bars. Gratuities Gratuities are not automatically added to the bill, except in some cases for large groups. Waiters and waitresses are usually given 15% to 20% of the bill. Taxi drivers usually receive 15% of the fare and doormen and $2 per night for hotel housekeeping. Skycaps and porters are normally tipped $1 per bag. Registration & Security AES is committed to providing a secure meeting environment. A formal security plan is developed in consultation with the Security Department at the Convention Center. All meeting attendees will be required to produce government-issued photo identification prior to receiving their badge and registration materials. Appropriate badges must be worn at all times while in attendance at the Annual Meeting and are required for admittance to all meeting activities. Security procedures will also be in place for exhibition materials and all deliveries to the Annual Meeting. Insurance / Liabilities AES cannot be held responsible for any personal injury, loss, damage, accident to private property or additional expenses incurred as a result of delays or changes in air, rail, sea, road, or other services, strikes, sickness, weather, acts of terrorism and any other cause. All participants are encouraged to make their own arrangements for health and travel insurance. Contact Information American Epilepsy Society 342 North Main Street, Suite 301 West Hartford, CT Safety and Security Information The following security measures have been designed to further enhance your personal and professional safety. Pick up any Convention Center house phone located in the facility and dial 5127 or Uniformed Convention Center employees have radios and are ready to assist you. Advise the dispatcher of the exact location within the Convention Center. We respectfully request that you do NOT call 911 directly. An EMT will be on duty in the Convention Center throughout the meeting. A government-issued photo identification is required to receive a badge and to replace a lost badge. Convention Center Security may randomly check packages and bags at the Convention Center entrances, meeting rooms and in the Exhibit Hall. You will be asked to always clearly display your name badge and to use only approved Convention Center entrances and exits. Appropriate badges will be required to enter all educational sessions, Poster Sessions, the Exhibit Hall and meetings. Due to safety and fire regulations, doors will be closed to all session rooms that fill to capacity. Throughout the meeting, you will notice security staff presence to monitor the safety of all participants. Do not leave unattended packages (i.e., briefcases, laptops, purses, etc.) in any area of the Convention Center or hotel. Please report any suspicious activity to security staff or to the AES registration desk staff. General Safety Tips Remove your badge once you leave the meeting facilities. Carry important telephone numbers with you. Do not display or carry large amounts of cash. Walk in groups, especially at night. Lock your hotel room door. Always verify hotel room repair or service calls. Do not disclose your room number to anyone. Never give your personal information (credit card, room number, etc.) over the phone; instead, go to the front desk if the hotel calls with questions. Phone: , ext. 512 Meeting Fax: info@aesnet.org Website: Faculty Ready Room and Photos Location: Convention Center Room 303, Level 3 Faculty need to have photos taken for repurposing of symposia on the AES website. All faculty PowerPoint presentations have already been uploaded through the AES Faculty Development Room. All faculty must stop by to reconfirm their presentation with an audiovisual technician. Thursday, December :00 p.m. - 8:00 p.m. Friday, December :00 a.m. - 6:00 p.m. Saturday, December :00 a.m. - 6:00 p.m. Sunday, December :00 a.m. - 6:00 p.m. Monday, December :00 a.m. - 6:00 p.m. Tuesday, December :00 a.m. - 11:00 a.m. 122

125 MAP OF SEATTLE, WA 8th 8 t h Av ve e. N. N. St d oa Br. St St ia ts t. in ew ar Vi St. St no ra Bl Le el no ra. no ra.. e. rs S on ve ve Av f fe ss t. r f fe so ns t. Al de t. rs t. Yesle Y Ye es er W Way ay SW Washington a s h n g to n S t. S Main M a n St. S Jackson J a c k s o n St. on I st S Je s na We ry a t tl e Je me St. n sla n ea t t CH IN L ATO SW We eller er SDt IS W TR N / I S Lane L a n e St. C T I S King K ng SN t T d a le W te r i Ta x Occidental O c c d e n t a Av ve e. S Se ash to V e r to 1st 1 s t Av ve e. S ry Fe r B re m Ja St. me re y to Bo Fe rr ER NE R E PIO UA SQ F e r r y to B a i n b r i d g e I s l a n d. ry. St. Ja PIER P R WA S WA STA TAT ATE FERRIES F RR ES r Te C r he ve ia mb ve t. ha ns lu 5. ha St. Co. ve e. M o a ri St on ha Av PI E R 5 5 ARGOS Y CRUISES/ TILLICUM VILL AGE on t. is ad 7t rn M is ad M gs 8t. ri n ri n 9t ve Sp t. gs St. Mi Sp 10 0 a St. 1 ec n Se ca.. S 3S e en Broadway Br o a d w ay ve. ve r Mi ve ha e niv y si t U on Unio Un n St. t. ntse WA W A SHIN SH N GT TO ON STA TAT T A AT nio U CONV NVE V NTIO ON C CENTER R 6 ve. U da te e. es Av T W t 1s KE Fe r P I E R 57 SE AT TLE GRE AT WHEEL V illag e ic u m r y to T ill St. 2n AR WATERFRONT PARK A S U n nio 4 ve M PIER 59 SE AT TLE AQUARIUM ha da E AC E 4t K PI E R S 6 2 & 6 3 W 8 3r W ay WE W E S TL LAKE AK t. St. PA PARK ke S e n Pi Pi PL N EI N PA BRU RK E C e. e. KE PI E R 6 6 BELL S T. CRUISE TERMINAL n Av e. e ha ST ka d e. 5t as Av Av 6t Al 1s t e.12 1 PI PIER 67 BELL HARBOR CONFERENCE CENTER 2n e. rg. St d ar ch an e. Av e. Av. Av Av Av Av h ve tt d h h.. St ll Be 3r lio h e. 9t 8t w. St y er tt 4t e. Ho. St t. W al ls ne e. Av Av re ha El Ba Av h ry ls rs t. ay rn 5t h 7t a B.C. P I E R 69 VIC TORIA CLIPPER te 7t 6t. c to r i e. Vi K es da Cl Av Ce oa Br R PA W e.. N ke Ave Wes ttllake DS d Ea St. gl AR W e ED St. E 1s t Bo Crowne Plaza Hotel Seat tle Grand Hyat t Seat tle Hilton Seat tle Motif Seat tle (formerly Red Lion) Renaissance Seat tle Hotel Sheraton Seat tle Hotel The Paramount Hotel May flower Park Hotel The Roosevelt The Fairmont Olympic Hotel Hyat t at Olive 8 War wick Seat tle Hotel C A L A N D E R SO N PARK A TL Denn D enn Te r Ya Y a YR SC O L U YM PALPT PIC RK UR E Ea E a M Denn D enny Wa Way ay LEGEND JJohn ohn DENN Y PA ARK Po P o JJohn ohn S St. t Min M n Fairvi Fa r v e w Av ve e. N. N Boren Bor e n Av e e. Thoma Th homass St. Terry T e r r y Av ve e. N. N Westlake W es t ake Av ve e. N. N 6 t h Av e e. N N. EMP MUSEUM E.. M E Mercer e rc e r St. Harrison H arr son Stt.. Taylor T a y o r Av ve e. N. CHIHULY GARDEN & G L A SS PACIFIC SCI E N CE CENTER Rep epublican ub c an St. E. Ro E. oyy S Stt. 9th 9 t h Av ve e. N. N SEAT TLE CENTER W J o h n St. W.John W. M MOH AI A L AKE K UNION I PAR ARK Merce M ercer St. 5th 5 t h Av ve e. N. N W. Thomas T h o m a s St. D ex xtte err Av ve e. N. Aurora A u r o r a Av ve e. N. Ro oyy St. BILL B LL & MELIN MEL NDA GAT G ATE AT ES F FOUN OUN DAT AT ON ATION Queen Q ueen Anne A n n e Av ve e. N. N W. Harrison H a r r s o n St. to V i Va alley St. Merce M ercerr St. W. Rep publican u b c a n St. Fe rr y 4 t h Av ve e. N. N 2nd 2 n d Av ve e. N. N 1sstt Av ve e. W. W Warren W a r r e n Av e e. N. 1st 1 s t Av ve e. N. N 2nd 2 n d Av ve e. W. W W.Ro oyy St. Aloh A oha a St. CENTURYLINK FIELD S Dearborn D e a r b o r n St. S Charles C h a r e s St. SP Plumme ummer St. Pike Place Market to CenturyLink Event Center: 1 mi / 1.6 km Pike Place Market to Space Needle: 1 mi / 1.6 km Pike Place Market to Convention Center: ½ mi / 800 m S. L A K E U N I O N S T R E E TC A R PARK BUS/LIGHT R AIL TUNNEL BUS/LIGHT R AIL TUNNEL STAT TION SE AT TLE CENTER MONOR AIL CONVENTION HOTEL INFORMAT TION CENTER DR. JOSE R IZ AL PARK A Ro oyya al B Brougham ro u g h a m W Way ay S A F E CO F I E L D Edgar E dgar Martinez Ma r t n ez W Way ay 4 t h Av ve e. MA JOR AT TR AC TION CENTURYLINK EVENT CENTER 123

126 WASHINGTON STATE CONVENTION CENTER LEVEL 3 Faculty Ready Room (302) Faculty Photo Room (303) Press Room (304) LEVEL 4 Registration Exhibit Hall Poster Sessions Poster entrance when exhibit hall is closed 124

127 WASHINGTON STATE CONVENTION CENTER LEVEL 6 Ballrooms 6C and 6E Session Rooms Scientific Exhibits 125

128 126 SHERATON SEATTLE HOTEL

129 Seattle Children s Epilepsy Program Offers Unsurpassed Care Seattle Children s Epilepsy Program is the largest on the West Coast dedicated to treating children and young adults up to age 21. As part of the University of Washington s Regional Epilepsy Center and the Northwest Epilepsy Consortium, Seattle Children s serves patients in Washington, Alaska, Idaho and Montana. Our six pediatric epileptologists collaborate with experts in neurosurgery, neuropsychology and neuroradiology to provide promising leading-edge options for children with epilepsy like laser ablation. We have special expertise in neurogenetics, participated in NIH sponsored EPGP and EPI-4K projects, and mitochondrial disorders. We are active in epilepsy research and offer clinical trial and study opportunities. Learn more at

130 THE MOST WIDELY READ AND HIGHLY CITED PEER-REVIEWED NEUROLOGY JOURNAL The Official Journal of the American Academy of Neurology Neurology brings you: One subscription...four ways to access Clinical/Scientific Notes Medical Hypothesis papers) in Neurologic Practice Images Online Correspondence Enjoy full-text online access, including expedited e-pub, presentation downloads, search functions, topic alerts, e-toc service, RSS feeds of current issues and podcasts, mobile device downloads, and a Resident & Fellow subsite. Plus, access Neurology on your ipad for a print-like reading experience enhanced with article-sharing features, links, and more! Neurology.org Visit Booth #400 for Meeting Discounts 4-R

131 Neurology Clinical Practice An Official Journal of the American Academy of Neurology Additional Series Sections: Neurology Clinical Practice AAN.com/Membership. Neurology.org/cp Visit Booth #400 for Meeting Discounts 129

132 Indexed In: Biological Abstracts, BIOSIS, Current Contents/Clinical Medicine, EMBASE, Excerpta Medica, Index Medicus, MEDLINE, Neuroscience Citation Index, Research Alert, Scopus and Scisearch Seminars in Neurology Editor-in-Chief: D. Greer 2015/Volume 35/6 issues p.a./issn USA and Canada Individuals: $316 $253 Institutions: $1,054 Please contact For institutional licenses, please contact Mexico, Central and South America Individuals: $343 $274 Institutions: $1,081 Please contact For institutional licenses, please contact Europe, Africa, Asia, Australia, New Zealand Individuals: Institutions: 1,084 (Please add shipping charges: 57.00) Please contact For institutional licenses, please contact Bangladesh, Bhutan, India, Nepal, Pakistan, and Sri Lanka For subscription rates in INR, please contact SUBSCRIBE NOW AND STAY UP-TO-DATE IN 2015 Visit in order to subscribe or renew your subscription. Take full advantage of your individual subscription by registering online at Individual subscribers get free online access to current and back issues of their journal(s) Advanced online access for select journals via the efirst service Up-to-date Alerts via or RSS-Feed Advanced search across our entire library of journals ORDER TODAY Become a fan at Follow 130

133 Exploring Critical Advances in Brain Connection Research Brain Connectivity is the premier peer-reviewed journal for cutting-edge research in the expanding area of systems neuroscience. Critical advancements in the diagnosis and treatment of neurodegenerative diseases and psychiatric disorders Vital information on brain mapping, new imaging modalities, and translating research discoveries from lab to clinic Accepted in MEDLINE in its first year Founding and Co-Editors-in-Chief: Christopher P. Pawela, PhD and Bharat B. Biswal, PhD Subscribe Today! 131

134 Adjunctive therapy for patients ages 12 and up with partial-onset seizures 1 NOVEL TARGET. NOVEL POTENTIAL. FYCOMPA the first and only non-competitive AMPA receptor antagonist 1-3 GET ON TARGET AT AES Visit us at Booth #305 Indication FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older. AES = American Epilepsy Society 132

135 Indication FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older. Important Safety Information WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking FYCOMPA These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking FYCOMPA or after discontinuing FYCOMPA Closely monitor patients particularly during the titration period and at higher doses FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening Serious Psychiatric and Behavioral Reactions Hostility- and aggression-related adverse reactions occurred in 12% and 20% of clinical trial patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 6% of patients in the placebo group. These effects were dose-related and generally appeared within the first 6 weeks of treatment, although new events continued to be observed through more than 37 weeks. These effects in FYCOMPA-treated patients led to dose reduction, interruption, and discontinuation more frequently than placebotreated patients. The combination of alcohol and FYCOMPA significantly worsened mood and increased anger. Patients taking FYCOMPA should avoid the use of alcohol. Patients, their caregivers, and families should be informed that FYCOMPA may increase the risk of psychiatric events. Patients should be monitored during treatment and for at least one month after the last dose of FYCOMPA, and especially when taking higher doses and during the initial few weeks of drug therapy (titration period) or at other times of dose increases. Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including FYCOMPA, increase the risk of suicidal thoughts or behavior in patients. Anyone considering prescribing FYCOMPA or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, their caregivers, and families should be informed of the risk and advised to monitor and immediately report the emergence or worsening of depression, suicidal thoughts or behavior, thoughts about self-harm, and/or any unusual changes in mood or behavior. Should suicidal thoughts or behavior emerge during treatment, consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Dizziness and Gait Disturbance FYCOMPA caused dose-related increases in events related to dizziness and disturbance in gait or coordination. Dizziness and vertigo were reported in 35% and 47% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 10% of placebo-treated patients. Gait disturbance related events were reported in 12% and 16% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 2% of placebo-treated patients. These adverse reactions occurred mostly during the titration phase. Somnolence and Fatigue FYCOMPA caused dose-dependent increases in somnolence and fatigue-related events. Somnolence was reported in 16% and 18% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 7% of placebo-treated patients. Fatigue-related events were reported in 12% and 15% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 5% of placebo-treated patients. In the controlled Phase 3 epilepsy clinical trials, these adverse reactions occurred mostly during the titration phase. Patients should be advised against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of FYCOMPA is known. Falls Falls were reported in 5% and 10% of patients randomized to receive FYCOMPA at doses of 8 mg and 12 mg/day, respectively, compared to 3% of placebo-treated patients. Withdrawal of AEDs A gradual withdrawal is generally recommended with antiepileptic drugs to minimize the potential of increased seizure frequency. Most Common Adverse Reactions In clinical trials, the most frequently reported dose-related adverse reactions in patients receiving FYCOMPA 8 mg or 12 mg vs placebo ( 4% and at least 1% higher than the placebo group) included dizziness (36% vs 9%), somnolence (16% vs 7%), fatigue (10% vs 5%), irritability (9% vs 3%), falls (7% vs 3%), nausea (7% vs 5%), ataxia (5% vs 0%), balance disorder (4% vs 1%), gait disturbance (4% vs 1%), vertigo (4% vs 1%), and weight gain (4% vs 1%). Drug Interactions FYCOMPA may decrease the efficacy of contraceptives containing levonorgestrel. Plasma levels of FYCOMPA were decreased when administered with carbamazepine, phenytoin and oxcarbazepine. Concomitant use with strong CYP3A inducers such as St. John s wort and rifampin should be avoided. Multiple dosing of FYCOMPA 12 mg/day enhanced the effects of alcohol on vigilance and alertness, and increased levels of anger, confusion, and depression. These effects may also be seen when FYCOMPA is used in combination with other CNS depressants. Pregnancy Category C and Lactation FYCOMPA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Physicians are advised to recommend that pregnant patients taking FYCOMPA enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. Caution should be exercised when FYCOMPA is administered to a nursing woman. Hepatic and Renal Impairment Use in patients with severe hepatic or severe renal impairment is not recommended. Dosage adjustments are recommended in patients with mild or moderate hepatic impairment. Use with caution in patients with moderate renal impairment. Drug Abuse and Dependence FYCOMPA is a Schedule III controlled drug substance and has the potential to be abused or lead to drug dependence. Please see Brief Summary of full Prescribing Information on the next page for Boxed WARNING and additional Important Safety Information. References: 1. Fycompa Prescribing Information. Woodcliff Lake, NJ: Eisai Inc.; June Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11: Hanada T, Hashizume Y, Tokuhara N, et al. Fycompa: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52: FYCOMPA is a registered trademark of Eisai R&D Management Co., Ltd., licensed to Eisai Inc. Manufactured and marketed by Eisai Inc., Woodcliff Lake, NJ Eisai Inc. All rights reserved. FYCO0788 September

136 134 NOTES

137 NOTES 135

138 136 NOTES

139 VISIT SUPERNUS PHARMACEUTICALS AT BOOTH #605 Get your Passport to Prizes stamped at booth #605 each day of the convention to be eligible for the daily prize drawing For more information visit and Proudly Supports the American Epilepsy Society (AES) 2014 Annual Meeting Trokendi XR and Oxtellar XR are registered trademarks of Supernus Pharmaceuticals, Inc Supernus Pharmaceuticals, Inc. All rights reserved. SPN